<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Pharmacological treatment of gastro‐oesophageal reflux in children - Tighe, MP - 2023 | Cochrane Library</title> <meta content="Pharmacological treatment of gastro‐oesophageal reflux in children - Tighe, MP - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008550.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Pharmacological treatment of gastro‐oesophageal reflux in children - Tighe, MP - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008550.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008550.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Pharmacological treatment of gastro‐oesophageal reflux in children" name="citation_title"/> <meta content="Mark P Tighe" name="citation_author"/> <meta content="University Hospitals Dorset" name="citation_author_institution"/> <meta content="mpt195@hotmail.com" name="citation_author_email"/> <meta content="Edward Andrews" name="citation_author"/> <meta content="University Hospitals Dorset" name="citation_author_institution"/> <meta content="Iona Liddicoat" name="citation_author"/> <meta content="University Hospitals Dorset" name="citation_author_institution"/> <meta content="Nadeem A Afzal" name="citation_author"/> <meta content="Portsmouth University" name="citation_author_institution"/> <meta content="Andrew Hayen" name="citation_author"/> <meta content="University of Technology Sydney" name="citation_author_institution"/> <meta content="R Mark Beattie" name="citation_author"/> <meta content="University Hospital Southampton NHS Foundation Trust" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD008550.pub3" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/08/22" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008550.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008550.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008550.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Esomeprazole; *Gastroesophageal Reflux [complications, drug therapy]; Omeprazole; Pantoprazole; Proton Pump Inhibitors [therapeutic use]; Rabeprazole; Ranitidine" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008550.pub3&amp;doi=10.1002/14651858.CD008550.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008550.pub3&amp;doi=10.1002/14651858.CD008550.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008550.pub3&amp;doi=10.1002/14651858.CD008550.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008550.pub3&amp;doi=10.1002/14651858.CD008550.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008550.pub3&amp;doi=10.1002/14651858.CD008550.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008550.pub3&amp;doi=10.1002/14651858.CD008550.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008550.pub3&amp;doi=10.1002/14651858.CD008550.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008550.pub3&amp;doi=10.1002/14651858.CD008550.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008550.pub3&amp;doi=10.1002/14651858.CD008550.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008550.pub3&amp;doi=10.1002/14651858.CD008550.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008550.pub3&amp;doi=10.1002/14651858.CD008550.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008550.pub3&amp;doi=10.1002/14651858.CD008550.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008550.pub3&amp;doi=10.1002/14651858.CD008550.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008550.pub3&amp;doi=10.1002/14651858.CD008550.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008550.pub3&amp;doi=10.1002/14651858.CD008550.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008550.pub3&amp;doi=10.1002/14651858.CD008550.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008550.pub3&amp;doi=10.1002/14651858.CD008550.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008550.pub3&amp;doi=10.1002/14651858.CD008550.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008550.pub3&amp;doi=10.1002/14651858.CD008550.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008550.pub3&amp;doi=10.1002/14651858.CD008550.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008550.pub3&amp;doi=10.1002/14651858.CD008550.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008550.pub3&amp;doi=10.1002/14651858.CD008550.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008550.pub3&amp;doi=10.1002/14651858.CD008550.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="9nGOjNGw";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008550\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008550\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008550\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008550\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ms","hr","fr","zh_HANS","zh_HANT","th","ja","fa","id","pl","ro","nl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008550.pub3",title:"Pharmacological treatment of gastro\\u2010oesophageal reflux in children",firstPublishedDate:"Aug 22, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gut Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=9nGOjNGw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008550.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008550.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008550.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008550.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008550.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008550.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;id&quot;,&quot;title&quot;:&quot;Saripati tinjauan sistematik&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;nl&quot;,&quot;title&quot;:&quot;Samenvatting in eenvoudige taal&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ro&quot;,&quot;title&quot;:&quot;Sumar&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008550.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008550.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008550.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008550.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5718 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008550.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008550.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008550.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008550.pub3/full#CD008550-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008550.pub3/full#CD008550-sec-0229"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008550.pub3/full#CD008550-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008550.pub3/full#CD008550-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008550.pub3/full#CD008550-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008550.pub3/full#CD008550-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008550.pub3/full#CD008550-sec-0058"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008550.pub3/full#CD008550-sec-0180"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008550.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008550.pub3/appendices#CD008550-sec-0234"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008550.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008550.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008550.pub3/media/CDSR/CD008550/supinfo/CD008550-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008550.pub3/media/CDSR/CD008550/supinfo/CD008550-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008550.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008550.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008550.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008550.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008550.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008550.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Pharmacological treatment of gastro‐oesophageal reflux in children</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008550.pub3/information#CD008550-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Mark P Tighe</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008550.pub3/information#CD008550-cr-0005">Edward Andrews</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008550.pub3/information#CD008550-cr-0006">Iona Liddicoat</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008550.pub3/information#CD008550-cr-0007">Nadeem A Afzal</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008550.pub3/information#CD008550-cr-0008">Andrew Hayen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008550.pub3/information#CD008550-cr-0009">R Mark Beattie</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/information/en#CD008550-sec-0242">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 22 August 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008550.pub3">https://doi.org/10.1002/14651858.CD008550.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008550-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008550-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008550-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008550-abs-0015">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008550-abs-0005">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD008550-abs-0012">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008550-abs-0009">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008550-abs-0001" lang="en"> <section id="CD008550-sec-0001"> <h3 class="title" id="CD008550-sec-0001">Background</h3> <p>Gastro‐oesophageal reflux (GOR) is characterised by the regurgitation of gastric contents into the oesophagus. GOR is a common presentation in infancy, both in primary and secondary care, affecting approximately 50% of infants under three months old. The natural history of GOR in infancy is generally of a self‐limiting condition that improves with age, but older children and children with co‐existing medical conditions can have more protracted symptoms. The distinction between gastro‐oesophageal reflux disease (GORD) and GOR is debated. Current National Institute of Health and Care Excellence (NICE) guidelines define GORD as GOR causing symptoms severe enough to merit treatment. This is an update of a review first published in 2014. </p> </section> <section id="CD008550-sec-0002"> <h3 class="title" id="CD008550-sec-0002">Objectives</h3> <p>To assess the effects of pharmacological treatments for GOR in infants and children.</p> </section> <section id="CD008550-sec-0003"> <h3 class="title" id="CD008550-sec-0003">Search methods</h3> <p>For this update, we searched CENTRAL, MEDLINE, Embase, and Web of Science up to 17 September 2022. We also searched for ongoing trials in clinical trials registries, contacted experts in the field, and searched the reference lists of trials and reviews for any additional trials. </p> </section> <section id="CD008550-sec-0004"> <h3 class="title" id="CD008550-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) that compared any currently‐available pharmacological treatment for GOR in children with placebo or another medication. We excluded studies assessing dietary management of GORD and studies of thickened feeds. We included studies in infants and children up to 16 years old. </p> </section> <section id="CD008550-sec-0005"> <h3 class="title" id="CD008550-sec-0005">Data collection and analysis</h3> <p>We used standard methodology expected by Cochrane.</p> </section> <section id="CD008550-sec-0006"> <h3 class="title" id="CD008550-sec-0006">Main results</h3> <p>We included 36 RCTs involving 2251 children and infants. We were able to extract summary data from 14 RCTs; the remaining trials had insufficient data for extraction. We were unable to pool results in a meta‐analysis due to methodological differences in the included studies (including heterogeneous outcomes, study populations, and study design). </p> <p>We present the results in two groups by age: infants up to 12 months old, and children aged 12 months to 16 years old. </p> <p><b>Infants</b> </p> <p>Omeprazole versus placebo: there is no clear effect on symptoms from omeprazole. One study (30 infants; very low‐certainty evidence) showed cry/fuss time in infants aged three to 12 months had altered from 246 ± 105 minutes/day at baseline (mean +/‐ standard deviation (SD)) to 191 ± 120 minutes/day in the omeprazole group and from 287 ± 132 minutes/day to 201 ± 100 minutes/day in the placebo group (mean difference (MD) 10 minutes/day lower (95% confidence interval (CI) ‐89.1 to 69.1)). The reflux index changed in the omeprazole group from 9.9 ± 5.8% in 24 hours to 1.0 ± 1.3% and in the placebo group from 7.2 ± 6.0% to 5.3 ± 4.9% in 24 hours (MD 7% lower, 95% CI ‐4.7 to ‐9.3). </p> <p>Omeprazole versus ranitidine: one study (76 infants; very low‐certainty evidence) showed omeprazole may or may not provide symptomatic benefit equivalent to ranitidine. Symptom scores in the omeprazole group changed from 51.9 ± 5.4 to 2.4 ± 1.2, and in the ranitidine group from 47 ± 5.6 to 2.5 ± 0.6 after two weeks: MD ‐4.97 (95% CI ‐7.33 to ‐2.61). </p> <p>Esomeprazole versus placebo: esomeprazole appeared to show no additional reduction in the number of GORD symptoms compared to placebo (1 study, 52 neonates; very low‐certainty evidence): both the esomeprazole group (184.7 ± 78.5 to 156.7 ± 75.1) and placebo group (183.1 ± 77.5 to 158.3 ± 75.9) improved: MD ‐3.2 (95% CI ‐4.6 to ‐1.8). </p> <p><b>Children</b> </p> <p>Proton pump inhibitors (PPIs) at different doses may provide little to no symptomatic and endoscopic benefit. </p> <p>Rabeprazole given at different doses (0.5 mg/kg and 1 mg/kg) may provide similar symptom improvement (127 children in total; very low‐certainty evidence). In the lower‐dose group (0.5 mg/kg), symptom scores improved in both a low‐weight group of children (&lt; 15 kg) (mean ‐10.6 ± SD 11.13) and a high‐weight group of children (&gt; 15 kg) (mean ‐13.6 ± 13.1). In the higher‐dose groups (1 mg/kg), scores improved in the low‐weight (‐9 ± 11.2) and higher‐weight groups (‐8.3 ± 9.2). For the higher‐weight group, symptom score mean difference between the two different dosing regimens was 2.3 (95% CI ‐2 to 6.6), and for the lower‐weight group, symptom score MD was 4.6 (95% CI ‐2.9 to 12). </p> <p>Pantoprazole: pantoprazole may or may not improve symptom scores at 0.3 mg/kg, 0.6 mg/kg, and 1.2 mg/kg pantoprazole in children aged one to five years by week eight, with no difference between 0.3 mg/kg and 1.2 mg/kg dosing (0.3 mg/kg mean −2.4 ± 1.7; 1.2 mg/kg −1.7 ± 1.2: MD 0.7 (95% CI ‐0.4 to 1.8)) (one study, 60 children; very low‐certainty evidence). </p> <p>There were insufficient summary data to assess other medications.</p> </section> <section id="CD008550-sec-0007"> <h3 class="title" id="CD008550-sec-0007">Authors' conclusions</h3> <p>There is very low‐certainty evidence about symptom improvements and changes in pH indices for infants. There are no summary data for endoscopic changes. Medications may or may not provide a benefit (based on very low‐certainty evidence) for infants whose symptoms remain bothersome, despite nonmedical interventions or parental reassurance. If a medication is required, there is no clear evidence based on summary data for omeprazole, esomeprazole (in neonates), H₂antagonists, and alginates for symptom improvements (very low‐certainty evidence). Further studies with longer follow‐up are needed. </p> <p>In older children with GORD, in studies with summary data extracted, there is very low‐certainty evidence that PPIs (rabeprazole and pantoprazole) may or may not improve GORD outcomes. No robust data exist for other medications. </p> <p>Further RCT evidence is required in all areas, including subgroups (preterm babies and children with neurodisabilities). </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008550-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008550-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008550-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008550-abs-0016">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008550-abs-0006">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD008550-abs-0004">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/id#CD008550-abs-0017">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="full/ja#CD008550-abs-0014">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD008550-abs-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/nl#CD008550-abs-0020">Nederlands</a> </li> <li class="section-language"> <a class="" href="full/pl#CD008550-abs-0018">Polski</a> </li> <li class="section-language"> <a class="" href="full/ro#CD008550-abs-0019">Română</a> </li> <li class="section-language"> <a class="" href="full/th#CD008550-abs-0013">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008550-abs-0010">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD008550-abs-0011">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008550-abs-0002" lang="en"> <h3>Medicines for children with reflux</h3> <p><b>Review question</b> </p> <p>What is the best and safest treatment for babies and children with gastro‐oesophageal reflux? </p> <p><b>Key messages:</b> </p> <p>‐ the evidence for medications for babies with gastro‐oesophageal reflux/reflux disease is very uncertain; </p> <p>‐ for children with gastro‐oesophageal reflux disease, the evidence is very uncertain regarding the effects of proton pump inhibitors. There was no adequate evidence to draw conclusions regarding other medications. </p> <p><b>What is gastro‐oesophageal reflux?</b> </p> <p>Gastro‐oesophageal reflux happens when stomach contents come back up into the oesophagus (food pipe). Most babies (under 1 year) grow out of reflux symptoms, but does medicine help? Children (older than 1 year) can have reflux just like adults. Reflux can be normal ('physiological reflux'), but in babies and children, it can cause symptoms, including pain or weight loss, as the oesophagus becomes inflamed (oesophagitis). Bothersome symptoms of reflux are called 'gastro‐oesophageal reflux disease' (GORD). </p> <p><b>How is gastro‐oesophageal reflux treated?</b> </p> <p>Medicines can thicken the stomach contents (alginates), neutralise stomach acid (ranitidine, omeprazole, lansoprazole), or help the stomach to empty faster (domperidone, erythromycin). </p> <p><b>What did we want to find out?</b> </p> <p>We wanted to learn the best way to reduce reflux in babies and children. We wanted to see if medicines help infants and children to feel better (symptom scores), heal the oesophagus (which is checked by using endoscopy, where a tiny camera is put down the oesophagus), or lower the time the oesophagus is exposed to stomach acid. We also investigated whether the medicines were safe by considering the harmful or unwanted effects reported in the studies. </p> <p><b>What did we do?</b> </p> <p>We searched for studies testing gastro‐oesophageal reflux medicines in babies and children. We included all studies comparing these medicines, or comparing them to an inactive medicine (placebo). We assessed results which are important to doctors, nurses, and parents, and performed our own analysis of the results. We rated our confidence in the evidence, based on factors such as study methods and sizes. </p> <p><b>What did we find?</b> </p> <p>We found 36 suitable studies (involving 2251 babies and children), conducted worldwide, with most in the USA. The largest study recruited 268 babies, the smallest, 16 children. Fifteen studies compared an active medicine to placebo; 8 compared one active medication to another; and 11 studies gave the same medication at different doses. We found useable outcome information in 14 of the 36 studies. The remaining studies either did not report outcomes we were interested in or did not report them in a way we could analyse. We could not combine the results of any studies because they were too different (in terms of how long they followed participants up and the outcomes they investigated) to use in a meaningful way. </p> <p><b>Key results</b> </p> <p><b>Babies.</b> There is no clear effect on symptoms or measured acidity (one measure is reflux index, which is the percentage of time in 24 hours the oesophagus is exposed to stomach acid) between babies given omeprazole or placebo. One study (30 babies) showed cry/fuss time went down from 287 to 201 minutes/day in the placebo group and 246 to 191 minutes/day in the omeprazole group. Reflux index changed in the omeprazole group from 9.9% to 1.0% in 24 hours, and in the placebo group from 7.2% to 5.3%. One study (76 babies) showed that omeprazole and ranitidine may have a similar benefit for symptoms after 2 weeks: symptom scores (higher scores mean worse symptoms) in the omeprazole group dropped from 51.9 to 2.4, and in the ranitidine group, from 47 to 2.5. In one study of 52 newborn babies, esomeprazole appeared to show no reduction in the number of symptoms (184.7 to 156.7) compared to placebo (183.1 to 158.3). None of the studies reported harmful events or results about changes to babies' oesophaguses. </p> <p><b>Children.</b> In children older than 1 year of age, no studies assessed medical treatment versus placebo. Proton pump inhibitors (PPIs), which block stomach acid production, at different doses may provide little to no improvements in symptoms or oesophagus healing. In one study (127 children), both lower‐weight and higher‐weight children given rabeprazole at lower and higher doses had both minimal – probably unimportant – changes in symptom scores and endoscopic scores (which indicate whether healing of the oesophagus has occurred). Pantoprazole may or may not improve symptom scores in children aged 1 to 5 years by week 8: there was no difference between lower and higher dosing in one study (60 children). Studies investigating other medications did not report enough information for us to assess their results properly. </p> <p><b>Quality of the evidence</b> </p> <p>We are not confident in the evidence, which was mainly based on single studies with few babies and children. Several studies had pharmaceutical company help with manuscript writing. The question of how best to treat children with disabilities, and whether any PPIs are better than other medicines remain. The evidence is current to 17 September 2022. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008550-sec-0229" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008550-sec-0229"></div> <h3 class="title" id="CD008550-sec-0230">Implications for practice</h3> <section id="CD008550-sec-0230"> <p>Based on studies with summary data, there was no evidence to draw conclusions about the efficacy of medications (proton pump inhibitors (PPIs), H₂ antagonists, alginates, and prokinetics) compared to placebo for infants with gastro‐oesophageal reflux (GOR). </p> <p>For infants with gastro‐oesophageal reflux disease (GORD), there was very low‐certainty evidence that PPIs (omeprazole and esomeprazole) were effective in improving symptoms, and very low‐certainty evidence of absence of symptomatic benefit from PPIs in preterm infants. There were no studies with summary data for prokinetics (such as domperidone), which remain of use only in specialist situations. There were no studies with summary data for alginates. As quince syrup is not clinically available, we did not evaluate the certainty of evidence for this treatment. </p> <p>In older children with GORD, there was very low‐certainty evidence that PPIs (pantoprazole and rabeprazole) may or may not help GORD outcomes, including symptoms and endoscopic/histological metrics. There were no data on pH indices. There was no clear evidence of a possible risk of increased adverse events based on very low‐certainty evidence with rabeprazole. There were no studies assessing the use of PPIs in physiological reflux. There was insufficient evidence based on summary data to assess the benefit from H₂ antagonists in providing symptomatic relief. There was no evidence for prokinetics (such as domperidone or erythromycin). As quince syrup is not clinically available, we did not evaluate the certainty of evidence for this treatment. Understanding the applicability to children with GOR of the single low‐quality study of baclofen is difficult. It should be noted that the current main clinical use of baclofen is in children with neurodisability receiving baclofen for hypertonia. We identified no studies in children with neurodisability (please see <a href="#CD008550-sec-0231">Implications for research</a>). </p> </section> <h3 class="title" id="CD008550-sec-0231">Implications for research</h3> <section id="CD008550-sec-0231"> <p>The burden on primary and secondary care of physiological reflux and GORD is large, and further research is essential to clarify the role of medications in treating GORD. Despite the Pediatric Written Request made by the Food and Drug Administration (FDA) in the USA to improve our knowledge of a class of medications (PPIs) that are widely prescribed, the summary data available remain scarce. Further studies are needed to confirm whether PPIs or H₂ antagonists are superior, and whether individual drugs offer superior efficacy. Our review confirms that the quality and certainty of the evidence would benefit from further studies, especially assessing common medications used to treat GOR (e.g. H₂ antagonists, sodium+magnesium alginate). We would also call for comparisons that include a placebo or a different drug arm, in addition to the current comparisons between same‐drug different‐dosing. It was also evident that some studies gave participants confounding interventions (e.g. thickened or hydrolysed feeds to infants) that may provide improvements as interventions in their own right. Agreeing on consistent outcome measures and normative values for pH‐impedance monitoring and endoscopy would help research progress in the field. Further studies with longer follow‐up periods are needed. Further studies of prokinetics, including quince syrup, are recommended. </p> <p>We would also highlight the need for randomised controlled trials (RCTs) specifically in children with underlying oesophageal dysmotility (e.g. children with cerebral palsy), who often have difficult and protracted reflux. Most of the trials included in this review excluded this subgroup. These children are often on maximal medical therapies, including prokinetics, for prolonged time periods. Treatment regimens for this group are often extrapolated from other groups of children. Premature babies are often also treated empirically for gastro‐oesophageal reflux; for example, as part of managing apnoea. Further RCTs in this age group are also recommended, using consistent outcomes. </p> <p>Separating industry funding for trials from involvement in manuscript preparation would improve the strength of evidence according to GRADE criteria, when considering future trial design. </p> <p>Evidence of medication efficacy in low‐income countries and over a longer time period would also be useful to consider. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD008550-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD008550-sec-0008"></div> <div class="table" id="CD008550-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Omeprazole compared to placebo for GORD in infants</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Omeprazole compared to placebo for GORD in infants</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> infants with GORD<br/><b>Setting:</b> outpatients<br/><b>Intervention:</b> omeprazole<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with omeprazole</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in symptoms in infants<br/>assessed with: cry/fuss diary (minutes/day)<br/>Follow‐up: mean 2 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean improvement in symptoms in infants was <b>‐66</b> minutes/day </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>10 minutes/day lower</b><br/>(89.1 lower to 69.1 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cry/fuss time in infants between 3 and 12 months of age (mean 5.4 months) improved from 246 ± 105 minutes/day at baseline (mean +/‐ SD) to 191 ± 120 minutes/day in the omeprazole group and from 287 ± 132 minutes/day to 201 ± 100 minutes/day in the placebo group (mean difference (MD) 10 minutes/day lower (95% confidence interval (CI) ‐89.1 to 69.1)) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There were no reports of adverse events in either the omeprazole or placebo group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in pH metrics in infants<br/>assessed with: reflux index<br/>Follow‐up: mean 2 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean improvement in pH metrics in infants was <b>1.9</b> % of time in 24 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>7% of time in 24 hours lower</b><br/>(4.66 lower to 9.34 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In the omeprazole group, the reflux index improved from 9.9 ± 5.8% in 24 hours to 1.0 ± 1.3% in 24 hours. In the placebo group, the reflux index improved from 7.2 ± 6.0% in 24 hours to 5.3 ± 4.9% in 24 hours. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endoscopic metrics ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no data to assess this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_429021146969853213" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_429021146969853213</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Risk of bias: outcomes were assessed with behaviour diary (potential for recall bias) and visual analogue score (potential for parental observer bias). There were concerns that some of these infants may not have had significant endoscopic or reflux index changes at inclusion. North American Society of Paediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) guidance in place at the time considered reflux index &gt; 10% to be pathological in infants, and no evidence of reflux oesophagitis was seen (erosions or ulcers) at entry endoscopy. The inclusion criteria considered loss of vascular pattern or friability enough for inclusion. Only seven infants had both endoscopic changes and reflux index &gt; 5%. With these concerns, we have downgraded the evidence by one step. <br/><sup>b</sup>Imprecision: for Moore 2003, there was a wide confidence interval crossing the clinical decision threshold and only 15 infants in each group so we have downgraded the evidence by two steps.<br/><sup>c</sup>Risk of bias: there were concerns that some of these infants may not have had significant endoscopic or reflux index changes at inclusion. NASPGHAN guidance in place at the time considered reflux index &gt; 10% to be pathological in infants, and no evidence of reflux oesophagitis was seen (erosions or ulcers) at entry endoscopy. The inclusion criteria considered loss of vascular pattern or friability enough for inclusion. Only seven infants had both endoscopic changes and reflux index. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008550-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Omeprazole compared to ranitidine for GORD in infants</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Omeprazole compared to ranitidine for GORD in infants</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> GORD in infants<br/><b>Setting:</b> outpatients<br/><b>Intervention:</b> omeprazole<br/><b>Comparison:</b> ranitidine </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with ranitidine</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with omeprazole</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in symptoms in infants<br/>assessed with: weekly gastro‐oesophageal reflux score (WGSS)<br/>Follow‐up: mean 2 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean improvement in symptoms in infants was <b>‐44.5</b> points </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>4.97 points lower</b><br/>(2.47 lower to 7.33 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Omeprazole (0.5 mg/kg/day) appears to provide some symptomatic benefit in infants between 2 and 12 months old, with improved scores after 2 weeks (51.93 ± 5.42 to 2.43 ± 1.15) equivalent to ranitidine (2 to 4 mg/kg/day) with scores improving (47 ± 5.6 to 2.47 ± 0.58): no differences between omeprazole and ranitidine were noted: MD ‐4.97 (95% CI ‐2.47 to ‐7.33). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events in infants ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data were available for this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in pH metrics in infants ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data were available for this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in endoscopic findings in infants ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data were available for this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_429020868699799221" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_429020868699799221</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Risk of bias: the certainty of evidence was downgraded by two steps due to issues with blinding (performance bias) as omeprazole was delivered as a capsule and ranitidine as a syrup so parents would be aware which medication was being offered. In addition, 16 infants were lost to follow‐up (attrition bias), severe pneumonia, premature discontinued drugs, and parental issues with the questionnaire<br/><sup>b</sup>Imprecision: as the confidence intervals do not overlap the clinical decision threshold between recommending and not recommending treatment, and the study had very small numbers, we downgraded the certainty of evidence by two steps (very serious), but the certainty of evidence was already very low. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008550-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Esomeprazole compared to placebo for GORD in infants</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Esomeprazole compared to placebo for GORD in infants</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> GORD in infants<br/><b>Setting:</b> inpatients in 3 neonatal intensive care units<br/><b>Intervention:</b> esomeprazole<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with esomeprazole</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in symptoms and signs in infants<br/>assessed with: total number of gastro‐oesophageal reflux disease (GORD) symptoms <br/>Follow‐up: mean 2 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean improvement in symptoms and signs in infants was <b>‐24.5</b> episodes </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>3.2 episodes fewer</b><br/>(4.6 fewer to 1.8 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Included data from premature babies to 1 m corrected gestational age. No data in older infants. For total number of GORD symptoms (from video monitoring) and GORD‐related signs (from cardiorespiratory monitoring), the esomeprazole group improved from baseline 184.7 (78.5) to 156.7 (75.1) and placebo group improved from 183.1 (77.5) to 158.3 (75.9). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>It was not possible to extract summary data, although there were no reported differences between the placebo and esomeprazole groups. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>pH indices ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data were available for this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endoscopic metrics ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data were available for this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_429020489057615413" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_429020489057615413</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Risk of bias: the certainty of evidence was downgraded by one step as the study was terminated early due to poor recruitment (the power calculation estimated needing 38 neonates in each group).<br/><sup>b</sup>Indirectness: the certainty of evidence was downgraded by one step as the population studied (neonates) is only a part of the population under assessment (infants).<br/><sup>c</sup>Imprecision: the certainty of evidence was downgraded by two steps due to small numbers and wide confidence intervals crossing the clinical decision threshold.<br/><sup>d</sup>Publication bias: this single study was industry‐funded, with support for manuscript‐writing, but the certainty of evidence was not downgraded by one step, as already at 'very low' </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008550-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Rabeprazole at higher doses (1 mg/kg) compared to rabeprazole at lower doses (0.5 mg/kg) for GORD in children over 1 year of age</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Rabeprazole at higher doses (1 mg/kg) compared to rabeprazole at lower doses (0.5 mg/kg) for GORD in children over 1 year of age</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> GORD in children over 1 year of age<br/><b>Setting:</b> outpatients<br/><b>Intervention:</b> rabeprazole at higher doses (1 mg/kg)<br/><b>Comparison:</b> rabeprazole at lower doses (0.5 mg/kg) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with rabeprazole at lower doses (0.5 mg/kg)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with rabeprazole at higher doses (1 mg/kg)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in symptoms<br/>assessed with: 'Total GORD Symptoms and Severity' score<br/>Follow‐up: mean 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean improvement in symptoms was <b>‐9.9</b> points </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>2.3 points higher</b><br/>(2 lower to 6.6 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rabeprazole at 0.5 mg/kg and 1 mg/kg may provide similar symptom improvement: in the 0.5 mg/kg group, symptom score improved in both the low‐weight (&lt; 15 kg) (n = 21 mean ‐10.6 ± SD 11.13)) and high‐weight (&gt; 15 kg) groups (n = 44 mean ‐13.6 ± 13.1). In the 1 mg/kg group, scores improved in the low‐weight (n = 19, ‐9 ± 11.2)) and higher‐weight groups (n = 43, ‐8.3 ± 9.2). For the higher‐weight group, MD 2.3 (95% CI ‐2 to 6.6), and low‐weight group: 0.5 mg/kg vs 1 mg/kg: MD 4.6 (95% CI ‐2.9 to 12). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events<br/>assessed with: parent‐reported events </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Rabeprazole at 0.5 mg/kg and 1 mg/kg may lead to some adverse events: 95 (84%) children had adverse events, including abdominal pain, nausea, vomiting, bronchopneumonia, gastroenteritis, cough, and choking. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no difference between the groups.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in endoscopic appearances<br/>assessed with: Hetzel‐Dent score<br/>Follow‐up: mean 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean improvement in endoscopic appearances was <b>‐1.4</b> points </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>0.1 points higher</b><br/>(0.23 lower to 0.43 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In the 0.5 mg/kg group, endoscopic appearances improved in both the low‐weight (‐1.4 ± 1.06) and higher‐weight groups (‐1.2 ± 0.75). In the 1 mg/kg group, endoscopic appearances also improved in the low‐weight (‐1.1 ± 0.72) and high‐weight groups (‐1.0 ± 0.85). In the low‐weight group: 0.5 mg/kg vs 1 mg/kg: MD 0.30 (95% CI ‐0.27 to 0.87) and in the higher‐weight group MD 0.1 (95% CI ‐0.23 to 0.43). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>pH indices ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data were available for this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_429021824944230742" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_429021824944230742</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Risk of bias: the certainty of evidence was downgraded by one step for selection bias: 30% of children had already received proton pump inhibitors, 15% H2 antagonists, and 2% prokinetics. 15% of participants had also withdrawn.<br/><sup>b</sup>Imprecision: the certainty of evidence was downgraded by one step as the wide confidence intervals crossed the clinical decision threshold.<br/><sup>c</sup>Publication bias: the certainty of evidence was downgraded by one step as this was a single study and was industry‐funded, with assistance in manuscript preparation, and authors were employed by a pharmaceutical company. The study design involved the same medication at different doses which is less clinically useful than comparison to placebo or an alternative medication. We do not have other studies to assess whether this would have had a material impact. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008550-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Pantoprazole in higher doses (1.2 mg/kg) compared to pantoprazole at lower doses (0.3 mg/kg) for GORD in children over 1 year of age</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Pantoprazole in higher doses (1.2 mg/kg) compared to pantoprazole at lower doses (0.3 mg/kg) for GORD in children over 1 year of age</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> GORD in children over 1 year of age<br/><b>Setting:</b> outpatients<br/><b>Intervention:</b> pantoprazole in higher doses (1.2 mg/kg)<br/><b>Comparison:</b> pantoprazole at lower doses (0.3 mg/kg) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with pantoprazole at lower doses (0.3 mg/kg)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Pantoprazole in higher doses (1.2 mg/kg)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in symptoms<br/>assessed with: weekly gastro‐oesophageal reflux score (WGSS)<br/>Follow‐up: mean 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean improvement in symptoms was <b>‐2.37</b> points </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>0.7 points higher</b><br/>(0.4 lower to 1.8 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pantoprazole appears to improve symptoms at 0.3 mg/kg, 0.6 mg/kg, and 1.2 mg/kg pantoprazole in 60 children aged 1 to 5 years. Symptom scores improved from baseline to week 8 (0.3 mg/kg MD ‐2.4, 95% CI ‐3.2 to ‐1.5; 1.2 mg/kg ‐1.7, 95% CI ‐2.9 to ‐0.39). There was no difference between 0.3 mg/kg and 1.2 mg/kg dosing: MD 0.7 (95% CI ‐0.4 to 1.8). Individual symptoms (abdominal pain, burping, heartburn, pain after eating and difficulty swallowing) improved in all groups after 8 weeks. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events<br/>assessed with: individual symptom reporting<br/>Follow‐up: 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Pantoprazole at all doses investigated may lead to adverse events: in the 0.3 mg/kg group, 1 child developed diarrhoea and nappy rash; in the 0.6 mg/kg group, 1 child had sleep disturbance and 1 developed abdominal pain; and in the 1.2 mg/kg group, 1 child had rectal bleeding. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no difference between the groups.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in pH indices ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data were available for this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in endoscopic metrics ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data were available for this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_429032441167302611" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_429032441167302611</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Risk of bias: we downgraded the certainty of evidence by one step as no comment was made about blinding and randomisation technique.<br/><sup>b</sup>Imprecision: we downgraded the certainty of evidence due to the small sample size, which would not meet the optimal information size, and confidence intervals that cross the decision‐making threshold. We would have downgraded by two steps but the certainty of evidence was already 'very low'.<br/><sup>c</sup>Publication bias: we downgraded the certainty of evidence by one step as this study was industry‐funded with support with manuscript writing. The study design involved the same medication at different doses which is less clinically useful than comparison to placebo or an alternative medication. It is difficult to estimate the degree of effect given other studies were not available to compare. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008550-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD008550-sec-0009"></div> <section id="CD008550-sec-0010"> <h3 class="title" id="CD008550-sec-0010">Description of the condition</h3> <p>Gastro‐oesophageal reflux (GOR) occurs when gastric contents come back up into the oesophagus (<a href="./references#CD008550-bbs2-0111" title="RosenR , VandenplasY , SingendonkM , CabanaM , DiLorenzoC , GottrandF , et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. Journal of Pediatric Gastroenterology and Nutrition2018;66(3):516-54. [DOI: 10.1097/MPG.0b013e3181b7f563]">NASPGHAN‐ESPGHAN guidelines 2018</a>). GOR is a very common presentation, both in primary and secondary care settings. Symptoms of GOR can affect approximately 50% of infants aged one to three months old (<a href="./references#CD008550-bbs2-0110" title="MiyazawaR , TomomasaT , KanekoH , TachibanaA , OgawaT , MorikawaA . Prevalence of gastro-esophageal reflux-related symptoms in Japanese infants. Pediatrics International2002;44(5):513-6.">Miyazawa 2002</a>; <a href="./references#CD008550-bbs2-0112" title="NelsonSP , ChenEH , SyniarGM , ChristoffelK . Prevalence of symptoms of gastro-oesophageal reflux during infancy: a paediatric practice-based survey. Archives of Pediatrics and Adolescent Medicine1997;151:569-72.">Nelson 1997</a>). The natural history of GOR is generally of improvement with age, with less than 5% to 10% of children with vomiting or regurgitation in infancy continuing to have symptoms after the age of 12 to 14 months (<a href="./references#CD008550-bbs2-0082" title="CampanozziA , BocciaG , PensabeneL , PanettaF , MarsegliaA , StrisciuglioP , et al. Prevalence and natural history of gastroesophageal reflux: pediatric prospective survey. Pediatrics2009;123(3):779-83.">Campanozzi 2009</a>; <a href="./references#CD008550-bbs2-0106" title="MartinAJ , PrattN , KennedyJD , RyanP , RuffinRE , MilesH , et al. Natural history and familial relationships of infant spilling to 9 years of age. Pediatrics2002;109(6):1061-7.">Martin 2002</a>). This is due to a combination of growth in length of the oesophagus, a more upright posture, increased tone of the lower oesophageal sphincter, and a more solid diet. </p> <p>Gastro‐oesophageal reflux disease (GORD) is defined as "GOR associated with bothersome symptoms or complications" (<a href="./references#CD008550-bbs2-0111" title="RosenR , VandenplasY , SingendonkM , CabanaM , DiLorenzoC , GottrandF , et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. Journal of Pediatric Gastroenterology and Nutrition2018;66(3):516-54. [DOI: 10.1097/MPG.0b013e3181b7f563]">NASPGHAN‐ESPGHAN guidelines 2018</a>; <a href="./references#CD008550-bbs2-0121" title="ShermanPM , HassallE , Fagundes-NetoU , GoldBD , KatoS , KoletzkoS , et al. A global, evidence-based consensus on the definition of gastroesophageal reflux disease in the pediatric population. American Journal of Gastroenterology2009;104(5):1278-95.">Sherman 2009</a>). Sherman and colleagues caution that this definition is complicated by unreliable reporting of symptoms in children under eight years of age (<a href="./references#CD008550-bbs2-0121" title="ShermanPM , HassallE , Fagundes-NetoU , GoldBD , KatoS , KoletzkoS , et al. A global, evidence-based consensus on the definition of gastroesophageal reflux disease in the pediatric population. American Journal of Gastroenterology2009;104(5):1278-95.">Sherman 2009</a>). Gastrointestinal sequelae include oesophagitis, haematemesis, oesophageal stricture formation, and Barrett's oesophagitis. Extraintestinal sequelae can include acute life‐threatening events, apnoea, chronic otitis media, sinusitis, secondary anaemia, and chronic respiratory disease (chronic wheezing/coughing or aspiration), as well as failure to thrive. The presence of severe oesophagitis has historically been shown to predict the need for surgical reconstruction (<a href="./references#CD008550-bbs2-0098" title="HyamsJS , Ricci A Jr, LeichtnerAM . Clinical and laboratory correlates of esophagitis. Journal of Pediatric Gastroenterology and Nutrition1988;7(1):52-6.">Hyams 1988</a>). </p> <p>GOR is distinguished from vomiting physiologically by the absence of (1) a central nervous system emetic reflex, (2) retrograde upper intestinal contractions, (3) nausea, and (4) retching. GOR is generally characterised as effortless and non‐projectile, although it may be forceful in infants (<a href="./references#CD008550-bbs2-0121" title="ShermanPM , HassallE , Fagundes-NetoU , GoldBD , KatoS , KoletzkoS , et al. A global, evidence-based consensus on the definition of gastroesophageal reflux disease in the pediatric population. American Journal of Gastroenterology2009;104(5):1278-95.">Sherman 2009</a>). Other conditions, such as rumination syndrome, are distinguished by the absence of nighttime symptoms, and features such as early satiety and bloating may point to functional dyspepsia (<a href="./references#CD008550-bbs2-0099" title="HyamsJS , Di LorenzoC , SapsM , ShulmanRJ , StaianoA , vanTilburgM . Childhood functional gastrointestinal disorders: child/adolescent. Gastroenterology2016;150:1456–68.">Hyams 2016</a>). </p> <p>Children with certain predisposing conditions are more prone to severe GORD. These conditions include neurological impairment (e.g. cerebral palsy), repaired oesophageal atresia or congenital diaphragmatic hernia, and chronic lung disease. </p> <p>Diagnosis of physiological or functional GOR (i.e. reflux symptoms that are likely to improve with gut maturation) in infants is usually made based on the symptoms alone, avoiding the need for expensive and possibly harmful investigations. Investigations to assess the severity of GORD, or in cases where GOR cannot be diagnosed on clinical grounds, include 24‐hour oesophageal pH monitoring, which can be combined with impedance monitoring, upper gastrointestinal endoscopy, scintigraphy, or oesophageal manometry. All have been shown to correlate poorly with symptomatology, and may not accurately predict the degree of improvement with treatment (<a href="./references#CD008550-bbs2-0079" title="AugoodC , MacLennonS , GilbertR , LoganS . Cisapride treatment for gastrooesophageal reflux in children. Cochrane Database of Systematic Reviews2003, Issue 3. Art. No: CD002300. [DOI: 10.1002/14651858.CD002300]">Augood 2003</a>; <a href="./references#CD008550-bbs2-0113" title="National Institute for Health and Care Excellence. Gastro-oesophageal reflux disease in children and young people: diagnosis and management (NG1); October 2019. www.nice.org.uk/guidance/ng1.">NICE 2019</a>). </p> <p>Clinical symptoms are commonly scored and reported individually. These symptoms include:</p> <p> <ul id="CD008550-list-0001"> <li> <p>number of vomiting episodes, back arching, regurgitation, failure to thrive, feeding difficulties, and abdominal pain in infants; </p> </li> <li> <p>heartburn, epigastric pain, and regurgitation symptoms in older children.</p> </li> </ul> </p> <p>Common scoring systems include the Paediatric Gastro‐oesophageal Symptom Questionnaire (PGSQ) for older children (<a href="./references#CD008550-bbs2-0102" title="KleinmanL , NelsonS , Kothari-TalwarS , RobertsL , OrensteinSR , ModyRR , et al. Development and psychometric evaluation of 2 age-stratified versions of the Pediatric GERD Symptom and Quality of Life Questionnaire. Journal of Pediatric Gastroenterology and Nutrition2011;52(5):514-22.">Kleinman 2011</a>), the GORD Assessment of Symptoms in Pediatrics Questionnaire (GASP‐Q) for younger children (<a href="./references#CD008550-bbs2-0090" title="FitzgeraldJF , VasundharaT , FragaP , PetersS , DonnellyC , MackM , et al. Age-specific questionaires distinguish symptom frequency and severity in young children with and without gastroesophageal reflux disease. In: Sixteenth Annual Meeting of NASPGHAN Poster, Montreal, Quebec. 2003.">Fitzgerald 2003</a>), and the Infant Gastro‐oesophageal Reflux Questionnaire Revised (I‐GERQ‐R) for infants (<a href="./references#CD008550-bbs2-0114" title="OrensteinSR . Symptoms and reflux in infants: Infant Gastroesophageal Reflux Questionnaire Revised (I-GERQ-R): utility for symptom tracking and diagnosis. Curr Gastroenterol Rep. 2010;12(6):431–6.">Orenstein 2010</a>). </p> <p>Normal gastric juices are acidic in nature, with a pH of approximately 1 to 3. The pH scale goes from 1 (strongly acidic) through 7 (neutral), to 14 (strongly alkaline). </p> <p>Investigations to assess disease severity include:</p> <p> <ul id="CD008550-list-0002"> <li> <p>pH‐impedance indices over 24 hours, including: reflux index on pH probe (percentage of time that oesophageal pH &lt; 4 in 24 hours); number of acid reflux/impedance episodes; and time length of reflux episodes where oesophageal pH is less than 4; </p> </li> <li> <p>endoscopic findings, including macroscopic appearance of oesophagus on endoscopy, and histological appearances. </p> </li> </ul> </p> <p>Consensus exists that there are insufficient data to recommend histology as a tool to diagnose or exclude GORD in children, but that histology is useful in confirming the presence of oesophagitis and ruling out other conditions, such as eosinophilic oesophagitis, Barrett's oesophagus, Crohn's disease, infection, and graft‐versus‐host disease (<a href="./references#CD008550-bbs2-0113" title="National Institute for Health and Care Excellence. Gastro-oesophageal reflux disease in children and young people: diagnosis and management (NG1); October 2019. www.nice.org.uk/guidance/ng1.">NICE 2019</a>). Histological scoring scales (e.g. the Hetzel‐Dent classification) are also commonly utilised to help assess improvement (<a href="./references#CD008550-bbs2-0111" title="RosenR , VandenplasY , SingendonkM , CabanaM , DiLorenzoC , GottrandF , et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. Journal of Pediatric Gastroenterology and Nutrition2018;66(3):516-54. [DOI: 10.1097/MPG.0b013e3181b7f563]">NASPGHAN‐ESPGHAN guidelines 2018</a>). </p> </section> <section id="CD008550-sec-0011"> <h3 class="title" id="CD008550-sec-0011">Description of the intervention</h3> <section id="CD008550-sec-0012"> <h4 class="title">Proton pump inhibitors (PPIs)</h4> <p>PPIs, such as omeprazole and lansoprazole, are a group of drugs that irreversibly inactivate H+/K+ ATPase, in the parietal cells of the stomach. There are five PPIs approved by the US Food and Drug Administration (FDA) in adults: omeprazole (since 1988), lansoprazole, pantoprazole, rabeprazole, and esomeprazole (the pure S‐isomer of omeprazole). The current National Institute for Health and Clinical Excellence (NICE) guidelines recommend only a two‐week trial of a PPI or a histamine receptor antagonist (H₂RA) for infants whose symptoms fail to improve with nonmedical interventions (<a href="./references#CD008550-bbs2-0113" title="National Institute for Health and Care Excellence. Gastro-oesophageal reflux disease in children and young people: diagnosis and management (NG1); October 2019. www.nice.org.uk/guidance/ng1.">NICE 2019</a>). Omeprazole is licensed for use in children over one year of age in the UK, with a half‐life of one hour, but due to the permanent receptor block, the effect can last for five to seven days. The dose range is 5 mg to 10 mg daily in infants, 10 mg to 20 mg daily in young children, and 20 mg to 40 mg daily in older children and adolescents. Lansoprazole is only recommended by the British National Formulary for children when treatment with the available formulations of omeprazole is unsuitable (<a href="./references#CD008550-bbs2-0081" title="British Medical Association, Royal Pharmaceutical Society of Great Britain, Royal College of Paediatrics and Child Health, Neonatal and Paediatric Pharmacists Group. British National Formulary for Children. London, UK: BMJ Group, Pharmaceutical Press, RCPCH Publications, 2021.">BNFc 2021</a>). It is used in doses of 7.5 mg to 15 mg in young children, and 15 mg to 30 mg in older children. The average elimination half‐life is 1.5 hours in infants and young children. The inhibition of acid secretion is about 50% of maximum at 24 hours and the duration of action is approximately 72 hours (<a href="./references#CD008550-bbs2-0124" title="WardRM , KearnsGL . Proton pump inhibitors in pediatrics: mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics. Paediatr Drugs 2013 Apr;15(2):119-31.">Ward 2013</a>). Esomeprazole is also licensed for GORD: for children aged one to 11 years with a body‐weight of 10 kg to 19 kg, 10 mg once daily; for children aged one to 11 years with a body‐weight of 20 kg and above, 10 mg to 20 mg once daily; for children aged 12 to 17 years, 20 mg to 40 mg once daily, and a maintenance dose of generally 20 mg daily. Pantoprazole and rabeprazole are not currently licensed for use in children. </p> <p>Gastric pH provides some protection against infection in children. Thus, there is evidence that potentiating the hypochlorhydria (low levels of stomach acid) in neonates further with PPIs can result in bacterial overgrowth (<a href="./references#CD008550-bbs2-0086" title="De BruyneP , ItoS . Toxicity of long-term use of proton pump inhibitors in children. Archives of Disease in Childhood2018;103(1):78-82.">De Bruyne 2018</a>). Increases in respiratory infections in critically‐ill inpatients have been identified, but in infants and children who are otherwise well, no clear ill effects have been demonstrated from this overgrowth. A Medicines and Healthcare products Regulatory Agency (MHRA) alert in 2012 highlighted that PPIs used for longer than three months may be associated with hypomagnesaemia (especially in those on therapy lasting for more than five years), and a possible increased risk of fractures (<a href="./references#CD008550-bbs2-0091" title="FleishmanN , RichardsonT , AttardT . The clinical characteristics of fractures in pediatric patients exposed to proton pump inhibitors. Journal of Pediatric Gastroenterology and Nutrition2020;70(6):815-9.">Fleishmann 2021</a>; <a href="./references#CD008550-bbs2-0108" title="Medicines Health Regulatory Authority. Proton pump inhibitors in long-term use: reports of hypomagnesaemia. Drug Safety Update2012;5(9):1.">MHRA 2012</a>). Since then, concerns have been raised about hypergastrinaemia (but the risk of cancer is not thought to be increased), <i>Clostridioides difficile</i> colitis, vitamin B12 deficiency (due to atrophic gastritis and hypochlorhydria, which produce bacterial overgrowth promoting increased digestion of cobalamin), and acute interstitial nephritis (a hypersensitivity reaction that can occur within days to 18 months of starting treatment and resolves on discontinuing the PPI) (<a href="./references#CD008550-bbs2-0081" title="British Medical Association, Royal Pharmaceutical Society of Great Britain, Royal College of Paediatrics and Child Health, Neonatal and Paediatric Pharmacists Group. British National Formulary for Children. London, UK: BMJ Group, Pharmaceutical Press, RCPCH Publications, 2021.">BNFc 2021</a>; <a href="./references#CD008550-bbs2-0113" title="National Institute for Health and Care Excellence. Gastro-oesophageal reflux disease in children and young people: diagnosis and management (NG1); October 2019. www.nice.org.uk/guidance/ng1.">NICE 2019</a>). There have been a handful of cases reported of PPI‐induced systemic cutaneous lupus erythematosus, and significant drug interactions (itraconazole, ketoconazole, isoniazid, oral iron supplements) (<a href="./references#CD008550-bbs2-0118" title="SchoenfeldAJ , GradyD . Adverse effects associated with proton pump inhibitors. JAMA Intern Med.2016;176(2):172-4.">Schoenfeld 2016</a>). PPIs are metabolised by the cytochrome P450 system in the liver and interactions include those medications that inhibit or enhance cytochrome P450 metabolism (listed in <a href="./references#CD008550-bbs2-0081" title="British Medical Association, Royal Pharmaceutical Society of Great Britain, Royal College of Paediatrics and Child Health, Neonatal and Paediatric Pharmacists Group. British National Formulary for Children. London, UK: BMJ Group, Pharmaceutical Press, RCPCH Publications, 2021.">BNFc 2021</a>). </p> </section> <section id="CD008550-sec-0013"> <h4 class="title">Histamine (H₂) receptor antagonists (H2RAs)</h4> <p>The most commonly used H2RA is ranitidine, which competitively blocks selective histamine receptors. Ranitidine is metabolised in the liver and renally excreted with a half‐life of two to four hours and length of action of 12 to 24 hours. Ranitidine is well‐tolerated and has a low incidence of side effects; these commonly include fatigue, dizziness, and diarrhoea (<a href="./references#CD008550-bbs2-0122" title="TigheMP , AfzalNA , BevanA , BeattieRM . Current pharmacological management of gastro-esophageal reflux in children. Pediatric Drugs2009;11(3):185-202.">Tighe 2009</a>). It also affects metabolism of other drugs by the cytochrome P450 system (<a href="./references#CD008550-bbs2-0081" title="British Medical Association, Royal Pharmaceutical Society of Great Britain, Royal College of Paediatrics and Child Health, Neonatal and Paediatric Pharmacists Group. British National Formulary for Children. London, UK: BMJ Group, Pharmaceutical Press, RCPCH Publications, 2021.">BNFc 2021</a>). Ranitidine has been withdrawn worldwide due to concerns regarding a low level of impurity of N‐nitrosodimethylamine (NDMA) (<a href="./references#CD008550-bbs2-0109" title="Medicines and Healthcare products Regulatory Agency. Ranitidine – MHRA drug alert issued for Teva UK recall, 2019. Available at: https://www.gov.uk/government/news/ ranitidine-mhra-drug-alert-issued-for-teva-uk-recall.">MHRA 2019</a>). Cimetidine is rarely used clinically because of concerns about its greater effects on the cytochrome P450, which cause multiple drug interactions, as well as its interference with vitamin D metabolism and endocrine function. Famotidine is a recently‐developed H₂ antagonist not commonly used in children but with similar pharmacodynamics to ranitidine. Tachyphylaxis from H₂ antagonists has been reported (<a href="./references#CD008550-bbs2-0107" title="McRorieJW , KirbyJA , MinerPB . Histamine2-receptor antagonists: rapid development of tachyphylaxis with repeat dosing. World Journal of Gastrointestinal Pharmacology and Therapeutics2014;5(2):57.">McRorie 2014</a>). </p> </section> <section id="CD008550-sec-0014"> <h4 class="title">Magnesium hydroxide and aluminium hydroxide (MHAH)</h4> <p>Magnesium hydroxide and aluminium hydroxide reduce gastric pH and are commercially available as Maalox. Aluminium should be avoided in chronic use, especially in infants and children with chronic renal failure, due to the risk of aluminium accumulation. </p> </section> <section id="CD008550-sec-0015"> <h4 class="title">Prokinetics</h4> <p>Domperidone is a dopamine‐receptor (D‐2) blocker that has relatively few side effects, but case reports of extrapyramidal side effects exist (<a href="./references#CD008550-bbs2-0092" title="FranckxJ , NoelP . Acute extrapyramidal dysfunction after domperidone administration: Report of a case. Helvetica Paediatrica Acta1984;39(3):285-8.">Franckx 1984</a>; <a href="./references#CD008550-bbs2-0120" title="ShafrirY , LevyY , Ben-AmitaiD , NitzanM , SteinherzR . Oculogyric crisis due to domperidone therapy. Helvetica Paediatrica Acta1985;40(1):95.">Shafrir 1985</a>), and there is concern about the risk of cardiac side effects (<a href="./references#CD008550-bbs2-0088" title="European Medicines Agency. PRAC recommends restricting use of domperidone; March 2014. www.ema.europa.eu/en/news/prac-recommends-restricting-use-domperidone\ Accessed prior to 20 May 2023. [EMA: EMA/129231/2014]">EMA 2014b</a>). Its use has declined except in specialist indications, since the publication of NICE guidance (<a href="./references#CD008550-bbs2-0113" title="National Institute for Health and Care Excellence. Gastro-oesophageal reflux disease in children and young people: diagnosis and management (NG1); October 2019. www.nice.org.uk/guidance/ng1.">NICE 2019</a>). Current advice is to not use it in children with co‐existing cardiac disease or in those taking CYP3A4 inhibitors, and not to exceed a daily dose of 30 mg/day in children over 12 years old and 250 micrograms/kg three times a day in younger children (<a href="./references#CD008550-bbs2-0088" title="European Medicines Agency. PRAC recommends restricting use of domperidone; March 2014. www.ema.europa.eu/en/news/prac-recommends-restricting-use-domperidone\ Accessed prior to 20 May 2023. [EMA: EMA/129231/2014]">EMA 2014b</a>). Domperidone is no longer marketed in the USA (<a href="./references#CD008550-bbs2-0080" title="BashashatiM , SarosiekI , SiddiquiT , McCallumR . Adverse effects of domperidone: prolonged quest for knowledge?Digestive Diseases and Sciences2016;61:3384-6.">Bashashati 2016</a>), but can be used as an investigational new drug and should not be used for nausea and vomiting for more than one week. </p> <p>Erythromycin is a macrolide antibiotic; its use as a prokinetic is as an unlicensed indication (<a href="./references#CD008550-bbs2-0081" title="British Medical Association, Royal Pharmaceutical Society of Great Britain, Royal College of Paediatrics and Child Health, Neonatal and Paediatric Pharmacists Group. British National Formulary for Children. London, UK: BMJ Group, Pharmaceutical Press, RCPCH Publications, 2021.">BNFc 2021</a>). </p> <p>Metoclopramide has been the subject of an FDA 'black box' warning (<a href="./references#CD008550-bbs2-0089" title="Food and Drug Administration (FDA). FDA requires boxed warning and risk mitigation strategy for metoclopramide-containing drugs [press release]. Food and Drug Administration; Rockville, MD2009.">FDA 2009</a>). In August 2013, the European Medicines Agency released a statement that the risk of neurological adverse events (such as short‐term extrapyramidal disorders and tardive dyskinesia) with metoclopramide outweighed the benefit, when taken for a prolonged period at a high dose (<a href="./references#CD008550-bbs2-0087" title="European Medicine Agency Committee on Medicinal Products for Human Use. European Medicines Agency recommends changes to the use of metoclopramide. www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/07/news_detail_001854.jsp&amp;mid=WC0b01ac058004d5c1 Accessed prior to 20 May 2023.">EMA 2014a</a>). Metoclopramide has also been assessed in a separate Cochrane Review (<a href="./references#CD008550-bbs2-0085" title="CraigWR , Hanlon-DearmanA , SinclairC , TabackS , MoffattM . Metoclopramide, thickened feedings, and positioning for gastro-oesophageal reflux in children under two years. Cochrane Database of Systematic Reviews2004, Issue 3. Art. No: CD003502. [DOI: 10.1002/14651858.CD003502.pub3]">Craig 2004</a>), so we did not review the associated literature for metoclopramide as it is not used to treat reflux in children, given the adverse event profile and NICE guidance (<a href="./references#CD008550-bbs2-0113" title="National Institute for Health and Care Excellence. Gastro-oesophageal reflux disease in children and young people: diagnosis and management (NG1); October 2019. www.nice.org.uk/guidance/ng1.">NICE 2019</a>). </p> <p>At its peak use, cisapride was prescribed to over 36 million children worldwide for GOR (<a href="./references#CD008550-bbs2-0123" title="VandenplasY . Diagnosis and treatment of gastroesophageal reflux disease in infants and children. World J Gastroenterol 1999 Oct;5(5):375-382.">Vandenplas 1999</a>). However, concerns about the effect of cisapride in prolonging the QT interval led to its removal from general paediatric use (<a href="./references#CD008550-bbs2-0083" title="Committee on Safety of Medicines and Medicines Control Agency. Cisapride (Propulsid) withdrawn. Curr Prob Pharmacovigil2000;26:9-14.">Com Safety Med 2000</a>). A Cochrane Review found that there was no clear evidence that cisapride reduces symptoms of GOR, and found evidence of substantial publication bias favouring studies showing a positive effect of cisapride (<a href="./references#CD008550-bbs2-0079" title="AugoodC , MacLennonS , GilbertR , LoganS . Cisapride treatment for gastrooesophageal reflux in children. Cochrane Database of Systematic Reviews2003, Issue 3. Art. No: CD002300. [DOI: 10.1002/14651858.CD002300]">Augood 2003</a>). Given the known risks of toxicity and its suspension of manufacture, further trials of cisapride are unlikely. </p> <p>Quince syrup (heated extract of <i>Cydonia oblonga</i> Mill.) belongs to the rose family (Rosacea) as a traditional Persian medicine to treat GORD (<a href="./references#CD008550-bbs2-0036" title="ZohalinezhadME , ImaniehMH , SamaniSM , MohagheghzadehA , DehghaniSM , HaghighatM , et al. Effects of quince syrup on clinical symptoms of children with symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Complementary Therapies in Clinical Practice2015;21(4):268-76. ZohalinezhadME , ZohalinezhadIS , SamaniA , MohagheghzadehF , DehghaniH . Efficacy of quince (Cydonia oblonga M) syrup in symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Planta Medica2016;82(1):1439. ">Zohalinezhad 2015</a>). It is unlicensed in the UK. </p> </section> <section id="CD008550-sec-0016"> <h4 class="title">Alginates</h4> <p>Compound alginate preparations differ from other alginate preparations, which can also contain sodium bicarbonate or potassium bicarbonate (<a href="./references#CD008550-bbs2-0081" title="British Medical Association, Royal Pharmaceutical Society of Great Britain, Royal College of Paediatrics and Child Health, Neonatal and Paediatric Pharmacists Group. British National Formulary for Children. London, UK: BMJ Group, Pharmaceutical Press, RCPCH Publications, 2021.">BNFc 2021</a>). </p> <p>Caution should be used with alginates that contain aluminium (see below), and in children with vomiting or diarrhoea, or children at risk of intestinal obstruction (<a href="./references#CD008550-bbs2-0093" title="Reckitt Benckiser Healthcare (UK) Limited. Gaviscon Product Information. Reckitt Benckiser Healthcare (UK) Limited, Dansom Lane, Hull.">Gaviscon Product Information 2021</a>). In children whose feeds are already thickened (e.g. Enfamil AR/SMA Staydown), coexistent Gaviscon Infant could potentially cause intestinal obstruction (<a href="./references#CD008550-bbs2-0101" title="KeadyS . Update on drugs for gastro-oesophageal reflux disease. Archives of Disease in Childhood2007;92:ep114-ep118.">Keady 2007</a>). Some alginate preparations contain sodium: for example, Gaviscon Infant contains 0.92 mmol Na<sup>+</sup>/dose, which should be considered if a child’s sodium intake needs to be monitored with caution (e.g. renal impairment, congestive cardiac failure, preterm infants, or children with diarrhoea and vomiting) (<a href="./references#CD008550-bbs2-0081" title="British Medical Association, Royal Pharmaceutical Society of Great Britain, Royal College of Paediatrics and Child Health, Neonatal and Paediatric Pharmacists Group. British National Formulary for Children. London, UK: BMJ Group, Pharmaceutical Press, RCPCH Publications, 2021.">BNFc 2021</a>). Gaviscon Infant has changed to become aluminium‐free, with different proportions of alginate, and other forms are now available (Gastrotuss and Refluxsan Nipio). Alginates for infants are generally prescribed at up to six doses per day with half a dual sachet in formula bottles of less than 210 mL and one dual sachet in formula bottles of more than 210 mL of milk. Breastfed babies have a dose mixed with expressed breast milk and given before or with a breastfeed by syringe. </p> <p>Two other Cochrane Reviews have assessed thickened feeds (<a href="./references#CD008550-bbs2-0085" title="CraigWR , Hanlon-DearmanA , SinclairC , TabackS , MoffattM . Metoclopramide, thickened feedings, and positioning for gastro-oesophageal reflux in children under two years. Cochrane Database of Systematic Reviews2004, Issue 3. Art. No: CD003502. [DOI: 10.1002/14651858.CD003502.pub3]">Craig 2004</a>; <a href="./references#CD008550-bbs2-0103" title="KwokTC , OjhaS , DorlingJ . Feed thickener for infants up to six months of age with gastro-oesophageal reflux. Cochrane Database of Systematic Reviews2017;12:CD003211.">Kwok 2017</a>). </p> </section> <section id="CD008550-sec-0017"> <h4 class="title">Antispasmodics</h4> <p>Baclofen is primarily an antispasmodic acting on gamma‐aminobutyric acid (GABA) receptors, commonly used in children with neurodisability, such as cerebral palsy (<a href="./references#CD008550-bbs2-0025" title="OmariTI , BenningaMA , SansomL , ButlerRN , DentJ , DavidsonGP . Effect of baclofen on esophagogastric motility and gastroesophageal reflux in children with gastroesophageal reflux disease: a randomized controlled trial. Journal of Pediatrics2006;149(4):468-74. ">Omari 2006</a>). It is not licensed for children with GORD (<a href="./references#CD008550-bbs2-0081" title="British Medical Association, Royal Pharmaceutical Society of Great Britain, Royal College of Paediatrics and Child Health, Neonatal and Paediatric Pharmacists Group. British National Formulary for Children. London, UK: BMJ Group, Pharmaceutical Press, RCPCH Publications, 2021.">BNFc 2021</a>). </p> </section> <section id="CD008550-sec-0018"> <h4 class="title">Conservative options</h4> <p>These include reassurance of parents, and positioning of the baby to reduce gastro‐oesophageal reflux, through the effect of gravity on gastric contents. This can include elevating the head of the cot or basket in which the baby is placed to sleep, or keeping the baby upright after a feed. </p> <p>Altering the feed's consistency can be achieved with feed thickeners (e.g. with rice starch/carob bean gum) and may reduce the reflux of gastric contents with increased viscosity. Some feeds are manufactured with a thickening agent added. Weaning also has a similar effect by increasing the viscosity of gastric contents, and gastro‐oesophageal reflux is known to improve with weaning. We have considered compound alginates in this review, but not other feed‐thickeners, which are assessed elsewhere (<a href="./references#CD008550-bbs2-0085" title="CraigWR , Hanlon-DearmanA , SinclairC , TabackS , MoffattM . Metoclopramide, thickened feedings, and positioning for gastro-oesophageal reflux in children under two years. Cochrane Database of Systematic Reviews2004, Issue 3. Art. No: CD003502. [DOI: 10.1002/14651858.CD003502.pub3]">Craig 2004</a>; <a href="./references#CD008550-bbs2-0103" title="KwokTC , OjhaS , DorlingJ . Feed thickener for infants up to six months of age with gastro-oesophageal reflux. Cochrane Database of Systematic Reviews2017;12:CD003211.">Kwok 2017</a>). </p> <p>Changes in feeding can also improve GOR. For breastfed babies, a breastfeeding assessment by health professionals experienced in breastfeeding is recommended initially, then elimination of cow's milk from the maternal diet can be trialled. For formula‐fed infants, after assessing for and correcting overfeeding, clinicians can consider recommendations supporting two to four weeks of a protein hydrolysate or amino acid‐based formula (<a href="./references#CD008550-bbs2-0111" title="RosenR , VandenplasY , SingendonkM , CabanaM , DiLorenzoC , GottrandF , et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. Journal of Pediatric Gastroenterology and Nutrition2018;66(3):516-54. [DOI: 10.1097/MPG.0b013e3181b7f563]">NASPGHAN‐ESPGHAN guidelines 2018</a>; <a href="./references#CD008550-bbs2-0113" title="National Institute for Health and Care Excellence. Gastro-oesophageal reflux disease in children and young people: diagnosis and management (NG1); October 2019. www.nice.org.uk/guidance/ng1.">NICE 2019</a>). </p> </section> <section id="CD008550-sec-0019"> <h4 class="title">Surgical options</h4> <p>Surgery is used to limit GORD. The most common strategy is a Nissen's fundoplication involving a 360º wrap (<a href="./references#CD008550-bbs2-0094" title="HassallE . Outcomes of fundoplication: causes for concern, newer options. Archives of Disease in Childhood2005;90(10):1047-52.">Hassall 2005</a>). This aims to combine antireflux factors, including creation of a high pressure zone at the distal oesophagus and recreation of the diaphragmatic crural mechanism. However, underlying dysmotility may persist and retching may continue as a prominent feature. Comparisons of these techniques are considered elsewhere (<a href="./references#CD008550-bbs2-0113" title="National Institute for Health and Care Excellence. Gastro-oesophageal reflux disease in children and young people: diagnosis and management (NG1); October 2019. www.nice.org.uk/guidance/ng1.">NICE 2019</a>). We have not assessed conservative and surgical strategies in this Cochrane Review, which seeks to assess medical treatments, to better inform medical practitioners (GPs/paediatricians). Surgery relates to a small minority of children with gastro‐oesophageal reflux and is beyond the scope of this review. </p> </section> </section> <section id="CD008550-sec-0020"> <h3 class="title" id="CD008550-sec-0020">How the intervention might work</h3> <p>Pharmacological treatments work by altering the gastric pH (e.g. PPIs, H₂ antagonists) and reducing the acidity of refluxate, by promoting gut motility (prokinetics), or by altering the viscosity of refluxate (alginates). Pharmacological treatments are considered if nonmedical measures have been ineffective. Dosing, metabolism interactions, and associated adverse events are described above. </p> <section id="CD008550-sec-0021"> <h4 class="title">Proton pump inhibitors (PPIs)</h4> <p>PPIs irreversibly inactivate H+/K+ ATPase, at the level of the parietal cell membrane transporter. This increases the pH of gastric contents and decreases the total volume of gastric secretion. Of the five PPIs approved by the FDA, three are licensed in the UK for children: omeprazole, lansoprazole, and esomeprazole. PPIs were the subject of a 'Pediatric Written Request' (PWR) made by the FDA to improve our knowledge of PPIs in children and infants. There is good clinical experience with PPIs in children, and an excellent evidence‐base of efficacy in adults (<a href="./references#CD008550-bbs2-0113" title="National Institute for Health and Care Excellence. Gastro-oesophageal reflux disease in children and young people: diagnosis and management (NG1); October 2019. www.nice.org.uk/guidance/ng1.">NICE 2019</a>). </p> </section> <section id="CD008550-sec-0022"> <h4 class="title">H₂ receptor antagonists (H2RAs)</h4> <p>H₂ antagonists also aim to increase the pH of gastric contents in children, and there is good clinical experience with H₂ antagonists in infants, children, and adults (<a href="./references#CD008550-bbs2-0113" title="National Institute for Health and Care Excellence. Gastro-oesophageal reflux disease in children and young people: diagnosis and management (NG1); October 2019. www.nice.org.uk/guidance/ng1.">NICE 2019</a>). </p> </section> <section id="CD008550-sec-0023"> <h4 class="title">Magnesium hydroxide and aluminium hydroxide (MHAH)</h4> <p>MHAH is designed to reduce gastric acid, and forms water as a by‐product. Its use in children is unlicensed. </p> </section> <section id="CD008550-sec-0024"> <h4 class="title">Prokinetics</h4> <p>Prokinetics are considered when GOR fails to improve with conservative measures. There are several classes of drugs designed to increase gastrointestinal motility. </p> <p>Domperidone acts to increase motility and gastric emptying through acting on dopamine receptors and decreases post‐prandial reflux time (<a href="./references#CD008550-bbs2-0092" title="FranckxJ , NoelP . Acute extrapyramidal dysfunction after domperidone administration: Report of a case. Helvetica Paediatrica Acta1984;39(3):285-8.">Franckx 1984</a>; <a href="./references#CD008550-bbs2-0120" title="ShafrirY , LevyY , Ben-AmitaiD , NitzanM , SteinherzR . Oculogyric crisis due to domperidone therapy. Helvetica Paediatrica Acta1985;40(1):95.">Shafrir 1985</a>). Domperidone had been commonly used in clinical practice, either as part of empirical medical therapy of gastro‐oesophageal reflux disease or if delayed gastric emptying has been demonstrated on a barium swallow or milk scan. </p> <p>Erythromycin binds to motilin receptors to promote peristalsis and gastric emptying, to decrease post‐prandial reflux time. Its use as a prokinetic is unlicensed. </p> <p>Metoclopramide has also been assessed in a separate Cochrane Review (<a href="./references#CD008550-bbs2-0085" title="CraigWR , Hanlon-DearmanA , SinclairC , TabackS , MoffattM . Metoclopramide, thickened feedings, and positioning for gastro-oesophageal reflux in children under two years. Cochrane Database of Systematic Reviews2004, Issue 3. Art. No: CD003502. [DOI: 10.1002/14651858.CD003502.pub3]">Craig 2004</a>), so we did not review the associated literature for metoclopramide as it is not used to treat reflux in children, given the adverse event profile and NICE guidance (<a href="./references#CD008550-bbs2-0113" title="National Institute for Health and Care Excellence. Gastro-oesophageal reflux disease in children and young people: diagnosis and management (NG1); October 2019. www.nice.org.uk/guidance/ng1.">NICE 2019</a>). </p> <p>Cisapride is a gastro‐oesophageal prokinetic agent which stimulates motility in the gastrointestinal tract by increasing acetylcholine release in the myenteric plexus, controlling smooth muscle. As cisapride has been the subject of a separate Cochrane Review (<a href="./references#CD008550-bbs2-0079" title="AugoodC , MacLennonS , GilbertR , LoganS . Cisapride treatment for gastrooesophageal reflux in children. Cochrane Database of Systematic Reviews2003, Issue 3. Art. No: CD002300. [DOI: 10.1002/14651858.CD002300]">Augood 2003</a>), and is now no longer manufactured, we have not reviewed the literature for this drug. </p> <p>Quince syrup has ulcer‐healing properties and is thought to increase the lower oesophageal sphincter tone (<a href="./references#CD008550-bbs2-0036" title="ZohalinezhadME , ImaniehMH , SamaniSM , MohagheghzadehA , DehghaniSM , HaghighatM , et al. Effects of quince syrup on clinical symptoms of children with symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Complementary Therapies in Clinical Practice2015;21(4):268-76. ZohalinezhadME , ZohalinezhadIS , SamaniA , MohagheghzadehF , DehghaniH . Efficacy of quince (Cydonia oblonga M) syrup in symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Planta Medica2016;82(1):1439. ">Zohalinezhad 2015</a>). </p> </section> <section id="CD008550-sec-0025"> <h4 class="title">Alginates</h4> <p>Compound alginate preparations prevent reflux in infants by increasing the viscosity of gastric contents (<a href="./references#CD008550-bbs2-0081" title="British Medical Association, Royal Pharmaceutical Society of Great Britain, Royal College of Paediatrics and Child Health, Neonatal and Paediatric Pharmacists Group. British National Formulary for Children. London, UK: BMJ Group, Pharmaceutical Press, RCPCH Publications, 2021.">BNFc 2021</a>). This contrasts with other Gaviscon preparations, which can also contain sodium bicarbonate/potassium bicarbonate that – in the presence of gastric acid – forms a gel in which carbon dioxide (derived from the breakdown of bicarbonate) is trapped. This 'foam raft' floats on top of the gastric contents and is designed to neutralise gastric acid (providing symptomatic relief), to thicken the feed (to reduce reflux), and to reduce oesophageal irritation (<a href="./references#CD008550-bbs2-0105" title="MandelKG , DaggyBP , BrodieDA , JacobyHI . Review article: alginate-raft formulations in the treatment of heartburn and acid reflux. Alimentary Pharmacology Therapeutics2000;14(6):669-90.">Mandel 2000</a>). </p> <p>Sodium and magnesium alginate (Gaviscon Infant) is a thickener, and other forms are now available (Gastrotuss and Refluxsan Nipio). </p> <p>Other thickening agents, such as carob bean gum (Carobel), have been assessed separately (<a href="./references#CD008550-bbs2-0085" title="CraigWR , Hanlon-DearmanA , SinclairC , TabackS , MoffattM . Metoclopramide, thickened feedings, and positioning for gastro-oesophageal reflux in children under two years. Cochrane Database of Systematic Reviews2004, Issue 3. Art. No: CD003502. [DOI: 10.1002/14651858.CD003502.pub3]">Craig 2004</a>; <a href="./references#CD008550-bbs2-0103" title="KwokTC , OjhaS , DorlingJ . Feed thickener for infants up to six months of age with gastro-oesophageal reflux. Cochrane Database of Systematic Reviews2017;12:CD003211.">Kwok 2017</a>). Current NICE guidance recommends discontinuing pre‐thickened formulas if alginates are trialled (<a href="./references#CD008550-bbs2-0113" title="National Institute for Health and Care Excellence. Gastro-oesophageal reflux disease in children and young people: diagnosis and management (NG1); October 2019. www.nice.org.uk/guidance/ng1.">NICE 2019</a>). </p> </section> <section id="CD008550-sec-0026"> <h4 class="title">Antispasmodics</h4> <p>Baclofen has been used to treat co‐existing reflux by aiming to improve the incoordination of the lower oesophageal sphincter, reducing the number of transient lower oesophageal sphincter relaxations (TLESRs) (<a href="./references#CD008550-bbs2-0025" title="OmariTI , BenningaMA , SansomL , ButlerRN , DentJ , DavidsonGP . Effect of baclofen on esophagogastric motility and gastroesophageal reflux in children with gastroesophageal reflux disease: a randomized controlled trial. Journal of Pediatrics2006;149(4):468-74. ">Omari 2006</a>). It is not part of clinical GORD consensus guidelines (<a href="./references#CD008550-bbs2-0111" title="RosenR , VandenplasY , SingendonkM , CabanaM , DiLorenzoC , GottrandF , et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. Journal of Pediatric Gastroenterology and Nutrition2018;66(3):516-54. [DOI: 10.1097/MPG.0b013e3181b7f563]">NASPGHAN‐ESPGHAN guidelines 2018</a>). </p> </section> </section> <section id="CD008550-sec-0027"> <h3 class="title" id="CD008550-sec-0027">Why it is important to do this review</h3> <p>Gastro‐oesophageal reflux in children is a common condition. Healthcare professionals frequently use pharmacological treatment of this condition for symptom relief. New studies have been published since the original version of this review (<a href="./references#CD008550-bbs2-0126" title="TigheM , AfzalNA , BevanA , HayenA , MunroA , BeattieRM . Pharmacological treatment of children with gastro-oesophageal reflux. Cochrane Database of Systematic Reviews2014, Issue 11. Art. No: CD008550. [DOI: 10.1002/14651858.CD008550.pub2]">Tighe 2014</a>), and new medicines to treat gastro‐oesophageal reflux are available. Thus, an up‐to‐date synthesis of the evidence, including the current balance of benefits and harms of these treatments, is required. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008550-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008550-sec-0028"></div> <p>To assess the effects of pharmacological treatments for GOR in infants and children.</p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008550-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008550-sec-0029"></div> <section id="CD008550-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008550-sec-0031"> <h4 class="title">Types of studies</h4> <p>We considered all randomised controlled trials (RCTs) for inclusion.</p> </section> <section id="CD008550-sec-0032"> <h4 class="title">Types of participants</h4> <p>We included all children (aged 0 to 16 years) with "GOR associated with bothersome symptoms or complications" (<a href="./references#CD008550-bbs2-0111" title="RosenR , VandenplasY , SingendonkM , CabanaM , DiLorenzoC , GottrandF , et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. Journal of Pediatric Gastroenterology and Nutrition2018;66(3):516-54. [DOI: 10.1097/MPG.0b013e3181b7f563]">NASPGHAN‐ESPGHAN guidelines 2018</a>; see also <a href="./references#CD008550-bbs2-0121" title="ShermanPM , HassallE , Fagundes-NetoU , GoldBD , KatoS , KoletzkoS , et al. A global, evidence-based consensus on the definition of gastroesophageal reflux disease in the pediatric population. American Journal of Gastroenterology2009;104(5):1278-95.">Sherman 2009</a>). </p> <p>We predefined two groups organised by age: infants up to 12 months old, and children aged 12 months to 16 years old. We included studies assessing preterm neonates and children with a neurodisability. </p> </section> <section id="CD008550-sec-0033"> <h4 class="title">Types of interventions</h4> <p>We included all currently available medical treatments for gastro‐oesophageal reflux in children. </p> <p>We considered all RCTs that compared a medication for GOR with a placebo or another medication. We imposed no restrictions on dosage, frequency, or duration of pharmacological treatment. </p> <p>We attempted comparisons of all active treatments versus placebo, by treatment class:</p> <p> <ul id="CD008550-list-0003"> <li> <p>proton pump inhibitors (PPIs: omeprazole, lansoprazole, pantoprazole, rabeprazole, and esomeprazole) versus placebo; </p> </li> <li> <p>H₂ antagonists (ranitidine, famotidine, cimetidine) versus placebo;</p> </li> <li> <p>prokinetics (domperidone, erythromycin, bethanechol) versus placebo;</p> </li> <li> <p>compound alginate preparations versus placebo</p> </li> <li> <p>sucralfate versus placebo.</p> </li> </ul> </p> <p>We included studies assessing quince syrup, a traditional Persian medicine to treat GOR. We outline the evidence base, but note that quince syrup is not currently a prescribable medicine in many countries, including the United Kingdom. </p> <p>We excluded studies assessing metoclopramide, thickened feeds, or using thickened feeds as a comparator. (In a 2004 Cochrane Review, Craig and colleagues assessed metoclopramide and thickened feeds for GOR in children under two years of age (<a href="./references#CD008550-bbs2-0085" title="CraigWR , Hanlon-DearmanA , SinclairC , TabackS , MoffattM . Metoclopramide, thickened feedings, and positioning for gastro-oesophageal reflux in children under two years. Cochrane Database of Systematic Reviews2004, Issue 3. Art. No: CD003502. [DOI: 10.1002/14651858.CD003502.pub3]">Craig 2004</a>); this review has since been withdrawn.) We excluded studies employing conservative treatment and surgical techniques for GOR, as well as studies assessing dietary management of GORD. We excluded studies assessing pharmacological treatments for GORD in people with coexistent conditions, such as tracheo‐oesophageal fistula (TOF) or asthma, that predispose them to GORD, to avoid heterogeneity between participants. </p> </section> <section id="CD008550-sec-0034"> <h4 class="title">Types of outcome measures</h4> <p>To make this update as robust as possible, and to assist the potential for meta‐analysis, we selected the same outcome measures in this updated review as in the previous version (<a href="./references#CD008550-bbs2-0126" title="TigheM , AfzalNA , BevanA , HayenA , MunroA , BeattieRM . Pharmacological treatment of children with gastro-oesophageal reflux. Cochrane Database of Systematic Reviews2014, Issue 11. Art. No: CD008550. [DOI: 10.1002/14651858.CD008550.pub2]">Tighe 2014</a>). We included all reported outcomes that are likely to be meaningful to clinicians making medical decisions about treating gastro‐oesophageal reflux. We included all time points for assessments. We identified studies with very short follow‐up periods (fewer than two weeks) as a potential source of bias. </p> <p>We did not exclude studies based on outcomes measured. However, we excluded studies assessing purely pharmacokinetic outcomes or taste, as these were not considered as primary or secondary outcome measures of interest. Nevertheless, to exclude outcome bias, we contacted corresponding authors of such trials to establish if there were any relevant data that had not been published. In cases of uncertainty, we contacted corresponding authors for clarification. </p> <section id="CD008550-sec-0035"> <h5 class="title">Primary outcomes</h5> <p>Our primary outcome was improvement in clinical symptoms, which was usually assessed through questionnaires completed by parents and childcare providers. The symptoms monitored included: </p> <p> <ul id="CD008550-list-0004"> <li> <p>number of vomiting episodes (continuous data);</p> </li> <li> <p>episodes of back arching (continuous data);</p> </li> <li> <p>number of regurgitation episodes (continuous data);</p> </li> <li> <p>failure to thrive (binary outcome);</p> </li> <li> <p>feeding difficulties (binary outcome);</p> </li> <li> <p>abdominal pain in infants (continuous data).</p> </li> </ul> </p> <p>In older children, the number of episodes of heartburn, epigastric pain, or regurgitation (continuous data) were again assessed through questionnaires completed by participants, parents, and health professionals. These included, for example, the Paediatric Gastro‐oesophageal Symptom Questionnaire (PGSQ) and the Infant Gastro‐oesophageal Reflux Questionnaire–Revised (I‐GER‐Q), which were completed daily by parents and health professionals to provide quantitative data through validated symptom scores. </p> </section> <section id="CD008550-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p>Our secondary outcomes were: adverse effects, 24‐hour pH‐impedance indices, and endoscopic metrics. </p> <section id="CD008550-sec-0037"> <h6 class="title">Adverse effects</h6> <p>We explored all studies for any adverse effects, as defined by the Medicines Health Regulation Authority (<a href="./references#CD008550-bbs2-0108" title="Medicines Health Regulatory Authority. Proton pump inhibitors in long-term use: reports of hypomagnesaemia. Drug Safety Update2012;5(9):1.">MHRA 2012</a>). In cases of uncertainty, we contacted corresponding authors for clarification. This exploratory approach aimed to identify unanticipated and rare adverse effects of an intervention and to look for data on possible associations between an intervention and a list of observed adverse events, to add to existing safety profiles. We assessed and reported adverse effects, and studies reporting the absence of adverse effects without separate data extraction, in line with Cochrane guidance (<a href="./references#CD008550-bbs2-0097" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3. Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Higgins 2022</a>). </p> </section> <section id="CD008550-sec-0038"> <h6 class="title">24‐hour pH‐impedance indices</h6> <p>Reflux monitoring measures the amount of reflux in the oesophagus during a 24‐hour period. The test is carried out by placing a catheter in the oesophagus. These indices assess: </p> <p> <ul id="CD008550-list-0005"> <li> <p>improvement in the reflux index (continuous data);</p> </li> <li> <p>number and duration of reflux episodes on a 24‐hour pH‐impedance probe (continuous data); </p> </li> <li> <p>results of non‐acid impedance studies (continuous data).</p> </li> </ul> </p> </section> <section id="CD008550-sec-0039"> <h6 class="title">Endoscopic metrics</h6> <p> <ul id="CD008550-list-0006"> <li> <p>Improvement of oesophagitis on endoscopy (visual appearance – this can be a binary outcome or continuous data if scored (e.g. Hetzel‐Dent classification)); </p> </li> <li> <p>Histology (continuous data).</p> </li> </ul> </p> <p>Different grading scales currently exist for classifying macroscopic appearances of the oesophagus, but no one grading scale has been demonstrated to show superior validity to the alternatives. We considered the description of histological changes, and histological scoring scales, and where relevant to help clinicians, we describe useful findings below. However, we did not include histological data in the summary of findings tables. </p> <p>The number of children within a study population who failed to improve and required fundoplication was considered a potential secondary outcome (binary outcome). </p> </section> </section> </section> </section> <section id="CD008550-sec-0040"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD008550-sec-0041"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases on 17 September 2022:</p> <p> <ul id="CD008550-list-0007"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) via Ovid Evidence‐Based Medicine Reviews Database (EBMR) (from inception to 2022) (<a href="./appendices#CD008550-sec-0235">Appendix 1</a>); </p> </li> <li> <p>MEDLINE via Ovid (from 1946 to 17 September 2022) (<a href="./appendices#CD008550-sec-0236">Appendix 2</a>); </p> </li> <li> <p>Embase via Ovid (from 1974 to 17 September 2022) (<a href="./appendices#CD008550-sec-0237">Appendix 3</a>); </p> </li> <li> <p>Science Citation Index via Web of Science (from inception to 17 September 2022) (<a href="./appendices#CD008550-sec-0238">Appendix 4</a>). </p> </li> </ul> </p> <p>We searched the World Health Organization International Clinical Trials Registry Platform (ICTRP) Search Portal (apps.who.int/trialsearch/) and ClinicalTrials.gov (<a href="https://www.ClinicalTrials.gov" target="_blank">www.ClinicalTrials.gov</a>). </p> <p>We developed this search strategy with assistance from the Information Specialist of the Cochrane Gut Group. </p> </section> <section id="CD008550-sec-0042"> <h4 class="title">Searching other resources</h4> <p>We checked the reference lists of all eligible studies and relevant reviews identified by the search and published within the past five years for possible references to RCTs. We also contacted experts in the field for any additional trials. </p> <section id="CD008550-sec-0043"> <h5 class="title">Adverse outcomes</h5> <p>We did not conduct a separate search for adverse events.</p> </section> <section id="CD008550-sec-0044"> <h5 class="title">Language</h5> <p>We did not restrict our searches by language, and translated papers as necessary.</p> </section> </section> </section> <section id="CD008550-sec-0045"> <h3 class="title" id="CD008550-sec-0045">Data collection and analysis</h3> <p>We used Review Manager 5.4 and RevMan Web for data collection and analysis (<a href="./references#CD008550-bbs2-0116" title="Review Manager (RevMan). Version 5.4. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2019.">RevMan 2019</a>; <a href="./references#CD008550-bbs2-0117" title="Review Manager Web (RevMan Web). Version 4.12.0. The Cochrane Collaboration, 2022. Available at revman.cochrane.org.">RevMan Web 2022</a>). </p> <section id="CD008550-sec-0046"> <h4 class="title">Selection of studies</h4> <p>Two review authors (MT, IL) downloaded all titles and abstracts retrieved by electronic searching to a reference management database and removed duplicates. Four review authors (MT, IL, EA, RMB) independently screened titles and abstracts for inclusion. We retrieved the full‐text reports/publications and independently applied the eligibility criteria to the full texts, identified studies for inclusion, and identified and recorded reasons for exclusion of ineligible studies. We resolved any disagreement through discussion or, when required, through consulting a fifth review author (NAA). </p> <p>We listed studies that initially appeared to meet the inclusion criteria but that we later excluded in the <a href="./references#CD008550-sec-0249" title="">Characteristics of excluded studies</a> table, with the reasons for their exclusion. We collated multiple reports of the same study so that each study, rather than each report, was the unit of interest in the review. We also provided any information we could obtain about ongoing studies. We entered studies that were only in abstract form, or were only identified in the ISRCTN register into the <a href="./references#CD008550-sec-0250" title="">Characteristics of studies awaiting classification</a> table. We recorded the selection process in sufficient detail to complete a PRISMA flow diagram (<a href="./references#CD008550-bbs2-0104" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GøtzschePC , IoannidisJP , et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Journal of Clinical Epidemiology2009;62(10):e1-34.">Liberati 2009</a>). </p> </section> <section id="CD008550-sec-0047"> <h4 class="title">Data extraction and management</h4> <p>Three review authors (MT, IL, EA) independently extracted the data using a robust data extraction form (utilised in the first review), checked and entered the data into RevMan 5.4/RevMan Web, analysed the data, and highlighted any discrepancies, with statistician supervision (AH). RMB supervised data collection and acted as arbiter for any disagreements. If studies had insufficient data, we did not extract summary data. We collected and archived data in a format to facilitate future access and data sharing. Where statistical analyses were not possible (or were inappropriate), we provided a descriptive summary. We looked at all studies, performing further analysis of those employing an intention‐to‐treat (ITT) analysis where such information existed, and have included single forest plots of studies with summary data extracted. </p> </section> <section id="CD008550-sec-0048"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>As in the original review, we have described each study in a risk of bias table, and addressed the following issues, which may be associated with biased estimates of treatment effect: recruitment strategy, random sequence generation, allocation sequence concealment, blinding, incomplete outcome data, selective outcome reporting, and other potential sources of bias (<a href="./references#CD008550-bbs2-0096" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). We commented specifically on: </p> <p> <ul id="CD008550-list-0008"> <li> <p>the method of generation of the randomisation sequence;</p> </li> <li> <p>the method of allocation concealment – it is considered 'adequate' if the assignment could not be foreseen, and should be independent of and remote from the investigators; </p> </li> <li> <p>who was blinded and not blinded (participants, clinicians, outcome assessors) if this was appropriate (up to and after the point of treatment allocation); </p> </li> <li> <p>how many participants were lost to follow‐up in each arm, and whether reasons for losses were adequately reported; </p> </li> <li> <p>whether all participants were analysed in the groups to which they were originally randomised (intention‐to‐treat principle). </p> </li> </ul> </p> <p>We also reported on:</p> <p> <ul id="CD008550-list-0009"> <li> <p>the baseline assessment of the participants for age, sex, and duration of symptoms, if suggestive of bias between the groups; </p> </li> <li> <p>whether outcome measures were described and their assessment was standardised;</p> </li> <li> <p>the use and appropriateness of statistical analyses, where we could not extract tabulated data from the original publication. </p> </li> </ul> </p> </section> <section id="CD008550-sec-0049"> <h4 class="title">Measures of treatment effect</h4> <p>The outcomes described above yielded both continuous and dichotomous data.</p> <p>Clinical symptoms produced continuous data (e.g. number of vomiting episodes), yielding outcomes described as the mean difference (MD) and standardised mean difference (SMD). We extracted continuous data (e.g. reflux index) for summary data: we used means and standard deviations (SDs) to derive a mean difference (MD) with a 95% confidence interval (95% CI) using a fixed‐effect model. </p> <p>The latest guidelines of the North American Society of Paediatric Gastroenterology Hepatology and Nutrition (NASPGHAN) and the European Society of Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) do not define normal values for pH‐metry and pH‐impedance (<a href="./references#CD008550-bbs2-0111" title="RosenR , VandenplasY , SingendonkM , CabanaM , DiLorenzoC , GottrandF , et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. Journal of Pediatric Gastroenterology and Nutrition2018;66(3):516-54. [DOI: 10.1097/MPG.0b013e3181b7f563]">NASPGHAN‐ESPGHAN guidelines 2018</a>). We therefore continued to treat reflux index as continuous data but removed consideration of whether baseline values were normal or abnormal (which had been discussed in the previous version of this review), and included any improvement/non‐improvement in values compared to the other agent or dose being tested, expressed as MD ± 95% CI. </p> <p>Dichotomous data, such as improvement/non‐improvement in endoscopic appearance, produced outcome data we presented as risk ratios. For studies of a single pharmacological agent (e.g. omeprazole) versus either placebo or a different drug, if sufficient trials were available and participant characteristics were clinically similar, we planned to conduct meta‐analyses of primary and secondary outcomes. </p> </section> <section id="CD008550-sec-0050"> <h4 class="title">Unit of analysis issues</h4> <p>We considered unit of analysis issues for any included trials with multiple treatment groups and cluster‐randomised designs. We considered cross‐over trials for inclusion and assessed only the first stage of therapy prior to cross‐over, but commented on results obtained after cross‐over if clinically relevant. We also considered issues arising from multiple observations for the same outcome (e.g. repeated pH‐impedance measurements), and planned to consult the Cochrane Gut group if clarification was required. For multi‐arm studies<i>,</i> we analysed multiple intervention groups appropriately to prevent arbitrary omission of relevant groups or double‐counting of participants. </p> </section> <section id="CD008550-sec-0051"> <h4 class="title">Dealing with missing data</h4> <p>Where we were uncertain about the specifics of a trial pertinent to analysis, we contacted trial authors or sponsors of studies published from 2014 to 2022 to request missing data or clarification. We detailed authors' and sponsors' contribution in <a href="./references#CD008550-sec-0248" title="">Characteristics of included studies</a>. </p> </section> <section id="CD008550-sec-0052"> <h4 class="title">Assessment of heterogeneity</h4> <p>We screened studies to assess clinical heterogeneity and planned subgroup analyses if appropriate, reporting on the extent of any heterogeneity using the I<sup>2</sup> statistic (<a href="./references#CD008550-bbs2-0095" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60.">Higgins 2003</a>). Where we found evidence of significant heterogeneity (I<sup>2</sup> &gt; 50%) in summary data extraction, we downgraded the evidence certainty. </p> </section> <section id="CD008550-sec-0053"> <h4 class="title">Assessment of reporting biases</h4> <p>We assessed selective reporting of results by comparing (where available) the outcomes listed in trials' original protocols to those reported in the final papers. We also searched clinical trials registries for details of the included trials. We contacted the primary investigator(s) of included trials to determine whether they were aware of any relevant unpublished data. We aimed to identify publication bias with the construction of funnel plots (<a href="./references#CD008550-bbs2-0115" title="PageMJ , HigginsJP , SterneJA . Chapter 13: Assessing risk of bias due to missing results in a synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. www.training.cochrane.org/handbook.">Page 2020</a>). However, insufficient trials were eligible for inclusion in the current version of the review. We plan to undertake this analysis in future if we can include more trials. </p> </section> <section id="CD008550-sec-0054"> <h4 class="title">Data synthesis</h4> <p>We were unable to combine studies meaningfully due to the heterogeneity of studies in terms of outcomes, comparisons, and populations. For continuous measurements, we had planned to use weighted mean differences to pool results from studies using a common measurement scale. Where studies used different measurement scales, we planned to pool standardised mean differences. Instead, we have presented difference in means and 95% confidence intervals for individual studies and summary effects, using the following order: Population &gt; Comparison &gt; Outcome. We assessed all individual treatments separately, given the individual study differences and heterogeneity in study design. We considered combining data – for example, on high‐dose versus low‐dose proton pump inhibitors (please see <a href="#CD008550-sec-0080">Effects of interventions</a>) – to attempt to increase the population size on which conclusions were based, only where similar outcomes in similar participants were assessed. However, we were unable to undertake this method due to the heterogeneity of study methodology. Due to the number of summary of finding tables, we limited our assessment of quince syrup, as it is not a prescribable medicine. We have not included quince syrup in the summary of findings tables, nor assessed the certainty of evidence for this intervention. </p> </section> <section id="CD008550-sec-0055"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We addressed subgroup analysis in two ways. First, we have distinguished between infants (up to 12 months in age) and children (one to 16 years in age) throughout the review. These subgroups have different GOR characteristics. For example, infants with symptomatic gastro‐oesophageal reflux have different symptoms from older children (who are generally on a more solid diet, and are upright). Some treatments, such as alginates, are mainly used in the infant cohort. </p> <p>Secondly, we looked for studies evaluating specific subgroups: (1) preterm infants, as this group of babies can be problematic to assess and often have empirical treatment for common symptoms (e.g. apnoeas and bradycardias) that can be caused by GORD, but are more commonly caused by other issues associated with prematurity; and (2) children with neurodisability, who often have considerable gut dysmotility, and are often on long‐term antireflux therapy. The results are outlined within <a href="#CD008550-sec-0080">Effects of interventions</a>. </p> <p>Where we found substantial heterogeneity (I<sup>2</sup> &gt; 50%) between studies for the primary outcome, we explored the reasons for heterogeneity (including severity of reflux, demographic differences (age and comorbidity) within the age subgroups, having considered varying outcomes, different comparison agents (same drug, different dosing)) and downgraded the evidence certainty. As it was inappropriate to pool the data because of clinical or statistical heterogeneity, which we discuss in <a href="#CD008550-sec-0221">Overall completeness and applicability of evidence</a>, we did not conduct meta‐analysis. There were insufficient studies within other specific subgroups (preterm infants and children within neurodisability) to consider heterogeneity. </p> </section> <section id="CD008550-sec-0056"> <h4 class="title">Sensitivity analysis</h4> <p>In this review update, we could not undertake meta‐analysis due to the heterogeneity of the included studies' populations, comparisons, and outcomes. Thus, sensitivity analysis was not required. In future updates of the review, if meta‐analysis is possible, we plan to undertake sensitivity analysis to explore whether a 12‐month age threshold for subgroups influences meta‐analytic robustness. We plan to integrate these findings into the results and conclusions. Additionally, if there are sufficient data in future updates of the review, we plan to explore whether endoscopic metrics, pH indices, and symptomatic outcomes are affected by either endoscopic descriptors (such as erosive or non‐erosive oesophagitis) or severity markers on 24‐hour pH‐impedance monitoring (such as reflux index). Other possible sensitivity analyses will depend on the type of meta‐analysis possible. </p> </section> <section id="CD008550-sec-0057"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>Two authors (MT, EA) independently used the five GRADE considerations (risk of bias, consistency of effect, imprecision, indirectness, and publication bias) to assess the certainty of the body of evidence for each outcome, and to draw conclusions about the certainty of evidence within the text of the review. We resolved any disagreements through discussion, involving all review authors if a disagreement could not be resolved. </p> <p>Our summary of findings tables prioritise comparisons and outcomes that will be of use to decision‐makers. We deferred the creation of summary of findings tables for treatments that are not currently available by prescription to future review updates. All review author reviewed the GRADE considerations in assessing the certainty of evidence (<a href="./references#CD008550-bbs2-0119" title="SchünemannH , BrożekJ , GuyattG , Oxman A (editors). Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013 Available from guidelinedevelopment.org/handbook. Available from guidelinedevelopment.org/handbook.">Schünemann 2013</a>), and integrated judgements into the summary of findings tables. </p> <p>All review authors agreed prior to data collection that the summary of findings tables should distinguish results by age (infants: 0 to 12 months; and children: aged 1 to 16 years old). The tables present these outcomes: symptoms, adverse events, pH impedance indices, and endoscopic metrics. We provide clear rationales where we downgraded evidence according to GRADE criteria. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008550-sec-0058" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008550-sec-0058"></div> <section id="CD008550-sec-0059"> <h3 class="title">Description of studies</h3> <section id="CD008550-sec-0060"> <h4 class="title">Results of the search</h4> <p>The first version of this review included 24 studies (<a href="./references#CD008550-bbs2-0126" title="TigheM , AfzalNA , BevanA , HayenA , MunroA , BeattieRM . Pharmacological treatment of children with gastro-oesophageal reflux. Cochrane Database of Systematic Reviews2014, Issue 11. Art. No: CD008550. [DOI: 10.1002/14651858.CD008550.pub2]">Tighe 2014</a>). In the September 2022 update searches, we identified 1427 records through electronic database searches and supplemental search methods. After the removal of duplicates, 1034 records remained. At this stage, we discarded 978 records as clearly irrelevant. We screened the full‐text publications of 54 studies (56 records). We excluded 40 studies (42 records) and listed two studies as 'awaiting classification.' We identified 12 new studies for inclusion. Thus, in this updated version, we have included a total of 36 RCTs assessing 2251 participants. We identified no ongoing studies (see <a href="#CD008550-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD008550-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA study flow diagram" data-id="CD008550-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008550.pub3/media/CDSR/CD008550/image_n/nCD008550-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA study flow diagram</p> </div> </div> </div> </section> <section id="CD008550-sec-0061"> <h4 class="title">Included studies</h4> <p>We present the main characteristics of the included studies in the <a href="./references#CD008550-sec-0248" title="">Characteristics of included studies</a> table. </p> <section id="CD008550-sec-0062"> <h5 class="title">Study design</h5> <p>Of the 36 RCTs, most (31) were of parallel‐group design (<a href="./references#CD008550-bbs2-0001" title="AzizollahiHR , RafeeyM . Efficacy of proton pump inhibitors and H2 blocker in the treatment of symptomatic gastroesophageal reflux disease in infants. Korean Journal of Pediatrics2016;59(5):226-30. ">Azizollahi 2016</a>; <a href="./references#CD008550-bbs2-0002" title="BakerR , TsouVM , TungJ , BakerSS , LiH , WangW , et al. Clinical results from a randomised, double-blind, dose-ranging study of pantoprazole in children aged 1 through 5 years with symptomatic histologic or erosive esophagitis. Clinical Pediatrics2010;49(9):852-65. ">Baker 2010</a>; <a href="./references#CD008550-bbs2-0004" title="BallengeeCR , DavalianF , ConawayMR , SauerCG , KaufmanDA . Erythromycin and reflux events in premature neonates: a randomized clinical trial. Journal of Pediatric Gastroenterology and Nutrition2018;67(6):720-25. ">Ballengee 2018</a>; <a href="./references#CD008550-bbs2-0005" title="BinesJE , QuinlanJE , TrevesS , KleinmanRE , WinterHS . Efficacy of domperidone in infants and children with gastroesophageal reflux. Journal of Pediatric Gastroenterology and Nutrition1992;14(4):400-5. ">Bines 1992</a>; <a href="./references#CD008550-bbs2-0006" title="BorrelliO , ReaP , Bueno De MesquitaM , AmbrosiniA , ManciniV , Di NardoG , et al. Efficacy of combined administration of an alginate formulation (Gaviscon) and Lansoprazole for children with gastroesophageal reflux. Italian Journal of Pediatrics2002;28(4):304-9. ">Borrelli 2002</a>; <a href="./references#CD008550-bbs2-0007" title="ButsJP , BarudiC , OtteJB . Double-blind controlled study on the efficacy of sodium alginate (Gaviscon) in reducing gastroesophageal reflux assessed by 24 h continuous pH monitoring in infants and children. European Journal of Pediatrics1987;146(2):156-8. ">Buts 1987</a>; <a href="./references#CD008550-bbs2-0008" title="CarroccioA , Iacono, MontaltoG , CavataioF , SoresiM , NotarbartoloA . Domperidone plus magnesium hydroxide and aluminium hydroxide: a valid therapy in children with gastroesophageal reflux. Scandinavian Journal of Gastroenterology1994;29(4):300-4. ">Carroccio 1994</a>; <a href="./references#CD008550-bbs2-0009" title="CresiF , MarinaccioC , RussoMC , MinieroR , SilvestroL . Short-term effect of domperidone on gastroesophageal reflux in newborns assessed by combined intraluminal impedance and pH monitoring. Journal of Perinatology2008;28:766-70. ">Cresi 2008</a>; <a href="./references#CD008550-bbs2-0010" title="CucchiaraS , StaianoA , RomanielloG , CapobiancoS , AurcchioS . Antacids and cimetidine treatment for gastrooesophageal reflux and peptic oesophagitis. Archives of Disease in Childhood1984;59:842-7. ">Cucchiara 1984</a>; <a href="./references#CD008550-bbs2-0011" title="CucchiaraS , MinellaR , IervolinoC , FrancoMT , CampanozziA , FranceschiM , et al. Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis. Archives of Disease in Childhood1993;69:655-9. ">Cucchiara 1993</a>; <a href="./references#CD008550-bbs2-0012" title="DavidsonG , WenzlTG , ThomsonM , OmariT , BarkerP , LundborgP , et al. Efficacy and safety of once-daily esomeprazole for the treatment of gastroesophageal reflux disease in neonatal patients. Journal of Pediatrics2013;163(3):692-8. ">Davidson 2013</a>; <a href="./references#CD008550-bbs2-0014" title="FamouriF , ZibanejadN , KabiriP , KelishadR . Comparison of hypoallergenic diet vs. ranitidine in treatment of gastroesophageal reflux disease of infants: a randomized clinical trial. Iranian Journal of Pediatrics2017;27(4):e5343. ">Famouri 2017</a>; <a href="./references#CD008550-bbs2-0015" title="ForbesD , HodgsonM , HillR . The effects of gaviscon and metoclopramide in gastroesophageal reflux in children. Journal of Pediatric Gastroenterology and Nutrition1986;5(4):556-9. ">Forbes 1986</a>; <a href="./references#CD008550-bbs2-0016" title="GilgerM , ToliaV , VandenplasY , YoussefN , TraxlerB , IlluecaM . Safety and tolerability of esomeprazole in children with gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2006;43(4):E20-21. GilgerMA , ToliaV , VandenplasY , YoussefNN , TraxlerB , IlluecaM . Safety and tolerability of esomeprazole in children with gastro-esophageal reflux disease. Gastroenterology2015;46(5):S16-23. ">Gilger 2006</a>; <a href="./references#CD008550-bbs2-0017" title="GunasekaranT , GuptaS , GremseD , KarolM , Pan W-J, Chin Y-L, et al. Lansoprazole in adolescents with gastroesophageal reflux disease: pharmacokinetics, pharmacodynamics, symptom relief efficacy, and tolerability. Journal of Pediatric Gastroenterology and Nutrition2002;35(4):S327-35. ">Gunesekaran 2003</a>; <a href="./references#CD008550-bbs2-0018" title="HaddadI , KierkusJ , TronE , UlmerA , HuP , SloanS , et al. Efficacy and safety of rabeprazole in children (1-11 years) with gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2013;57(6):798-807. ">Haddad 2013</a>; <a href="./references#CD008550-bbs2-0020" title="KierkusJ , Furmaga-JablonskaW , SullivanJE , DavidES , StewartDL , RathN , et al. Pharmacodynamics and safety of pantoprazole in neonates, preterm infants, and infants aged 1-11 months with a clinical diagnosis of gastroesophageal reflux disease. Digestive Diseases and Sciences2011;56:425-34. ">Kierkus 2011</a>; <a href="./references#CD008550-bbs2-0021" title="LootsC , KritasS , vanWijkM , McCallL , PeetersL , LewindonP , et al. Body positioning and medical therapy for infantile gastroesophageal reflux symptoms. Journal of Pediatric Gastroenterology and Nutrition2014;59(2):237-43. ">Loots 2014</a>; <a href="./references#CD008550-bbs2-0022" title="MillerS . Comparison of the efficacy and safety of a new aluminum-free paediatric alginate preparation and placebo in infants with recurrent gastro-oesophageal reflux. Current Medical Research and Opinion1999;15(3):160-8. ">Miller 1999</a>; <a href="./references#CD008550-bbs2-0024" title="NaeimiM , KianifarH , MemarianiZ , KamalinejadM , BijaniA , SaghebiR , et al. Comparison of the efficacy of ranitidine and quince syrup on gastroesophageal reflux disease in children. Complementary Therapies in Medicine2019;45:215-21. ">Naeimi 2019</a>; <a href="./references#CD008550-bbs2-0025" title="OmariTI , BenningaMA , SansomL , ButlerRN , DentJ , DavidsonGP . Effect of baclofen on esophagogastric motility and gastroesophageal reflux in children with gastroesophageal reflux disease: a randomized controlled trial. Journal of Pediatrics2006;149(4):468-74. ">Omari 2006</a>; <a href="./references#CD008550-bbs2-0026" title="OmariT , DavidsonG , BondarovP , NauclerE , NilssonC , LundborgP . Pharmacokinetics and acid-suppressive effects of esomeprazole in infants 1-24 months old with symptoms of gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2007;45(5):530-7. [MEDLINE: Published in abstract form in JPGN:2006: 42: E1-110]OmariT , DavidsonG , BondarovP , NauclerE , NilssonC , LundborgP . Pharmacokinetics and acid-suppressive effects of esomeprazole in infants 1-24 months old with symptoms of gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2015;60:S2-S8. ">Omari 2007</a>; <a href="./references#CD008550-bbs2-0028" title="OrensteinSR , HassallE , Furmaga-JablonskaW , AtkinsonS , RaananM . Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. Journal of Pediatrics2009;154(4):514-20. ">Orenstein 2008</a>; <a href="./references#CD008550-bbs2-0029" title="PfefferkornMD , CroffieJM , GuptaSK , MollestonJP , EckertGJ , CorkinsMR , et al. Nocturnal acid breakthrough in children with reflux esophagitis taking proton pump inhibitors. Journal of Pediatric Gastroenterology and Nutrition2006;42(2):160-5. ">Pfefferkorn 2006</a>; <a href="./references#CD008550-bbs2-0030" title="SimeoneD , CariaMC , MieleE , StaianoA . Treatment of childhood peptic esophagitis: a double-blind placebo-controlled trial of nizatidine. Journal of Pediatric Gastroenterology and Nutrition1997;25(1):51-5. ">Simeone 1997</a>; <a href="./references#CD008550-bbs2-0031" title="ToliaV , BishopPR , TsouVM , GremseD , SofferEF , ComerGM , et al. Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5-11 years) with symptomatic gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2006;42(4):384-91. ">Tolia 2006</a>; <a href="./references#CD008550-bbs2-0032" title="ToliaV , GilgerMA , BarkerPN , IlluecaM . Healing of erosive esophagitis and improvement of symptoms of gastroesophageal reflux disease after esomeprazole treatment in children 12 to 36 months old. Journal of Pediatric Gastroenterology and Nutrition2010;51(5):593-8. ">Tolia 2010a</a>; <a href="./references#CD008550-bbs2-0033" title="ToliaV , YoussefNN , GilgerMA , TraxlerB , IlluecaM . Esomeprazole for the treatment of erosive esophagitis in children: an international, multicenter, randomized, parallel-group, double-blind (for dose) study. BMC Pediatrics2010;10:41-50. [DOI: 10.1186/1471-2431-10-41]ToliaV , YoussefNN , GilgerMA , TraxlerB , IlluecaM . Esomeprazole for the treatment of erosive esophagitis in children: an international, multicenter, randomized, parallel-group, double-blind (for dose) study. Journal of Pediatric Gastroenterology and Nutrition2015;10(1):S24-30. ">Tolia 2010b</a>; <a href="./references#CD008550-bbs2-0034" title="TsouVM , BakerR , BookL , HammoAH , SofferEF , WangW , et al. Multicenter, randomized, double-blind study comparing 20 and 40 mg of pantoprazole for symptom relief in adolescents (12 to 16 years of age) with gastroesophageal reflux disease (GERD). Clinical Pediatrics2006;45(8):741-9. ">Tsou 2006</a>; <a href="./references#CD008550-bbs2-0035" title="UmmarinoD , MieleE , MartinelliM , ScarpatoE , CrocettoF , SciorioE , et al. Effect of magnesium alginate plus simethicone on gastroesophageal reflux in infants. Journal of Pediatric Gastroenterology and Nutrition2015;60(2):230-5. ">Ummarino 2015</a>; <a href="./references#CD008550-bbs2-0036" title="ZohalinezhadME , ImaniehMH , SamaniSM , MohagheghzadehA , DehghaniSM , HaghighatM , et al. Effects of quince syrup on clinical symptoms of children with symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Complementary Therapies in Clinical Practice2015;21(4):268-76. ZohalinezhadME , ZohalinezhadIS , SamaniA , MohagheghzadehF , DehghaniH . Efficacy of quince (Cydonia oblonga M) syrup in symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Planta Medica2016;82(1):1439. ">Zohalinezhad 2015</a>); two were cross‐over studies (<a href="./references#CD008550-bbs2-0003" title="BaldassarreME , Di MauroA , PignatelliMC , FanelliM , SalvatoreS , Di NardoG , et al. Magnesium alginate in gastro-esophageal reflux: a randomized multicenter cross-over study in infants. International Journal of Environmental Research and Public Health2020;17(1):83. ">Baldassarre 2020</a>; <a href="./references#CD008550-bbs2-0023" title="MooreDJ , TaoBS , LinesDR , HirteC , HeddleML , DavidsonGP . Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. Journal of Pediatrics2003;143(2):219-23. ">Moore 2003</a>), two were withdrawal studies (<a href="./references#CD008550-bbs2-0019" title="HussainS , KierkusJ , HuP , HoffmanD , LekichR , SloanS , et al. Safety and efficacy of delayed release rabeprazole in 1- to 11-month-old infants with symptomatic GERD. Journal of Pediatric Gastroenterology and Nutrition2014;58(2):226-36. ">Hussain 2014</a>; <a href="./references#CD008550-bbs2-0027" title="OrensteinSR , ShalabyTM , DevandrySN , LiacourasCA , CzinnSJ , DiceJE , et al. Famotidine for infant gastro-oesophageal reflux: a multi-centre, randomized, placebo-controlled, withdrawal trial. Alimentary Pharmacology and Therapeutics2003;17(9):1097-107. ">Orenstein 2002</a>), and one had a more complex design (<a href="./references#CD008550-bbs2-0013" title="Del BuonoR , WenzlTG , BallG , KeadyS , ThomsonM . Effect of Gaviscon Infant on gastro-oesophageal reflux in infants assessed by combined intraluminal impedance/pH. Archives of Disease in Childhood2005;90:460-3. ">Del Buono 2005</a>). Twenty‐two studies (61%) enroled more than 40 participants (<a href="./references#CD008550-bbs2-0001" title="AzizollahiHR , RafeeyM . Efficacy of proton pump inhibitors and H2 blocker in the treatment of symptomatic gastroesophageal reflux disease in infants. Korean Journal of Pediatrics2016;59(5):226-30. ">Azizollahi 2016</a>; <a href="./references#CD008550-bbs2-0002" title="BakerR , TsouVM , TungJ , BakerSS , LiH , WangW , et al. Clinical results from a randomised, double-blind, dose-ranging study of pantoprazole in children aged 1 through 5 years with symptomatic histologic or erosive esophagitis. Clinical Pediatrics2010;49(9):852-65. ">Baker 2010</a>; <a href="./references#CD008550-bbs2-0003" title="BaldassarreME , Di MauroA , PignatelliMC , FanelliM , SalvatoreS , Di NardoG , et al. Magnesium alginate in gastro-esophageal reflux: a randomized multicenter cross-over study in infants. International Journal of Environmental Research and Public Health2020;17(1):83. ">Baldassarre 2020</a>; <a href="./references#CD008550-bbs2-0008" title="CarroccioA , Iacono, MontaltoG , CavataioF , SoresiM , NotarbartoloA . Domperidone plus magnesium hydroxide and aluminium hydroxide: a valid therapy in children with gastroesophageal reflux. Scandinavian Journal of Gastroenterology1994;29(4):300-4. ">Carroccio 1994</a>; <a href="./references#CD008550-bbs2-0010" title="CucchiaraS , StaianoA , RomanielloG , CapobiancoS , AurcchioS . Antacids and cimetidine treatment for gastrooesophageal reflux and peptic oesophagitis. Archives of Disease in Childhood1984;59:842-7. ">Cucchiara 1984</a>; <a href="./references#CD008550-bbs2-0012" title="DavidsonG , WenzlTG , ThomsonM , OmariT , BarkerP , LundborgP , et al. Efficacy and safety of once-daily esomeprazole for the treatment of gastroesophageal reflux disease in neonatal patients. Journal of Pediatrics2013;163(3):692-8. ">Davidson 2013</a>; <a href="./references#CD008550-bbs2-0014" title="FamouriF , ZibanejadN , KabiriP , KelishadR . Comparison of hypoallergenic diet vs. ranitidine in treatment of gastroesophageal reflux disease of infants: a randomized clinical trial. Iranian Journal of Pediatrics2017;27(4):e5343. ">Famouri 2017</a>; <a href="./references#CD008550-bbs2-0016" title="GilgerM , ToliaV , VandenplasY , YoussefN , TraxlerB , IlluecaM . Safety and tolerability of esomeprazole in children with gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2006;43(4):E20-21. GilgerMA , ToliaV , VandenplasY , YoussefNN , TraxlerB , IlluecaM . Safety and tolerability of esomeprazole in children with gastro-esophageal reflux disease. Gastroenterology2015;46(5):S16-23. ">Gilger 2006</a>; <a href="./references#CD008550-bbs2-0017" title="GunasekaranT , GuptaS , GremseD , KarolM , Pan W-J, Chin Y-L, et al. Lansoprazole in adolescents with gastroesophageal reflux disease: pharmacokinetics, pharmacodynamics, symptom relief efficacy, and tolerability. Journal of Pediatric Gastroenterology and Nutrition2002;35(4):S327-35. ">Gunesekaran 2003</a>; <a href="./references#CD008550-bbs2-0018" title="HaddadI , KierkusJ , TronE , UlmerA , HuP , SloanS , et al. Efficacy and safety of rabeprazole in children (1-11 years) with gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2013;57(6):798-807. ">Haddad 2013</a>; <a href="./references#CD008550-bbs2-0019" title="HussainS , KierkusJ , HuP , HoffmanD , LekichR , SloanS , et al. Safety and efficacy of delayed release rabeprazole in 1- to 11-month-old infants with symptomatic GERD. Journal of Pediatric Gastroenterology and Nutrition2014;58(2):226-36. ">Hussain 2014</a>; <a href="./references#CD008550-bbs2-0021" title="LootsC , KritasS , vanWijkM , McCallL , PeetersL , LewindonP , et al. Body positioning and medical therapy for infantile gastroesophageal reflux symptoms. Journal of Pediatric Gastroenterology and Nutrition2014;59(2):237-43. ">Loots 2014</a>; <a href="./references#CD008550-bbs2-0022" title="MillerS . Comparison of the efficacy and safety of a new aluminum-free paediatric alginate preparation and placebo in infants with recurrent gastro-oesophageal reflux. Current Medical Research and Opinion1999;15(3):160-8. ">Miller 1999</a>; <a href="./references#CD008550-bbs2-0024" title="NaeimiM , KianifarH , MemarianiZ , KamalinejadM , BijaniA , SaghebiR , et al. Comparison of the efficacy of ranitidine and quince syrup on gastroesophageal reflux disease in children. Complementary Therapies in Medicine2019;45:215-21. ">Naeimi 2019</a>; <a href="./references#CD008550-bbs2-0026" title="OmariT , DavidsonG , BondarovP , NauclerE , NilssonC , LundborgP . Pharmacokinetics and acid-suppressive effects of esomeprazole in infants 1-24 months old with symptoms of gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2007;45(5):530-7. [MEDLINE: Published in abstract form in JPGN:2006: 42: E1-110]OmariT , DavidsonG , BondarovP , NauclerE , NilssonC , LundborgP . Pharmacokinetics and acid-suppressive effects of esomeprazole in infants 1-24 months old with symptoms of gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2015;60:S2-S8. ">Omari 2007</a>; <a href="./references#CD008550-bbs2-0028" title="OrensteinSR , HassallE , Furmaga-JablonskaW , AtkinsonS , RaananM . Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. Journal of Pediatrics2009;154(4):514-20. ">Orenstein 2008</a>; <a href="./references#CD008550-bbs2-0031" title="ToliaV , BishopPR , TsouVM , GremseD , SofferEF , ComerGM , et al. Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5-11 years) with symptomatic gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2006;42(4):384-91. ">Tolia 2006</a>; <a href="./references#CD008550-bbs2-0032" title="ToliaV , GilgerMA , BarkerPN , IlluecaM . Healing of erosive esophagitis and improvement of symptoms of gastroesophageal reflux disease after esomeprazole treatment in children 12 to 36 months old. Journal of Pediatric Gastroenterology and Nutrition2010;51(5):593-8. ">Tolia 2010a</a>; <a href="./references#CD008550-bbs2-0033" title="ToliaV , YoussefNN , GilgerMA , TraxlerB , IlluecaM . Esomeprazole for the treatment of erosive esophagitis in children: an international, multicenter, randomized, parallel-group, double-blind (for dose) study. BMC Pediatrics2010;10:41-50. [DOI: 10.1186/1471-2431-10-41]ToliaV , YoussefNN , GilgerMA , TraxlerB , IlluecaM . Esomeprazole for the treatment of erosive esophagitis in children: an international, multicenter, randomized, parallel-group, double-blind (for dose) study. Journal of Pediatric Gastroenterology and Nutrition2015;10(1):S24-30. ">Tolia 2010b</a>; <a href="./references#CD008550-bbs2-0034" title="TsouVM , BakerR , BookL , HammoAH , SofferEF , WangW , et al. Multicenter, randomized, double-blind study comparing 20 and 40 mg of pantoprazole for symptom relief in adolescents (12 to 16 years of age) with gastroesophageal reflux disease (GERD). Clinical Pediatrics2006;45(8):741-9. ">Tsou 2006</a>; <a href="./references#CD008550-bbs2-0035" title="UmmarinoD , MieleE , MartinelliM , ScarpatoE , CrocettoF , SciorioE , et al. Effect of magnesium alginate plus simethicone on gastroesophageal reflux in infants. Journal of Pediatric Gastroenterology and Nutrition2015;60(2):230-5. ">Ummarino 2015</a>; <a href="./references#CD008550-bbs2-0036" title="ZohalinezhadME , ImaniehMH , SamaniSM , MohagheghzadehA , DehghaniSM , HaghighatM , et al. Effects of quince syrup on clinical symptoms of children with symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Complementary Therapies in Clinical Practice2015;21(4):268-76. ZohalinezhadME , ZohalinezhadIS , SamaniA , MohagheghzadehF , DehghaniH . Efficacy of quince (Cydonia oblonga M) syrup in symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Planta Medica2016;82(1):1439. ">Zohalinezhad 2015</a>), and 14 studies enroled fewer than 40 participants (<a href="./references#CD008550-bbs2-0004" title="BallengeeCR , DavalianF , ConawayMR , SauerCG , KaufmanDA . Erythromycin and reflux events in premature neonates: a randomized clinical trial. Journal of Pediatric Gastroenterology and Nutrition2018;67(6):720-25. ">Ballengee 2018</a>; <a href="./references#CD008550-bbs2-0005" title="BinesJE , QuinlanJE , TrevesS , KleinmanRE , WinterHS . Efficacy of domperidone in infants and children with gastroesophageal reflux. Journal of Pediatric Gastroenterology and Nutrition1992;14(4):400-5. ">Bines 1992</a>; <a href="./references#CD008550-bbs2-0006" title="BorrelliO , ReaP , Bueno De MesquitaM , AmbrosiniA , ManciniV , Di NardoG , et al. Efficacy of combined administration of an alginate formulation (Gaviscon) and Lansoprazole for children with gastroesophageal reflux. Italian Journal of Pediatrics2002;28(4):304-9. ">Borrelli 2002</a>; <a href="./references#CD008550-bbs2-0007" title="ButsJP , BarudiC , OtteJB . Double-blind controlled study on the efficacy of sodium alginate (Gaviscon) in reducing gastroesophageal reflux assessed by 24 h continuous pH monitoring in infants and children. European Journal of Pediatrics1987;146(2):156-8. ">Buts 1987</a>; <a href="./references#CD008550-bbs2-0009" title="CresiF , MarinaccioC , RussoMC , MinieroR , SilvestroL . Short-term effect of domperidone on gastroesophageal reflux in newborns assessed by combined intraluminal impedance and pH monitoring. Journal of Perinatology2008;28:766-70. ">Cresi 2008</a>; <a href="./references#CD008550-bbs2-0011" title="CucchiaraS , MinellaR , IervolinoC , FrancoMT , CampanozziA , FranceschiM , et al. Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis. Archives of Disease in Childhood1993;69:655-9. ">Cucchiara 1993</a>; <a href="./references#CD008550-bbs2-0013" title="Del BuonoR , WenzlTG , BallG , KeadyS , ThomsonM . Effect of Gaviscon Infant on gastro-oesophageal reflux in infants assessed by combined intraluminal impedance/pH. Archives of Disease in Childhood2005;90:460-3. ">Del Buono 2005</a>; <a href="./references#CD008550-bbs2-0015" title="ForbesD , HodgsonM , HillR . The effects of gaviscon and metoclopramide in gastroesophageal reflux in children. Journal of Pediatric Gastroenterology and Nutrition1986;5(4):556-9. ">Forbes 1986</a>; <a href="./references#CD008550-bbs2-0020" title="KierkusJ , Furmaga-JablonskaW , SullivanJE , DavidES , StewartDL , RathN , et al. Pharmacodynamics and safety of pantoprazole in neonates, preterm infants, and infants aged 1-11 months with a clinical diagnosis of gastroesophageal reflux disease. Digestive Diseases and Sciences2011;56:425-34. ">Kierkus 2011</a>; <a href="./references#CD008550-bbs2-0023" title="MooreDJ , TaoBS , LinesDR , HirteC , HeddleML , DavidsonGP . Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. Journal of Pediatrics2003;143(2):219-23. ">Moore 2003</a>; <a href="./references#CD008550-bbs2-0025" title="OmariTI , BenningaMA , SansomL , ButlerRN , DentJ , DavidsonGP . Effect of baclofen on esophagogastric motility and gastroesophageal reflux in children with gastroesophageal reflux disease: a randomized controlled trial. Journal of Pediatrics2006;149(4):468-74. ">Omari 2006</a>; <a href="./references#CD008550-bbs2-0125" title="World Bank. Country and Lending Groups classification of countries by income. datatopics.worldbank.org/world-development-indicators/the-world-by-income-and-region.html Accessed prior to 20 May 2023.">World Bank 2022</a>; <a href="./references#CD008550-bbs2-0029" title="PfefferkornMD , CroffieJM , GuptaSK , MollestonJP , EckertGJ , CorkinsMR , et al. Nocturnal acid breakthrough in children with reflux esophagitis taking proton pump inhibitors. Journal of Pediatric Gastroenterology and Nutrition2006;42(2):160-5. ">Pfefferkorn 2006</a>; <a href="./references#CD008550-bbs2-0030" title="SimeoneD , CariaMC , MieleE , StaianoA . Treatment of childhood peptic esophagitis: a double-blind placebo-controlled trial of nizatidine. Journal of Pediatric Gastroenterology and Nutrition1997;25(1):51-5. ">Simeone 1997</a>). The largest study enroled 268 participants (<a href="./references#CD008550-bbs2-0019" title="HussainS , KierkusJ , HuP , HoffmanD , LekichR , SloanS , et al. Safety and efficacy of delayed release rabeprazole in 1- to 11-month-old infants with symptomatic GERD. Journal of Pediatric Gastroenterology and Nutrition2014;58(2):226-36. ">Hussain 2014</a>). </p> <p>Fifteen studies were multicentre (<a href="./references#CD008550-bbs2-0002" title="BakerR , TsouVM , TungJ , BakerSS , LiH , WangW , et al. Clinical results from a randomised, double-blind, dose-ranging study of pantoprazole in children aged 1 through 5 years with symptomatic histologic or erosive esophagitis. Clinical Pediatrics2010;49(9):852-65. ">Baker 2010</a>; <a href="./references#CD008550-bbs2-0003" title="BaldassarreME , Di MauroA , PignatelliMC , FanelliM , SalvatoreS , Di NardoG , et al. Magnesium alginate in gastro-esophageal reflux: a randomized multicenter cross-over study in infants. International Journal of Environmental Research and Public Health2020;17(1):83. ">Baldassarre 2020</a>; <a href="./references#CD008550-bbs2-0012" title="DavidsonG , WenzlTG , ThomsonM , OmariT , BarkerP , LundborgP , et al. Efficacy and safety of once-daily esomeprazole for the treatment of gastroesophageal reflux disease in neonatal patients. Journal of Pediatrics2013;163(3):692-8. ">Davidson 2013</a>; <a href="./references#CD008550-bbs2-0016" title="GilgerM , ToliaV , VandenplasY , YoussefN , TraxlerB , IlluecaM . Safety and tolerability of esomeprazole in children with gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2006;43(4):E20-21. GilgerMA , ToliaV , VandenplasY , YoussefNN , TraxlerB , IlluecaM . Safety and tolerability of esomeprazole in children with gastro-esophageal reflux disease. Gastroenterology2015;46(5):S16-23. ">Gilger 2006</a>; <a href="./references#CD008550-bbs2-0017" title="GunasekaranT , GuptaS , GremseD , KarolM , Pan W-J, Chin Y-L, et al. Lansoprazole in adolescents with gastroesophageal reflux disease: pharmacokinetics, pharmacodynamics, symptom relief efficacy, and tolerability. Journal of Pediatric Gastroenterology and Nutrition2002;35(4):S327-35. ">Gunesekaran 2003</a>; <a href="./references#CD008550-bbs2-0018" title="HaddadI , KierkusJ , TronE , UlmerA , HuP , SloanS , et al. Efficacy and safety of rabeprazole in children (1-11 years) with gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2013;57(6):798-807. ">Haddad 2013</a>; <a href="./references#CD008550-bbs2-0019" title="HussainS , KierkusJ , HuP , HoffmanD , LekichR , SloanS , et al. Safety and efficacy of delayed release rabeprazole in 1- to 11-month-old infants with symptomatic GERD. Journal of Pediatric Gastroenterology and Nutrition2014;58(2):226-36. ">Hussain 2014</a>; <a href="./references#CD008550-bbs2-0021" title="LootsC , KritasS , vanWijkM , McCallL , PeetersL , LewindonP , et al. Body positioning and medical therapy for infantile gastroesophageal reflux symptoms. Journal of Pediatric Gastroenterology and Nutrition2014;59(2):237-43. ">Loots 2014</a>; <a href="./references#CD008550-bbs2-0022" title="MillerS . Comparison of the efficacy and safety of a new aluminum-free paediatric alginate preparation and placebo in infants with recurrent gastro-oesophageal reflux. Current Medical Research and Opinion1999;15(3):160-8. ">Miller 1999</a>; <a href="./references#CD008550-bbs2-0027" title="OrensteinSR , ShalabyTM , DevandrySN , LiacourasCA , CzinnSJ , DiceJE , et al. Famotidine for infant gastro-oesophageal reflux: a multi-centre, randomized, placebo-controlled, withdrawal trial. Alimentary Pharmacology and Therapeutics2003;17(9):1097-107. ">Orenstein 2002</a>; <a href="./references#CD008550-bbs2-0028" title="OrensteinSR , HassallE , Furmaga-JablonskaW , AtkinsonS , RaananM . Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. Journal of Pediatrics2009;154(4):514-20. ">Orenstein 2008</a>; <a href="./references#CD008550-bbs2-0031" title="ToliaV , BishopPR , TsouVM , GremseD , SofferEF , ComerGM , et al. Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5-11 years) with symptomatic gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2006;42(4):384-91. ">Tolia 2006</a>; <a href="./references#CD008550-bbs2-0032" title="ToliaV , GilgerMA , BarkerPN , IlluecaM . Healing of erosive esophagitis and improvement of symptoms of gastroesophageal reflux disease after esomeprazole treatment in children 12 to 36 months old. Journal of Pediatric Gastroenterology and Nutrition2010;51(5):593-8. ">Tolia 2010a</a>; <a href="./references#CD008550-bbs2-0033" title="ToliaV , YoussefNN , GilgerMA , TraxlerB , IlluecaM . Esomeprazole for the treatment of erosive esophagitis in children: an international, multicenter, randomized, parallel-group, double-blind (for dose) study. BMC Pediatrics2010;10:41-50. [DOI: 10.1186/1471-2431-10-41]ToliaV , YoussefNN , GilgerMA , TraxlerB , IlluecaM . Esomeprazole for the treatment of erosive esophagitis in children: an international, multicenter, randomized, parallel-group, double-blind (for dose) study. Journal of Pediatric Gastroenterology and Nutrition2015;10(1):S24-30. ">Tolia 2010b</a>; <a href="./references#CD008550-bbs2-0034" title="TsouVM , BakerR , BookL , HammoAH , SofferEF , WangW , et al. Multicenter, randomized, double-blind study comparing 20 and 40 mg of pantoprazole for symptom relief in adolescents (12 to 16 years of age) with gastroesophageal reflux disease (GERD). Clinical Pediatrics2006;45(8):741-9. ">Tsou 2006</a>) and 21 were single‐centre (<a href="./references#CD008550-bbs2-0001" title="AzizollahiHR , RafeeyM . Efficacy of proton pump inhibitors and H2 blocker in the treatment of symptomatic gastroesophageal reflux disease in infants. Korean Journal of Pediatrics2016;59(5):226-30. ">Azizollahi 2016</a>; <a href="./references#CD008550-bbs2-0004" title="BallengeeCR , DavalianF , ConawayMR , SauerCG , KaufmanDA . Erythromycin and reflux events in premature neonates: a randomized clinical trial. Journal of Pediatric Gastroenterology and Nutrition2018;67(6):720-25. ">Ballengee 2018</a>; <a href="./references#CD008550-bbs2-0005" title="BinesJE , QuinlanJE , TrevesS , KleinmanRE , WinterHS . Efficacy of domperidone in infants and children with gastroesophageal reflux. Journal of Pediatric Gastroenterology and Nutrition1992;14(4):400-5. ">Bines 1992</a>; <a href="./references#CD008550-bbs2-0006" title="BorrelliO , ReaP , Bueno De MesquitaM , AmbrosiniA , ManciniV , Di NardoG , et al. Efficacy of combined administration of an alginate formulation (Gaviscon) and Lansoprazole for children with gastroesophageal reflux. Italian Journal of Pediatrics2002;28(4):304-9. ">Borrelli 2002</a>; <a href="./references#CD008550-bbs2-0007" title="ButsJP , BarudiC , OtteJB . Double-blind controlled study on the efficacy of sodium alginate (Gaviscon) in reducing gastroesophageal reflux assessed by 24 h continuous pH monitoring in infants and children. European Journal of Pediatrics1987;146(2):156-8. ">Buts 1987</a>; <a href="./references#CD008550-bbs2-0008" title="CarroccioA , Iacono, MontaltoG , CavataioF , SoresiM , NotarbartoloA . Domperidone plus magnesium hydroxide and aluminium hydroxide: a valid therapy in children with gastroesophageal reflux. Scandinavian Journal of Gastroenterology1994;29(4):300-4. ">Carroccio 1994</a>; <a href="./references#CD008550-bbs2-0009" title="CresiF , MarinaccioC , RussoMC , MinieroR , SilvestroL . Short-term effect of domperidone on gastroesophageal reflux in newborns assessed by combined intraluminal impedance and pH monitoring. Journal of Perinatology2008;28:766-70. ">Cresi 2008</a>; <a href="./references#CD008550-bbs2-0010" title="CucchiaraS , StaianoA , RomanielloG , CapobiancoS , AurcchioS . Antacids and cimetidine treatment for gastrooesophageal reflux and peptic oesophagitis. Archives of Disease in Childhood1984;59:842-7. ">Cucchiara 1984</a>; <a href="./references#CD008550-bbs2-0011" title="CucchiaraS , MinellaR , IervolinoC , FrancoMT , CampanozziA , FranceschiM , et al. Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis. Archives of Disease in Childhood1993;69:655-9. ">Cucchiara 1993</a>; <a href="./references#CD008550-bbs2-0013" title="Del BuonoR , WenzlTG , BallG , KeadyS , ThomsonM . Effect of Gaviscon Infant on gastro-oesophageal reflux in infants assessed by combined intraluminal impedance/pH. Archives of Disease in Childhood2005;90:460-3. ">Del Buono 2005</a>; <a href="./references#CD008550-bbs2-0014" title="FamouriF , ZibanejadN , KabiriP , KelishadR . Comparison of hypoallergenic diet vs. ranitidine in treatment of gastroesophageal reflux disease of infants: a randomized clinical trial. Iranian Journal of Pediatrics2017;27(4):e5343. ">Famouri 2017</a>; <a href="./references#CD008550-bbs2-0015" title="ForbesD , HodgsonM , HillR . The effects of gaviscon and metoclopramide in gastroesophageal reflux in children. Journal of Pediatric Gastroenterology and Nutrition1986;5(4):556-9. ">Forbes 1986</a>; <a href="./references#CD008550-bbs2-0020" title="KierkusJ , Furmaga-JablonskaW , SullivanJE , DavidES , StewartDL , RathN , et al. Pharmacodynamics and safety of pantoprazole in neonates, preterm infants, and infants aged 1-11 months with a clinical diagnosis of gastroesophageal reflux disease. Digestive Diseases and Sciences2011;56:425-34. ">Kierkus 2011</a>; <a href="./references#CD008550-bbs2-0023" title="MooreDJ , TaoBS , LinesDR , HirteC , HeddleML , DavidsonGP . Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. Journal of Pediatrics2003;143(2):219-23. ">Moore 2003</a>; <a href="./references#CD008550-bbs2-0024" title="NaeimiM , KianifarH , MemarianiZ , KamalinejadM , BijaniA , SaghebiR , et al. Comparison of the efficacy of ranitidine and quince syrup on gastroesophageal reflux disease in children. Complementary Therapies in Medicine2019;45:215-21. ">Naeimi 2019</a>; <a href="./references#CD008550-bbs2-0025" title="OmariTI , BenningaMA , SansomL , ButlerRN , DentJ , DavidsonGP . Effect of baclofen on esophagogastric motility and gastroesophageal reflux in children with gastroesophageal reflux disease: a randomized controlled trial. Journal of Pediatrics2006;149(4):468-74. ">Omari 2006</a>; <a href="./references#CD008550-bbs2-0026" title="OmariT , DavidsonG , BondarovP , NauclerE , NilssonC , LundborgP . Pharmacokinetics and acid-suppressive effects of esomeprazole in infants 1-24 months old with symptoms of gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2007;45(5):530-7. [MEDLINE: Published in abstract form in JPGN:2006: 42: E1-110]OmariT , DavidsonG , BondarovP , NauclerE , NilssonC , LundborgP . Pharmacokinetics and acid-suppressive effects of esomeprazole in infants 1-24 months old with symptoms of gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2015;60:S2-S8. ">Omari 2007</a>; <a href="./references#CD008550-bbs2-0029" title="PfefferkornMD , CroffieJM , GuptaSK , MollestonJP , EckertGJ , CorkinsMR , et al. Nocturnal acid breakthrough in children with reflux esophagitis taking proton pump inhibitors. Journal of Pediatric Gastroenterology and Nutrition2006;42(2):160-5. ">Pfefferkorn 2006</a>; <a href="./references#CD008550-bbs2-0030" title="SimeoneD , CariaMC , MieleE , StaianoA . Treatment of childhood peptic esophagitis: a double-blind placebo-controlled trial of nizatidine. Journal of Pediatric Gastroenterology and Nutrition1997;25(1):51-5. ">Simeone 1997</a>; <a href="./references#CD008550-bbs2-0035" title="UmmarinoD , MieleE , MartinelliM , ScarpatoE , CrocettoF , SciorioE , et al. Effect of magnesium alginate plus simethicone on gastroesophageal reflux in infants. Journal of Pediatric Gastroenterology and Nutrition2015;60(2):230-5. ">Ummarino 2015</a>; <a href="./references#CD008550-bbs2-0036" title="ZohalinezhadME , ImaniehMH , SamaniSM , MohagheghzadehA , DehghaniSM , HaghighatM , et al. Effects of quince syrup on clinical symptoms of children with symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Complementary Therapies in Clinical Practice2015;21(4):268-76. ZohalinezhadME , ZohalinezhadIS , SamaniA , MohagheghzadehF , DehghaniH . Efficacy of quince (Cydonia oblonga M) syrup in symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Planta Medica2016;82(1):1439. ">Zohalinezhad 2015</a>). Seventeen studies had a placebo‐controlled arm (<a href="./references#CD008550-bbs2-0004" title="BallengeeCR , DavalianF , ConawayMR , SauerCG , KaufmanDA . Erythromycin and reflux events in premature neonates: a randomized clinical trial. Journal of Pediatric Gastroenterology and Nutrition2018;67(6):720-25. ">Ballengee 2018</a>; <a href="./references#CD008550-bbs2-0005" title="BinesJE , QuinlanJE , TrevesS , KleinmanRE , WinterHS . Efficacy of domperidone in infants and children with gastroesophageal reflux. Journal of Pediatric Gastroenterology and Nutrition1992;14(4):400-5. ">Bines 1992</a>; <a href="./references#CD008550-bbs2-0007" title="ButsJP , BarudiC , OtteJB . Double-blind controlled study on the efficacy of sodium alginate (Gaviscon) in reducing gastroesophageal reflux assessed by 24 h continuous pH monitoring in infants and children. European Journal of Pediatrics1987;146(2):156-8. ">Buts 1987</a>; <a href="./references#CD008550-bbs2-0008" title="CarroccioA , Iacono, MontaltoG , CavataioF , SoresiM , NotarbartoloA . Domperidone plus magnesium hydroxide and aluminium hydroxide: a valid therapy in children with gastroesophageal reflux. Scandinavian Journal of Gastroenterology1994;29(4):300-4. ">Carroccio 1994</a>; <a href="./references#CD008550-bbs2-0009" title="CresiF , MarinaccioC , RussoMC , MinieroR , SilvestroL . Short-term effect of domperidone on gastroesophageal reflux in newborns assessed by combined intraluminal impedance and pH monitoring. Journal of Perinatology2008;28:766-70. ">Cresi 2008</a>; <a href="./references#CD008550-bbs2-0012" title="DavidsonG , WenzlTG , ThomsonM , OmariT , BarkerP , LundborgP , et al. Efficacy and safety of once-daily esomeprazole for the treatment of gastroesophageal reflux disease in neonatal patients. Journal of Pediatrics2013;163(3):692-8. ">Davidson 2013</a>; <a href="./references#CD008550-bbs2-0013" title="Del BuonoR , WenzlTG , BallG , KeadyS , ThomsonM . Effect of Gaviscon Infant on gastro-oesophageal reflux in infants assessed by combined intraluminal impedance/pH. Archives of Disease in Childhood2005;90:460-3. ">Del Buono 2005</a>; <a href="./references#CD008550-bbs2-0014" title="FamouriF , ZibanejadN , KabiriP , KelishadR . Comparison of hypoallergenic diet vs. ranitidine in treatment of gastroesophageal reflux disease of infants: a randomized clinical trial. Iranian Journal of Pediatrics2017;27(4):e5343. ">Famouri 2017</a>; <a href="./references#CD008550-bbs2-0015" title="ForbesD , HodgsonM , HillR . The effects of gaviscon and metoclopramide in gastroesophageal reflux in children. Journal of Pediatric Gastroenterology and Nutrition1986;5(4):556-9. ">Forbes 1986</a>; <a href="./references#CD008550-bbs2-0019" title="HussainS , KierkusJ , HuP , HoffmanD , LekichR , SloanS , et al. Safety and efficacy of delayed release rabeprazole in 1- to 11-month-old infants with symptomatic GERD. Journal of Pediatric Gastroenterology and Nutrition2014;58(2):226-36. ">Hussain 2014</a>; <a href="./references#CD008550-bbs2-0021" title="LootsC , KritasS , vanWijkM , McCallL , PeetersL , LewindonP , et al. Body positioning and medical therapy for infantile gastroesophageal reflux symptoms. Journal of Pediatric Gastroenterology and Nutrition2014;59(2):237-43. ">Loots 2014</a>; <a href="./references#CD008550-bbs2-0022" title="MillerS . Comparison of the efficacy and safety of a new aluminum-free paediatric alginate preparation and placebo in infants with recurrent gastro-oesophageal reflux. Current Medical Research and Opinion1999;15(3):160-8. ">Miller 1999</a>; <a href="./references#CD008550-bbs2-0023" title="MooreDJ , TaoBS , LinesDR , HirteC , HeddleML , DavidsonGP . Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. Journal of Pediatrics2003;143(2):219-23. ">Moore 2003</a>; <a href="./references#CD008550-bbs2-0025" title="OmariTI , BenningaMA , SansomL , ButlerRN , DentJ , DavidsonGP . Effect of baclofen on esophagogastric motility and gastroesophageal reflux in children with gastroesophageal reflux disease: a randomized controlled trial. Journal of Pediatrics2006;149(4):468-74. ">Omari 2006</a>; <a href="./references#CD008550-bbs2-0027" title="OrensteinSR , ShalabyTM , DevandrySN , LiacourasCA , CzinnSJ , DiceJE , et al. Famotidine for infant gastro-oesophageal reflux: a multi-centre, randomized, placebo-controlled, withdrawal trial. Alimentary Pharmacology and Therapeutics2003;17(9):1097-107. ">Orenstein 2002</a>; <a href="./references#CD008550-bbs2-0028" title="OrensteinSR , HassallE , Furmaga-JablonskaW , AtkinsonS , RaananM . Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. Journal of Pediatrics2009;154(4):514-20. ">Orenstein 2008</a>; <a href="./references#CD008550-bbs2-0030" title="SimeoneD , CariaMC , MieleE , StaianoA . Treatment of childhood peptic esophagitis: a double-blind placebo-controlled trial of nizatidine. Journal of Pediatric Gastroenterology and Nutrition1997;25(1):51-5. ">Simeone 1997</a>). Ten studies compared the active medication to a comparator medication (<a href="./references#CD008550-bbs2-0001" title="AzizollahiHR , RafeeyM . Efficacy of proton pump inhibitors and H2 blocker in the treatment of symptomatic gastroesophageal reflux disease in infants. Korean Journal of Pediatrics2016;59(5):226-30. ">Azizollahi 2016</a>; <a href="./references#CD008550-bbs2-0003" title="BaldassarreME , Di MauroA , PignatelliMC , FanelliM , SalvatoreS , Di NardoG , et al. Magnesium alginate in gastro-esophageal reflux: a randomized multicenter cross-over study in infants. International Journal of Environmental Research and Public Health2020;17(1):83. ">Baldassarre 2020</a>; <a href="./references#CD008550-bbs2-0006" title="BorrelliO , ReaP , Bueno De MesquitaM , AmbrosiniA , ManciniV , Di NardoG , et al. Efficacy of combined administration of an alginate formulation (Gaviscon) and Lansoprazole for children with gastroesophageal reflux. Italian Journal of Pediatrics2002;28(4):304-9. ">Borrelli 2002</a>; <a href="./references#CD008550-bbs2-0008" title="CarroccioA , Iacono, MontaltoG , CavataioF , SoresiM , NotarbartoloA . Domperidone plus magnesium hydroxide and aluminium hydroxide: a valid therapy in children with gastroesophageal reflux. Scandinavian Journal of Gastroenterology1994;29(4):300-4. ">Carroccio 1994</a>; <a href="./references#CD008550-bbs2-0010" title="CucchiaraS , StaianoA , RomanielloG , CapobiancoS , AurcchioS . Antacids and cimetidine treatment for gastrooesophageal reflux and peptic oesophagitis. Archives of Disease in Childhood1984;59:842-7. ">Cucchiara 1984</a>; <a href="./references#CD008550-bbs2-0011" title="CucchiaraS , MinellaR , IervolinoC , FrancoMT , CampanozziA , FranceschiM , et al. Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis. Archives of Disease in Childhood1993;69:655-9. ">Cucchiara 1993</a>; <a href="./references#CD008550-bbs2-0024" title="NaeimiM , KianifarH , MemarianiZ , KamalinejadM , BijaniA , SaghebiR , et al. Comparison of the efficacy of ranitidine and quince syrup on gastroesophageal reflux disease in children. Complementary Therapies in Medicine2019;45:215-21. ">Naeimi 2019</a>; <a href="./references#CD008550-bbs2-0029" title="PfefferkornMD , CroffieJM , GuptaSK , MollestonJP , EckertGJ , CorkinsMR , et al. Nocturnal acid breakthrough in children with reflux esophagitis taking proton pump inhibitors. Journal of Pediatric Gastroenterology and Nutrition2006;42(2):160-5. ">Pfefferkorn 2006</a>; <a href="./references#CD008550-bbs2-0035" title="UmmarinoD , MieleE , MartinelliM , ScarpatoE , CrocettoF , SciorioE , et al. Effect of magnesium alginate plus simethicone on gastroesophageal reflux in infants. Journal of Pediatric Gastroenterology and Nutrition2015;60(2):230-5. ">Ummarino 2015</a>; <a href="./references#CD008550-bbs2-0036" title="ZohalinezhadME , ImaniehMH , SamaniSM , MohagheghzadehA , DehghaniSM , HaghighatM , et al. Effects of quince syrup on clinical symptoms of children with symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Complementary Therapies in Clinical Practice2015;21(4):268-76. ZohalinezhadME , ZohalinezhadIS , SamaniA , MohagheghzadehF , DehghaniH . Efficacy of quince (Cydonia oblonga M) syrup in symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Planta Medica2016;82(1):1439. ">Zohalinezhad 2015</a>), and 10 studies used the same medication at different doses (<a href="./references#CD008550-bbs2-0002" title="BakerR , TsouVM , TungJ , BakerSS , LiH , WangW , et al. Clinical results from a randomised, double-blind, dose-ranging study of pantoprazole in children aged 1 through 5 years with symptomatic histologic or erosive esophagitis. Clinical Pediatrics2010;49(9):852-65. ">Baker 2010</a>; <a href="./references#CD008550-bbs2-0016" title="GilgerM , ToliaV , VandenplasY , YoussefN , TraxlerB , IlluecaM . Safety and tolerability of esomeprazole in children with gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2006;43(4):E20-21. GilgerMA , ToliaV , VandenplasY , YoussefNN , TraxlerB , IlluecaM . Safety and tolerability of esomeprazole in children with gastro-esophageal reflux disease. Gastroenterology2015;46(5):S16-23. ">Gilger 2006</a>; <a href="./references#CD008550-bbs2-0033" title="ToliaV , YoussefNN , GilgerMA , TraxlerB , IlluecaM . Esomeprazole for the treatment of erosive esophagitis in children: an international, multicenter, randomized, parallel-group, double-blind (for dose) study. BMC Pediatrics2010;10:41-50. [DOI: 10.1186/1471-2431-10-41]ToliaV , YoussefNN , GilgerMA , TraxlerB , IlluecaM . Esomeprazole for the treatment of erosive esophagitis in children: an international, multicenter, randomized, parallel-group, double-blind (for dose) study. Journal of Pediatric Gastroenterology and Nutrition2015;10(1):S24-30. ">Tolia 2010b</a>; <a href="./references#CD008550-bbs2-0017" title="GunasekaranT , GuptaS , GremseD , KarolM , Pan W-J, Chin Y-L, et al. Lansoprazole in adolescents with gastroesophageal reflux disease: pharmacokinetics, pharmacodynamics, symptom relief efficacy, and tolerability. Journal of Pediatric Gastroenterology and Nutrition2002;35(4):S327-35. ">Gunesekaran 2003</a>; <a href="./references#CD008550-bbs2-0018" title="HaddadI , KierkusJ , TronE , UlmerA , HuP , SloanS , et al. Efficacy and safety of rabeprazole in children (1-11 years) with gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2013;57(6):798-807. ">Haddad 2013</a>; <a href="./references#CD008550-bbs2-0020" title="KierkusJ , Furmaga-JablonskaW , SullivanJE , DavidES , StewartDL , RathN , et al. Pharmacodynamics and safety of pantoprazole in neonates, preterm infants, and infants aged 1-11 months with a clinical diagnosis of gastroesophageal reflux disease. Digestive Diseases and Sciences2011;56:425-34. ">Kierkus 2011</a>; <a href="./references#CD008550-bbs2-0031" title="ToliaV , BishopPR , TsouVM , GremseD , SofferEF , ComerGM , et al. Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5-11 years) with symptomatic gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2006;42(4):384-91. ">Tolia 2006</a>; <a href="./references#CD008550-bbs2-0032" title="ToliaV , GilgerMA , BarkerPN , IlluecaM . Healing of erosive esophagitis and improvement of symptoms of gastroesophageal reflux disease after esomeprazole treatment in children 12 to 36 months old. Journal of Pediatric Gastroenterology and Nutrition2010;51(5):593-8. ">Tolia 2010a</a>; <a href="./references#CD008550-bbs2-0033" title="ToliaV , YoussefNN , GilgerMA , TraxlerB , IlluecaM . Esomeprazole for the treatment of erosive esophagitis in children: an international, multicenter, randomized, parallel-group, double-blind (for dose) study. BMC Pediatrics2010;10:41-50. [DOI: 10.1186/1471-2431-10-41]ToliaV , YoussefNN , GilgerMA , TraxlerB , IlluecaM . Esomeprazole for the treatment of erosive esophagitis in children: an international, multicenter, randomized, parallel-group, double-blind (for dose) study. Journal of Pediatric Gastroenterology and Nutrition2015;10(1):S24-30. ">Tolia 2010b</a>; <a href="./references#CD008550-bbs2-0034" title="TsouVM , BakerR , BookL , HammoAH , SofferEF , WangW , et al. Multicenter, randomized, double-blind study comparing 20 and 40 mg of pantoprazole for symptom relief in adolescents (12 to 16 years of age) with gastroesophageal reflux disease (GERD). Clinical Pediatrics2006;45(8):741-9. ">Tsou 2006</a>). One study compared improvements on the active medication to baseline (<a href="./references#CD008550-bbs2-0025" title="OmariTI , BenningaMA , SansomL , ButlerRN , DentJ , DavidsonGP . Effect of baclofen on esophagogastric motility and gastroesophageal reflux in children with gastroesophageal reflux disease: a randomized controlled trial. Journal of Pediatrics2006;149(4):468-74. ">Omari 2006</a>). All the studies were conducted on outpatients except <a href="./references#CD008550-bbs2-0009" title="CresiF , MarinaccioC , RussoMC , MinieroR , SilvestroL . Short-term effect of domperidone on gastroesophageal reflux in newborns assessed by combined intraluminal impedance and pH monitoring. Journal of Perinatology2008;28:766-70. ">Cresi 2008</a> and <a href="./references#CD008550-bbs2-0012" title="DavidsonG , WenzlTG , ThomsonM , OmariT , BarkerP , LundborgP , et al. Efficacy and safety of once-daily esomeprazole for the treatment of gastroesophageal reflux disease in neonatal patients. Journal of Pediatrics2013;163(3):692-8. ">Davidson 2013</a> which were conducted on inpatients in neonatal intensive care units (NICUs). All bar four of the studies were conducted in high‐income countries: <a href="./references#CD008550-bbs2-0001" title="AzizollahiHR , RafeeyM . Efficacy of proton pump inhibitors and H2 blocker in the treatment of symptomatic gastroesophageal reflux disease in infants. Korean Journal of Pediatrics2016;59(5):226-30. ">Azizollahi 2016</a>, <a href="./references#CD008550-bbs2-0014" title="FamouriF , ZibanejadN , KabiriP , KelishadR . Comparison of hypoallergenic diet vs. ranitidine in treatment of gastroesophageal reflux disease of infants: a randomized clinical trial. Iranian Journal of Pediatrics2017;27(4):e5343. ">Famouri 2017</a>, <a href="./references#CD008550-bbs2-0024" title="NaeimiM , KianifarH , MemarianiZ , KamalinejadM , BijaniA , SaghebiR , et al. Comparison of the efficacy of ranitidine and quince syrup on gastroesophageal reflux disease in children. Complementary Therapies in Medicine2019;45:215-21. ">Naeimi 2019</a>, and <a href="./references#CD008550-bbs2-0036" title="ZohalinezhadME , ImaniehMH , SamaniSM , MohagheghzadehA , DehghaniSM , HaghighatM , et al. Effects of quince syrup on clinical symptoms of children with symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Complementary Therapies in Clinical Practice2015;21(4):268-76. ZohalinezhadME , ZohalinezhadIS , SamaniA , MohagheghzadehF , DehghaniH . Efficacy of quince (Cydonia oblonga M) syrup in symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Planta Medica2016;82(1):1439. ">Zohalinezhad 2015</a> were conducted in Iran, a lower‐middle income country (<a href="./references#CD008550-bbs2-0125" title="World Bank. Country and Lending Groups classification of countries by income. datatopics.worldbank.org/world-development-indicators/the-world-by-income-and-region.html Accessed prior to 20 May 2023.">World Bank 2022</a>). </p> </section> <section id="CD008550-sec-0063"> <h5 class="title">Participants</h5> <p>Nineteen studies assessed infants only, six studies assessed infants and children, and 11 assessed children aged one year or older. Of the studies that assessed infants only, 14 included infants with symptomatic GORD (<a href="./references#CD008550-bbs2-0001" title="AzizollahiHR , RafeeyM . Efficacy of proton pump inhibitors and H2 blocker in the treatment of symptomatic gastroesophageal reflux disease in infants. Korean Journal of Pediatrics2016;59(5):226-30. ">Azizollahi 2016</a>; <a href="./references#CD008550-bbs2-0003" title="BaldassarreME , Di MauroA , PignatelliMC , FanelliM , SalvatoreS , Di NardoG , et al. Magnesium alginate in gastro-esophageal reflux: a randomized multicenter cross-over study in infants. International Journal of Environmental Research and Public Health2020;17(1):83. ">Baldassarre 2020</a>; <a href="./references#CD008550-bbs2-0005" title="BinesJE , QuinlanJE , TrevesS , KleinmanRE , WinterHS . Efficacy of domperidone in infants and children with gastroesophageal reflux. Journal of Pediatric Gastroenterology and Nutrition1992;14(4):400-5. ">Bines 1992</a>; <a href="./references#CD008550-bbs2-0009" title="CresiF , MarinaccioC , RussoMC , MinieroR , SilvestroL . Short-term effect of domperidone on gastroesophageal reflux in newborns assessed by combined intraluminal impedance and pH monitoring. Journal of Perinatology2008;28:766-70. ">Cresi 2008</a>; <a href="./references#CD008550-bbs2-0012" title="DavidsonG , WenzlTG , ThomsonM , OmariT , BarkerP , LundborgP , et al. Efficacy and safety of once-daily esomeprazole for the treatment of gastroesophageal reflux disease in neonatal patients. Journal of Pediatrics2013;163(3):692-8. ">Davidson 2013</a>; <a href="./references#CD008550-bbs2-0013" title="Del BuonoR , WenzlTG , BallG , KeadyS , ThomsonM . Effect of Gaviscon Infant on gastro-oesophageal reflux in infants assessed by combined intraluminal impedance/pH. Archives of Disease in Childhood2005;90:460-3. ">Del Buono 2005</a>; <a href="./references#CD008550-bbs2-0014" title="FamouriF , ZibanejadN , KabiriP , KelishadR . Comparison of hypoallergenic diet vs. ranitidine in treatment of gastroesophageal reflux disease of infants: a randomized clinical trial. Iranian Journal of Pediatrics2017;27(4):e5343. ">Famouri 2017</a>; <a href="./references#CD008550-bbs2-0015" title="ForbesD , HodgsonM , HillR . The effects of gaviscon and metoclopramide in gastroesophageal reflux in children. Journal of Pediatric Gastroenterology and Nutrition1986;5(4):556-9. ">Forbes 1986</a>; <a href="./references#CD008550-bbs2-0019" title="HussainS , KierkusJ , HuP , HoffmanD , LekichR , SloanS , et al. Safety and efficacy of delayed release rabeprazole in 1- to 11-month-old infants with symptomatic GERD. Journal of Pediatric Gastroenterology and Nutrition2014;58(2):226-36. ">Hussain 2014</a>; <a href="./references#CD008550-bbs2-0021" title="LootsC , KritasS , vanWijkM , McCallL , PeetersL , LewindonP , et al. Body positioning and medical therapy for infantile gastroesophageal reflux symptoms. Journal of Pediatric Gastroenterology and Nutrition2014;59(2):237-43. ">Loots 2014</a>; <a href="./references#CD008550-bbs2-0022" title="MillerS . Comparison of the efficacy and safety of a new aluminum-free paediatric alginate preparation and placebo in infants with recurrent gastro-oesophageal reflux. Current Medical Research and Opinion1999;15(3):160-8. ">Miller 1999</a>; <a href="./references#CD008550-bbs2-0027" title="OrensteinSR , ShalabyTM , DevandrySN , LiacourasCA , CzinnSJ , DiceJE , et al. Famotidine for infant gastro-oesophageal reflux: a multi-centre, randomized, placebo-controlled, withdrawal trial. Alimentary Pharmacology and Therapeutics2003;17(9):1097-107. ">Orenstein 2002</a>; <a href="./references#CD008550-bbs2-0028" title="OrensteinSR , HassallE , Furmaga-JablonskaW , AtkinsonS , RaananM . Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. Journal of Pediatrics2009;154(4):514-20. ">Orenstein 2008</a>; <a href="./references#CD008550-bbs2-0035" title="UmmarinoD , MieleE , MartinelliM , ScarpatoE , CrocettoF , SciorioE , et al. Effect of magnesium alginate plus simethicone on gastroesophageal reflux in infants. Journal of Pediatric Gastroenterology and Nutrition2015;60(2):230-5. ">Ummarino 2015</a>), four studies included infants with symptoms and signs of GORD on 24‐hour pH/impedance monitoring (<a href="./references#CD008550-bbs2-0004" title="BallengeeCR , DavalianF , ConawayMR , SauerCG , KaufmanDA . Erythromycin and reflux events in premature neonates: a randomized clinical trial. Journal of Pediatric Gastroenterology and Nutrition2018;67(6):720-25. ">Ballengee 2018</a>; <a href="./references#CD008550-bbs2-0020" title="KierkusJ , Furmaga-JablonskaW , SullivanJE , DavidES , StewartDL , RathN , et al. Pharmacodynamics and safety of pantoprazole in neonates, preterm infants, and infants aged 1-11 months with a clinical diagnosis of gastroesophageal reflux disease. Digestive Diseases and Sciences2011;56:425-34. ">Kierkus 2011</a>; <a href="./references#CD008550-bbs2-0023" title="MooreDJ , TaoBS , LinesDR , HirteC , HeddleML , DavidsonGP . Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. Journal of Pediatrics2003;143(2):219-23. ">Moore 2003</a>; <a href="./references#CD008550-bbs2-0026" title="OmariT , DavidsonG , BondarovP , NauclerE , NilssonC , LundborgP . Pharmacokinetics and acid-suppressive effects of esomeprazole in infants 1-24 months old with symptoms of gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2007;45(5):530-7. [MEDLINE: Published in abstract form in JPGN:2006: 42: E1-110]OmariT , DavidsonG , BondarovP , NauclerE , NilssonC , LundborgP . Pharmacokinetics and acid-suppressive effects of esomeprazole in infants 1-24 months old with symptoms of gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2015;60:S2-S8. ">Omari 2007</a>); one study included infants with endoscopic changes (<a href="./references#CD008550-bbs2-0029" title="PfefferkornMD , CroffieJM , GuptaSK , MollestonJP , EckertGJ , CorkinsMR , et al. Nocturnal acid breakthrough in children with reflux esophagitis taking proton pump inhibitors. Journal of Pediatric Gastroenterology and Nutrition2006;42(2):160-5. ">Pfefferkorn 2006</a>); and one study included infants with either significant pH indices or endoscopic changes (<a href="./references#CD008550-bbs2-0023" title="MooreDJ , TaoBS , LinesDR , HirteC , HeddleML , DavidsonGP . Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. Journal of Pediatrics2003;143(2):219-23. ">Moore 2003</a>). Of those studies in both infants and children, one study included participants with symptomatic GORD (<a href="./references#CD008550-bbs2-0036" title="ZohalinezhadME , ImaniehMH , SamaniSM , MohagheghzadehA , DehghaniSM , HaghighatM , et al. Effects of quince syrup on clinical symptoms of children with symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Complementary Therapies in Clinical Practice2015;21(4):268-76. ZohalinezhadME , ZohalinezhadIS , SamaniA , MohagheghzadehF , DehghaniH . Efficacy of quince (Cydonia oblonga M) syrup in symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Planta Medica2016;82(1):1439. ">Zohalinezhad 2015</a>), and six studies undertook corroborative investigations (pH/impedance and endoscopy) (<a href="./references#CD008550-bbs2-0007" title="ButsJP , BarudiC , OtteJB . Double-blind controlled study on the efficacy of sodium alginate (Gaviscon) in reducing gastroesophageal reflux assessed by 24 h continuous pH monitoring in infants and children. European Journal of Pediatrics1987;146(2):156-8. ">Buts 1987</a>; <a href="./references#CD008550-bbs2-0008" title="CarroccioA , Iacono, MontaltoG , CavataioF , SoresiM , NotarbartoloA . Domperidone plus magnesium hydroxide and aluminium hydroxide: a valid therapy in children with gastroesophageal reflux. Scandinavian Journal of Gastroenterology1994;29(4):300-4. ">Carroccio 1994</a>; <a href="./references#CD008550-bbs2-0010" title="CucchiaraS , StaianoA , RomanielloG , CapobiancoS , AurcchioS . Antacids and cimetidine treatment for gastrooesophageal reflux and peptic oesophagitis. Archives of Disease in Childhood1984;59:842-7. ">Cucchiara 1984</a>; <a href="./references#CD008550-bbs2-0011" title="CucchiaraS , MinellaR , IervolinoC , FrancoMT , CampanozziA , FranceschiM , et al. Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis. Archives of Disease in Childhood1993;69:655-9. ">Cucchiara 1993</a>; <a href="./references#CD008550-bbs2-0020" title="KierkusJ , Furmaga-JablonskaW , SullivanJE , DavidES , StewartDL , RathN , et al. Pharmacodynamics and safety of pantoprazole in neonates, preterm infants, and infants aged 1-11 months with a clinical diagnosis of gastroesophageal reflux disease. Digestive Diseases and Sciences2011;56:425-34. ">Kierkus 2011</a>; <a href="./references#CD008550-bbs2-0030" title="SimeoneD , CariaMC , MieleE , StaianoA . Treatment of childhood peptic esophagitis: a double-blind placebo-controlled trial of nizatidine. Journal of Pediatric Gastroenterology and Nutrition1997;25(1):51-5. ">Simeone 1997</a>). Of the studies in children aged one year or older, one study included children with symptomatic GORD (<a href="./references#CD008550-bbs2-0024" title="NaeimiM , KianifarH , MemarianiZ , KamalinejadM , BijaniA , SaghebiR , et al. Comparison of the efficacy of ranitidine and quince syrup on gastroesophageal reflux disease in children. Complementary Therapies in Medicine2019;45:215-21. ">Naeimi 2019</a>), and 10 studies undertook corroborative investigations (endoscopy, pH/impedance studies, or both) (<a href="./references#CD008550-bbs2-0002" title="BakerR , TsouVM , TungJ , BakerSS , LiH , WangW , et al. Clinical results from a randomised, double-blind, dose-ranging study of pantoprazole in children aged 1 through 5 years with symptomatic histologic or erosive esophagitis. Clinical Pediatrics2010;49(9):852-65. ">Baker 2010</a>; <a href="./references#CD008550-bbs2-0006" title="BorrelliO , ReaP , Bueno De MesquitaM , AmbrosiniA , ManciniV , Di NardoG , et al. Efficacy of combined administration of an alginate formulation (Gaviscon) and Lansoprazole for children with gastroesophageal reflux. Italian Journal of Pediatrics2002;28(4):304-9. ">Borrelli 2002</a>; <a href="./references#CD008550-bbs2-0016" title="GilgerM , ToliaV , VandenplasY , YoussefN , TraxlerB , IlluecaM . Safety and tolerability of esomeprazole in children with gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2006;43(4):E20-21. GilgerMA , ToliaV , VandenplasY , YoussefNN , TraxlerB , IlluecaM . Safety and tolerability of esomeprazole in children with gastro-esophageal reflux disease. Gastroenterology2015;46(5):S16-23. ">Gilger 2006</a>; <a href="./references#CD008550-bbs2-0017" title="GunasekaranT , GuptaS , GremseD , KarolM , Pan W-J, Chin Y-L, et al. Lansoprazole in adolescents with gastroesophageal reflux disease: pharmacokinetics, pharmacodynamics, symptom relief efficacy, and tolerability. Journal of Pediatric Gastroenterology and Nutrition2002;35(4):S327-35. ">Gunesekaran 2003</a>; <a href="./references#CD008550-bbs2-0018" title="HaddadI , KierkusJ , TronE , UlmerA , HuP , SloanS , et al. Efficacy and safety of rabeprazole in children (1-11 years) with gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2013;57(6):798-807. ">Haddad 2013</a>; <a href="./references#CD008550-bbs2-0025" title="OmariTI , BenningaMA , SansomL , ButlerRN , DentJ , DavidsonGP . Effect of baclofen on esophagogastric motility and gastroesophageal reflux in children with gastroesophageal reflux disease: a randomized controlled trial. Journal of Pediatrics2006;149(4):468-74. ">Omari 2006</a>; <a href="./references#CD008550-bbs2-0031" title="ToliaV , BishopPR , TsouVM , GremseD , SofferEF , ComerGM , et al. Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5-11 years) with symptomatic gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2006;42(4):384-91. ">Tolia 2006</a>; <a href="./references#CD008550-bbs2-0032" title="ToliaV , GilgerMA , BarkerPN , IlluecaM . Healing of erosive esophagitis and improvement of symptoms of gastroesophageal reflux disease after esomeprazole treatment in children 12 to 36 months old. Journal of Pediatric Gastroenterology and Nutrition2010;51(5):593-8. ">Tolia 2010a</a>; <a href="./references#CD008550-bbs2-0033" title="ToliaV , YoussefNN , GilgerMA , TraxlerB , IlluecaM . Esomeprazole for the treatment of erosive esophagitis in children: an international, multicenter, randomized, parallel-group, double-blind (for dose) study. BMC Pediatrics2010;10:41-50. [DOI: 10.1186/1471-2431-10-41]ToliaV , YoussefNN , GilgerMA , TraxlerB , IlluecaM . Esomeprazole for the treatment of erosive esophagitis in children: an international, multicenter, randomized, parallel-group, double-blind (for dose) study. Journal of Pediatric Gastroenterology and Nutrition2015;10(1):S24-30. ">Tolia 2010b</a>; <a href="./references#CD008550-bbs2-0034" title="TsouVM , BakerR , BookL , HammoAH , SofferEF , WangW , et al. Multicenter, randomized, double-blind study comparing 20 and 40 mg of pantoprazole for symptom relief in adolescents (12 to 16 years of age) with gastroesophageal reflux disease (GERD). Clinical Pediatrics2006;45(8):741-9. ">Tsou 2006</a>). Fourteen studies contained suitable summary data for extraction (described below in 'Interventions and comparisons'). Of those 14 studies, two studies had data on both infants and children (<a href="./references#CD008550-bbs2-0010" title="CucchiaraS , StaianoA , RomanielloG , CapobiancoS , AurcchioS . Antacids and cimetidine treatment for gastrooesophageal reflux and peptic oesophagitis. Archives of Disease in Childhood1984;59:842-7. ">Cucchiara 1984</a>; <a href="./references#CD008550-bbs2-0036" title="ZohalinezhadME , ImaniehMH , SamaniSM , MohagheghzadehA , DehghaniSM , HaghighatM , et al. Effects of quince syrup on clinical symptoms of children with symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Complementary Therapies in Clinical Practice2015;21(4):268-76. ZohalinezhadME , ZohalinezhadIS , SamaniA , MohagheghzadehF , DehghaniH . Efficacy of quince (Cydonia oblonga M) syrup in symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Planta Medica2016;82(1):1439. ">Zohalinezhad 2015</a>); we discuss these in <a href="#CD008550-sec-0061">Included studies</a> and <a href="#CD008550-sec-0080">Effects of interventions</a> but do not present them in the summary of findings tables. </p> </section> <section id="CD008550-sec-0064"> <h5 class="title">Interventions and comparisons</h5> <section id="CD008550-sec-0065"> <h6 class="title">Studies in infants</h6> <p>Two studies with summary data assessed proton pump inhibitors (PPIs) versus placebo (<a href="./references#CD008550-bbs2-0023" title="MooreDJ , TaoBS , LinesDR , HirteC , HeddleML , DavidsonGP . Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. Journal of Pediatrics2003;143(2):219-23. ">Moore 2003</a> assessed omeprazole, <a href="./references#CD008550-bbs2-0012" title="DavidsonG , WenzlTG , ThomsonM , OmariT , BarkerP , LundborgP , et al. Efficacy and safety of once-daily esomeprazole for the treatment of gastroesophageal reflux disease in neonatal patients. Journal of Pediatrics2013;163(3):692-8. ">Davidson 2013</a> assessed esomeprazole); one study with summary data compared a PPI (omeprazole) with another medication (ranitidine) (<a href="./references#CD008550-bbs2-0001" title="AzizollahiHR , RafeeyM . Efficacy of proton pump inhibitors and H2 blocker in the treatment of symptomatic gastroesophageal reflux disease in infants. Korean Journal of Pediatrics2016;59(5):226-30. ">Azizollahi 2016</a>); and two studies with summary data assessed a PPI given in different doses (<a href="./references#CD008550-bbs2-0020" title="KierkusJ , Furmaga-JablonskaW , SullivanJE , DavidES , StewartDL , RathN , et al. Pharmacodynamics and safety of pantoprazole in neonates, preterm infants, and infants aged 1-11 months with a clinical diagnosis of gastroesophageal reflux disease. Digestive Diseases and Sciences2011;56:425-34. ">Kierkus 2011</a> assessed pantoprazole, <a href="./references#CD008550-bbs2-0019" title="HussainS , KierkusJ , HuP , HoffmanD , LekichR , SloanS , et al. Safety and efficacy of delayed release rabeprazole in 1- to 11-month-old infants with symptomatic GERD. Journal of Pediatric Gastroenterology and Nutrition2014;58(2):226-36. ">Hussain 2014</a> assessed rabeprazole). For H₂ antagonists, <a href="./references#CD008550-bbs2-0001" title="AzizollahiHR , RafeeyM . Efficacy of proton pump inhibitors and H2 blocker in the treatment of symptomatic gastroesophageal reflux disease in infants. Korean Journal of Pediatrics2016;59(5):226-30. ">Azizollahi 2016</a> compared ranitidine with another medication (omeprazole). There were no studies with summary data that assessed prokinetics or magnesium alginate. </p> </section> <section id="CD008550-sec-0066"> <h6 class="title">Studies in children</h6> <p>Six studies with summary data assessed a PPI. Two studies compared a PPI with another medication: <a href="./references#CD008550-bbs2-0029" title="PfefferkornMD , CroffieJM , GuptaSK , MollestonJP , EckertGJ , CorkinsMR , et al. Nocturnal acid breakthrough in children with reflux esophagitis taking proton pump inhibitors. Journal of Pediatric Gastroenterology and Nutrition2006;42(2):160-5. ">Pfefferkorn 2006</a> compared omeprazole to additional ranitidine, and <a href="./references#CD008550-bbs2-0036" title="ZohalinezhadME , ImaniehMH , SamaniSM , MohagheghzadehA , DehghaniSM , HaghighatM , et al. Effects of quince syrup on clinical symptoms of children with symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Complementary Therapies in Clinical Practice2015;21(4):268-76. ZohalinezhadME , ZohalinezhadIS , SamaniA , MohagheghzadehF , DehghaniH . Efficacy of quince (Cydonia oblonga M) syrup in symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Planta Medica2016;82(1):1439. ">Zohalinezhad 2015</a> compared omeprazole to quince syrup. Three studies compared different doses of a PPI: <a href="./references#CD008550-bbs2-0002" title="BakerR , TsouVM , TungJ , BakerSS , LiH , WangW , et al. Clinical results from a randomised, double-blind, dose-ranging study of pantoprazole in children aged 1 through 5 years with symptomatic histologic or erosive esophagitis. Clinical Pediatrics2010;49(9):852-65. ">Baker 2010</a> and <a href="./references#CD008550-bbs2-0031" title="ToliaV , BishopPR , TsouVM , GremseD , SofferEF , ComerGM , et al. Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5-11 years) with symptomatic gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2006;42(4):384-91. ">Tolia 2006</a> assessed pantoprazole, <a href="./references#CD008550-bbs2-0018" title="HaddadI , KierkusJ , TronE , UlmerA , HuP , SloanS , et al. Efficacy and safety of rabeprazole in children (1-11 years) with gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2013;57(6):798-807. ">Haddad 2013</a> assessed rabeprazole. For H₂ antagonists, as noted above, <a href="./references#CD008550-bbs2-0001" title="AzizollahiHR , RafeeyM . Efficacy of proton pump inhibitors and H2 blocker in the treatment of symptomatic gastroesophageal reflux disease in infants. Korean Journal of Pediatrics2016;59(5):226-30. ">Azizollahi 2016</a> compared ranitidine to omeprazole. Two studies assessed quince syrup: as noted above, <a href="./references#CD008550-bbs2-0036" title="ZohalinezhadME , ImaniehMH , SamaniSM , MohagheghzadehA , DehghaniSM , HaghighatM , et al. Effects of quince syrup on clinical symptoms of children with symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Complementary Therapies in Clinical Practice2015;21(4):268-76. ZohalinezhadME , ZohalinezhadIS , SamaniA , MohagheghzadehF , DehghaniH . Efficacy of quince (Cydonia oblonga M) syrup in symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Planta Medica2016;82(1):1439. ">Zohalinezhad 2015</a> compared quince syrup to omeprazole, and <a href="./references#CD008550-bbs2-0024" title="NaeimiM , KianifarH , MemarianiZ , KamalinejadM , BijaniA , SaghebiR , et al. Comparison of the efficacy of ranitidine and quince syrup on gastroesophageal reflux disease in children. Complementary Therapies in Medicine2019;45:215-21. ">Naeimi 2019</a> compared ranitidine plus quince syrup to ranitidine alone. </p> </section> </section> <section id="CD008550-sec-0067"> <h5 class="title">Outcomes</h5> <section id="CD008550-sec-0068"> <h6 class="title">Studies in infants</h6> <p>Of studies which compared a PPI to placebo, one study with summary data provided data on clinical symptoms (<a href="./references#CD008550-bbs2-0023" title="MooreDJ , TaoBS , LinesDR , HirteC , HeddleML , DavidsonGP . Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. Journal of Pediatrics2003;143(2):219-23. ">Moore 2003</a>), and three studies provided data on pH/impedance outcomes: <a href="./references#CD008550-bbs2-0023" title="MooreDJ , TaoBS , LinesDR , HirteC , HeddleML , DavidsonGP . Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. Journal of Pediatrics2003;143(2):219-23. ">Moore 2003</a> assessed omeprazole, <a href="./references#CD008550-bbs2-0012" title="DavidsonG , WenzlTG , ThomsonM , OmariT , BarkerP , LundborgP , et al. Efficacy and safety of once-daily esomeprazole for the treatment of gastroesophageal reflux disease in neonatal patients. Journal of Pediatrics2013;163(3):692-8. ">Davidson 2013</a> assessed esomeprazole, and <a href="./references#CD008550-bbs2-0020" title="KierkusJ , Furmaga-JablonskaW , SullivanJE , DavidES , StewartDL , RathN , et al. Pharmacodynamics and safety of pantoprazole in neonates, preterm infants, and infants aged 1-11 months with a clinical diagnosis of gastroesophageal reflux disease. Digestive Diseases and Sciences2011;56:425-34. ">Kierkus 2011</a> assessed pantoprazole. One study on a PPI versus another medication (ranitidine) provided summary symptomatic data (<a href="./references#CD008550-bbs2-0001" title="AzizollahiHR , RafeeyM . Efficacy of proton pump inhibitors and H2 blocker in the treatment of symptomatic gastroesophageal reflux disease in infants. Korean Journal of Pediatrics2016;59(5):226-30. ">Azizollahi 2016</a>). One study on pantoprazole at different doses provided 24‐hour pH/impedance outcome data (<a href="./references#CD008550-bbs2-0020" title="KierkusJ , Furmaga-JablonskaW , SullivanJE , DavidES , StewartDL , RathN , et al. Pharmacodynamics and safety of pantoprazole in neonates, preterm infants, and infants aged 1-11 months with a clinical diagnosis of gastroesophageal reflux disease. Digestive Diseases and Sciences2011;56:425-34. ">Kierkus 2011</a>). One study with summary data assessed a PPI given in different doses (rabeprazole) (<a href="./references#CD008550-bbs2-0019" title="HussainS , KierkusJ , HuP , HoffmanD , LekichR , SloanS , et al. Safety and efficacy of delayed release rabeprazole in 1- to 11-month-old infants with symptomatic GERD. Journal of Pediatric Gastroenterology and Nutrition2014;58(2):226-36. ">Hussain 2014</a>). For H₂ antagonists, one study with symptomatic summary data compared ranitidine to another medication (omeprazole: <a href="./references#CD008550-bbs2-0001" title="AzizollahiHR , RafeeyM . Efficacy of proton pump inhibitors and H2 blocker in the treatment of symptomatic gastroesophageal reflux disease in infants. Korean Journal of Pediatrics2016;59(5):226-30. ">Azizollahi 2016</a>). There were no studies with summary data assessing prokinetics or alginates. </p> </section> <section id="CD008550-sec-0069"> <h6 class="title">Studies in children</h6> <p>We included six studies assessing a PPI from which we were able to extract summary data, as follows. <a href="./references#CD008550-bbs2-0029" title="PfefferkornMD , CroffieJM , GuptaSK , MollestonJP , EckertGJ , CorkinsMR , et al. Nocturnal acid breakthrough in children with reflux esophagitis taking proton pump inhibitors. Journal of Pediatric Gastroenterology and Nutrition2006;42(2):160-5. ">Pfefferkorn 2006</a> assessed omeprazole versus additional ranitidine and provided symptoms scores and reflux index data. <a href="./references#CD008550-bbs2-0036" title="ZohalinezhadME , ImaniehMH , SamaniSM , MohagheghzadehA , DehghaniSM , HaghighatM , et al. Effects of quince syrup on clinical symptoms of children with symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Complementary Therapies in Clinical Practice2015;21(4):268-76. ZohalinezhadME , ZohalinezhadIS , SamaniA , MohagheghzadehF , DehghaniH . Efficacy of quince (Cydonia oblonga M) syrup in symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Planta Medica2016;82(1):1439. ">Zohalinezhad 2015</a> provided symptom scores in a comparison of omeprazole to quince syrup. Three studies of pantoprazole provided extracted summary data: <a href="./references#CD008550-bbs2-0002" title="BakerR , TsouVM , TungJ , BakerSS , LiH , WangW , et al. Clinical results from a randomised, double-blind, dose-ranging study of pantoprazole in children aged 1 through 5 years with symptomatic histologic or erosive esophagitis. Clinical Pediatrics2010;49(9):852-65. ">Baker 2010</a> and <a href="./references#CD008550-bbs2-0031" title="ToliaV , BishopPR , TsouVM , GremseD , SofferEF , ComerGM , et al. Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5-11 years) with symptomatic gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2006;42(4):384-91. ">Tolia 2006</a> provided symptom scores, and endoscopic and histological scores, and <a href="./references#CD008550-bbs2-0034" title="TsouVM , BakerR , BookL , HammoAH , SofferEF , WangW , et al. Multicenter, randomized, double-blind study comparing 20 and 40 mg of pantoprazole for symptom relief in adolescents (12 to 16 years of age) with gastroesophageal reflux disease (GERD). Clinical Pediatrics2006;45(8):741-9. ">Tsou 2006</a> provided symptom scores. <a href="./references#CD008550-bbs2-0018" title="HaddadI , KierkusJ , TronE , UlmerA , HuP , SloanS , et al. Efficacy and safety of rabeprazole in children (1-11 years) with gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2013;57(6):798-807. ">Haddad 2013</a> studied rabeprazole and provided symptom scores and endoscopic and histological scores. </p> <p>As stated above, <a href="./references#CD008550-bbs2-0001" title="AzizollahiHR , RafeeyM . Efficacy of proton pump inhibitors and H2 blocker in the treatment of symptomatic gastroesophageal reflux disease in infants. Korean Journal of Pediatrics2016;59(5):226-30. ">Azizollahi 2016</a> assessed an H₂ antagonist (additional ranitidine with omeprazole) and provided summary symptomatic data. Two studies provided symptomatic summary data only on quince syrup (<a href="./references#CD008550-bbs2-0036" title="ZohalinezhadME , ImaniehMH , SamaniSM , MohagheghzadehA , DehghaniSM , HaghighatM , et al. Effects of quince syrup on clinical symptoms of children with symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Complementary Therapies in Clinical Practice2015;21(4):268-76. ZohalinezhadME , ZohalinezhadIS , SamaniA , MohagheghzadehF , DehghaniH . Efficacy of quince (Cydonia oblonga M) syrup in symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Planta Medica2016;82(1):1439. ">Zohalinezhad 2015</a> compared quince syrup to omeprazole, and <a href="./references#CD008550-bbs2-0024" title="NaeimiM , KianifarH , MemarianiZ , KamalinejadM , BijaniA , SaghebiR , et al. Comparison of the efficacy of ranitidine and quince syrup on gastroesophageal reflux disease in children. Complementary Therapies in Medicine2019;45:215-21. ">Naeimi 2019</a> compared ranitidine plus quince syrup to ranitidine alone). </p> <p>Included studies adopted different definitions of adverse events. Studies also varied in terms of reporting of adverse events and patient monitoring, and potential incomplete reporting. We have presented all reported adverse events. </p> <p>No studies provided long‐term data on the number of infants or children failing to respond to medication and requiring fundoplication. </p> </section> </section> </section> <section id="CD008550-sec-0070"> <h4 class="title">Excluded studies</h4> <p>We excluded 40 studies (42 records) at the full‐text screening stage. The primary reasons for exclusion were: ineligible study design (36 studies); ineligible intervention (three studies); ineligible population (one study). Please see <a href="./references#CD008550-sec-0249" title="">Characteristics of excluded studies</a> for further details. </p> </section> </section> <section id="CD008550-sec-0071"> <h3 class="title">Risk of bias in included studies</h3> <p>We detail our risk of bias assessments by study in <a href="#CD008550-fig-0002">Figure 2</a> and <a href="#CD008550-fig-0003">Figure 3</a>. With many of the older studies, it was difficult to clarify methodological issues from the published protocol. </p> <div class="figure" id="CD008550-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD008550-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008550.pub3/media/CDSR/CD008550/image_n/nCD008550-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <div class="figure" id="CD008550-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements presented as percentages across all included studies" data-id="CD008550-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008550.pub3/media/CDSR/CD008550/image_n/nCD008550-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements presented as percentages across all included studies </p> </div> </div> </div> <section id="CD008550-sec-0072"> <h4 class="title">Random sequence generation (selection bias)</h4> <p>Fifteen studies clearly described an adequate method of random sequence generation, such as blocked randomisation; we assessed these as having a low risk of bias (<a href="./references#CD008550-bbs2-0001" title="AzizollahiHR , RafeeyM . Efficacy of proton pump inhibitors and H2 blocker in the treatment of symptomatic gastroesophageal reflux disease in infants. Korean Journal of Pediatrics2016;59(5):226-30. ">Azizollahi 2016</a>; <a href="./references#CD008550-bbs2-0003" title="BaldassarreME , Di MauroA , PignatelliMC , FanelliM , SalvatoreS , Di NardoG , et al. Magnesium alginate in gastro-esophageal reflux: a randomized multicenter cross-over study in infants. International Journal of Environmental Research and Public Health2020;17(1):83. ">Baldassarre 2020</a>; <a href="./references#CD008550-bbs2-0004" title="BallengeeCR , DavalianF , ConawayMR , SauerCG , KaufmanDA . Erythromycin and reflux events in premature neonates: a randomized clinical trial. Journal of Pediatric Gastroenterology and Nutrition2018;67(6):720-25. ">Ballengee 2018</a>; <a href="./references#CD008550-bbs2-0006" title="BorrelliO , ReaP , Bueno De MesquitaM , AmbrosiniA , ManciniV , Di NardoG , et al. Efficacy of combined administration of an alginate formulation (Gaviscon) and Lansoprazole for children with gastroesophageal reflux. Italian Journal of Pediatrics2002;28(4):304-9. ">Borrelli 2002</a>; <a href="./references#CD008550-bbs2-0008" title="CarroccioA , Iacono, MontaltoG , CavataioF , SoresiM , NotarbartoloA . Domperidone plus magnesium hydroxide and aluminium hydroxide: a valid therapy in children with gastroesophageal reflux. Scandinavian Journal of Gastroenterology1994;29(4):300-4. ">Carroccio 1994</a>; <a href="./references#CD008550-bbs2-0009" title="CresiF , MarinaccioC , RussoMC , MinieroR , SilvestroL . Short-term effect of domperidone on gastroesophageal reflux in newborns assessed by combined intraluminal impedance and pH monitoring. Journal of Perinatology2008;28:766-70. ">Cresi 2008</a>; <a href="./references#CD008550-bbs2-0012" title="DavidsonG , WenzlTG , ThomsonM , OmariT , BarkerP , LundborgP , et al. Efficacy and safety of once-daily esomeprazole for the treatment of gastroesophageal reflux disease in neonatal patients. Journal of Pediatrics2013;163(3):692-8. ">Davidson 2013</a>; <a href="./references#CD008550-bbs2-0017" title="GunasekaranT , GuptaS , GremseD , KarolM , Pan W-J, Chin Y-L, et al. Lansoprazole in adolescents with gastroesophageal reflux disease: pharmacokinetics, pharmacodynamics, symptom relief efficacy, and tolerability. Journal of Pediatric Gastroenterology and Nutrition2002;35(4):S327-35. ">Gunesekaran 2003</a>; <a href="./references#CD008550-bbs2-0020" title="KierkusJ , Furmaga-JablonskaW , SullivanJE , DavidES , StewartDL , RathN , et al. Pharmacodynamics and safety of pantoprazole in neonates, preterm infants, and infants aged 1-11 months with a clinical diagnosis of gastroesophageal reflux disease. Digestive Diseases and Sciences2011;56:425-34. ">Kierkus 2011</a>; <a href="./references#CD008550-bbs2-0021" title="LootsC , KritasS , vanWijkM , McCallL , PeetersL , LewindonP , et al. Body positioning and medical therapy for infantile gastroesophageal reflux symptoms. Journal of Pediatric Gastroenterology and Nutrition2014;59(2):237-43. ">Loots 2014</a>; <a href="./references#CD008550-bbs2-0023" title="MooreDJ , TaoBS , LinesDR , HirteC , HeddleML , DavidsonGP . Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. Journal of Pediatrics2003;143(2):219-23. ">Moore 2003</a>; <a href="./references#CD008550-bbs2-0024" title="NaeimiM , KianifarH , MemarianiZ , KamalinejadM , BijaniA , SaghebiR , et al. Comparison of the efficacy of ranitidine and quince syrup on gastroesophageal reflux disease in children. Complementary Therapies in Medicine2019;45:215-21. ">Naeimi 2019</a>; <a href="./references#CD008550-bbs2-0028" title="OrensteinSR , HassallE , Furmaga-JablonskaW , AtkinsonS , RaananM . Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. Journal of Pediatrics2009;154(4):514-20. ">Orenstein 2008</a>; <a href="./references#CD008550-bbs2-0029" title="PfefferkornMD , CroffieJM , GuptaSK , MollestonJP , EckertGJ , CorkinsMR , et al. Nocturnal acid breakthrough in children with reflux esophagitis taking proton pump inhibitors. Journal of Pediatric Gastroenterology and Nutrition2006;42(2):160-5. ">Pfefferkorn 2006</a>; <a href="./references#CD008550-bbs2-0036" title="ZohalinezhadME , ImaniehMH , SamaniSM , MohagheghzadehA , DehghaniSM , HaghighatM , et al. Effects of quince syrup on clinical symptoms of children with symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Complementary Therapies in Clinical Practice2015;21(4):268-76. ZohalinezhadME , ZohalinezhadIS , SamaniA , MohagheghzadehF , DehghaniH . Efficacy of quince (Cydonia oblonga M) syrup in symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Planta Medica2016;82(1):1439. ">Zohalinezhad 2015</a>). Nineteen studies made no reference to or incompletely outlined the method of randomisation used in their trial; we assessed these as having an unclear risk of bias (<a href="./references#CD008550-bbs2-0002" title="BakerR , TsouVM , TungJ , BakerSS , LiH , WangW , et al. Clinical results from a randomised, double-blind, dose-ranging study of pantoprazole in children aged 1 through 5 years with symptomatic histologic or erosive esophagitis. Clinical Pediatrics2010;49(9):852-65. ">Baker 2010</a>; <a href="./references#CD008550-bbs2-0005" title="BinesJE , QuinlanJE , TrevesS , KleinmanRE , WinterHS . Efficacy of domperidone in infants and children with gastroesophageal reflux. Journal of Pediatric Gastroenterology and Nutrition1992;14(4):400-5. ">Bines 1992</a>; <a href="./references#CD008550-bbs2-0007" title="ButsJP , BarudiC , OtteJB . Double-blind controlled study on the efficacy of sodium alginate (Gaviscon) in reducing gastroesophageal reflux assessed by 24 h continuous pH monitoring in infants and children. European Journal of Pediatrics1987;146(2):156-8. ">Buts 1987</a>; <a href="./references#CD008550-bbs2-0010" title="CucchiaraS , StaianoA , RomanielloG , CapobiancoS , AurcchioS . Antacids and cimetidine treatment for gastrooesophageal reflux and peptic oesophagitis. Archives of Disease in Childhood1984;59:842-7. ">Cucchiara 1984</a>; <a href="./references#CD008550-bbs2-0011" title="CucchiaraS , MinellaR , IervolinoC , FrancoMT , CampanozziA , FranceschiM , et al. Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis. Archives of Disease in Childhood1993;69:655-9. ">Cucchiara 1993</a>; <a href="./references#CD008550-bbs2-0013" title="Del BuonoR , WenzlTG , BallG , KeadyS , ThomsonM . Effect of Gaviscon Infant on gastro-oesophageal reflux in infants assessed by combined intraluminal impedance/pH. Archives of Disease in Childhood2005;90:460-3. ">Del Buono 2005</a>; <a href="./references#CD008550-bbs2-0015" title="ForbesD , HodgsonM , HillR . The effects of gaviscon and metoclopramide in gastroesophageal reflux in children. Journal of Pediatric Gastroenterology and Nutrition1986;5(4):556-9. ">Forbes 1986</a>; <a href="./references#CD008550-bbs2-0014" title="FamouriF , ZibanejadN , KabiriP , KelishadR . Comparison of hypoallergenic diet vs. ranitidine in treatment of gastroesophageal reflux disease of infants: a randomized clinical trial. Iranian Journal of Pediatrics2017;27(4):e5343. ">Famouri 2017</a>; <a href="./references#CD008550-bbs2-0016" title="GilgerM , ToliaV , VandenplasY , YoussefN , TraxlerB , IlluecaM . Safety and tolerability of esomeprazole in children with gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2006;43(4):E20-21. GilgerMA , ToliaV , VandenplasY , YoussefNN , TraxlerB , IlluecaM . Safety and tolerability of esomeprazole in children with gastro-esophageal reflux disease. Gastroenterology2015;46(5):S16-23. ">Gilger 2006</a>; <a href="./references#CD008550-bbs2-0018" title="HaddadI , KierkusJ , TronE , UlmerA , HuP , SloanS , et al. Efficacy and safety of rabeprazole in children (1-11 years) with gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2013;57(6):798-807. ">Haddad 2013</a>; <a href="./references#CD008550-bbs2-0019" title="HussainS , KierkusJ , HuP , HoffmanD , LekichR , SloanS , et al. Safety and efficacy of delayed release rabeprazole in 1- to 11-month-old infants with symptomatic GERD. Journal of Pediatric Gastroenterology and Nutrition2014;58(2):226-36. ">Hussain 2014</a>; <a href="./references#CD008550-bbs2-0022" title="MillerS . Comparison of the efficacy and safety of a new aluminum-free paediatric alginate preparation and placebo in infants with recurrent gastro-oesophageal reflux. Current Medical Research and Opinion1999;15(3):160-8. ">Miller 1999</a>; <a href="./references#CD008550-bbs2-0025" title="OmariTI , BenningaMA , SansomL , ButlerRN , DentJ , DavidsonGP . Effect of baclofen on esophagogastric motility and gastroesophageal reflux in children with gastroesophageal reflux disease: a randomized controlled trial. Journal of Pediatrics2006;149(4):468-74. ">Omari 2006</a>; <a href="./references#CD008550-bbs2-0026" title="OmariT , DavidsonG , BondarovP , NauclerE , NilssonC , LundborgP . Pharmacokinetics and acid-suppressive effects of esomeprazole in infants 1-24 months old with symptoms of gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2007;45(5):530-7. [MEDLINE: Published in abstract form in JPGN:2006: 42: E1-110]OmariT , DavidsonG , BondarovP , NauclerE , NilssonC , LundborgP . Pharmacokinetics and acid-suppressive effects of esomeprazole in infants 1-24 months old with symptoms of gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2015;60:S2-S8. ">Omari 2007</a>; <a href="./references#CD008550-bbs2-0027" title="OrensteinSR , ShalabyTM , DevandrySN , LiacourasCA , CzinnSJ , DiceJE , et al. Famotidine for infant gastro-oesophageal reflux: a multi-centre, randomized, placebo-controlled, withdrawal trial. Alimentary Pharmacology and Therapeutics2003;17(9):1097-107. ">Orenstein 2002</a>; <a href="./references#CD008550-bbs2-0030" title="SimeoneD , CariaMC , MieleE , StaianoA . Treatment of childhood peptic esophagitis: a double-blind placebo-controlled trial of nizatidine. Journal of Pediatric Gastroenterology and Nutrition1997;25(1):51-5. ">Simeone 1997</a>; <a href="./references#CD008550-bbs2-0031" title="ToliaV , BishopPR , TsouVM , GremseD , SofferEF , ComerGM , et al. Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5-11 years) with symptomatic gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2006;42(4):384-91. ">Tolia 2006</a>; <a href="./references#CD008550-bbs2-0034" title="TsouVM , BakerR , BookL , HammoAH , SofferEF , WangW , et al. Multicenter, randomized, double-blind study comparing 20 and 40 mg of pantoprazole for symptom relief in adolescents (12 to 16 years of age) with gastroesophageal reflux disease (GERD). Clinical Pediatrics2006;45(8):741-9. ">Tsou 2006</a>; <a href="./references#CD008550-bbs2-0035" title="UmmarinoD , MieleE , MartinelliM , ScarpatoE , CrocettoF , SciorioE , et al. Effect of magnesium alginate plus simethicone on gastroesophageal reflux in infants. Journal of Pediatric Gastroenterology and Nutrition2015;60(2):230-5. ">Ummarino 2015</a>). We judged the remaining two studies to be at high risk of selection bias (<a href="./references#CD008550-bbs2-0032" title="ToliaV , GilgerMA , BarkerPN , IlluecaM . Healing of erosive esophagitis and improvement of symptoms of gastroesophageal reflux disease after esomeprazole treatment in children 12 to 36 months old. Journal of Pediatric Gastroenterology and Nutrition2010;51(5):593-8. ">Tolia 2010a</a> due to the nature of a post hoc analysis and the risk of bias posed by the selection of participants with oesophagitis who have not responded satisfactorily to other approved therapy; <a href="./references#CD008550-bbs2-0033" title="ToliaV , YoussefNN , GilgerMA , TraxlerB , IlluecaM . Esomeprazole for the treatment of erosive esophagitis in children: an international, multicenter, randomized, parallel-group, double-blind (for dose) study. BMC Pediatrics2010;10:41-50. [DOI: 10.1186/1471-2431-10-41]ToliaV , YoussefNN , GilgerMA , TraxlerB , IlluecaM . Esomeprazole for the treatment of erosive esophagitis in children: an international, multicenter, randomized, parallel-group, double-blind (for dose) study. Journal of Pediatric Gastroenterology and Nutrition2015;10(1):S24-30. ">Tolia 2010b</a> due to the risk of bias posed by the selection of participants for initial endoscopy and then enrolment being performed at the discretion of the investigator). </p> </section> <section id="CD008550-sec-0073"> <h4 class="title">Allocation</h4> <p>Nine studies specified the method of allocation, such as randomised computer‐generated allocation; we assessed these studies as having a low risk of bias in this domain (<a href="./references#CD008550-bbs2-0001" title="AzizollahiHR , RafeeyM . Efficacy of proton pump inhibitors and H2 blocker in the treatment of symptomatic gastroesophageal reflux disease in infants. Korean Journal of Pediatrics2016;59(5):226-30. ">Azizollahi 2016</a>; <a href="./references#CD008550-bbs2-0003" title="BaldassarreME , Di MauroA , PignatelliMC , FanelliM , SalvatoreS , Di NardoG , et al. Magnesium alginate in gastro-esophageal reflux: a randomized multicenter cross-over study in infants. International Journal of Environmental Research and Public Health2020;17(1):83. ">Baldassarre 2020</a>; <a href="./references#CD008550-bbs2-0008" title="CarroccioA , Iacono, MontaltoG , CavataioF , SoresiM , NotarbartoloA . Domperidone plus magnesium hydroxide and aluminium hydroxide: a valid therapy in children with gastroesophageal reflux. Scandinavian Journal of Gastroenterology1994;29(4):300-4. ">Carroccio 1994</a>; <a href="./references#CD008550-bbs2-0009" title="CresiF , MarinaccioC , RussoMC , MinieroR , SilvestroL . Short-term effect of domperidone on gastroesophageal reflux in newborns assessed by combined intraluminal impedance and pH monitoring. Journal of Perinatology2008;28:766-70. ">Cresi 2008</a>; <a href="./references#CD008550-bbs2-0012" title="DavidsonG , WenzlTG , ThomsonM , OmariT , BarkerP , LundborgP , et al. Efficacy and safety of once-daily esomeprazole for the treatment of gastroesophageal reflux disease in neonatal patients. Journal of Pediatrics2013;163(3):692-8. ">Davidson 2013</a>; <a href="./references#CD008550-bbs2-0017" title="GunasekaranT , GuptaS , GremseD , KarolM , Pan W-J, Chin Y-L, et al. Lansoprazole in adolescents with gastroesophageal reflux disease: pharmacokinetics, pharmacodynamics, symptom relief efficacy, and tolerability. Journal of Pediatric Gastroenterology and Nutrition2002;35(4):S327-35. ">Gunesekaran 2003</a>; <a href="./references#CD008550-bbs2-0018" title="HaddadI , KierkusJ , TronE , UlmerA , HuP , SloanS , et al. Efficacy and safety of rabeprazole in children (1-11 years) with gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2013;57(6):798-807. ">Haddad 2013</a>; <a href="./references#CD008550-bbs2-0023" title="MooreDJ , TaoBS , LinesDR , HirteC , HeddleML , DavidsonGP . Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. Journal of Pediatrics2003;143(2):219-23. ">Moore 2003</a>; <a href="./references#CD008550-bbs2-0024" title="NaeimiM , KianifarH , MemarianiZ , KamalinejadM , BijaniA , SaghebiR , et al. Comparison of the efficacy of ranitidine and quince syrup on gastroesophageal reflux disease in children. Complementary Therapies in Medicine2019;45:215-21. ">Naeimi 2019</a>). Twenty‐four studies made no reference to or incompletely outlined the method of allocation used in their trial; we assessed these as having an unclear risk of bias (<a href="./references#CD008550-bbs2-0002" title="BakerR , TsouVM , TungJ , BakerSS , LiH , WangW , et al. Clinical results from a randomised, double-blind, dose-ranging study of pantoprazole in children aged 1 through 5 years with symptomatic histologic or erosive esophagitis. Clinical Pediatrics2010;49(9):852-65. ">Baker 2010</a>; <a href="./references#CD008550-bbs2-0004" title="BallengeeCR , DavalianF , ConawayMR , SauerCG , KaufmanDA . Erythromycin and reflux events in premature neonates: a randomized clinical trial. Journal of Pediatric Gastroenterology and Nutrition2018;67(6):720-25. ">Ballengee 2018</a>; <a href="./references#CD008550-bbs2-0005" title="BinesJE , QuinlanJE , TrevesS , KleinmanRE , WinterHS . Efficacy of domperidone in infants and children with gastroesophageal reflux. Journal of Pediatric Gastroenterology and Nutrition1992;14(4):400-5. ">Bines 1992</a>; <a href="./references#CD008550-bbs2-0006" title="BorrelliO , ReaP , Bueno De MesquitaM , AmbrosiniA , ManciniV , Di NardoG , et al. Efficacy of combined administration of an alginate formulation (Gaviscon) and Lansoprazole for children with gastroesophageal reflux. Italian Journal of Pediatrics2002;28(4):304-9. ">Borrelli 2002</a>; <a href="./references#CD008550-bbs2-0007" title="ButsJP , BarudiC , OtteJB . Double-blind controlled study on the efficacy of sodium alginate (Gaviscon) in reducing gastroesophageal reflux assessed by 24 h continuous pH monitoring in infants and children. European Journal of Pediatrics1987;146(2):156-8. ">Buts 1987</a>; <a href="./references#CD008550-bbs2-0010" title="CucchiaraS , StaianoA , RomanielloG , CapobiancoS , AurcchioS . Antacids and cimetidine treatment for gastrooesophageal reflux and peptic oesophagitis. Archives of Disease in Childhood1984;59:842-7. ">Cucchiara 1984</a>; <a href="./references#CD008550-bbs2-0011" title="CucchiaraS , MinellaR , IervolinoC , FrancoMT , CampanozziA , FranceschiM , et al. Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis. Archives of Disease in Childhood1993;69:655-9. ">Cucchiara 1993</a>; <a href="./references#CD008550-bbs2-0013" title="Del BuonoR , WenzlTG , BallG , KeadyS , ThomsonM . Effect of Gaviscon Infant on gastro-oesophageal reflux in infants assessed by combined intraluminal impedance/pH. Archives of Disease in Childhood2005;90:460-3. ">Del Buono 2005</a>; <a href="./references#CD008550-bbs2-0015" title="ForbesD , HodgsonM , HillR . The effects of gaviscon and metoclopramide in gastroesophageal reflux in children. Journal of Pediatric Gastroenterology and Nutrition1986;5(4):556-9. ">Forbes 1986</a>; <a href="./references#CD008550-bbs2-0014" title="FamouriF , ZibanejadN , KabiriP , KelishadR . Comparison of hypoallergenic diet vs. ranitidine in treatment of gastroesophageal reflux disease of infants: a randomized clinical trial. Iranian Journal of Pediatrics2017;27(4):e5343. ">Famouri 2017</a>; <a href="./references#CD008550-bbs2-0016" title="GilgerM , ToliaV , VandenplasY , YoussefN , TraxlerB , IlluecaM . Safety and tolerability of esomeprazole in children with gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2006;43(4):E20-21. GilgerMA , ToliaV , VandenplasY , YoussefNN , TraxlerB , IlluecaM . Safety and tolerability of esomeprazole in children with gastro-esophageal reflux disease. Gastroenterology2015;46(5):S16-23. ">Gilger 2006</a>; <a href="./references#CD008550-bbs2-0019" title="HussainS , KierkusJ , HuP , HoffmanD , LekichR , SloanS , et al. Safety and efficacy of delayed release rabeprazole in 1- to 11-month-old infants with symptomatic GERD. Journal of Pediatric Gastroenterology and Nutrition2014;58(2):226-36. ">Hussain 2014</a>; <a href="./references#CD008550-bbs2-0020" title="KierkusJ , Furmaga-JablonskaW , SullivanJE , DavidES , StewartDL , RathN , et al. Pharmacodynamics and safety of pantoprazole in neonates, preterm infants, and infants aged 1-11 months with a clinical diagnosis of gastroesophageal reflux disease. Digestive Diseases and Sciences2011;56:425-34. ">Kierkus 2011</a>; <a href="./references#CD008550-bbs2-0021" title="LootsC , KritasS , vanWijkM , McCallL , PeetersL , LewindonP , et al. Body positioning and medical therapy for infantile gastroesophageal reflux symptoms. Journal of Pediatric Gastroenterology and Nutrition2014;59(2):237-43. ">Loots 2014</a>; <a href="./references#CD008550-bbs2-0022" title="MillerS . Comparison of the efficacy and safety of a new aluminum-free paediatric alginate preparation and placebo in infants with recurrent gastro-oesophageal reflux. Current Medical Research and Opinion1999;15(3):160-8. ">Miller 1999</a>; <a href="./references#CD008550-bbs2-0025" title="OmariTI , BenningaMA , SansomL , ButlerRN , DentJ , DavidsonGP . Effect of baclofen on esophagogastric motility and gastroesophageal reflux in children with gastroesophageal reflux disease: a randomized controlled trial. Journal of Pediatrics2006;149(4):468-74. ">Omari 2006</a>; <a href="./references#CD008550-bbs2-0026" title="OmariT , DavidsonG , BondarovP , NauclerE , NilssonC , LundborgP . Pharmacokinetics and acid-suppressive effects of esomeprazole in infants 1-24 months old with symptoms of gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2007;45(5):530-7. [MEDLINE: Published in abstract form in JPGN:2006: 42: E1-110]OmariT , DavidsonG , BondarovP , NauclerE , NilssonC , LundborgP . Pharmacokinetics and acid-suppressive effects of esomeprazole in infants 1-24 months old with symptoms of gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2015;60:S2-S8. ">Omari 2007</a>; <a href="./references#CD008550-bbs2-0027" title="OrensteinSR , ShalabyTM , DevandrySN , LiacourasCA , CzinnSJ , DiceJE , et al. Famotidine for infant gastro-oesophageal reflux: a multi-centre, randomized, placebo-controlled, withdrawal trial. Alimentary Pharmacology and Therapeutics2003;17(9):1097-107. ">Orenstein 2002</a>; <a href="./references#CD008550-bbs2-0028" title="OrensteinSR , HassallE , Furmaga-JablonskaW , AtkinsonS , RaananM . Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. Journal of Pediatrics2009;154(4):514-20. ">Orenstein 2008</a>, <a href="./references#CD008550-bbs2-0029" title="PfefferkornMD , CroffieJM , GuptaSK , MollestonJP , EckertGJ , CorkinsMR , et al. Nocturnal acid breakthrough in children with reflux esophagitis taking proton pump inhibitors. Journal of Pediatric Gastroenterology and Nutrition2006;42(2):160-5. ">Pfefferkorn 2006</a>; <a href="./references#CD008550-bbs2-0030" title="SimeoneD , CariaMC , MieleE , StaianoA . Treatment of childhood peptic esophagitis: a double-blind placebo-controlled trial of nizatidine. Journal of Pediatric Gastroenterology and Nutrition1997;25(1):51-5. ">Simeone 1997</a>; <a href="./references#CD008550-bbs2-0031" title="ToliaV , BishopPR , TsouVM , GremseD , SofferEF , ComerGM , et al. Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5-11 years) with symptomatic gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2006;42(4):384-91. ">Tolia 2006</a>; <a href="./references#CD008550-bbs2-0034" title="TsouVM , BakerR , BookL , HammoAH , SofferEF , WangW , et al. Multicenter, randomized, double-blind study comparing 20 and 40 mg of pantoprazole for symptom relief in adolescents (12 to 16 years of age) with gastroesophageal reflux disease (GERD). Clinical Pediatrics2006;45(8):741-9. ">Tsou 2006</a>; <a href="./references#CD008550-bbs2-0035" title="UmmarinoD , MieleE , MartinelliM , ScarpatoE , CrocettoF , SciorioE , et al. Effect of magnesium alginate plus simethicone on gastroesophageal reflux in infants. Journal of Pediatric Gastroenterology and Nutrition2015;60(2):230-5. ">Ummarino 2015</a>). We judged the remaining three studies to be at high risk of selection bias: <a href="./references#CD008550-bbs2-0032" title="ToliaV , GilgerMA , BarkerPN , IlluecaM . Healing of erosive esophagitis and improvement of symptoms of gastroesophageal reflux disease after esomeprazole treatment in children 12 to 36 months old. Journal of Pediatric Gastroenterology and Nutrition2010;51(5):593-8. ">Tolia 2010a</a> due to the nature of a post hoc analysis and the risk posed by the enrolment of participants who have not responded satisfactorily to other approved therapy; <a href="./references#CD008550-bbs2-0033" title="ToliaV , YoussefNN , GilgerMA , TraxlerB , IlluecaM . Esomeprazole for the treatment of erosive esophagitis in children: an international, multicenter, randomized, parallel-group, double-blind (for dose) study. BMC Pediatrics2010;10:41-50. [DOI: 10.1186/1471-2431-10-41]ToliaV , YoussefNN , GilgerMA , TraxlerB , IlluecaM . Esomeprazole for the treatment of erosive esophagitis in children: an international, multicenter, randomized, parallel-group, double-blind (for dose) study. Journal of Pediatric Gastroenterology and Nutrition2015;10(1):S24-30. ">Tolia 2010b</a> due to the risk of bias of enrolment based on initial endoscopy being performed at the discretion of the investigator; <a href="./references#CD008550-bbs2-0036" title="ZohalinezhadME , ImaniehMH , SamaniSM , MohagheghzadehA , DehghaniSM , HaghighatM , et al. Effects of quince syrup on clinical symptoms of children with symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Complementary Therapies in Clinical Practice2015;21(4):268-76. ZohalinezhadME , ZohalinezhadIS , SamaniA , MohagheghzadehF , DehghaniH . Efficacy of quince (Cydonia oblonga M) syrup in symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Planta Medica2016;82(1):1439. ">Zohalinezhad 2015</a> due to the marked difference in baseline symptom score in the omeprazole group, affecting outcomes such as refusal to feed and weight gain. </p> </section> <section id="CD008550-sec-0074"> <h4 class="title">Blinding</h4> <section id="CD008550-sec-0075"> <h5 class="title">Performance bias</h5> <p>We assessed 13 studies as low risk, with additional detail outlining methodological strategies to ensure equal care between groups and blinding of parents and participants (<a href="./references#CD008550-bbs2-0004" title="BallengeeCR , DavalianF , ConawayMR , SauerCG , KaufmanDA . Erythromycin and reflux events in premature neonates: a randomized clinical trial. Journal of Pediatric Gastroenterology and Nutrition2018;67(6):720-25. ">Ballengee 2018</a>; <a href="./references#CD008550-bbs2-0010" title="CucchiaraS , StaianoA , RomanielloG , CapobiancoS , AurcchioS . Antacids and cimetidine treatment for gastrooesophageal reflux and peptic oesophagitis. Archives of Disease in Childhood1984;59:842-7. ">Cucchiara 1984</a>; <a href="./references#CD008550-bbs2-0013" title="Del BuonoR , WenzlTG , BallG , KeadyS , ThomsonM . Effect of Gaviscon Infant on gastro-oesophageal reflux in infants assessed by combined intraluminal impedance/pH. Archives of Disease in Childhood2005;90:460-3. ">Del Buono 2005</a>; <a href="./references#CD008550-bbs2-0016" title="GilgerM , ToliaV , VandenplasY , YoussefN , TraxlerB , IlluecaM . Safety and tolerability of esomeprazole in children with gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2006;43(4):E20-21. GilgerMA , ToliaV , VandenplasY , YoussefNN , TraxlerB , IlluecaM . Safety and tolerability of esomeprazole in children with gastro-esophageal reflux disease. Gastroenterology2015;46(5):S16-23. ">Gilger 2006</a>; <a href="./references#CD008550-bbs2-0018" title="HaddadI , KierkusJ , TronE , UlmerA , HuP , SloanS , et al. Efficacy and safety of rabeprazole in children (1-11 years) with gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2013;57(6):798-807. ">Haddad 2013</a>; <a href="./references#CD008550-bbs2-0023" title="MooreDJ , TaoBS , LinesDR , HirteC , HeddleML , DavidsonGP . Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. Journal of Pediatrics2003;143(2):219-23. ">Moore 2003</a>; <a href="./references#CD008550-bbs2-0024" title="NaeimiM , KianifarH , MemarianiZ , KamalinejadM , BijaniA , SaghebiR , et al. Comparison of the efficacy of ranitidine and quince syrup on gastroesophageal reflux disease in children. Complementary Therapies in Medicine2019;45:215-21. ">Naeimi 2019</a>; <a href="./references#CD008550-bbs2-0025" title="OmariTI , BenningaMA , SansomL , ButlerRN , DentJ , DavidsonGP . Effect of baclofen on esophagogastric motility and gastroesophageal reflux in children with gastroesophageal reflux disease: a randomized controlled trial. Journal of Pediatrics2006;149(4):468-74. ">Omari 2006</a>; <a href="./references#CD008550-bbs2-0028" title="OrensteinSR , HassallE , Furmaga-JablonskaW , AtkinsonS , RaananM . Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. Journal of Pediatrics2009;154(4):514-20. ">Orenstein 2008</a>; <a href="./references#CD008550-bbs2-0029" title="PfefferkornMD , CroffieJM , GuptaSK , MollestonJP , EckertGJ , CorkinsMR , et al. Nocturnal acid breakthrough in children with reflux esophagitis taking proton pump inhibitors. Journal of Pediatric Gastroenterology and Nutrition2006;42(2):160-5. ">Pfefferkorn 2006</a>; <a href="./references#CD008550-bbs2-0032" title="ToliaV , GilgerMA , BarkerPN , IlluecaM . Healing of erosive esophagitis and improvement of symptoms of gastroesophageal reflux disease after esomeprazole treatment in children 12 to 36 months old. Journal of Pediatric Gastroenterology and Nutrition2010;51(5):593-8. ">Tolia 2010a</a>; <a href="./references#CD008550-bbs2-0033" title="ToliaV , YoussefNN , GilgerMA , TraxlerB , IlluecaM . Esomeprazole for the treatment of erosive esophagitis in children: an international, multicenter, randomized, parallel-group, double-blind (for dose) study. BMC Pediatrics2010;10:41-50. [DOI: 10.1186/1471-2431-10-41]ToliaV , YoussefNN , GilgerMA , TraxlerB , IlluecaM . Esomeprazole for the treatment of erosive esophagitis in children: an international, multicenter, randomized, parallel-group, double-blind (for dose) study. Journal of Pediatric Gastroenterology and Nutrition2015;10(1):S24-30. ">Tolia 2010b</a>; <a href="./references#CD008550-bbs2-0036" title="ZohalinezhadME , ImaniehMH , SamaniSM , MohagheghzadehA , DehghaniSM , HaghighatM , et al. Effects of quince syrup on clinical symptoms of children with symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Complementary Therapies in Clinical Practice2015;21(4):268-76. ZohalinezhadME , ZohalinezhadIS , SamaniA , MohagheghzadehF , DehghaniH . Efficacy of quince (Cydonia oblonga M) syrup in symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Planta Medica2016;82(1):1439. ">Zohalinezhad 2015</a>). Eleven studies had an unclear risk of performance bias, where the blinding between groups was not explained in sufficient detail (<a href="./references#CD008550-bbs2-0002" title="BakerR , TsouVM , TungJ , BakerSS , LiH , WangW , et al. Clinical results from a randomised, double-blind, dose-ranging study of pantoprazole in children aged 1 through 5 years with symptomatic histologic or erosive esophagitis. Clinical Pediatrics2010;49(9):852-65. ">Baker 2010</a>; <a href="./references#CD008550-bbs2-0006" title="BorrelliO , ReaP , Bueno De MesquitaM , AmbrosiniA , ManciniV , Di NardoG , et al. Efficacy of combined administration of an alginate formulation (Gaviscon) and Lansoprazole for children with gastroesophageal reflux. Italian Journal of Pediatrics2002;28(4):304-9. ">Borrelli 2002</a>; <a href="./references#CD008550-bbs2-0007" title="ButsJP , BarudiC , OtteJB . Double-blind controlled study on the efficacy of sodium alginate (Gaviscon) in reducing gastroesophageal reflux assessed by 24 h continuous pH monitoring in infants and children. European Journal of Pediatrics1987;146(2):156-8. ">Buts 1987</a>; <a href="./references#CD008550-bbs2-0008" title="CarroccioA , Iacono, MontaltoG , CavataioF , SoresiM , NotarbartoloA . Domperidone plus magnesium hydroxide and aluminium hydroxide: a valid therapy in children with gastroesophageal reflux. Scandinavian Journal of Gastroenterology1994;29(4):300-4. ">Carroccio 1994</a>; <a href="./references#CD008550-bbs2-0012" title="DavidsonG , WenzlTG , ThomsonM , OmariT , BarkerP , LundborgP , et al. Efficacy and safety of once-daily esomeprazole for the treatment of gastroesophageal reflux disease in neonatal patients. Journal of Pediatrics2013;163(3):692-8. ">Davidson 2013</a>; <a href="./references#CD008550-bbs2-0017" title="GunasekaranT , GuptaS , GremseD , KarolM , Pan W-J, Chin Y-L, et al. Lansoprazole in adolescents with gastroesophageal reflux disease: pharmacokinetics, pharmacodynamics, symptom relief efficacy, and tolerability. Journal of Pediatric Gastroenterology and Nutrition2002;35(4):S327-35. ">Gunesekaran 2003</a>; <a href="./references#CD008550-bbs2-0019" title="HussainS , KierkusJ , HuP , HoffmanD , LekichR , SloanS , et al. Safety and efficacy of delayed release rabeprazole in 1- to 11-month-old infants with symptomatic GERD. Journal of Pediatric Gastroenterology and Nutrition2014;58(2):226-36. ">Hussain 2014</a>; <a href="./references#CD008550-bbs2-0022" title="MillerS . Comparison of the efficacy and safety of a new aluminum-free paediatric alginate preparation and placebo in infants with recurrent gastro-oesophageal reflux. Current Medical Research and Opinion1999;15(3):160-8. ">Miller 1999</a>; <a href="./references#CD008550-bbs2-0025" title="OmariTI , BenningaMA , SansomL , ButlerRN , DentJ , DavidsonGP . Effect of baclofen on esophagogastric motility and gastroesophageal reflux in children with gastroesophageal reflux disease: a randomized controlled trial. Journal of Pediatrics2006;149(4):468-74. ">Omari 2006</a>; <a href="./references#CD008550-bbs2-0030" title="SimeoneD , CariaMC , MieleE , StaianoA . Treatment of childhood peptic esophagitis: a double-blind placebo-controlled trial of nizatidine. Journal of Pediatric Gastroenterology and Nutrition1997;25(1):51-5. ">Simeone 1997</a>; <a href="./references#CD008550-bbs2-0031" title="ToliaV , BishopPR , TsouVM , GremseD , SofferEF , ComerGM , et al. Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5-11 years) with symptomatic gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2006;42(4):384-91. ">Tolia 2006</a>). <a href="./references#CD008550-bbs2-0019" title="HussainS , KierkusJ , HuP , HoffmanD , LekichR , SloanS , et al. Safety and efficacy of delayed release rabeprazole in 1- to 11-month-old infants with symptomatic GERD. Journal of Pediatric Gastroenterology and Nutrition2014;58(2):226-36. ">Hussain 2014</a> did not specify blinding technique but did use identical placebo and active preparations, we assessed this study as having an unclear risk of bias in this domain. Twelve studies were at high risk of performance bias (<a href="./references#CD008550-bbs2-0001" title="AzizollahiHR , RafeeyM . Efficacy of proton pump inhibitors and H2 blocker in the treatment of symptomatic gastroesophageal reflux disease in infants. Korean Journal of Pediatrics2016;59(5):226-30. ">Azizollahi 2016</a>; <a href="./references#CD008550-bbs2-0003" title="BaldassarreME , Di MauroA , PignatelliMC , FanelliM , SalvatoreS , Di NardoG , et al. Magnesium alginate in gastro-esophageal reflux: a randomized multicenter cross-over study in infants. International Journal of Environmental Research and Public Health2020;17(1):83. ">Baldassarre 2020</a>; <a href="./references#CD008550-bbs2-0005" title="BinesJE , QuinlanJE , TrevesS , KleinmanRE , WinterHS . Efficacy of domperidone in infants and children with gastroesophageal reflux. Journal of Pediatric Gastroenterology and Nutrition1992;14(4):400-5. ">Bines 1992</a>; <a href="./references#CD008550-bbs2-0011" title="CucchiaraS , MinellaR , IervolinoC , FrancoMT , CampanozziA , FranceschiM , et al. Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis. Archives of Disease in Childhood1993;69:655-9. ">Cucchiara 1993</a>; <a href="./references#CD008550-bbs2-0009" title="CresiF , MarinaccioC , RussoMC , MinieroR , SilvestroL . Short-term effect of domperidone on gastroesophageal reflux in newborns assessed by combined intraluminal impedance and pH monitoring. Journal of Perinatology2008;28:766-70. ">Cresi 2008</a>; <a href="./references#CD008550-bbs2-0014" title="FamouriF , ZibanejadN , KabiriP , KelishadR . Comparison of hypoallergenic diet vs. ranitidine in treatment of gastroesophageal reflux disease of infants: a randomized clinical trial. Iranian Journal of Pediatrics2017;27(4):e5343. ">Famouri 2017</a>; <a href="./references#CD008550-bbs2-0015" title="ForbesD , HodgsonM , HillR . The effects of gaviscon and metoclopramide in gastroesophageal reflux in children. Journal of Pediatric Gastroenterology and Nutrition1986;5(4):556-9. ">Forbes 1986</a>; <a href="./references#CD008550-bbs2-0020" title="KierkusJ , Furmaga-JablonskaW , SullivanJE , DavidES , StewartDL , RathN , et al. Pharmacodynamics and safety of pantoprazole in neonates, preterm infants, and infants aged 1-11 months with a clinical diagnosis of gastroesophageal reflux disease. Digestive Diseases and Sciences2011;56:425-34. ">Kierkus 2011</a>; <a href="./references#CD008550-bbs2-0021" title="LootsC , KritasS , vanWijkM , McCallL , PeetersL , LewindonP , et al. Body positioning and medical therapy for infantile gastroesophageal reflux symptoms. Journal of Pediatric Gastroenterology and Nutrition2014;59(2):237-43. ">Loots 2014</a>; <a href="./references#CD008550-bbs2-0027" title="OrensteinSR , ShalabyTM , DevandrySN , LiacourasCA , CzinnSJ , DiceJE , et al. Famotidine for infant gastro-oesophageal reflux: a multi-centre, randomized, placebo-controlled, withdrawal trial. Alimentary Pharmacology and Therapeutics2003;17(9):1097-107. ">Orenstein 2002</a>; <a href="./references#CD008550-bbs2-0034" title="TsouVM , BakerR , BookL , HammoAH , SofferEF , WangW , et al. Multicenter, randomized, double-blind study comparing 20 and 40 mg of pantoprazole for symptom relief in adolescents (12 to 16 years of age) with gastroesophageal reflux disease (GERD). Clinical Pediatrics2006;45(8):741-9. ">Tsou 2006</a>; <a href="./references#CD008550-bbs2-0035" title="UmmarinoD , MieleE , MartinelliM , ScarpatoE , CrocettoF , SciorioE , et al. Effect of magnesium alginate plus simethicone on gastroesophageal reflux in infants. Journal of Pediatric Gastroenterology and Nutrition2015;60(2):230-5. ">Ummarino 2015</a>). The <a href="./references#CD008550-bbs2-0001" title="AzizollahiHR , RafeeyM . Efficacy of proton pump inhibitors and H2 blocker in the treatment of symptomatic gastroesophageal reflux disease in infants. Korean Journal of Pediatrics2016;59(5):226-30. ">Azizollahi 2016</a> study used different preparations (omeprazole capsule versus ranitidine syrup), increasing the risk of bias. <a href="./references#CD008550-bbs2-0003" title="BaldassarreME , Di MauroA , PignatelliMC , FanelliM , SalvatoreS , Di NardoG , et al. Magnesium alginate in gastro-esophageal reflux: a randomized multicenter cross-over study in infants. International Journal of Environmental Research and Public Health2020;17(1):83. ">Baldassarre 2020</a>, <a href="./references#CD008550-bbs2-0009" title="CresiF , MarinaccioC , RussoMC , MinieroR , SilvestroL . Short-term effect of domperidone on gastroesophageal reflux in newborns assessed by combined intraluminal impedance and pH monitoring. Journal of Perinatology2008;28:766-70. ">Cresi 2008</a>, <a href="./references#CD008550-bbs2-0014" title="FamouriF , ZibanejadN , KabiriP , KelishadR . Comparison of hypoallergenic diet vs. ranitidine in treatment of gastroesophageal reflux disease of infants: a randomized clinical trial. Iranian Journal of Pediatrics2017;27(4):e5343. ">Famouri 2017</a>, <a href="./references#CD008550-bbs2-0020" title="KierkusJ , Furmaga-JablonskaW , SullivanJE , DavidES , StewartDL , RathN , et al. Pharmacodynamics and safety of pantoprazole in neonates, preterm infants, and infants aged 1-11 months with a clinical diagnosis of gastroesophageal reflux disease. Digestive Diseases and Sciences2011;56:425-34. ">Kierkus 2011</a>, and <a href="./references#CD008550-bbs2-0034" title="TsouVM , BakerR , BookL , HammoAH , SofferEF , WangW , et al. Multicenter, randomized, double-blind study comparing 20 and 40 mg of pantoprazole for symptom relief in adolescents (12 to 16 years of age) with gastroesophageal reflux disease (GERD). Clinical Pediatrics2006;45(8):741-9. ">Tsou 2006</a> were open‐label, as was the second part of the <a href="./references#CD008550-bbs2-0005" title="BinesJE , QuinlanJE , TrevesS , KleinmanRE , WinterHS . Efficacy of domperidone in infants and children with gastroesophageal reflux. Journal of Pediatric Gastroenterology and Nutrition1992;14(4):400-5. ">Bines 1992</a> study and the first part of the <a href="./references#CD008550-bbs2-0027" title="OrensteinSR , ShalabyTM , DevandrySN , LiacourasCA , CzinnSJ , DiceJE , et al. Famotidine for infant gastro-oesophageal reflux: a multi-centre, randomized, placebo-controlled, withdrawal trial. Alimentary Pharmacology and Therapeutics2003;17(9):1097-107. ">Orenstein 2002</a> study. There was no detail regarding blinding for <a href="./references#CD008550-bbs2-0011" title="CucchiaraS , MinellaR , IervolinoC , FrancoMT , CampanozziA , FranceschiM , et al. Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis. Archives of Disease in Childhood1993;69:655-9. ">Cucchiara 1993</a>, but the participants were on ranitidine twice daily before the trial, and the ranitidine group continued receiving twice‐daily dosing, while the omeprazole group received once‐daily dosing. <a href="./references#CD008550-bbs2-0015" title="ForbesD , HodgsonM , HillR . The effects of gaviscon and metoclopramide in gastroesophageal reflux in children. Journal of Pediatric Gastroenterology and Nutrition1986;5(4):556-9. ">Forbes 1986</a> and <a href="./references#CD008550-bbs2-0035" title="UmmarinoD , MieleE , MartinelliM , ScarpatoE , CrocettoF , SciorioE , et al. Effect of magnesium alginate plus simethicone on gastroesophageal reflux in infants. Journal of Pediatric Gastroenterology and Nutrition2015;60(2):230-5. ">Ummarino 2015</a> had clinician blinding but not parental blinding. In <a href="./references#CD008550-bbs2-0021" title="LootsC , KritasS , vanWijkM , McCallL , PeetersL , LewindonP , et al. Body positioning and medical therapy for infantile gastroesophageal reflux symptoms. Journal of Pediatric Gastroenterology and Nutrition2014;59(2):237-43. ">Loots 2014</a>, the medications were double‐blind but the children's body positioning was single‐blind and parents were aware. This could affect reported symptom control outcomes, which rely heavily on parental reporting and diaries. </p> </section> <section id="CD008550-sec-0076"> <h5 class="title">Detection bias</h5> <p>We assessed 10 studies as low risk with additional detailing of blinding assessment methods for assessors (<a href="./references#CD008550-bbs2-0004" title="BallengeeCR , DavalianF , ConawayMR , SauerCG , KaufmanDA . Erythromycin and reflux events in premature neonates: a randomized clinical trial. Journal of Pediatric Gastroenterology and Nutrition2018;67(6):720-25. ">Ballengee 2018</a>; <a href="./references#CD008550-bbs2-0012" title="DavidsonG , WenzlTG , ThomsonM , OmariT , BarkerP , LundborgP , et al. Efficacy and safety of once-daily esomeprazole for the treatment of gastroesophageal reflux disease in neonatal patients. Journal of Pediatrics2013;163(3):692-8. ">Davidson 2013</a>; <a href="./references#CD008550-bbs2-0013" title="Del BuonoR , WenzlTG , BallG , KeadyS , ThomsonM . Effect of Gaviscon Infant on gastro-oesophageal reflux in infants assessed by combined intraluminal impedance/pH. Archives of Disease in Childhood2005;90:460-3. ">Del Buono 2005</a>; <a href="./references#CD008550-bbs2-0015" title="ForbesD , HodgsonM , HillR . The effects of gaviscon and metoclopramide in gastroesophageal reflux in children. Journal of Pediatric Gastroenterology and Nutrition1986;5(4):556-9. ">Forbes 1986</a>; <a href="./references#CD008550-bbs2-0018" title="HaddadI , KierkusJ , TronE , UlmerA , HuP , SloanS , et al. Efficacy and safety of rabeprazole in children (1-11 years) with gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2013;57(6):798-807. ">Haddad 2013</a>; <a href="./references#CD008550-bbs2-0021" title="LootsC , KritasS , vanWijkM , McCallL , PeetersL , LewindonP , et al. Body positioning and medical therapy for infantile gastroesophageal reflux symptoms. Journal of Pediatric Gastroenterology and Nutrition2014;59(2):237-43. ">Loots 2014</a>; <a href="./references#CD008550-bbs2-0024" title="NaeimiM , KianifarH , MemarianiZ , KamalinejadM , BijaniA , SaghebiR , et al. Comparison of the efficacy of ranitidine and quince syrup on gastroesophageal reflux disease in children. Complementary Therapies in Medicine2019;45:215-21. ">Naeimi 2019</a>; <a href="./references#CD008550-bbs2-0033" title="ToliaV , YoussefNN , GilgerMA , TraxlerB , IlluecaM . Esomeprazole for the treatment of erosive esophagitis in children: an international, multicenter, randomized, parallel-group, double-blind (for dose) study. BMC Pediatrics2010;10:41-50. [DOI: 10.1186/1471-2431-10-41]ToliaV , YoussefNN , GilgerMA , TraxlerB , IlluecaM . Esomeprazole for the treatment of erosive esophagitis in children: an international, multicenter, randomized, parallel-group, double-blind (for dose) study. Journal of Pediatric Gastroenterology and Nutrition2015;10(1):S24-30. ">Tolia 2010b</a>; <a href="./references#CD008550-bbs2-0035" title="UmmarinoD , MieleE , MartinelliM , ScarpatoE , CrocettoF , SciorioE , et al. Effect of magnesium alginate plus simethicone on gastroesophageal reflux in infants. Journal of Pediatric Gastroenterology and Nutrition2015;60(2):230-5. ">Ummarino 2015</a>; <a href="./references#CD008550-bbs2-0036" title="ZohalinezhadME , ImaniehMH , SamaniSM , MohagheghzadehA , DehghaniSM , HaghighatM , et al. Effects of quince syrup on clinical symptoms of children with symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Complementary Therapies in Clinical Practice2015;21(4):268-76. ZohalinezhadME , ZohalinezhadIS , SamaniA , MohagheghzadehF , DehghaniH . Efficacy of quince (Cydonia oblonga M) syrup in symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Planta Medica2016;82(1):1439. ">Zohalinezhad 2015</a>). Twenty studies had unclear risk, as they provided insufficient details about assessor blinding to determine risk of bias (<a href="./references#CD008550-bbs2-0001" title="AzizollahiHR , RafeeyM . Efficacy of proton pump inhibitors and H2 blocker in the treatment of symptomatic gastroesophageal reflux disease in infants. Korean Journal of Pediatrics2016;59(5):226-30. ">Azizollahi 2016</a>; <a href="./references#CD008550-bbs2-0002" title="BakerR , TsouVM , TungJ , BakerSS , LiH , WangW , et al. Clinical results from a randomised, double-blind, dose-ranging study of pantoprazole in children aged 1 through 5 years with symptomatic histologic or erosive esophagitis. Clinical Pediatrics2010;49(9):852-65. ">Baker 2010</a>; <a href="./references#CD008550-bbs2-0005" title="BinesJE , QuinlanJE , TrevesS , KleinmanRE , WinterHS . Efficacy of domperidone in infants and children with gastroesophageal reflux. Journal of Pediatric Gastroenterology and Nutrition1992;14(4):400-5. ">Bines 1992</a>; <a href="./references#CD008550-bbs2-0006" title="BorrelliO , ReaP , Bueno De MesquitaM , AmbrosiniA , ManciniV , Di NardoG , et al. Efficacy of combined administration of an alginate formulation (Gaviscon) and Lansoprazole for children with gastroesophageal reflux. Italian Journal of Pediatrics2002;28(4):304-9. ">Borrelli 2002</a>; <a href="./references#CD008550-bbs2-0007" title="ButsJP , BarudiC , OtteJB . Double-blind controlled study on the efficacy of sodium alginate (Gaviscon) in reducing gastroesophageal reflux assessed by 24 h continuous pH monitoring in infants and children. European Journal of Pediatrics1987;146(2):156-8. ">Buts 1987</a>; <a href="./references#CD008550-bbs2-0008" title="CarroccioA , Iacono, MontaltoG , CavataioF , SoresiM , NotarbartoloA . Domperidone plus magnesium hydroxide and aluminium hydroxide: a valid therapy in children with gastroesophageal reflux. Scandinavian Journal of Gastroenterology1994;29(4):300-4. ">Carroccio 1994</a>; <a href="./references#CD008550-bbs2-0010" title="CucchiaraS , StaianoA , RomanielloG , CapobiancoS , AurcchioS . Antacids and cimetidine treatment for gastrooesophageal reflux and peptic oesophagitis. Archives of Disease in Childhood1984;59:842-7. ">Cucchiara 1984</a>; <a href="./references#CD008550-bbs2-0011" title="CucchiaraS , MinellaR , IervolinoC , FrancoMT , CampanozziA , FranceschiM , et al. Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis. Archives of Disease in Childhood1993;69:655-9. ">Cucchiara 1993</a>; <a href="./references#CD008550-bbs2-0014" title="FamouriF , ZibanejadN , KabiriP , KelishadR . Comparison of hypoallergenic diet vs. ranitidine in treatment of gastroesophageal reflux disease of infants: a randomized clinical trial. Iranian Journal of Pediatrics2017;27(4):e5343. ">Famouri 2017</a>; <a href="./references#CD008550-bbs2-0016" title="GilgerM , ToliaV , VandenplasY , YoussefN , TraxlerB , IlluecaM . Safety and tolerability of esomeprazole in children with gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2006;43(4):E20-21. GilgerMA , ToliaV , VandenplasY , YoussefNN , TraxlerB , IlluecaM . Safety and tolerability of esomeprazole in children with gastro-esophageal reflux disease. Gastroenterology2015;46(5):S16-23. ">Gilger 2006</a>; <a href="./references#CD008550-bbs2-0017" title="GunasekaranT , GuptaS , GremseD , KarolM , Pan W-J, Chin Y-L, et al. Lansoprazole in adolescents with gastroesophageal reflux disease: pharmacokinetics, pharmacodynamics, symptom relief efficacy, and tolerability. Journal of Pediatric Gastroenterology and Nutrition2002;35(4):S327-35. ">Gunesekaran 2003</a>; <a href="./references#CD008550-bbs2-0019" title="HussainS , KierkusJ , HuP , HoffmanD , LekichR , SloanS , et al. Safety and efficacy of delayed release rabeprazole in 1- to 11-month-old infants with symptomatic GERD. Journal of Pediatric Gastroenterology and Nutrition2014;58(2):226-36. ">Hussain 2014</a>; <a href="./references#CD008550-bbs2-0022" title="MillerS . Comparison of the efficacy and safety of a new aluminum-free paediatric alginate preparation and placebo in infants with recurrent gastro-oesophageal reflux. Current Medical Research and Opinion1999;15(3):160-8. ">Miller 1999</a>; <a href="./references#CD008550-bbs2-0025" title="OmariTI , BenningaMA , SansomL , ButlerRN , DentJ , DavidsonGP . Effect of baclofen on esophagogastric motility and gastroesophageal reflux in children with gastroesophageal reflux disease: a randomized controlled trial. Journal of Pediatrics2006;149(4):468-74. ">Omari 2006</a>; <a href="./references#CD008550-bbs2-0026" title="OmariT , DavidsonG , BondarovP , NauclerE , NilssonC , LundborgP . Pharmacokinetics and acid-suppressive effects of esomeprazole in infants 1-24 months old with symptoms of gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2007;45(5):530-7. [MEDLINE: Published in abstract form in JPGN:2006: 42: E1-110]OmariT , DavidsonG , BondarovP , NauclerE , NilssonC , LundborgP . Pharmacokinetics and acid-suppressive effects of esomeprazole in infants 1-24 months old with symptoms of gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2015;60:S2-S8. ">Omari 2007</a>; <a href="./references#CD008550-bbs2-0028" title="OrensteinSR , HassallE , Furmaga-JablonskaW , AtkinsonS , RaananM . Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. Journal of Pediatrics2009;154(4):514-20. ">Orenstein 2008</a>; <a href="./references#CD008550-bbs2-0029" title="PfefferkornMD , CroffieJM , GuptaSK , MollestonJP , EckertGJ , CorkinsMR , et al. Nocturnal acid breakthrough in children with reflux esophagitis taking proton pump inhibitors. Journal of Pediatric Gastroenterology and Nutrition2006;42(2):160-5. ">Pfefferkorn 2006</a>; <a href="./references#CD008550-bbs2-0030" title="SimeoneD , CariaMC , MieleE , StaianoA . Treatment of childhood peptic esophagitis: a double-blind placebo-controlled trial of nizatidine. Journal of Pediatric Gastroenterology and Nutrition1997;25(1):51-5. ">Simeone 1997</a>; <a href="./references#CD008550-bbs2-0032" title="ToliaV , GilgerMA , BarkerPN , IlluecaM . Healing of erosive esophagitis and improvement of symptoms of gastroesophageal reflux disease after esomeprazole treatment in children 12 to 36 months old. Journal of Pediatric Gastroenterology and Nutrition2010;51(5):593-8. ">Tolia 2010a</a>; <a href="./references#CD008550-bbs2-0034" title="TsouVM , BakerR , BookL , HammoAH , SofferEF , WangW , et al. Multicenter, randomized, double-blind study comparing 20 and 40 mg of pantoprazole for symptom relief in adolescents (12 to 16 years of age) with gastroesophageal reflux disease (GERD). Clinical Pediatrics2006;45(8):741-9. ">Tsou 2006</a>). We assessed the six remaining studies as high risk (<a href="./references#CD008550-bbs2-0003" title="BaldassarreME , Di MauroA , PignatelliMC , FanelliM , SalvatoreS , Di NardoG , et al. Magnesium alginate in gastro-esophageal reflux: a randomized multicenter cross-over study in infants. International Journal of Environmental Research and Public Health2020;17(1):83. ">Baldassarre 2020</a>; <a href="./references#CD008550-bbs2-0009" title="CresiF , MarinaccioC , RussoMC , MinieroR , SilvestroL . Short-term effect of domperidone on gastroesophageal reflux in newborns assessed by combined intraluminal impedance and pH monitoring. Journal of Perinatology2008;28:766-70. ">Cresi 2008</a>; <a href="./references#CD008550-bbs2-0020" title="KierkusJ , Furmaga-JablonskaW , SullivanJE , DavidES , StewartDL , RathN , et al. Pharmacodynamics and safety of pantoprazole in neonates, preterm infants, and infants aged 1-11 months with a clinical diagnosis of gastroesophageal reflux disease. Digestive Diseases and Sciences2011;56:425-34. ">Kierkus 2011</a>; <a href="./references#CD008550-bbs2-0023" title="MooreDJ , TaoBS , LinesDR , HirteC , HeddleML , DavidsonGP . Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. Journal of Pediatrics2003;143(2):219-23. ">Moore 2003</a>; <a href="./references#CD008550-bbs2-0027" title="OrensteinSR , ShalabyTM , DevandrySN , LiacourasCA , CzinnSJ , DiceJE , et al. Famotidine for infant gastro-oesophageal reflux: a multi-centre, randomized, placebo-controlled, withdrawal trial. Alimentary Pharmacology and Therapeutics2003;17(9):1097-107. ">Orenstein 2002</a>; <a href="./references#CD008550-bbs2-0031" title="ToliaV , BishopPR , TsouVM , GremseD , SofferEF , ComerGM , et al. Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5-11 years) with symptomatic gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2006;42(4):384-91. ">Tolia 2006</a>). Assessors were aware of the outcome for <a href="./references#CD008550-bbs2-0003" title="BaldassarreME , Di MauroA , PignatelliMC , FanelliM , SalvatoreS , Di NardoG , et al. Magnesium alginate in gastro-esophageal reflux: a randomized multicenter cross-over study in infants. International Journal of Environmental Research and Public Health2020;17(1):83. ">Baldassarre 2020</a>, <a href="./references#CD008550-bbs2-0009" title="CresiF , MarinaccioC , RussoMC , MinieroR , SilvestroL . Short-term effect of domperidone on gastroesophageal reflux in newborns assessed by combined intraluminal impedance and pH monitoring. Journal of Perinatology2008;28:766-70. ">Cresi 2008</a>, and <a href="./references#CD008550-bbs2-0020" title="KierkusJ , Furmaga-JablonskaW , SullivanJE , DavidES , StewartDL , RathN , et al. Pharmacodynamics and safety of pantoprazole in neonates, preterm infants, and infants aged 1-11 months with a clinical diagnosis of gastroesophageal reflux disease. Digestive Diseases and Sciences2011;56:425-34. ">Kierkus 2011</a>. Parental diaries and visual analogue scores in <a href="./references#CD008550-bbs2-0023" title="MooreDJ , TaoBS , LinesDR , HirteC , HeddleML , DavidsonGP . Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. Journal of Pediatrics2003;143(2):219-23. ">Moore 2003</a> were open to recall bias. In <a href="./references#CD008550-bbs2-0027" title="OrensteinSR , ShalabyTM , DevandrySN , LiacourasCA , CzinnSJ , DiceJE , et al. Famotidine for infant gastro-oesophageal reflux: a multi-centre, randomized, placebo-controlled, withdrawal trial. Alimentary Pharmacology and Therapeutics2003;17(9):1097-107. ">Orenstein 2002</a>, the parents were unblinded to the interventions in part one, affecting the risk of bias for the parental assessment. <a href="./references#CD008550-bbs2-0031" title="ToliaV , BishopPR , TsouVM , GremseD , SofferEF , ComerGM , et al. Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5-11 years) with symptomatic gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2006;42(4):384-91. ">Tolia 2006</a> was assessed as high risk as the endoscopic outcomes were not assessed in one group. </p> </section> </section> <section id="CD008550-sec-0077"> <h4 class="title">Incomplete outcome data</h4> <p>Studies with good completion of outcome data were: <a href="./references#CD008550-bbs2-0002" title="BakerR , TsouVM , TungJ , BakerSS , LiH , WangW , et al. Clinical results from a randomised, double-blind, dose-ranging study of pantoprazole in children aged 1 through 5 years with symptomatic histologic or erosive esophagitis. Clinical Pediatrics2010;49(9):852-65. ">Baker 2010</a>; <a href="./references#CD008550-bbs2-0003" title="BaldassarreME , Di MauroA , PignatelliMC , FanelliM , SalvatoreS , Di NardoG , et al. Magnesium alginate in gastro-esophageal reflux: a randomized multicenter cross-over study in infants. International Journal of Environmental Research and Public Health2020;17(1):83. ">Baldassarre 2020</a>; <a href="./references#CD008550-bbs2-0004" title="BallengeeCR , DavalianF , ConawayMR , SauerCG , KaufmanDA . Erythromycin and reflux events in premature neonates: a randomized clinical trial. Journal of Pediatric Gastroenterology and Nutrition2018;67(6):720-25. ">Ballengee 2018</a>; <a href="./references#CD008550-bbs2-0008" title="CarroccioA , Iacono, MontaltoG , CavataioF , SoresiM , NotarbartoloA . Domperidone plus magnesium hydroxide and aluminium hydroxide: a valid therapy in children with gastroesophageal reflux. Scandinavian Journal of Gastroenterology1994;29(4):300-4. ">Carroccio 1994</a>; <a href="./references#CD008550-bbs2-0010" title="CucchiaraS , StaianoA , RomanielloG , CapobiancoS , AurcchioS . Antacids and cimetidine treatment for gastrooesophageal reflux and peptic oesophagitis. Archives of Disease in Childhood1984;59:842-7. ">Cucchiara 1984</a>; <a href="./references#CD008550-bbs2-0012" title="DavidsonG , WenzlTG , ThomsonM , OmariT , BarkerP , LundborgP , et al. Efficacy and safety of once-daily esomeprazole for the treatment of gastroesophageal reflux disease in neonatal patients. Journal of Pediatrics2013;163(3):692-8. ">Davidson 2013</a>; <a href="./references#CD008550-bbs2-0016" title="GilgerM , ToliaV , VandenplasY , YoussefN , TraxlerB , IlluecaM . Safety and tolerability of esomeprazole in children with gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2006;43(4):E20-21. GilgerMA , ToliaV , VandenplasY , YoussefNN , TraxlerB , IlluecaM . Safety and tolerability of esomeprazole in children with gastro-esophageal reflux disease. Gastroenterology2015;46(5):S16-23. ">Gilger 2006</a>; <a href="./references#CD008550-bbs2-0021" title="LootsC , KritasS , vanWijkM , McCallL , PeetersL , LewindonP , et al. Body positioning and medical therapy for infantile gastroesophageal reflux symptoms. Journal of Pediatric Gastroenterology and Nutrition2014;59(2):237-43. ">Loots 2014</a>; <a href="./references#CD008550-bbs2-0023" title="MooreDJ , TaoBS , LinesDR , HirteC , HeddleML , DavidsonGP . Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. Journal of Pediatrics2003;143(2):219-23. ">Moore 2003</a>; <a href="./references#CD008550-bbs2-0024" title="NaeimiM , KianifarH , MemarianiZ , KamalinejadM , BijaniA , SaghebiR , et al. Comparison of the efficacy of ranitidine and quince syrup on gastroesophageal reflux disease in children. Complementary Therapies in Medicine2019;45:215-21. ">Naeimi 2019</a>; <a href="./references#CD008550-bbs2-0027" title="OrensteinSR , ShalabyTM , DevandrySN , LiacourasCA , CzinnSJ , DiceJE , et al. Famotidine for infant gastro-oesophageal reflux: a multi-centre, randomized, placebo-controlled, withdrawal trial. Alimentary Pharmacology and Therapeutics2003;17(9):1097-107. ">Orenstein 2002</a>; <a href="./references#CD008550-bbs2-0031" title="ToliaV , BishopPR , TsouVM , GremseD , SofferEF , ComerGM , et al. Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5-11 years) with symptomatic gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2006;42(4):384-91. ">Tolia 2006</a>; <a href="./references#CD008550-bbs2-0035" title="UmmarinoD , MieleE , MartinelliM , ScarpatoE , CrocettoF , SciorioE , et al. Effect of magnesium alginate plus simethicone on gastroesophageal reflux in infants. Journal of Pediatric Gastroenterology and Nutrition2015;60(2):230-5. ">Ummarino 2015</a>; and <a href="./references#CD008550-bbs2-0036" title="ZohalinezhadME , ImaniehMH , SamaniSM , MohagheghzadehA , DehghaniSM , HaghighatM , et al. Effects of quince syrup on clinical symptoms of children with symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Complementary Therapies in Clinical Practice2015;21(4):268-76. ZohalinezhadME , ZohalinezhadIS , SamaniA , MohagheghzadehF , DehghaniH . Efficacy of quince (Cydonia oblonga M) syrup in symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Planta Medica2016;82(1):1439. ">Zohalinezhad 2015</a>. We rated these fourteen studies as low risk of bias in this domain. In both <a href="./references#CD008550-bbs2-0036" title="ZohalinezhadME , ImaniehMH , SamaniSM , MohagheghzadehA , DehghaniSM , HaghighatM , et al. Effects of quince syrup on clinical symptoms of children with symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Complementary Therapies in Clinical Practice2015;21(4):268-76. ZohalinezhadME , ZohalinezhadIS , SamaniA , MohagheghzadehF , DehghaniH . Efficacy of quince (Cydonia oblonga M) syrup in symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Planta Medica2016;82(1):1439. ">Zohalinezhad 2015</a> and <a href="./references#CD008550-bbs2-0016" title="GilgerM , ToliaV , VandenplasY , YoussefN , TraxlerB , IlluecaM . Safety and tolerability of esomeprazole in children with gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2006;43(4):E20-21. GilgerMA , ToliaV , VandenplasY , YoussefNN , TraxlerB , IlluecaM . Safety and tolerability of esomeprazole in children with gastro-esophageal reflux disease. Gastroenterology2015;46(5):S16-23. ">Gilger 2006</a>, only one participant was lost. <a href="./references#CD008550-bbs2-0021" title="LootsC , KritasS , vanWijkM , McCallL , PeetersL , LewindonP , et al. Body positioning and medical therapy for infantile gastroesophageal reflux symptoms. Journal of Pediatric Gastroenterology and Nutrition2014;59(2):237-43. ">Loots 2014</a> lost six of 51 participants. <a href="./references#CD008550-bbs2-0004" title="BallengeeCR , DavalianF , ConawayMR , SauerCG , KaufmanDA . Erythromycin and reflux events in premature neonates: a randomized clinical trial. Journal of Pediatric Gastroenterology and Nutrition2018;67(6):720-25. ">Ballengee 2018</a> lost two participants (one from each arm of the study) out of 31 and clearly stated the reason for loss (one died and the other developed sepsis). <a href="./references#CD008550-bbs2-0003" title="BaldassarreME , Di MauroA , PignatelliMC , FanelliM , SalvatoreS , Di NardoG , et al. Magnesium alginate in gastro-esophageal reflux: a randomized multicenter cross-over study in infants. International Journal of Environmental Research and Public Health2020;17(1):83. ">Baldassarre 2020</a> had no loss of participants after randomisation. In <a href="./references#CD008550-bbs2-0024" title="NaeimiM , KianifarH , MemarianiZ , KamalinejadM , BijaniA , SaghebiR , et al. Comparison of the efficacy of ranitidine and quince syrup on gastroesophageal reflux disease in children. Complementary Therapies in Medicine2019;45:215-21. ">Naeimi 2019</a>, four participants withdrew from the control (ranitidine) arm and one withdrew from the treatment arm (ranitidine and quince syrup). </p> <p>Eighteen studies did not have enough evidence to determine risk of attrition bias: <a href="./references#CD008550-bbs2-0005" title="BinesJE , QuinlanJE , TrevesS , KleinmanRE , WinterHS . Efficacy of domperidone in infants and children with gastroesophageal reflux. Journal of Pediatric Gastroenterology and Nutrition1992;14(4):400-5. ">Bines 1992</a>; <a href="./references#CD008550-bbs2-0006" title="BorrelliO , ReaP , Bueno De MesquitaM , AmbrosiniA , ManciniV , Di NardoG , et al. Efficacy of combined administration of an alginate formulation (Gaviscon) and Lansoprazole for children with gastroesophageal reflux. Italian Journal of Pediatrics2002;28(4):304-9. ">Borrelli 2002</a>; <a href="./references#CD008550-bbs2-0007" title="ButsJP , BarudiC , OtteJB . Double-blind controlled study on the efficacy of sodium alginate (Gaviscon) in reducing gastroesophageal reflux assessed by 24 h continuous pH monitoring in infants and children. European Journal of Pediatrics1987;146(2):156-8. ">Buts 1987</a>; <a href="./references#CD008550-bbs2-0009" title="CresiF , MarinaccioC , RussoMC , MinieroR , SilvestroL . Short-term effect of domperidone on gastroesophageal reflux in newborns assessed by combined intraluminal impedance and pH monitoring. Journal of Perinatology2008;28:766-70. ">Cresi 2008</a>; <a href="./references#CD008550-bbs2-0011" title="CucchiaraS , MinellaR , IervolinoC , FrancoMT , CampanozziA , FranceschiM , et al. Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis. Archives of Disease in Childhood1993;69:655-9. ">Cucchiara 1993</a>; <a href="./references#CD008550-bbs2-0013" title="Del BuonoR , WenzlTG , BallG , KeadyS , ThomsonM . Effect of Gaviscon Infant on gastro-oesophageal reflux in infants assessed by combined intraluminal impedance/pH. Archives of Disease in Childhood2005;90:460-3. ">Del Buono 2005</a>; <a href="./references#CD008550-bbs2-0014" title="FamouriF , ZibanejadN , KabiriP , KelishadR . Comparison of hypoallergenic diet vs. ranitidine in treatment of gastroesophageal reflux disease of infants: a randomized clinical trial. Iranian Journal of Pediatrics2017;27(4):e5343. ">Famouri 2017</a>; <a href="./references#CD008550-bbs2-0015" title="ForbesD , HodgsonM , HillR . The effects of gaviscon and metoclopramide in gastroesophageal reflux in children. Journal of Pediatric Gastroenterology and Nutrition1986;5(4):556-9. ">Forbes 1986</a>; <a href="./references#CD008550-bbs2-0017" title="GunasekaranT , GuptaS , GremseD , KarolM , Pan W-J, Chin Y-L, et al. Lansoprazole in adolescents with gastroesophageal reflux disease: pharmacokinetics, pharmacodynamics, symptom relief efficacy, and tolerability. Journal of Pediatric Gastroenterology and Nutrition2002;35(4):S327-35. ">Gunesekaran 2003</a>; <a href="./references#CD008550-bbs2-0018" title="HaddadI , KierkusJ , TronE , UlmerA , HuP , SloanS , et al. Efficacy and safety of rabeprazole in children (1-11 years) with gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2013;57(6):798-807. ">Haddad 2013</a>; <a href="./references#CD008550-bbs2-0019" title="HussainS , KierkusJ , HuP , HoffmanD , LekichR , SloanS , et al. Safety and efficacy of delayed release rabeprazole in 1- to 11-month-old infants with symptomatic GERD. Journal of Pediatric Gastroenterology and Nutrition2014;58(2):226-36. ">Hussain 2014</a>; <a href="./references#CD008550-bbs2-0020" title="KierkusJ , Furmaga-JablonskaW , SullivanJE , DavidES , StewartDL , RathN , et al. Pharmacodynamics and safety of pantoprazole in neonates, preterm infants, and infants aged 1-11 months with a clinical diagnosis of gastroesophageal reflux disease. Digestive Diseases and Sciences2011;56:425-34. ">Kierkus 2011</a>; <a href="./references#CD008550-bbs2-0022" title="MillerS . Comparison of the efficacy and safety of a new aluminum-free paediatric alginate preparation and placebo in infants with recurrent gastro-oesophageal reflux. Current Medical Research and Opinion1999;15(3):160-8. ">Miller 1999</a>; <a href="./references#CD008550-bbs2-0025" title="OmariTI , BenningaMA , SansomL , ButlerRN , DentJ , DavidsonGP . Effect of baclofen on esophagogastric motility and gastroesophageal reflux in children with gastroesophageal reflux disease: a randomized controlled trial. Journal of Pediatrics2006;149(4):468-74. ">Omari 2006</a>; <a href="./references#CD008550-bbs2-0026" title="OmariT , DavidsonG , BondarovP , NauclerE , NilssonC , LundborgP . Pharmacokinetics and acid-suppressive effects of esomeprazole in infants 1-24 months old with symptoms of gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2007;45(5):530-7. [MEDLINE: Published in abstract form in JPGN:2006: 42: E1-110]OmariT , DavidsonG , BondarovP , NauclerE , NilssonC , LundborgP . Pharmacokinetics and acid-suppressive effects of esomeprazole in infants 1-24 months old with symptoms of gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2015;60:S2-S8. ">Omari 2007</a>; <a href="./references#CD008550-bbs2-0028" title="OrensteinSR , HassallE , Furmaga-JablonskaW , AtkinsonS , RaananM . Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. Journal of Pediatrics2009;154(4):514-20. ">Orenstein 2008</a>; <a href="./references#CD008550-bbs2-0029" title="PfefferkornMD , CroffieJM , GuptaSK , MollestonJP , EckertGJ , CorkinsMR , et al. Nocturnal acid breakthrough in children with reflux esophagitis taking proton pump inhibitors. Journal of Pediatric Gastroenterology and Nutrition2006;42(2):160-5. ">Pfefferkorn 2006</a>; <a href="./references#CD008550-bbs2-0030" title="SimeoneD , CariaMC , MieleE , StaianoA . Treatment of childhood peptic esophagitis: a double-blind placebo-controlled trial of nizatidine. Journal of Pediatric Gastroenterology and Nutrition1997;25(1):51-5. ">Simeone 1997</a>. We assessed these as having an unclear risk of bias in this domain. </p> <p>Four studies showed evidence of significant incomplete outcome data, particularly <a href="./references#CD008550-bbs2-0001" title="AzizollahiHR , RafeeyM . Efficacy of proton pump inhibitors and H2 blocker in the treatment of symptomatic gastroesophageal reflux disease in infants. Korean Journal of Pediatrics2016;59(5):226-30. ">Azizollahi 2016</a>, <a href="./references#CD008550-bbs2-0032" title="ToliaV , GilgerMA , BarkerPN , IlluecaM . Healing of erosive esophagitis and improvement of symptoms of gastroesophageal reflux disease after esomeprazole treatment in children 12 to 36 months old. Journal of Pediatric Gastroenterology and Nutrition2010;51(5):593-8. ">Tolia 2010a</a>, <a href="./references#CD008550-bbs2-0033" title="ToliaV , YoussefNN , GilgerMA , TraxlerB , IlluecaM . Esomeprazole for the treatment of erosive esophagitis in children: an international, multicenter, randomized, parallel-group, double-blind (for dose) study. BMC Pediatrics2010;10:41-50. [DOI: 10.1186/1471-2431-10-41]ToliaV , YoussefNN , GilgerMA , TraxlerB , IlluecaM . Esomeprazole for the treatment of erosive esophagitis in children: an international, multicenter, randomized, parallel-group, double-blind (for dose) study. Journal of Pediatric Gastroenterology and Nutrition2015;10(1):S24-30. ">Tolia 2010b</a>, and <a href="./references#CD008550-bbs2-0034" title="TsouVM , BakerR , BookL , HammoAH , SofferEF , WangW , et al. Multicenter, randomized, double-blind study comparing 20 and 40 mg of pantoprazole for symptom relief in adolescents (12 to 16 years of age) with gastroesophageal reflux disease (GERD). Clinical Pediatrics2006;45(8):741-9. ">Tsou 2006</a>, sufficient to be considered at high risk of bias in this domain. We obtained further data for <a href="./references#CD008550-bbs2-0032" title="ToliaV , GilgerMA , BarkerPN , IlluecaM . Healing of erosive esophagitis and improvement of symptoms of gastroesophageal reflux disease after esomeprazole treatment in children 12 to 36 months old. Journal of Pediatric Gastroenterology and Nutrition2010;51(5):593-8. ">Tolia 2010a</a> after direct communication with the authors. </p> </section> <section id="CD008550-sec-0078"> <h4 class="title">Selective reporting</h4> <p>The risk of bias was low in <a href="./references#CD008550-bbs2-0003" title="BaldassarreME , Di MauroA , PignatelliMC , FanelliM , SalvatoreS , Di NardoG , et al. Magnesium alginate in gastro-esophageal reflux: a randomized multicenter cross-over study in infants. International Journal of Environmental Research and Public Health2020;17(1):83. ">Baldassarre 2020</a>, <a href="./references#CD008550-bbs2-0012" title="DavidsonG , WenzlTG , ThomsonM , OmariT , BarkerP , LundborgP , et al. Efficacy and safety of once-daily esomeprazole for the treatment of gastroesophageal reflux disease in neonatal patients. Journal of Pediatrics2013;163(3):692-8. ">Davidson 2013</a>, <a href="./references#CD008550-bbs2-0025" title="OmariTI , BenningaMA , SansomL , ButlerRN , DentJ , DavidsonGP . Effect of baclofen on esophagogastric motility and gastroesophageal reflux in children with gastroesophageal reflux disease: a randomized controlled trial. Journal of Pediatrics2006;149(4):468-74. ">Omari 2006</a>, <a href="./references#CD008550-bbs2-0035" title="UmmarinoD , MieleE , MartinelliM , ScarpatoE , CrocettoF , SciorioE , et al. Effect of magnesium alginate plus simethicone on gastroesophageal reflux in infants. Journal of Pediatric Gastroenterology and Nutrition2015;60(2):230-5. ">Ummarino 2015</a>, and <a href="./references#CD008550-bbs2-0036" title="ZohalinezhadME , ImaniehMH , SamaniSM , MohagheghzadehA , DehghaniSM , HaghighatM , et al. Effects of quince syrup on clinical symptoms of children with symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Complementary Therapies in Clinical Practice2015;21(4):268-76. ZohalinezhadME , ZohalinezhadIS , SamaniA , MohagheghzadehF , DehghaniH . Efficacy of quince (Cydonia oblonga M) syrup in symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Planta Medica2016;82(1):1439. ">Zohalinezhad 2015</a>. </p> <p>Twenty‐five studies did not have enough evidence to determine risk of reporting bias (<a href="./references#CD008550-bbs2-0001" title="AzizollahiHR , RafeeyM . Efficacy of proton pump inhibitors and H2 blocker in the treatment of symptomatic gastroesophageal reflux disease in infants. Korean Journal of Pediatrics2016;59(5):226-30. ">Azizollahi 2016</a>; <a href="./references#CD008550-bbs2-0002" title="BakerR , TsouVM , TungJ , BakerSS , LiH , WangW , et al. Clinical results from a randomised, double-blind, dose-ranging study of pantoprazole in children aged 1 through 5 years with symptomatic histologic or erosive esophagitis. Clinical Pediatrics2010;49(9):852-65. ">Baker 2010</a>; <a href="./references#CD008550-bbs2-0004" title="BallengeeCR , DavalianF , ConawayMR , SauerCG , KaufmanDA . Erythromycin and reflux events in premature neonates: a randomized clinical trial. Journal of Pediatric Gastroenterology and Nutrition2018;67(6):720-25. ">Ballengee 2018</a>; <a href="./references#CD008550-bbs2-0007" title="ButsJP , BarudiC , OtteJB . Double-blind controlled study on the efficacy of sodium alginate (Gaviscon) in reducing gastroesophageal reflux assessed by 24 h continuous pH monitoring in infants and children. European Journal of Pediatrics1987;146(2):156-8. ">Buts 1987</a>; <a href="./references#CD008550-bbs2-0008" title="CarroccioA , Iacono, MontaltoG , CavataioF , SoresiM , NotarbartoloA . Domperidone plus magnesium hydroxide and aluminium hydroxide: a valid therapy in children with gastroesophageal reflux. Scandinavian Journal of Gastroenterology1994;29(4):300-4. ">Carroccio 1994</a>; <a href="./references#CD008550-bbs2-0009" title="CresiF , MarinaccioC , RussoMC , MinieroR , SilvestroL . Short-term effect of domperidone on gastroesophageal reflux in newborns assessed by combined intraluminal impedance and pH monitoring. Journal of Perinatology2008;28:766-70. ">Cresi 2008</a>; <a href="./references#CD008550-bbs2-0010" title="CucchiaraS , StaianoA , RomanielloG , CapobiancoS , AurcchioS . Antacids and cimetidine treatment for gastrooesophageal reflux and peptic oesophagitis. Archives of Disease in Childhood1984;59:842-7. ">Cucchiara 1984</a>; <a href="./references#CD008550-bbs2-0011" title="CucchiaraS , MinellaR , IervolinoC , FrancoMT , CampanozziA , FranceschiM , et al. Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis. Archives of Disease in Childhood1993;69:655-9. ">Cucchiara 1993</a>; <a href="./references#CD008550-bbs2-0013" title="Del BuonoR , WenzlTG , BallG , KeadyS , ThomsonM . Effect of Gaviscon Infant on gastro-oesophageal reflux in infants assessed by combined intraluminal impedance/pH. Archives of Disease in Childhood2005;90:460-3. ">Del Buono 2005</a>; <a href="./references#CD008550-bbs2-0014" title="FamouriF , ZibanejadN , KabiriP , KelishadR . Comparison of hypoallergenic diet vs. ranitidine in treatment of gastroesophageal reflux disease of infants: a randomized clinical trial. Iranian Journal of Pediatrics2017;27(4):e5343. ">Famouri 2017</a>; <a href="./references#CD008550-bbs2-0015" title="ForbesD , HodgsonM , HillR . The effects of gaviscon and metoclopramide in gastroesophageal reflux in children. Journal of Pediatric Gastroenterology and Nutrition1986;5(4):556-9. ">Forbes 1986</a>; <a href="./references#CD008550-bbs2-0016" title="GilgerM , ToliaV , VandenplasY , YoussefN , TraxlerB , IlluecaM . Safety and tolerability of esomeprazole in children with gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2006;43(4):E20-21. GilgerMA , ToliaV , VandenplasY , YoussefNN , TraxlerB , IlluecaM . Safety and tolerability of esomeprazole in children with gastro-esophageal reflux disease. Gastroenterology2015;46(5):S16-23. ">Gilger 2006</a>; <a href="./references#CD008550-bbs2-0017" title="GunasekaranT , GuptaS , GremseD , KarolM , Pan W-J, Chin Y-L, et al. Lansoprazole in adolescents with gastroesophageal reflux disease: pharmacokinetics, pharmacodynamics, symptom relief efficacy, and tolerability. Journal of Pediatric Gastroenterology and Nutrition2002;35(4):S327-35. ">Gunesekaran 2003</a>; <a href="./references#CD008550-bbs2-0018" title="HaddadI , KierkusJ , TronE , UlmerA , HuP , SloanS , et al. Efficacy and safety of rabeprazole in children (1-11 years) with gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2013;57(6):798-807. ">Haddad 2013</a>; <a href="./references#CD008550-bbs2-0020" title="KierkusJ , Furmaga-JablonskaW , SullivanJE , DavidES , StewartDL , RathN , et al. Pharmacodynamics and safety of pantoprazole in neonates, preterm infants, and infants aged 1-11 months with a clinical diagnosis of gastroesophageal reflux disease. Digestive Diseases and Sciences2011;56:425-34. ">Kierkus 2011</a>; <a href="./references#CD008550-bbs2-0021" title="LootsC , KritasS , vanWijkM , McCallL , PeetersL , LewindonP , et al. Body positioning and medical therapy for infantile gastroesophageal reflux symptoms. Journal of Pediatric Gastroenterology and Nutrition2014;59(2):237-43. ">Loots 2014</a>; <a href="./references#CD008550-bbs2-0022" title="MillerS . Comparison of the efficacy and safety of a new aluminum-free paediatric alginate preparation and placebo in infants with recurrent gastro-oesophageal reflux. Current Medical Research and Opinion1999;15(3):160-8. ">Miller 1999</a>; <a href="./references#CD008550-bbs2-0023" title="MooreDJ , TaoBS , LinesDR , HirteC , HeddleML , DavidsonGP . Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. Journal of Pediatrics2003;143(2):219-23. ">Moore 2003</a>; <a href="./references#CD008550-bbs2-0024" title="NaeimiM , KianifarH , MemarianiZ , KamalinejadM , BijaniA , SaghebiR , et al. Comparison of the efficacy of ranitidine and quince syrup on gastroesophageal reflux disease in children. Complementary Therapies in Medicine2019;45:215-21. ">Naeimi 2019</a>; <a href="./references#CD008550-bbs2-0026" title="OmariT , DavidsonG , BondarovP , NauclerE , NilssonC , LundborgP . Pharmacokinetics and acid-suppressive effects of esomeprazole in infants 1-24 months old with symptoms of gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2007;45(5):530-7. [MEDLINE: Published in abstract form in JPGN:2006: 42: E1-110]OmariT , DavidsonG , BondarovP , NauclerE , NilssonC , LundborgP . Pharmacokinetics and acid-suppressive effects of esomeprazole in infants 1-24 months old with symptoms of gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2015;60:S2-S8. ">Omari 2007</a>; <a href="./references#CD008550-bbs2-0027" title="OrensteinSR , ShalabyTM , DevandrySN , LiacourasCA , CzinnSJ , DiceJE , et al. Famotidine for infant gastro-oesophageal reflux: a multi-centre, randomized, placebo-controlled, withdrawal trial. Alimentary Pharmacology and Therapeutics2003;17(9):1097-107. ">Orenstein 2002</a>; <a href="./references#CD008550-bbs2-0028" title="OrensteinSR , HassallE , Furmaga-JablonskaW , AtkinsonS , RaananM . Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. Journal of Pediatrics2009;154(4):514-20. ">Orenstein 2008</a>; <a href="./references#CD008550-bbs2-0029" title="PfefferkornMD , CroffieJM , GuptaSK , MollestonJP , EckertGJ , CorkinsMR , et al. Nocturnal acid breakthrough in children with reflux esophagitis taking proton pump inhibitors. Journal of Pediatric Gastroenterology and Nutrition2006;42(2):160-5. ">Pfefferkorn 2006</a>; <a href="./references#CD008550-bbs2-0030" title="SimeoneD , CariaMC , MieleE , StaianoA . Treatment of childhood peptic esophagitis: a double-blind placebo-controlled trial of nizatidine. Journal of Pediatric Gastroenterology and Nutrition1997;25(1):51-5. ">Simeone 1997</a>; <a href="./references#CD008550-bbs2-0031" title="ToliaV , BishopPR , TsouVM , GremseD , SofferEF , ComerGM , et al. Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5-11 years) with symptomatic gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2006;42(4):384-91. ">Tolia 2006</a>). </p> <p>Reporting bias was evident in: <a href="./references#CD008550-bbs2-0005" title="BinesJE , QuinlanJE , TrevesS , KleinmanRE , WinterHS . Efficacy of domperidone in infants and children with gastroesophageal reflux. Journal of Pediatric Gastroenterology and Nutrition1992;14(4):400-5. ">Bines 1992</a>; <a href="./references#CD008550-bbs2-0006" title="BorrelliO , ReaP , Bueno De MesquitaM , AmbrosiniA , ManciniV , Di NardoG , et al. Efficacy of combined administration of an alginate formulation (Gaviscon) and Lansoprazole for children with gastroesophageal reflux. Italian Journal of Pediatrics2002;28(4):304-9. ">Borrelli 2002</a> (excluded severe oesophagitis); <a href="./references#CD008550-bbs2-0019" title="HussainS , KierkusJ , HuP , HoffmanD , LekichR , SloanS , et al. Safety and efficacy of delayed release rabeprazole in 1- to 11-month-old infants with symptomatic GERD. Journal of Pediatric Gastroenterology and Nutrition2014;58(2):226-36. ">Hussain 2014</a> due to the post hoc analyses; <a href="./references#CD008550-bbs2-0032" title="ToliaV , GilgerMA , BarkerPN , IlluecaM . Healing of erosive esophagitis and improvement of symptoms of gastroesophageal reflux disease after esomeprazole treatment in children 12 to 36 months old. Journal of Pediatric Gastroenterology and Nutrition2010;51(5):593-8. ">Tolia 2010a</a>; <a href="./references#CD008550-bbs2-0034" title="TsouVM , BakerR , BookL , HammoAH , SofferEF , WangW , et al. Multicenter, randomized, double-blind study comparing 20 and 40 mg of pantoprazole for symptom relief in adolescents (12 to 16 years of age) with gastroesophageal reflux disease (GERD). Clinical Pediatrics2006;45(8):741-9. ">Tsou 2006</a>; <a href="./references#CD008550-bbs2-0033" title="ToliaV , YoussefNN , GilgerMA , TraxlerB , IlluecaM . Esomeprazole for the treatment of erosive esophagitis in children: an international, multicenter, randomized, parallel-group, double-blind (for dose) study. BMC Pediatrics2010;10:41-50. [DOI: 10.1186/1471-2431-10-41]ToliaV , YoussefNN , GilgerMA , TraxlerB , IlluecaM . Esomeprazole for the treatment of erosive esophagitis in children: an international, multicenter, randomized, parallel-group, double-blind (for dose) study. Journal of Pediatric Gastroenterology and Nutrition2015;10(1):S24-30. ">Tolia 2010b</a>. We rated these as high risk. </p> </section> <section id="CD008550-sec-0079"> <h4 class="title">Other potential sources of bias</h4> <p>We identified other sources of bias leading to a judgement of 'high risk' in 23 studies. These included studies with a follow‐up of less than two weeks (<a href="./references#CD008550-bbs2-0003" title="BaldassarreME , Di MauroA , PignatelliMC , FanelliM , SalvatoreS , Di NardoG , et al. Magnesium alginate in gastro-esophageal reflux: a randomized multicenter cross-over study in infants. International Journal of Environmental Research and Public Health2020;17(1):83. ">Baldassarre 2020</a>; <a href="./references#CD008550-bbs2-0007" title="ButsJP , BarudiC , OtteJB . Double-blind controlled study on the efficacy of sodium alginate (Gaviscon) in reducing gastroesophageal reflux assessed by 24 h continuous pH monitoring in infants and children. European Journal of Pediatrics1987;146(2):156-8. ">Buts 1987</a>; <a href="./references#CD008550-bbs2-0009" title="CresiF , MarinaccioC , RussoMC , MinieroR , SilvestroL . Short-term effect of domperidone on gastroesophageal reflux in newborns assessed by combined intraluminal impedance and pH monitoring. Journal of Perinatology2008;28:766-70. ">Cresi 2008</a>; <a href="./references#CD008550-bbs2-0012" title="DavidsonG , WenzlTG , ThomsonM , OmariT , BarkerP , LundborgP , et al. Efficacy and safety of once-daily esomeprazole for the treatment of gastroesophageal reflux disease in neonatal patients. Journal of Pediatrics2013;163(3):692-8. ">Davidson 2013</a>; <a href="./references#CD008550-bbs2-0013" title="Del BuonoR , WenzlTG , BallG , KeadyS , ThomsonM . Effect of Gaviscon Infant on gastro-oesophageal reflux in infants assessed by combined intraluminal impedance/pH. Archives of Disease in Childhood2005;90:460-3. ">Del Buono 2005</a>; <a href="./references#CD008550-bbs2-0017" title="GunasekaranT , GuptaS , GremseD , KarolM , Pan W-J, Chin Y-L, et al. Lansoprazole in adolescents with gastroesophageal reflux disease: pharmacokinetics, pharmacodynamics, symptom relief efficacy, and tolerability. Journal of Pediatric Gastroenterology and Nutrition2002;35(4):S327-35. ">Gunesekaran 2003</a>; <a href="./references#CD008550-bbs2-0020" title="KierkusJ , Furmaga-JablonskaW , SullivanJE , DavidES , StewartDL , RathN , et al. Pharmacodynamics and safety of pantoprazole in neonates, preterm infants, and infants aged 1-11 months with a clinical diagnosis of gastroesophageal reflux disease. Digestive Diseases and Sciences2011;56:425-34. ">Kierkus 2011</a>; <a href="./references#CD008550-bbs2-0025" title="OmariTI , BenningaMA , SansomL , ButlerRN , DentJ , DavidsonGP . Effect of baclofen on esophagogastric motility and gastroesophageal reflux in children with gastroesophageal reflux disease: a randomized controlled trial. Journal of Pediatrics2006;149(4):468-74. ">Omari 2006</a>; <a href="./references#CD008550-bbs2-0026" title="OmariT , DavidsonG , BondarovP , NauclerE , NilssonC , LundborgP . Pharmacokinetics and acid-suppressive effects of esomeprazole in infants 1-24 months old with symptoms of gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2007;45(5):530-7. [MEDLINE: Published in abstract form in JPGN:2006: 42: E1-110]OmariT , DavidsonG , BondarovP , NauclerE , NilssonC , LundborgP . Pharmacokinetics and acid-suppressive effects of esomeprazole in infants 1-24 months old with symptoms of gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2015;60:S2-S8. ">Omari 2007</a>). In <a href="./references#CD008550-bbs2-0005" title="BinesJE , QuinlanJE , TrevesS , KleinmanRE , WinterHS . Efficacy of domperidone in infants and children with gastroesophageal reflux. Journal of Pediatric Gastroenterology and Nutrition1992;14(4):400-5. ">Bines 1992</a>, participants agreeing to an open‐label trial may be biased towards those who believed they had an initial benefit from treatment. In <a href="./references#CD008550-bbs2-0003" title="BaldassarreME , Di MauroA , PignatelliMC , FanelliM , SalvatoreS , Di NardoG , et al. Magnesium alginate in gastro-esophageal reflux: a randomized multicenter cross-over study in infants. International Journal of Environmental Research and Public Health2020;17(1):83. ">Baldassarre 2020</a>, the comparator was a thickened formula. In <a href="./references#CD008550-bbs2-0008" title="CarroccioA , Iacono, MontaltoG , CavataioF , SoresiM , NotarbartoloA . Domperidone plus magnesium hydroxide and aluminium hydroxide: a valid therapy in children with gastroesophageal reflux. Scandinavian Journal of Gastroenterology1994;29(4):300-4. ">Carroccio 1994</a>, children received frequent short feeds, positioning advice, and all formula milk was thickened with Medigel 1%. Similarly, in <a href="./references#CD008550-bbs2-0010" title="CucchiaraS , StaianoA , RomanielloG , CapobiancoS , AurcchioS . Antacids and cimetidine treatment for gastrooesophageal reflux and peptic oesophagitis. Archives of Disease in Childhood1984;59:842-7. ">Cucchiara 1984</a>, all infants had thickener added (Nestargel 1%). <a href="./references#CD008550-bbs2-0012" title="DavidsonG , WenzlTG , ThomsonM , OmariT , BarkerP , LundborgP , et al. Efficacy and safety of once-daily esomeprazole for the treatment of gastroesophageal reflux disease in neonatal patients. Journal of Pediatrics2013;163(3):692-8. ">Davidson 2013</a> was discontinued prematurely because of poor enrolment: the study estimated needing to recruit 90 participants to achieve 38 neonates in each group to achieve higher than 80% power at the 2‐sided alpha level of 0.05 to detect a difference between esomeprazole and placebo in the change in number of symptoms from baseline. In <a href="./references#CD008550-bbs2-0023" title="MooreDJ , TaoBS , LinesDR , HirteC , HeddleML , DavidsonGP . Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. Journal of Pediatrics2003;143(2):219-23. ">Moore 2003</a>, there was no evidence of reflux oesophagitis seen (erosions or ulcers) at entry endoscopy; loss of vascular pattern or friability was sufficient for inclusion. <a href="./references#CD008550-bbs2-0023" title="MooreDJ , TaoBS , LinesDR , HirteC , HeddleML , DavidsonGP . Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. Journal of Pediatrics2003;143(2):219-23. ">Moore 2003</a> included infants with reflux index higher than 5% in 24 hours, only seven infants had endoscopic changes and reflux index higher than 5% in 24 hours, so some of these infants may have had functional reflux. </p> <p>We assessed the following studies as high risk for other bias as they either had pharmaceutical company support for manuscript‐writing, an author was employed by a pharmaceutical company, or both (<a href="./references#CD008550-bbs2-0002" title="BakerR , TsouVM , TungJ , BakerSS , LiH , WangW , et al. Clinical results from a randomised, double-blind, dose-ranging study of pantoprazole in children aged 1 through 5 years with symptomatic histologic or erosive esophagitis. Clinical Pediatrics2010;49(9):852-65. ">Baker 2010</a>, <a href="./references#CD008550-bbs2-0003" title="BaldassarreME , Di MauroA , PignatelliMC , FanelliM , SalvatoreS , Di NardoG , et al. Magnesium alginate in gastro-esophageal reflux: a randomized multicenter cross-over study in infants. International Journal of Environmental Research and Public Health2020;17(1):83. ">Baldassarre 2020</a>; <a href="./references#CD008550-bbs2-0011" title="CucchiaraS , MinellaR , IervolinoC , FrancoMT , CampanozziA , FranceschiM , et al. Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis. Archives of Disease in Childhood1993;69:655-9. ">Cucchiara 1993</a>; <a href="./references#CD008550-bbs2-0012" title="DavidsonG , WenzlTG , ThomsonM , OmariT , BarkerP , LundborgP , et al. Efficacy and safety of once-daily esomeprazole for the treatment of gastroesophageal reflux disease in neonatal patients. Journal of Pediatrics2013;163(3):692-8. ">Davidson 2013</a>; <a href="./references#CD008550-bbs2-0016" title="GilgerM , ToliaV , VandenplasY , YoussefN , TraxlerB , IlluecaM . Safety and tolerability of esomeprazole in children with gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2006;43(4):E20-21. GilgerMA , ToliaV , VandenplasY , YoussefNN , TraxlerB , IlluecaM . Safety and tolerability of esomeprazole in children with gastro-esophageal reflux disease. Gastroenterology2015;46(5):S16-23. ">Gilger 2006</a>; <a href="./references#CD008550-bbs2-0018" title="HaddadI , KierkusJ , TronE , UlmerA , HuP , SloanS , et al. Efficacy and safety of rabeprazole in children (1-11 years) with gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2013;57(6):798-807. ">Haddad 2013</a>; <a href="./references#CD008550-bbs2-0019" title="HussainS , KierkusJ , HuP , HoffmanD , LekichR , SloanS , et al. Safety and efficacy of delayed release rabeprazole in 1- to 11-month-old infants with symptomatic GERD. Journal of Pediatric Gastroenterology and Nutrition2014;58(2):226-36. ">Hussain 2014</a>; <a href="./references#CD008550-bbs2-0020" title="KierkusJ , Furmaga-JablonskaW , SullivanJE , DavidES , StewartDL , RathN , et al. Pharmacodynamics and safety of pantoprazole in neonates, preterm infants, and infants aged 1-11 months with a clinical diagnosis of gastroesophageal reflux disease. Digestive Diseases and Sciences2011;56:425-34. ">Kierkus 2011</a>; <a href="./references#CD008550-bbs2-0026" title="OmariT , DavidsonG , BondarovP , NauclerE , NilssonC , LundborgP . Pharmacokinetics and acid-suppressive effects of esomeprazole in infants 1-24 months old with symptoms of gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2007;45(5):530-7. [MEDLINE: Published in abstract form in JPGN:2006: 42: E1-110]OmariT , DavidsonG , BondarovP , NauclerE , NilssonC , LundborgP . Pharmacokinetics and acid-suppressive effects of esomeprazole in infants 1-24 months old with symptoms of gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2015;60:S2-S8. ">Omari 2007</a>; <a href="./references#CD008550-bbs2-0031" title="ToliaV , BishopPR , TsouVM , GremseD , SofferEF , ComerGM , et al. Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5-11 years) with symptomatic gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2006;42(4):384-91. ">Tolia 2006</a>; <a href="./references#CD008550-bbs2-0032" title="ToliaV , GilgerMA , BarkerPN , IlluecaM . Healing of erosive esophagitis and improvement of symptoms of gastroesophageal reflux disease after esomeprazole treatment in children 12 to 36 months old. Journal of Pediatric Gastroenterology and Nutrition2010;51(5):593-8. ">Tolia 2010a</a>; <a href="./references#CD008550-bbs2-0033" title="ToliaV , YoussefNN , GilgerMA , TraxlerB , IlluecaM . Esomeprazole for the treatment of erosive esophagitis in children: an international, multicenter, randomized, parallel-group, double-blind (for dose) study. BMC Pediatrics2010;10:41-50. [DOI: 10.1186/1471-2431-10-41]ToliaV , YoussefNN , GilgerMA , TraxlerB , IlluecaM . Esomeprazole for the treatment of erosive esophagitis in children: an international, multicenter, randomized, parallel-group, double-blind (for dose) study. Journal of Pediatric Gastroenterology and Nutrition2015;10(1):S24-30. ">Tolia 2010b</a>; <a href="./references#CD008550-bbs2-0034" title="TsouVM , BakerR , BookL , HammoAH , SofferEF , WangW , et al. Multicenter, randomized, double-blind study comparing 20 and 40 mg of pantoprazole for symptom relief in adolescents (12 to 16 years of age) with gastroesophageal reflux disease (GERD). Clinical Pediatrics2006;45(8):741-9. ">Tsou 2006</a>). </p> <p>Other sources of bias are diverse, and are discussed in <a href="./references#CD008550-bbs1-0001" title="">Included studies</a> but were not assessed as providing a significant additional risk of bias. </p> <p>We considered three studies to be of lower risk due to identified independent funding (<a href="./references#CD008550-bbs2-0024" title="NaeimiM , KianifarH , MemarianiZ , KamalinejadM , BijaniA , SaghebiR , et al. Comparison of the efficacy of ranitidine and quince syrup on gastroesophageal reflux disease in children. Complementary Therapies in Medicine2019;45:215-21. ">Naeimi 2019</a>; <a href="./references#CD008550-bbs2-0029" title="PfefferkornMD , CroffieJM , GuptaSK , MollestonJP , EckertGJ , CorkinsMR , et al. Nocturnal acid breakthrough in children with reflux esophagitis taking proton pump inhibitors. Journal of Pediatric Gastroenterology and Nutrition2006;42(2):160-5. ">Pfefferkorn 2006</a>; <a href="./references#CD008550-bbs2-0036" title="ZohalinezhadME , ImaniehMH , SamaniSM , MohagheghzadehA , DehghaniSM , HaghighatM , et al. Effects of quince syrup on clinical symptoms of children with symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Complementary Therapies in Clinical Practice2015;21(4):268-76. ZohalinezhadME , ZohalinezhadIS , SamaniA , MohagheghzadehF , DehghaniH . Efficacy of quince (Cydonia oblonga M) syrup in symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Planta Medica2016;82(1):1439. ">Zohalinezhad 2015</a>). </p> </section> </section> <section id="CD008550-sec-0080"> <h3 class="title" id="CD008550-sec-0080">Effects of interventions</h3> <p>See: <a href="./full#CD008550-tbl-0001"><b>Summary of findings 1</b> Omeprazole compared to placebo for GORD in infants</a>; <a href="./full#CD008550-tbl-0002"><b>Summary of findings 2</b> Omeprazole compared to ranitidine for GORD in infants</a>; <a href="./full#CD008550-tbl-0003"><b>Summary of findings 3</b> Esomeprazole compared to placebo for GORD in infants</a>; <a href="./full#CD008550-tbl-0004"><b>Summary of findings 4</b> Rabeprazole at higher doses (1 mg/kg) compared to rabeprazole at lower doses (0.5 mg/kg) for GORD in children over 1 year of age</a>; <a href="./full#CD008550-tbl-0005"><b>Summary of findings 5</b> Pantoprazole in higher doses (1.2 mg/kg) compared to pantoprazole at lower doses (0.3 mg/kg) for GORD in children over 1 year of age</a> </p> <p>We present results below ordered by population (first infants (aged zero to 12 months) then children (aged one to 16 years)), treatment class, comparisons, and outcomes (improvement in clinical symptoms; adverse events; pH‐impedance indices; endoscopic findings). Most of the included studies offered an appraisal of improvement in clinical symptoms. However, there was considerable heterogeneity in symptom assessment, such as the use of composite scores as well as individual symptom assessment. Studies in infants commonly assessed number of vomiting episodes, back arching, regurgitation, failure to thrive, feeding difficulties, or abdominal pain/colic. Studies in older children commonly assessed heartburn, epigastric pain, or regurgitation symptoms. Several studies used 24‐hour pH/impedance studies, with reflux index and number of reflux episodes the most commonly‐used outcomes. The macroscopic appearance of the oesophagus on endoscopy and histological improvement were the most common endoscopic improvement metrics. Most studies described adverse events, and we have summarised these below. We attempted to extract summary statistics from all studies, and where available, we expressed these as the difference in means (i.e. the mean difference, MD) with a 95% confidence interval (CI). </p> <section id="CD008550-sec-0081"> <h4 class="title">I. Infants</h4> <section id="CD008550-sec-0082"> <h5 class="title">Proton pump inhibitors (PPIs)</h5> <section id="CD008550-sec-0083"> <h6 class="title">Omeprazole</h6> <section id="CD008550-sec-0084"> <p><b>Omeprazole versus placebo</b></p> <p>See <a href="./full#CD008550-tbl-0001">summary of findings Table 1</a>. </p> <p><b>Improvement in clinical symptoms</b> </p> <p>Based on the results of one study (<a href="./references#CD008550-bbs2-0023" title="MooreDJ , TaoBS , LinesDR , HirteC , HeddleML , DavidsonGP . Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. Journal of Pediatrics2003;143(2):219-23. ">Moore 2003</a>), the evidence is very uncertain about the effect of omeprazole on cry/fuss time compared to placebo (MD ‐10.0 minutes (min)/24 hours, 95% CI ‐89.1 to 69.1; 30 infants; very low‐certainty evidence; <a href="./references#CD008550-fig-0004" title="">Analysis 1.1</a>). </p> <p><b>Adverse events</b> </p> <p>Although <a href="./references#CD008550-bbs2-0023" title="MooreDJ , TaoBS , LinesDR , HirteC , HeddleML , DavidsonGP . Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. Journal of Pediatrics2003;143(2):219-23. ">Moore 2003</a> reported no adverse events in either the omeprazole or placebo groups (30 infants), there was insufficient evidence to extract summary data on adverse events. </p> <p><b>pH‐impedance indices</b> </p> <p>The evidence is very uncertain about the effect of omeprazole on reflux index compared to placebo, based on one study assessing reflux index (<a href="./references#CD008550-bbs2-0023" title="MooreDJ , TaoBS , LinesDR , HirteC , HeddleML , DavidsonGP . Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. Journal of Pediatrics2003;143(2):219-23. ">Moore 2003</a>) (MD ‐7.0% in 24 hours, 95% CI ‐4.66 to ‐9.34; 30 infants; very low‐certainty evidence; <a href="./references#CD008550-fig-0005" title="">Analysis 1.2</a>). </p> <p><b>Endoscopic findings</b> </p> <p>No studies were available for this outcome.</p> </section> <section id="CD008550-sec-0085"> <p><b>Omeprazole versus other treatments: ranitidine</b></p> <p>See <a href="./full#CD008550-tbl-0002">summary of findings Table 2</a>. </p> <p><b>Improvement in clinical symptoms</b> </p> <p>Omeprazole and ranitidine may result in similar symptomatic improvement. Based on evidence from a single study (<a href="./references#CD008550-bbs2-0001" title="AzizollahiHR , RafeeyM . Efficacy of proton pump inhibitors and H2 blocker in the treatment of symptomatic gastroesophageal reflux disease in infants. Korean Journal of Pediatrics2016;59(5):226-30. ">Azizollahi 2016</a>), omeprazole (0.5 mg/kg/day) provided symptomatic benefit equivalent to ranitidine (2 to 4 mg/kg/day) in 76 infants with troublesome symptoms of GORD. Symptom scores in the omeprazole group improved from 51.93 ± 5.42 to 2.43 ± 1.15, and in the ranitidine group, from 47 ± 5.6 to 2.47 ± 0.58 after two weeks (MD ‐4.97, 95% CI ‐2.47 to ‐7.33; 1 study, 76 infants; very low‐certainty evidence; <a href="./references#CD008550-fig-0006" title="">Analysis 2.1</a>). Another study noted improvements in symptom scores in participants treated with omeprazole (<a href="./references#CD008550-bbs2-0011" title="CucchiaraS , MinellaR , IervolinoC , FrancoMT , CampanozziA , FranceschiM , et al. Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis. Archives of Disease in Childhood1993;69:655-9. ">Cucchiara 1993</a>). However, <a href="./references#CD008550-bbs2-0011" title="CucchiaraS , MinellaR , IervolinoC , FrancoMT , CampanozziA , FranceschiM , et al. Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis. Archives of Disease in Childhood1993;69:655-9. ">Cucchiara 1993</a> did not report the outcome in sufficient detail to allow extraction of summary statistics and did not differentiate between infants and children, so we did not include this study in the assessment of evidence certainty. </p> <p><b>Adverse events</b> </p> <p><a href="./references#CD008550-bbs2-0011" title="CucchiaraS , MinellaR , IervolinoC , FrancoMT , CampanozziA , FranceschiM , et al. Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis. Archives of Disease in Childhood1993;69:655-9. ">Cucchiara 1993</a> noted that, in those randomised to eight weeks of either standard doses of omeprazole (40 mg/day/1.73 m<sup>2</sup> surface area) or higher doses of ranitidine (20 mg/kg/day), one participant sustained a fever and a respiratory infection and was withdrawn. The study did not specify the participant's age or treatment group, so we did not include this result in the assessment of evidence certainty, and there were insufficient data for summary data extraction. <a href="./references#CD008550-bbs2-0001" title="AzizollahiHR , RafeeyM . Efficacy of proton pump inhibitors and H2 blocker in the treatment of symptomatic gastroesophageal reflux disease in infants. Korean Journal of Pediatrics2016;59(5):226-30. ">Azizollahi 2016</a> found that, overall, 16 participants withdrew, due to being lost to follow‐up, prematurely discontinuing medication, having severe pneumonia, and the mother being unable to complete questionnaires. <a href="./references#CD008550-bbs2-0001" title="AzizollahiHR , RafeeyM . Efficacy of proton pump inhibitors and H2 blocker in the treatment of symptomatic gastroesophageal reflux disease in infants. Korean Journal of Pediatrics2016;59(5):226-30. ">Azizollahi 2016</a> did not describe the number of participants with severe pneumonia, so this result was not suitable for inclusion in the summary of findings table. </p> <p><b>pH‐impedance indices</b> </p> <p>Although the <a href="./references#CD008550-bbs2-0011" title="CucchiaraS , MinellaR , IervolinoC , FrancoMT , CampanozziA , FranceschiM , et al. Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis. Archives of Disease in Childhood1993;69:655-9. ">Cucchiara 1993</a> study assessed this outcome, trialists did not distinguish between infants and children. We were therefore unable to extract suitable data and did not include this study in our assessment of the evidence certainty. </p> <p><b>Endoscopic findings</b> </p> <p>Although the <a href="./references#CD008550-bbs2-0011" title="CucchiaraS , MinellaR , IervolinoC , FrancoMT , CampanozziA , FranceschiM , et al. Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis. Archives of Disease in Childhood1993;69:655-9. ">Cucchiara 1993</a> study assessed this outcome, trialists did not distinguish between infants and children. We were therefore unable to extract suitable data and did not include this study in our assessment of the evidence certainty. </p> </section> <section id="CD008550-sec-0086"> <p><b>Omeprazole versus other treatments: quince syrup</b></p> <p><a href="./references#CD008550-bbs2-0036" title="ZohalinezhadME , ImaniehMH , SamaniSM , MohagheghzadehA , DehghaniSM , HaghighatM , et al. Effects of quince syrup on clinical symptoms of children with symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Complementary Therapies in Clinical Practice2015;21(4):268-76. ZohalinezhadME , ZohalinezhadIS , SamaniA , MohagheghzadehF , DehghaniH . Efficacy of quince (Cydonia oblonga M) syrup in symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Planta Medica2016;82(1):1439. ">Zohalinezhad 2015</a> used omeprazole as a comparator to assess the efficacy of quince syrup for gastro‐oesophageal reflux. </p> <p><b>Improvement in clinical symptoms</b> </p> <p>Although the <a href="./references#CD008550-bbs2-0036" title="ZohalinezhadME , ImaniehMH , SamaniSM , MohagheghzadehA , DehghaniSM , HaghighatM , et al. Effects of quince syrup on clinical symptoms of children with symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Complementary Therapies in Clinical Practice2015;21(4):268-76. ZohalinezhadME , ZohalinezhadIS , SamaniA , MohagheghzadehF , DehghaniH . Efficacy of quince (Cydonia oblonga M) syrup in symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Planta Medica2016;82(1):1439. ">Zohalinezhad 2015</a> study assessed this outcome, trialists did not distinguish between infants and children. We were therefore unable to extract suitable data and did not include this study in our assessment of the evidence certainty. </p> <p><b>Adverse events</b> </p> <p>Although the <a href="./references#CD008550-bbs2-0036" title="ZohalinezhadME , ImaniehMH , SamaniSM , MohagheghzadehA , DehghaniSM , HaghighatM , et al. Effects of quince syrup on clinical symptoms of children with symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Complementary Therapies in Clinical Practice2015;21(4):268-76. ZohalinezhadME , ZohalinezhadIS , SamaniA , MohagheghzadehF , DehghaniH . Efficacy of quince (Cydonia oblonga M) syrup in symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Planta Medica2016;82(1):1439. ">Zohalinezhad 2015</a> study assessed this outcome, trialists did not distinguish between infants and children. We were therefore unable to extract suitable data and did not include this study in our assessment of the evidence certainty. <a href="./references#CD008550-bbs2-0036" title="ZohalinezhadME , ImaniehMH , SamaniSM , MohagheghzadehA , DehghaniSM , HaghighatM , et al. Effects of quince syrup on clinical symptoms of children with symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Complementary Therapies in Clinical Practice2015;21(4):268-76. ZohalinezhadME , ZohalinezhadIS , SamaniA , MohagheghzadehF , DehghaniH . Efficacy of quince (Cydonia oblonga M) syrup in symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Planta Medica2016;82(1):1439. ">Zohalinezhad 2015</a> reported no adverse events in 37 infants and young children (under 60 months of age) in either the quince syrup or omeprazole groups. </p> <p><b>pH‐impedance indices</b> </p> <p>No studies were available for this outcome.</p> <p><b>Endoscopic findings</b> </p> <p><a href="./references#CD008550-bbs2-0036" title="ZohalinezhadME , ImaniehMH , SamaniSM , MohagheghzadehA , DehghaniSM , HaghighatM , et al. Effects of quince syrup on clinical symptoms of children with symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Complementary Therapies in Clinical Practice2015;21(4):268-76. ZohalinezhadME , ZohalinezhadIS , SamaniA , MohagheghzadehF , DehghaniH . Efficacy of quince (Cydonia oblonga M) syrup in symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Planta Medica2016;82(1):1439. ">Zohalinezhad 2015</a> did not identify how many participants underwent endoscopy, so we did not include this result in the summary of findings tables and did not assess evidence certainty. </p> </section> <section id="CD008550-sec-0087"> <p><b>Omeprazole at different doses</b></p> <p>No studies were available for this comparison.</p> </section> </section> <section id="CD008550-sec-0088"> <h6 class="title">Lansoprazole</h6> <section id="CD008550-sec-0089"> <p><b>Lansoprazole versus placebo</b></p> <p><b>Improvement in clinical symptoms</b> </p> <p>A single study assessing 162 infants (age range: four to 51 weeks) showed no improvement in the lansoprazole group compared to placebo, based on observer assessments and symptom diaries (<a href="./references#CD008550-bbs2-0028" title="OrensteinSR , HassallE , Furmaga-JablonskaW , AtkinsonS , RaananM . Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. Journal of Pediatrics2009;154(4):514-20. ">Orenstein 2008</a>). For participants who went on to take lansoprazole open‐label (n = 55), there was no improvement in symptoms, but the trial did not report the outcome in sufficient detail to allow extraction of summary statistics. There was no investigation to confirm GORD in participants, and many of the participants enroled may have had functional reflux. Thus, we were unable to extract summary statistics with which to judge the efficacy of lansoprazole on symptomatic improvement compared to placebo. </p> <p><b>Adverse events</b> </p> <p>The <a href="./references#CD008550-bbs2-0028" title="OrensteinSR , HassallE , Furmaga-JablonskaW , AtkinsonS , RaananM . Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. Journal of Pediatrics2009;154(4):514-20. ">Orenstein 2008</a> study noted that adverse events were more common in the lansoprazole group (10 participants versus two placebo participants from a total of 162 participants). These included lower respiratory‐tract infections (five participants versus one on placebo), diarrhoea (two participants), ileus (one participant), and dehydration (one participant). The trial did not report the outcome in sufficient detail to allow extraction of summary statistics or to estimate the certainty of the evidence. Thus, we were unable to extract summary statistics with which to judge the risk of adverse events. </p> <p><b>pH‐impedance indices and endoscopic findings</b> </p> <p>No studies were available for these outcomes.</p> </section> <section id="CD008550-sec-0090"> <p><b>Lansoprazole versus other treatments or at different doses</b></p> <p>No studies were available for these comparisons.</p> </section> </section> <section id="CD008550-sec-0091"> <h6 class="title">Esomeprazole</h6> <section id="CD008550-sec-0092"> <p><b>Esomeprazole versus placebo</b></p> <p>See <a href="./full#CD008550-tbl-0003">summary of findings Table 3</a>. </p> <p><b>Improvement in clinical symptoms</b> </p> <p>Esomeprazole may provide no symptomatic improvement compared to placebo, based on evidence from a single study. <a href="./references#CD008550-bbs2-0012" title="DavidsonG , WenzlTG , ThomsonM , OmariT , BarkerP , LundborgP , et al. Efficacy and safety of once-daily esomeprazole for the treatment of gastroesophageal reflux disease in neonatal patients. Journal of Pediatrics2013;163(3):692-8. ">Davidson 2013</a> compared 52 neonates (premature to one month corrected age) given 0.5 mg/kg esomeprazole or placebo, and noted no improvement compared to placebo in the total number of GORD symptoms (from video monitoring) and GORD‐related signs (from cardiorespiratory monitoring) (MD 3.2 episodes fewer, 95% CI 4.6 fewer to 1.8 fewer; 1 study, 52 neonates; very low‐certainty evidence; <a href="./references#CD008550-fig-0007" title="">Analysis 3.1</a>). </p> <p><b>Adverse events</b> </p> <p>In the single study comparing esomeprazole to placebo (<a href="./references#CD008550-bbs2-0012" title="DavidsonG , WenzlTG , ThomsonM , OmariT , BarkerP , LundborgP , et al. Efficacy and safety of once-daily esomeprazole for the treatment of gastroesophageal reflux disease in neonatal patients. Journal of Pediatrics2013;163(3):692-8. ">Davidson 2013</a>), the study did not report the outcome in sufficient detail to allow extraction of summary statistics. We were therefore unable to include this study in our assessment of the evidence certainty. </p> <p><b>pH‐impedance indices and endoscopic findings</b> </p> <p>No studies were available for these outcomes.</p> </section> <section id="CD008550-sec-0093"> <p><b>Esomeprazole versus other treatments: magnesium hydroxide</b></p> <p><b>Improvement in clinical symptoms</b> </p> <p>A single study was available for this comparison: <a href="./references#CD008550-bbs2-0021" title="LootsC , KritasS , vanWijkM , McCallL , PeetersL , LewindonP , et al. Body positioning and medical therapy for infantile gastroesophageal reflux symptoms. Journal of Pediatric Gastroenterology and Nutrition2014;59(2):237-43. ">Loots 2014</a> compared esomeprazole and antacid (aluminium hydroxide and magnesium hydroxide (Mylanta)) therapy to left lateral positioning (LLP). In this study, 51 infants (aged two weeks to 26 weeks) with symptoms of GOR were randomised to one of four groups: (1) esomeprazole plus LLP; (2) esomeprazole plus head‐of‐cot elevation; (3) antacid plus LLP; or (4) antacid plus head‐of‐cot elevation. After two weeks, the esomeprazole groups' symptoms were reported to have improved more than those of the antacid groups, but the trial did not report the outcome in sufficient detail to allow extraction of summary statistics. </p> <p><b>Adverse events</b> </p> <p><a href="./references#CD008550-bbs2-0021" title="LootsC , KritasS , vanWijkM , McCallL , PeetersL , LewindonP , et al. Body positioning and medical therapy for infantile gastroesophageal reflux symptoms. Journal of Pediatric Gastroenterology and Nutrition2014;59(2):237-43. ">Loots 2014</a> reported five adverse events. Three were not considered serious: urinary tract infection, constipation, and diarrhoea and vomiting (following immunisation). Two of the adverse events were deemed serious: one participant (randomised to esomeprazole plus head elevation) was admitted with rotavirus infection; another (randomised to esomeprazole plus head elevation) was admitted because of reduced oral intake and weight loss. None were thought to be treatment‐related. However, the study did not report adverse events in sufficient detail to allow extraction of summary statistics or to assess evidence certainty. </p> <p><b>pH‐impedance indices</b> </p> <p><a href="./references#CD008550-bbs2-0021" title="LootsC , KritasS , vanWijkM , McCallL , PeetersL , LewindonP , et al. Body positioning and medical therapy for infantile gastroesophageal reflux symptoms. Journal of Pediatric Gastroenterology and Nutrition2014;59(2):237-43. ">Loots 2014</a> reported improved reflux index for the esomeprazole groups compared with the antacid groups (although reflux index &lt; 10% in 24 hours in infants is not considered pathological by the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN)). This study did not report the outcome in sufficient detail to allow extraction of summary statistics or to judge evidence certainty. </p> <p><b>Endoscopic findings</b> </p> <p>No studies were available for this outcome.</p> </section> <section id="CD008550-sec-0094"> <p><b>Esomeprazole at different doses</b></p> <p><b>Improvement in clinical symptoms</b> </p> <p><a href="./references#CD008550-bbs2-0026" title="OmariT , DavidsonG , BondarovP , NauclerE , NilssonC , LundborgP . Pharmacokinetics and acid-suppressive effects of esomeprazole in infants 1-24 months old with symptoms of gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2007;45(5):530-7. [MEDLINE: Published in abstract form in JPGN:2006: 42: E1-110]OmariT , DavidsonG , BondarovP , NauclerE , NilssonC , LundborgP . Pharmacokinetics and acid-suppressive effects of esomeprazole in infants 1-24 months old with symptoms of gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2015;60:S2-S8. ">Omari 2007</a> reported on 50 infants with symptoms of GORD and a reflux index suggestive of acid GOR (&gt; 4% in 24 hours) who were given oral esomeprazole 0.25 mg/kg or 1 mg/kg for eight days. They noted greater symptom improvement in the lower‐dose group. However, the trial did not report the outcome in sufficient detail to allow extraction of summary statistics for judging the efficacy of different doses of esomeprazole on symptomatic improvement. </p> <p><b>Adverse events</b> </p> <p><a href="./references#CD008550-bbs2-0026" title="OmariT , DavidsonG , BondarovP , NauclerE , NilssonC , LundborgP . Pharmacokinetics and acid-suppressive effects of esomeprazole in infants 1-24 months old with symptoms of gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2007;45(5):530-7. [MEDLINE: Published in abstract form in JPGN:2006: 42: E1-110]OmariT , DavidsonG , BondarovP , NauclerE , NilssonC , LundborgP . Pharmacokinetics and acid-suppressive effects of esomeprazole in infants 1-24 months old with symptoms of gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2015;60:S2-S8. ">Omari 2007</a> reported that only one infant with pre‐existing colic developed excessive irritability and was withdrawn. However, this study did not report the outcome in sufficient detail to allow extraction of summary statistics for judging the risk of adverse events at different doses. </p> <p><b>pH‐impedance indices</b> </p> <p><a href="./references#CD008550-bbs2-0026" title="OmariT , DavidsonG , BondarovP , NauclerE , NilssonC , LundborgP . Pharmacokinetics and acid-suppressive effects of esomeprazole in infants 1-24 months old with symptoms of gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2007;45(5):530-7. [MEDLINE: Published in abstract form in JPGN:2006: 42: E1-110]OmariT , DavidsonG , BondarovP , NauclerE , NilssonC , LundborgP . Pharmacokinetics and acid-suppressive effects of esomeprazole in infants 1-24 months old with symptoms of gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2015;60:S2-S8. ">Omari 2007</a> reported that reflux index improved in both groups (oral esomeprazole 0.25 mg/kg or 1 mg/kg), with greater improvement seen in the lower‐dose group. However, this study did not report the outcome in sufficient detail to allow extraction of summary statistics for assessing the efficacy of esomeprazole on pH‐impedance indices. </p> <p><b>Endoscopic findings</b> </p> <p>No studies were available for this outcome.</p> </section> </section> <section id="CD008550-sec-0095"> <h6 class="title">Rabeprazole</h6> <section id="CD008550-sec-0096"> <p><b>Rabeprazole versus placebo or other treatments</b></p> <p>No studies were available for these comparisons.</p> </section> <section id="CD008550-sec-0097"> <p><b>Rabeprazole at different doses</b></p> <p><b>Improvement in clinical symptoms</b> </p> <p>The <a href="./references#CD008550-bbs2-0019" title="HussainS , KierkusJ , HuP , HoffmanD , LekichR , SloanS , et al. Safety and efficacy of delayed release rabeprazole in 1- to 11-month-old infants with symptomatic GERD. Journal of Pediatric Gastroenterology and Nutrition2014;58(2):226-36. ">Hussain 2014</a> study was a five‐week, double‐blind withdrawal study (following a one‐ to three‐week open‐label phase) that compared rabeprazole 5 mg and 10 mg groups to placebo in 268 infants (aged one to 11 months). Only those infants who had improved went on to the double‐blind withdrawal phase. Of the 268 randomised infants (placebo: 90; rabeprazole 5 mg: 90; rabeprazole 10 mg: 88), 231 (86%) completed the study. Efficacy endpoints were similarly improved during the open‐label phase in all groups, and continued improving during the double‐blind withdrawal phase with no difference between the placebo and combined rabeprazole groups. No difference in primary endpoints (I‐GERQ scores) were noted. On post hoc analysis outcomes, a reduction in mean regurgitation frequency was seen (−0.79 versus −1.20 times a day), in I‐GERQ‐Revised scores (−3.6 (−25%) versus −3.9 points (−27%); MD 0.5, 95% CI −1.4 to 2.4), in I‐GERQ‐Daily Diary scores (−1.87 (−19%) versus −1.85 (−19%); MD 0.5, 95% CI −1.12 to 2.12), indicating equal improvement between the groups. However, given the serious risk of bias inherent in the post hoc nature of the study and given that only infants who had improved went on to the withdrawal phase, we did not include these data in the summary of findings tables. </p> <p><b>Adverse events</b> </p> <p>In the double‐blind phase of the study, <a href="./references#CD008550-bbs2-0019" title="HussainS , KierkusJ , HuP , HoffmanD , LekichR , SloanS , et al. Safety and efficacy of delayed release rabeprazole in 1- to 11-month-old infants with symptomatic GERD. Journal of Pediatric Gastroenterology and Nutrition2014;58(2):226-36. ">Hussain 2014</a> noted equal rates (47%: n = 42) of adverse events between placebo and combined rabeprazole groups (diarrhoea, constipation, flatulence, crying, and rash). Vomiting and worsened GORD was reportedly more common in the placebo group, and eight participants in the rabeprazole groups had elevated gastrin levels noted. However, the study did not report the outcome in sufficient detail to allow extraction of summary adverse events statistics at different doses. </p> <p><b>pH‐impedance indices</b> </p> <p>No studies were available for this outcome.</p> <p><b>Endoscopic findings</b> </p> <p><a href="./references#CD008550-bbs2-0019" title="HussainS , KierkusJ , HuP , HoffmanD , LekichR , SloanS , et al. Safety and efficacy of delayed release rabeprazole in 1- to 11-month-old infants with symptomatic GERD. Journal of Pediatric Gastroenterology and Nutrition2014;58(2):226-36. ">Hussain 2014</a> performed 12 endoscopies at baseline, but did not repeat them, so we were therefore unable to extract summary data and did not include this study in our assessment of the evidence certainty. </p> </section> </section> <section id="CD008550-sec-0098"> <h6 class="title">Pantoprazole</h6> <section id="CD008550-sec-0099"> <p><b>Pantoprazole versus placebo or other treatments</b></p> <p>No studies were available for these comparisons.</p> </section> <section id="CD008550-sec-0100"> <p><b>Pantoprazole at different doses</b></p> <p><b>Improvement in clinical symptoms</b> </p> <p>No studies were available for this outcome.</p> <p><b>Adverse events</b> </p> <p><a href="./references#CD008550-bbs2-0020" title="KierkusJ , Furmaga-JablonskaW , SullivanJE , DavidES , StewartDL , RathN , et al. Pharmacodynamics and safety of pantoprazole in neonates, preterm infants, and infants aged 1-11 months with a clinical diagnosis of gastroesophageal reflux disease. Digestive Diseases and Sciences2011;56:425-34. ">Kierkus 2011</a> assessed high‐dose (1.2 mg/kg) versus low‐dose pantoprazole (0.6 mg/kg) with a 24‐hour pH probe performed at baseline and then at day five. One participant developed excessive vomiting (trialists did not explicitly state which group this infant was in), and the participant was withdrawn from the study during the open‐label phase (24 infants). There was not enough evidence for pantoprazole at different doses to assess adverse events appropriately. </p> <p><b>pH‐impedance indices</b> </p> <p>The evidence is very uncertain about the effect of different doses of pantoprazole on pH‐impedance indices, based on the <a href="./references#CD008550-bbs2-0020" title="KierkusJ , Furmaga-JablonskaW , SullivanJE , DavidES , StewartDL , RathN , et al. Pharmacodynamics and safety of pantoprazole in neonates, preterm infants, and infants aged 1-11 months with a clinical diagnosis of gastroesophageal reflux disease. Digestive Diseases and Sciences2011;56:425-34. ">Kierkus 2011</a> study. Trialists noted improvements in reflux index from baseline in both groups (MD −0.4% in 24 hours (95% CI −0.99 to 0.19)), number of episodes (103.0 (95% CI −3.8 to 209.8)), number of reflux episodes lasting more than five minutes (2.0 (95% CI −0.38 to 4.38)), and duration of the longest reflux episodes (9.0 minutes (95% CI 1.46 to 16.54)). In each group, 50% to 70% of infants had normal reflux indices on enrolment (reflux index &lt; 5% in 24 hours; defined by the authors), but there was no difference between the low‐dose and high‐dose groups (1 study, 24 infants; very low‐certainty evidence). However, the insufficient data at baseline affected our ability to extract summary data, so we have not included this study in the summary of findings tables. </p> <p><b>Endoscopic findings</b> </p> <p>No studies were available for this outcome.</p> </section> </section> </section> <section id="CD008550-sec-0101"> <h5 class="title">H₂ antagonists</h5> <section id="CD008550-sec-0102"> <h6 class="title">Ranitidine</h6> <section id="CD008550-sec-0103"> <p><b>Ranitidine versus placebo</b></p> <p>No studies were available for this comparison</p> </section> <section id="CD008550-sec-0104"> <p><b>Ranitidine versus other treatments: omeprazole</b></p> <p><b>Improvement in clinical symptoms</b> </p> <p>Evidence from <a href="./references#CD008550-bbs2-0001" title="AzizollahiHR , RafeeyM . Efficacy of proton pump inhibitors and H2 blocker in the treatment of symptomatic gastroesophageal reflux disease in infants. Korean Journal of Pediatrics2016;59(5):226-30. ">Azizollahi 2016</a> indicated that ranitidine was likely to improve clinical symptoms but was not superior to omeprazole. <a href="./references#CD008550-bbs2-0001" title="AzizollahiHR , RafeeyM . Efficacy of proton pump inhibitors and H2 blocker in the treatment of symptomatic gastroesophageal reflux disease in infants. Korean Journal of Pediatrics2016;59(5):226-30. ">Azizollahi 2016</a> performed a randomised double‐blind trial in 76 infants with troublesome symptoms (diagnosed as GORD) aged between two months and 12 months. Participants had two weeks of standard treatment (smaller, more frequent feeds, hypoallergenic thickened formula), and were then randomised for two weeks to ranitidine (2 to 4 mg/kg/day) or omeprazole (0.5 mg/kg/day). Symptom scores (one of five GORD symptoms (vomiting/regurgitation, irritability/fussing, choking/gagging, arching back, refusal to feed) were assessed weekly for two weeks. In the ranitidine group, symptom scores improved from 47 ± 5.6 to 2.47 ± 0.58 (mean ± SD) compared to the omeprazole group, which improved from a higher mean baseline of 51.93 ± 5.42 to 2.43 ± 1.15 (MD of symptom score change ‐4.97 (95% CI ‐2.47 to ‐7.33). No difference between ranitidine and omeprazole was seen (1 study, 76 infants; very low‐certainty evidence). Please see <a href="./full#CD008550-tbl-0002">summary of findings Table 2</a>. </p> <p><b>Adverse events</b> </p> <p><a href="./references#CD008550-bbs2-0001" title="AzizollahiHR , RafeeyM . Efficacy of proton pump inhibitors and H2 blocker in the treatment of symptomatic gastroesophageal reflux disease in infants. Korean Journal of Pediatrics2016;59(5):226-30. ">Azizollahi 2016</a> found no adverse events (76 infants) but provided insufficient detail. We were therefore unable to extract summary data and did not include this study in our assessment of the evidence certainty regarding adverse events. </p> <p><b>pH‐impedance indices and endoscopic findings</b> </p> <p>No studies were available for these outcomes.</p> </section> <section id="CD008550-sec-0105"> <p><b>Ranitidine versus other treatments: hypoallergenic diet or formula</b></p> <p><b>Improvement in clinical symptoms</b> </p> <p>There were no suitable summary statistics to assess outcomes. A single study assessed ranitidine (6 mg/kg daily in two divided doses) against a hypoallergenic diet (mothers of breastfed infants were advised to consume only a hypoallergenic diet; formula‐fed infants were to feed on hydrolysed protein or amino acid‐based formula) in 50 infants aged less than one year with I‐GERQ‐R scores of more than 7 (<a href="./references#CD008550-bbs2-0014" title="FamouriF , ZibanejadN , KabiriP , KelishadR . Comparison of hypoallergenic diet vs. ranitidine in treatment of gastroesophageal reflux disease of infants: a randomized clinical trial. Iranian Journal of Pediatrics2017;27(4):e5343. ">Famouri 2017</a>). The study reported that an improvement in vomiting and respiratory symptoms was noted, but improvement in irritability, arching, or feed refusal was not observed. The study did not report the outcome in sufficient detail to allow extraction of summary statistics. </p> <p><b>Adverse events</b> </p> <p>Although a single study noted no adverse events (50 infants) (<a href="./references#CD008550-bbs2-0014" title="FamouriF , ZibanejadN , KabiriP , KelishadR . Comparison of hypoallergenic diet vs. ranitidine in treatment of gastroesophageal reflux disease of infants: a randomized clinical trial. Iranian Journal of Pediatrics2017;27(4):e5343. ">Famouri 2017</a>), we were unable to extract suitable data and did not include this study in our assessment of the evidence certainty. </p> <p><b>pH‐impedance indices and endoscopic findings</b> </p> <p>No studies were available for these outcomes.</p> </section> <section id="CD008550-sec-0106"> <p><b>Ranitidine at different doses</b></p> <p>No studies were available for any outcome.</p> </section> </section> <section id="CD008550-sec-0107"> <h6 class="title">Cimetidine</h6> <section id="CD008550-sec-0108"> <p><b>Cimetidine versus placebo</b></p> <p>No studies were available for any outcome.</p> </section> <section id="CD008550-sec-0109"> <p><b>Cimetidine versus other treatment: Maalox</b></p> <p><b>Improvement in clinical symptoms</b> </p> <p>One study compared cimetidine to Maalox over 12 weeks in 33 infants and children (aged two months to 42 months) with a diagnosis of GORD based on symptoms, oesophagitis on endoscopy, and acid reflux on pH probe (<a href="./references#CD008550-bbs2-0010" title="CucchiaraS , StaianoA , RomanielloG , CapobiancoS , AurcchioS . Antacids and cimetidine treatment for gastrooesophageal reflux and peptic oesophagitis. Archives of Disease in Childhood1984;59:842-7. ">Cucchiara 1984</a>). They found that cimetidine and Maalox both provided symptomatic relief (MD 0.29 (95% CI ‐0.27 to 3.24). However, this study did not report the outcome in sufficient detail to differentiate between infants and children and was not included in the assessment of evidence certainty. </p> <p><b>Adverse events</b> </p> <p><a href="./references#CD008550-bbs2-0010" title="CucchiaraS , StaianoA , RomanielloG , CapobiancoS , AurcchioS . Antacids and cimetidine treatment for gastrooesophageal reflux and peptic oesophagitis. Archives of Disease in Childhood1984;59:842-7. ">Cucchiara 1984</a> reported only that two participants on cimetidine had diarrhoea compared to placebo. However, this study did not differentiate between infants and children, so we did not include these data in the assessment of evidence certainty. </p> <p><b>pH‐impedance indices</b> </p> <p><a href="./references#CD008550-bbs2-0010" title="CucchiaraS , StaianoA , RomanielloG , CapobiancoS , AurcchioS . Antacids and cimetidine treatment for gastrooesophageal reflux and peptic oesophagitis. Archives of Disease in Childhood1984;59:842-7. ">Cucchiara 1984</a> observed that the reflux index was improved in both groups compared to baseline; neither group was superior (MD 0.31% in 24 hours (95% CI −1.45 to 2.1)). However, this study did not report the outcome in sufficient detail to differentiate between infants and children, so we did not include these data in the assessment of evidence certainty. </p> <p><b>Endoscopic findings</b> </p> <p><a href="./references#CD008550-bbs2-0010" title="CucchiaraS , StaianoA , RomanielloG , CapobiancoS , AurcchioS . Antacids and cimetidine treatment for gastrooesophageal reflux and peptic oesophagitis. Archives of Disease in Childhood1984;59:842-7. ">Cucchiara 1984</a> found that endoscopic appearances were improved (MD 0.19 (95% CI ‐2.47 to 2.85)) but the trial did not report the outcome in sufficient detail to differentiate between infants and children and was not included in the assessment of evidence certainty. </p> </section> <section id="CD008550-sec-0110"> <p><b>Cimetidine at different doses</b></p> <p>No studies were available for any outcome.</p> </section> </section> <section id="CD008550-sec-0111"> <h6 class="title">Famotidine</h6> <section id="CD008550-sec-0112"> <p><b>Famotidine versus placebo</b></p> <p><b>Improvement in clinical symptoms</b> </p> <p>The single RCT for this comparison, <a href="./references#CD008550-bbs2-0027" title="OrensteinSR , ShalabyTM , DevandrySN , LiacourasCA , CzinnSJ , DiceJE , et al. Famotidine for infant gastro-oesophageal reflux: a multi-centre, randomized, placebo-controlled, withdrawal trial. Alimentary Pharmacology and Therapeutics2003;17(9):1097-107. ">Orenstein 2002</a>, assessed 35 infants (age range 1.3 to 10.5 months) with symptomatic GORD who were given four weeks of famotidine 0.5 mg/kg versus famotidine 1 mg/kg (Phase 1: discussed in 'Famotidine at different doses' comparison below) and then four weeks' double‐blind withdrawal comparison of each dose with placebo (Phase 2). Only 8 of 35 participants completed phase 2, giving insufficient data for meaningful comparison. There were no suitable summary statistics to assess improvement outcomes. </p> <p><b>Adverse events</b> </p> <p><a href="./references#CD008550-bbs2-0027" title="OrensteinSR , ShalabyTM , DevandrySN , LiacourasCA , CzinnSJ , DiceJE , et al. Famotidine for infant gastro-oesophageal reflux: a multi-centre, randomized, placebo-controlled, withdrawal trial. Alimentary Pharmacology and Therapeutics2003;17(9):1097-107. ">Orenstein 2002</a> noted that only eight of 35 participants completed phase 2 of the study, giving insufficient data for meaningful comparison, so we were therefore unable to extract summary data and did not include this study in our assessment of the evidence certainty. However, in addition to the adverse events reported below, the study report noted that four participants in the famotidine group and four in the placebo group experienced asymptomatic neutropenia which resolved. </p> <p><b>pH‐impedance indices and endoscopic findings</b> </p> <p>No studies were available for these outcomes.</p> </section> <section id="CD008550-sec-0113"> <p><b>Famotidine versus other treatments</b></p> <p>No studies were available for any outcome.</p> </section> <section id="CD008550-sec-0114"> <p><b>Famotidine at different doses</b></p> <p><b>Improvement in clinical symptoms</b> </p> <p>As described above, a single RCT for this comparison, <a href="./references#CD008550-bbs2-0027" title="OrensteinSR , ShalabyTM , DevandrySN , LiacourasCA , CzinnSJ , DiceJE , et al. Famotidine for infant gastro-oesophageal reflux: a multi-centre, randomized, placebo-controlled, withdrawal trial. Alimentary Pharmacology and Therapeutics2003;17(9):1097-107. ">Orenstein 2002</a>, assessed 35 infants (age range 1.3 to 10.5 months) with symptomatic GORD who were given four weeks of famotidine 0.5 mg/kg versus famotidine 1 mg/kg (Phase 1), followed by four weeks' double‐blind withdrawal comparison of each dose with placebo (Phase 2). Twenty‐seven participants completed phase 1. In terms of symptom outcomes, a slight improvement in regurgitation frequency/volume and crying time in those infants receiving the reduced dose of famotidine was noted, as well as improved global assessments by parents and physicians. However, the data were not expressed in enough detail to allow extraction of summary symptom or observer statistics. There were no suitable summary statistics to assess outcomes. </p> <p><b>Adverse events</b> </p> <p><a href="./references#CD008550-bbs2-0027" title="OrensteinSR , ShalabyTM , DevandrySN , LiacourasCA , CzinnSJ , DiceJE , et al. Famotidine for infant gastro-oesophageal reflux: a multi-centre, randomized, placebo-controlled, withdrawal trial. Alimentary Pharmacology and Therapeutics2003;17(9):1097-107. ">Orenstein 2002</a> observed that 72% of infants receiving famotidine 0.5 mg/kg experienced adverse events and all infants receiving famotidine 1 mg/kg experienced adverse events. However, the data provided did not distinguish between the two groups, so we were unable to extract summary data to assess the certainty of evidence for this outcome. Trialists noted six participants with agitation or irritability (manifested as head‐rubbing in two), three participants with somnolence, two participants with anorexia, two with headache, one participant with vomiting, one participant with hiccups, and one participant with candidiasis. Six infants on famotidine experienced new agitation/irritability; two had accompanying head rubbing and all resolved within days of ending therapy (35 infants). </p> <p><b>pH‐impedance indices and endoscopic findings</b> </p> <p>No studies were available for these outcomes.</p> </section> </section> <section id="CD008550-sec-0115"> <h6 class="title">Nizatidine</h6> <p>No studies were available for any comparison.</p> </section> </section> <section id="CD008550-sec-0116"> <h5 class="title">Prokinetics</h5> <section id="CD008550-sec-0117"> <h6 class="title">Domperidone</h6> <section id="CD008550-sec-0118"> <p><b>Domperidone versus placebo</b></p> <p><b>Improvement in clinical symptoms</b> </p> <p><a href="./references#CD008550-bbs2-0008" title="CarroccioA , Iacono, MontaltoG , CavataioF , SoresiM , NotarbartoloA . Domperidone plus magnesium hydroxide and aluminium hydroxide: a valid therapy in children with gastroesophageal reflux. Scandinavian Journal of Gastroenterology1994;29(4):300-4. ">Carroccio 1994</a> assessed symptoms, and noted no difference between domperidone and placebo. The trial did not report the outcome in sufficient detail to allow extraction of summary statistics, and did not differentiate between infants and children over one year of age, so we did not consider this study in assessing the certainty of evidence. </p> <p><b>Adverse events</b> </p> <p>There was insufficient evidence to assess adverse events appropriately for domperidone compared to placebo, based on one study (<a href="./references#CD008550-bbs2-0009" title="CresiF , MarinaccioC , RussoMC , MinieroR , SilvestroL . Short-term effect of domperidone on gastroesophageal reflux in newborns assessed by combined intraluminal impedance and pH monitoring. Journal of Perinatology2008;28:766-70. ">Cresi 2008</a>). No adverse events were seen (26 neonates). </p> <p><b>pH‐impedance indices</b> </p> <p>Two studies were considered. <a href="./references#CD008550-bbs2-0009" title="CresiF , MarinaccioC , RussoMC , MinieroR , SilvestroL . Short-term effect of domperidone on gastroesophageal reflux in newborns assessed by combined intraluminal impedance and pH monitoring. Journal of Perinatology2008;28:766-70. ">Cresi 2008</a> randomised 26 neonates to domperidone 0.3 mg/kg or placebo over 24 hours with assessment through a 24‐hour oesophageal pH study. Reflux frequency was increased (difference in means between domperidone epochs and placebo: MD ‐1.26 episodes/hour (95% CI ‐2.31 to ‐0.21), but duration was improved in this brief study (MD 3.5 seconds (95% CI ‐1.67 to 8.67)). Reflux height (MD ‐0.03 (95% CI ‐0.63 to 0.57)) and mean reflux pH (‐0.12 (95% CI ‐0.90 to 0.66)) were no different. As this study only assessed short epochs (8 hours) of data, we have not assessed the certainty of the evidence nor included it in our summary of findings table. <a href="./references#CD008550-bbs2-0008" title="CarroccioA , Iacono, MontaltoG , CavataioF , SoresiM , NotarbartoloA . Domperidone plus magnesium hydroxide and aluminium hydroxide: a valid therapy in children with gastroesophageal reflux. Scandinavian Journal of Gastroenterology1994;29(4):300-4. ">Carroccio 1994</a> also assessed pH indices, and noted no difference between domperidone and placebo. The trial did not report the outcome in sufficient detail to allow extraction of summary statistics, and did not differentiate between infants and children over one year of age, so we did not consider this study in assessing the certainty of the evidence. </p> <p><b>Endoscopic findings</b> </p> <p>No studies were available for this outcome.</p> </section> <section id="CD008550-sec-0119"> <p><b>Domperidone compared to other treatments</b></p> <p><b>Improvement in clinical symptoms</b> </p> <p><a href="./references#CD008550-bbs2-0008" title="CarroccioA , Iacono, MontaltoG , CavataioF , SoresiM , NotarbartoloA . Domperidone plus magnesium hydroxide and aluminium hydroxide: a valid therapy in children with gastroesophageal reflux. Scandinavian Journal of Gastroenterology1994;29(4):300-4. ">Carroccio 1994</a> performed an RCT in 80 participants (one month to 18 months old, with symptoms of reflux) in four groups (domperidone with alginate, domperidone alone, placebo, and domperidone with Maalox, with 20 participants in each group). Trialists assessed symptoms and 24‐hour oesophageal pH indices. There were suggested improvement in symptoms in all four groups: it was reported that symptoms were resolved in 16 of 20 participants in the domperidone with Maalox group; in eight of 20 participants in the domperidone with alginate group; in nine of 20 participants in the domperidone alone group; and an improvement in symptoms in seven of 20 participants in the placebo group. However, the trial did not report the outcome in sufficient detail to allow extraction of summary statistics and did not differentiate between infants and children over one year of age, so we did not consider this study in assessing the certainty of the evidence. </p> <p><b>Adverse events</b> </p> <p>No studies were available for this outcome.</p> <p><b>pH‐impedance indices</b> </p> <p><a href="./references#CD008550-bbs2-0008" title="CarroccioA , Iacono, MontaltoG , CavataioF , SoresiM , NotarbartoloA . Domperidone plus magnesium hydroxide and aluminium hydroxide: a valid therapy in children with gastroesophageal reflux. Scandinavian Journal of Gastroenterology1994;29(4):300-4. ">Carroccio 1994</a> assessed 24‐hour oesophageal pH indices but did not report the outcome in sufficient detail to allow extraction of summary statistics and did not differentiate between infants and children over one year of age, so we did not consider this study in assessing the certainty of the evidence. </p> <p><b>Endoscopic findings</b> </p> <p>No studies were available for this outcome.</p> </section> <section id="CD008550-sec-0120"> <p><b>Domperidone at different doses</b></p> <p>No studies were available for this comparison.</p> </section> </section> <section id="CD008550-sec-0121"> <h6 class="title">Erythromycin</h6> <section id="CD008550-sec-0122"> <p><b>Erythromycin versus placebo</b></p> <p><b>Improvement in clinical symptoms</b> </p> <p><a href="./references#CD008550-bbs2-0004" title="BallengeeCR , DavalianF , ConawayMR , SauerCG , KaufmanDA . Erythromycin and reflux events in premature neonates: a randomized clinical trial. Journal of Pediatric Gastroenterology and Nutrition2018;67(6):720-25. ">Ballengee 2018</a> compared erythromycin (50 mg/kg/day) to a visually‐indistinguishable placebo in 33 preterm infants with reflux events on pH‐impedance monitoring (mean gestational age 27 weeks), and noted no improvement in nurse‐reported apnoea/bradycardia and desaturations compared to placebo. However, the trial did not report the outcome in sufficient detail to allow extraction of summary statistics or assessment of evidence certainty. </p> <p><b>Adverse events</b> </p> <p>Whilst <a href="./references#CD008550-bbs2-0004" title="BallengeeCR , DavalianF , ConawayMR , SauerCG , KaufmanDA . Erythromycin and reflux events in premature neonates: a randomized clinical trial. Journal of Pediatric Gastroenterology and Nutrition2018;67(6):720-25. ">Ballengee 2018</a> reported no increase in apnoeas, bradycardias, and desaturations in the erythromycin group compared to placebo, there were insufficient data for extraction of summary statistics (33 infants) and for judging evidence certainty. </p> <p><b>pH‐impedance indices</b> </p> <p>For <a href="./references#CD008550-bbs2-0004" title="BallengeeCR , DavalianF , ConawayMR , SauerCG , KaufmanDA . Erythromycin and reflux events in premature neonates: a randomized clinical trial. Journal of Pediatric Gastroenterology and Nutrition2018;67(6):720-25. ">Ballengee 2018</a>, the primary outcome measure was the total number of reflux events on 24‐hour pH‐impedance monitoring after one week on erythromycin or placebo. The study found that erythromycin may be inferior to placebo in reducing reflux events, but the trial did not report the outcome in sufficient detail to allow extraction of summary statistics. </p> <p><b>Endoscopic findings</b> </p> <p>No studies were available for this outcome.</p> </section> <section id="CD008550-sec-0123"> <p><b>Erythromycin versus other treatments or at different doses</b></p> <p>No studies were available for these comparisons.</p> </section> </section> </section> <section id="CD008550-sec-0124"> <h5 class="title">Compound alginate preparations</h5> <section id="CD008550-sec-0125"> <h6 class="title">Sodium alginate plus magnesium alginate versus placebo</h6> <p><b>Improvement in clinical symptoms</b> </p> <p>Five studies evaluated sodium alginate plus magnesium alginate (sodium+magnesium alginate; i.e. Gaviscon Infant) (<a href="./references#CD008550-bbs2-0007" title="ButsJP , BarudiC , OtteJB . Double-blind controlled study on the efficacy of sodium alginate (Gaviscon) in reducing gastroesophageal reflux assessed by 24 h continuous pH monitoring in infants and children. European Journal of Pediatrics1987;146(2):156-8. ">Buts 1987</a>; <a href="./references#CD008550-bbs2-0008" title="CarroccioA , Iacono, MontaltoG , CavataioF , SoresiM , NotarbartoloA . Domperidone plus magnesium hydroxide and aluminium hydroxide: a valid therapy in children with gastroesophageal reflux. Scandinavian Journal of Gastroenterology1994;29(4):300-4. ">Carroccio 1994</a>; <a href="./references#CD008550-bbs2-0013" title="Del BuonoR , WenzlTG , BallG , KeadyS , ThomsonM . Effect of Gaviscon Infant on gastro-oesophageal reflux in infants assessed by combined intraluminal impedance/pH. Archives of Disease in Childhood2005;90:460-3. ">Del Buono 2005</a>; <a href="./references#CD008550-bbs2-0015" title="ForbesD , HodgsonM , HillR . The effects of gaviscon and metoclopramide in gastroesophageal reflux in children. Journal of Pediatric Gastroenterology and Nutrition1986;5(4):556-9. ">Forbes 1986</a>; <a href="./references#CD008550-bbs2-0022" title="MillerS . Comparison of the efficacy and safety of a new aluminum-free paediatric alginate preparation and placebo in infants with recurrent gastro-oesophageal reflux. Current Medical Research and Opinion1999;15(3):160-8. ">Miller 1999</a>). <a href="./references#CD008550-bbs2-0022" title="MillerS . Comparison of the efficacy and safety of a new aluminum-free paediatric alginate preparation and placebo in infants with recurrent gastro-oesophageal reflux. Current Medical Research and Opinion1999;15(3):160-8. ">Miller 1999</a> and <a href="./references#CD008550-bbs2-0007" title="ButsJP , BarudiC , OtteJB . Double-blind controlled study on the efficacy of sodium alginate (Gaviscon) in reducing gastroesophageal reflux assessed by 24 h continuous pH monitoring in infants and children. European Journal of Pediatrics1987;146(2):156-8. ">Buts 1987</a> found symptomatic improvement, but were limited by short follow‐up and did not have enough data for extraction of summary statistics. <a href="./references#CD008550-bbs2-0007" title="ButsJP , BarudiC , OtteJB . Double-blind controlled study on the efficacy of sodium alginate (Gaviscon) in reducing gastroesophageal reflux assessed by 24 h continuous pH monitoring in infants and children. European Journal of Pediatrics1987;146(2):156-8. ">Buts 1987</a> noted that the number of episodes of regurgitations per day reported by parents was reduced during the trial (20 participants), although summary statistics could not be extracted and the authors did not differentiate between infants and children over one year of age. We did not include these data in the summary of findings tables. </p> <p><b>Adverse events</b> </p> <p>Four studies in sodium+magnesium alginate evaluated adverse events (<a href="./references#CD008550-bbs2-0007" title="ButsJP , BarudiC , OtteJB . Double-blind controlled study on the efficacy of sodium alginate (Gaviscon) in reducing gastroesophageal reflux assessed by 24 h continuous pH monitoring in infants and children. European Journal of Pediatrics1987;146(2):156-8. ">Buts 1987</a>; <a href="./references#CD008550-bbs2-0008" title="CarroccioA , Iacono, MontaltoG , CavataioF , SoresiM , NotarbartoloA . Domperidone plus magnesium hydroxide and aluminium hydroxide: a valid therapy in children with gastroesophageal reflux. Scandinavian Journal of Gastroenterology1994;29(4):300-4. ">Carroccio 1994</a>; <a href="./references#CD008550-bbs2-0015" title="ForbesD , HodgsonM , HillR . The effects of gaviscon and metoclopramide in gastroesophageal reflux in children. Journal of Pediatric Gastroenterology and Nutrition1986;5(4):556-9. ">Forbes 1986</a>; <a href="./references#CD008550-bbs2-0022" title="MillerS . Comparison of the efficacy and safety of a new aluminum-free paediatric alginate preparation and placebo in infants with recurrent gastro-oesophageal reflux. Current Medical Research and Opinion1999;15(3):160-8. ">Miller 1999</a>). <a href="./references#CD008550-bbs2-0007" title="ButsJP , BarudiC , OtteJB . Double-blind controlled study on the efficacy of sodium alginate (Gaviscon) in reducing gastroesophageal reflux assessed by 24 h continuous pH monitoring in infants and children. European Journal of Pediatrics1987;146(2):156-8. ">Buts 1987</a> found no adverse events in 20 children but had insufficient data for extraction of summary statistics. Trialists did not differentiate infants from children over one year of age, so we did not assess the certainty of the evidence or include the data in the summary of findings tables. <a href="./references#CD008550-bbs2-0015" title="ForbesD , HodgsonM , HillR . The effects of gaviscon and metoclopramide in gastroesophageal reflux in children. Journal of Pediatric Gastroenterology and Nutrition1986;5(4):556-9. ">Forbes 1986</a> noted no adverse events, but these authors also did not differentiate between infants and children, so we did not include the data in the summary of findings tables or assess the certainty of the evidence. <a href="./references#CD008550-bbs2-0008" title="CarroccioA , Iacono, MontaltoG , CavataioF , SoresiM , NotarbartoloA . Domperidone plus magnesium hydroxide and aluminium hydroxide: a valid therapy in children with gastroesophageal reflux. Scandinavian Journal of Gastroenterology1994;29(4):300-4. ">Carroccio 1994</a> also did not report adverse events in sufficient detail to allow extraction of summary statistics and did not differentiate between infants and children, so we did not consider these data in assessing the certainty of the evidence. <a href="./references#CD008550-bbs2-0022" title="MillerS . Comparison of the efficacy and safety of a new aluminum-free paediatric alginate preparation and placebo in infants with recurrent gastro-oesophageal reflux. Current Medical Research and Opinion1999;15(3):160-8. ">Miller 1999</a> noted that 13 participants withdrew due to adverse effects, including diarrhoea and constipation, but with no difference between groups. The trial did not report the outcome in sufficient detail to allow extraction of summary statistics, and we did not consider these data in assessing the certainty of the evidence. </p> <p><b>pH‐impedance indices</b> </p> <p>Two studies assessed this outcome: <a href="./references#CD008550-bbs2-0013" title="Del BuonoR , WenzlTG , BallG , KeadyS , ThomsonM . Effect of Gaviscon Infant on gastro-oesophageal reflux in infants assessed by combined intraluminal impedance/pH. Archives of Disease in Childhood2005;90:460-3. ">Del Buono 2005</a> only noted an improvement in reflux height on manometry, with no other differences compared to placebo, but the trial did not report the outcome in sufficient detail to allow extraction of summary pH statistics. An older formulation of sodium+magnesium alginate (Gaviscon Infant) was evaluated by <a href="./references#CD008550-bbs2-0015" title="ForbesD , HodgsonM , HillR . The effects of gaviscon and metoclopramide in gastroesophageal reflux in children. Journal of Pediatric Gastroenterology and Nutrition1986;5(4):556-9. ">Forbes 1986</a>, showing no difference in pH indices after 24 hours of treatment, but conclusions were limited by the short‐term nature of this study (24 hours). The total number of reflux events per hour were similar between groups (MD −32.0 (95% CI −85.5 to 21.5)) as well as total duration of reflux episodes (MD 22.0 seconds (95% CI −63.6 to 107.1)). As the authors did not differentiate between infants and children over one year of age, we did not include the data in the summary of findings tables or judge the certainty of the evidence. </p> <p><b>Endoscopic findings</b> </p> <p>No data were available for this outcome.</p> </section> <section id="CD008550-sec-0126"> <h6 class="title">Sodium+magnesium alginate versus other treatments</h6> <p><b>Improvement in clinical symptoms</b> </p> <p>No data were available for this outcome. As discussed above, <a href="./references#CD008550-bbs2-0008" title="CarroccioA , Iacono, MontaltoG , CavataioF , SoresiM , NotarbartoloA . Domperidone plus magnesium hydroxide and aluminium hydroxide: a valid therapy in children with gastroesophageal reflux. Scandinavian Journal of Gastroenterology1994;29(4):300-4. ">Carroccio 1994</a> demonstrated no symptomatic benefit in the domperidone and sodium+magnesium alginate group (20 children), compared to placebo or to domperidone, but the trial did not report the outcome in sufficient detail to allow extraction of summary statistics. However, a confounding factor may have been the thickening of all feeds in all groups by Medigel 1%. </p> <p><b>Adverse events</b> </p> <p>As discussed above, <a href="./references#CD008550-bbs2-0008" title="CarroccioA , Iacono, MontaltoG , CavataioF , SoresiM , NotarbartoloA . Domperidone plus magnesium hydroxide and aluminium hydroxide: a valid therapy in children with gastroesophageal reflux. Scandinavian Journal of Gastroenterology1994;29(4):300-4. ">Carroccio 1994</a> did not comment on adverse events, so we did not consider this study in assessing the certainty of the evidence. </p> <p><b>pH‐impedance indices</b> </p> <p><a href="./references#CD008550-bbs2-0008" title="CarroccioA , Iacono, MontaltoG , CavataioF , SoresiM , NotarbartoloA . Domperidone plus magnesium hydroxide and aluminium hydroxide: a valid therapy in children with gastroesophageal reflux. Scandinavian Journal of Gastroenterology1994;29(4):300-4. ">Carroccio 1994</a> performed an RCT in 80 participants (infants aged one month to 18 months old with symptoms of reflux) in four groups, and assessed 24‐hour oesophageal pH indices. However, the trial did not report the outcome in sufficient detail to allow extraction of summary statistics and did not differentiate between infants and children over one year of age, so we did not consider this study in assessing the certainty of the evidence. </p> <p><b>Endoscopic findings</b> </p> <p>No studies were available for this outcome.</p> </section> <section id="CD008550-sec-0127"> <h6 class="title">Sodium+magnesium alginate at different doses</h6> <p>No studies were available for this comparison.</p> </section> <section id="CD008550-sec-0128"> <h6 class="title">Magnesium (Mg) alginate</h6> <section id="CD008550-sec-0129"> <p><b>Magnesium alginate versus placebo</b></p> <p>No studies were available for this comparison</p> </section> <section id="CD008550-sec-0130"> <p><b>Magnesium alginate versus other treatments</b></p> <p><b>Improvement in clinical symptoms</b> </p> <p>We identified two studies. <a href="./references#CD008550-bbs2-0003" title="BaldassarreME , Di MauroA , PignatelliMC , FanelliM , SalvatoreS , Di NardoG , et al. Magnesium alginate in gastro-esophageal reflux: a randomized multicenter cross-over study in infants. International Journal of Environmental Research and Public Health2020;17(1):83. ">Baldassarre 2020</a> assessed 53 formula‐fed infants and 19 breastfed infants (aged three weeks to four months) with IGERQ‐R scores above 16, and noted that in formula‐fed infants, while both groups improved, no differences in score reduction between magnesium alginate and thickened formula was seen. The breastfed arm did not have a control arm so was not considered. However, the trial included a thickener as a comparator arm, so we have not considered these data in assessing the certainty of evidence. <a href="./references#CD008550-bbs2-0035" title="UmmarinoD , MieleE , MartinelliM , ScarpatoE , CrocettoF , SciorioE , et al. Effect of magnesium alginate plus simethicone on gastroesophageal reflux in infants. Journal of Pediatric Gastroenterology and Nutrition2015;60(2):230-5. ">Ummarino 2015</a> was not included as the trial did not report the outcome in sufficient detail to allow extraction of summary statistics. This study noted magnesium alginate plus simethicone showed improved symptoms compared to thickened formula and lifestyle advice. </p> <p><b>Adverse events</b> </p> <p>We identified two studies. One study noted no adverse events in the magnesium alginate group (75 infants) (<a href="./references#CD008550-bbs2-0035" title="UmmarinoD , MieleE , MartinelliM , ScarpatoE , CrocettoF , SciorioE , et al. Effect of magnesium alginate plus simethicone on gastroesophageal reflux in infants. Journal of Pediatric Gastroenterology and Nutrition2015;60(2):230-5. ">Ummarino 2015</a>). <a href="./references#CD008550-bbs2-0003" title="BaldassarreME , Di MauroA , PignatelliMC , FanelliM , SalvatoreS , Di NardoG , et al. Magnesium alginate in gastro-esophageal reflux: a randomized multicenter cross-over study in infants. International Journal of Environmental Research and Public Health2020;17(1):83. ">Baldassarre 2020</a> monitored for adverse events and reported that no participants withdrew due to adverse events. However, trialists did not report the presence or absence of adverse events, and so we did not consider this study in assessing evidence certainty. </p> <p><b>pH‐impedance indices and endoscopic findings</b> </p> <p>No studies were available for these outcomes.</p> </section> <section id="CD008550-sec-0131"> <p><b>Magnesium alginate at different doses</b></p> <p>No studies were available for this comparison.</p> </section> </section> </section> </section> <section id="CD008550-sec-0132"> <h4 class="title">II. Children older than one year</h4> <section id="CD008550-sec-0133"> <h5 class="title">Proton pump inhibitors</h5> <section id="CD008550-sec-0134"> <h6 class="title">Omeprazole</h6> <section id="CD008550-sec-0135"> <p><b>Omeprazole versus placebo</b></p> <p>No studies were available for this comparison</p> </section> <section id="CD008550-sec-0136"> <p><b>Omeprazole versus ranitidine</b></p> <p><b>Improvement in clinical symptoms</b> </p> <p>We assessed two studies (<a href="./references#CD008550-bbs2-0011" title="CucchiaraS , MinellaR , IervolinoC , FrancoMT , CampanozziA , FranceschiM , et al. Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis. Archives of Disease in Childhood1993;69:655-9. ">Cucchiara 1993</a>; <a href="./references#CD008550-bbs2-0029" title="PfefferkornMD , CroffieJM , GuptaSK , MollestonJP , EckertGJ , CorkinsMR , et al. Nocturnal acid breakthrough in children with reflux esophagitis taking proton pump inhibitors. Journal of Pediatric Gastroenterology and Nutrition2006;42(2):160-5. ">Pfefferkorn 2006</a>). <a href="./references#CD008550-bbs2-0029" title="PfefferkornMD , CroffieJM , GuptaSK , MollestonJP , EckertGJ , CorkinsMR , et al. Nocturnal acid breakthrough in children with reflux esophagitis taking proton pump inhibitors. Journal of Pediatric Gastroenterology and Nutrition2006;42(2):160-5. ">Pfefferkorn 2006</a> assessed nocturnal acid breakthrough symptoms after three weeks in 16 participants (aged one to 13 years) with symptomatic GORD with endoscopic/histological changes treated with omeprazole. In the omeprazole group, symptom scores improved from 2.0 ± 0 at baseline, to 0.6 ± 0.4 at week three, to 0.4 ± 0.45 at week 9, to 0.4 ± 0.5 at week 17; difference in means from baseline to week 17: MD ‐1.6 (95% CI ‐1.9 to ‐1.2). The study also reported no additional benefit from adding ranitidine in those with breakthrough symptoms. There was insufficient detail to compare omeprazole plus ranitidine to omeprazole plus placebo for inclusion in a summary of findings table or to assess the certainty of evidence. As discussed above, <a href="./references#CD008550-bbs2-0011" title="CucchiaraS , MinellaR , IervolinoC , FrancoMT , CampanozziA , FranceschiM , et al. Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis. Archives of Disease in Childhood1993;69:655-9. ">Cucchiara 1993</a> noted similar improvements in symptoms in both those randomised to eight weeks of standard doses of omeprazole (40 mg/day/1.73m<sup>2</sup> surface area) and higher doses of ranitidine (20 mg/kg/day). However, we did not consider this evidence further as the trial did not report the outcome in sufficient detail to allow extraction of summary statistics, and did not differentiate between infants and children so was not considered in the certainty of evidence. </p> <p><b>Adverse events</b> </p> <p>We assessed two studies (<a href="./references#CD008550-bbs2-0011" title="CucchiaraS , MinellaR , IervolinoC , FrancoMT , CampanozziA , FranceschiM , et al. Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis. Archives of Disease in Childhood1993;69:655-9. ">Cucchiara 1993</a>; <a href="./references#CD008550-bbs2-0029" title="PfefferkornMD , CroffieJM , GuptaSK , MollestonJP , EckertGJ , CorkinsMR , et al. Nocturnal acid breakthrough in children with reflux esophagitis taking proton pump inhibitors. Journal of Pediatric Gastroenterology and Nutrition2006;42(2):160-5. ">Pfefferkorn 2006</a>). One study noted no adverse events (16 participants) (<a href="./references#CD008550-bbs2-0029" title="PfefferkornMD , CroffieJM , GuptaSK , MollestonJP , EckertGJ , CorkinsMR , et al. Nocturnal acid breakthrough in children with reflux esophagitis taking proton pump inhibitors. Journal of Pediatric Gastroenterology and Nutrition2006;42(2):160-5. ">Pfefferkorn 2006</a>). <a href="./references#CD008550-bbs2-0011" title="CucchiaraS , MinellaR , IervolinoC , FrancoMT , CampanozziA , FranceschiM , et al. Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis. Archives of Disease in Childhood1993;69:655-9. ">Cucchiara 1993</a> noted one participant was withdrawn due to a temperature and a respiratory infection, but it was uncertain which treatment group this participant was from (omeprazole or high‐dose ranitidine). We did not consider this evidence further as the trial did not report the outcome in sufficient detail to allow extraction of summary statistics, or differentiate between infants and children so was not considered in the certainty of evidence. </p> <p><b>pH‐impedance indices</b> </p> <p>Two studies assessed the impact of omeprazole versus ranitidine on pH‐impedance indices. Additional ranitidine may not provide additional benefit. <a href="./references#CD008550-bbs2-0029" title="PfefferkornMD , CroffieJM , GuptaSK , MollestonJP , EckertGJ , CorkinsMR , et al. Nocturnal acid breakthrough in children with reflux esophagitis taking proton pump inhibitors. Journal of Pediatric Gastroenterology and Nutrition2006;42(2):160-5. ">Pfefferkorn 2006</a> assessed nocturnal acid breakthrough symptoms after three weeks in 16 participants with symptomatic GORD with endoscopic/histological changes (aged one to 13 years) treated with omeprazole. Oesophageal pH studies were performed at baseline, week three, and week 17 on omeprazole. Reflux index improved following initiation of therapy from 14.3 ± 11.5% in 24 hours at baseline to 2.0 ± 2.9% in 24 hours at week three (MD ‐12.3 (95% CI‐18.4 to ‐6.4)). The reflux index did not change from week three (2.0 ± 2.9% in 24 hours) to week 17 after initiation of ranitidine (5.1 ± 5.1% in 24 hours) (MD 3.1 (95% CI‐1.0 to 7.2)). However, as both arms contained omeprazole, we have not included this result in a summary of findings table or assessed the certainty of evidence. <a href="./references#CD008550-bbs2-0011" title="CucchiaraS , MinellaR , IervolinoC , FrancoMT , CampanozziA , FranceschiM , et al. Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis. Archives of Disease in Childhood1993;69:655-9. ">Cucchiara 1993</a> noted improvements in pH indices but was not further considered as the trial did not report the outcome in sufficient detail to allow extraction of summary statistics, and did not differentiate between infants and children so was not considered in the certainty of evidence. </p> <p><b>Endoscopic findings</b> </p> <p>Two studies assessed the impact of omeprazole versus ranitidine on endoscopic findings. Additional ranitidine may not provide additional benefit. <a href="./references#CD008550-bbs2-0029" title="PfefferkornMD , CroffieJM , GuptaSK , MollestonJP , EckertGJ , CorkinsMR , et al. Nocturnal acid breakthrough in children with reflux esophagitis taking proton pump inhibitors. Journal of Pediatric Gastroenterology and Nutrition2006;42(2):160-5. ">Pfefferkorn 2006</a> assessed endoscopy appearances at baseline and week 17 using Hetzel‐Dent scoring (grade 0 to 4). Improvement in endoscopic grade from 3.1 ± 1.4 to 1.6 ± 1.8 occurred in those children receiving omeprazole: MD ‐1.5 (95% CI‐3.1 to 0.1). Improvement in mean histology scores of all participants from baseline (1.8 ± 0.7) to week 17 (0.8 ± 0.9): MD ‐1.0 (95% CI ‐1.8 to ‐0.2) was also seen. However, as both arms contained omeprazole, we have not included this result in a summary of findings table nor assessed the certainty of evidence. Further detail on the effect of ranitidine is discussed below. As discussed above, <a href="./references#CD008550-bbs2-0011" title="CucchiaraS , MinellaR , IervolinoC , FrancoMT , CampanozziA , FranceschiM , et al. Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis. Archives of Disease in Childhood1993;69:655-9. ">Cucchiara 1993</a> noted similar improvements in endoscopic appearances in those randomised to eight weeks of standard doses of omeprazole (40 mg/day/1.73m<sup>2</sup> surface area) or higher doses of ranitidine (20 mg/kg/day). This result was not further considered as the trial did not report the outcome in sufficient detail to allow extraction of summary statistics, and did not differentiate between infants and children so was not considered in the certainty of evidence. </p> </section> <section id="CD008550-sec-0137"> <p><b>Omeprazole versus quince syrup</b></p> <p><a href="./references#CD008550-bbs2-0036" title="ZohalinezhadME , ImaniehMH , SamaniSM , MohagheghzadehA , DehghaniSM , HaghighatM , et al. Effects of quince syrup on clinical symptoms of children with symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Complementary Therapies in Clinical Practice2015;21(4):268-76. ZohalinezhadME , ZohalinezhadIS , SamaniA , MohagheghzadehF , DehghaniH . Efficacy of quince (Cydonia oblonga M) syrup in symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Planta Medica2016;82(1):1439. ">Zohalinezhad 2015</a> was the only included study which investigated this comparison, using omeprazole as a comparator to assess the efficacy of quince syrup. </p> <p><b>Improvement in clinical symptoms</b> </p> <p>Omeprazole may provide symptomatic relief but was not superior to quince syrup, based on one study in 80 children (aged 0 to 18 years) with GORD (<a href="./references#CD008550-bbs2-0036" title="ZohalinezhadME , ImaniehMH , SamaniSM , MohagheghzadehA , DehghaniSM , HaghighatM , et al. Effects of quince syrup on clinical symptoms of children with symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Complementary Therapies in Clinical Practice2015;21(4):268-76. ZohalinezhadME , ZohalinezhadIS , SamaniA , MohagheghzadehF , DehghaniH . Efficacy of quince (Cydonia oblonga M) syrup in symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Planta Medica2016;82(1):1439. ">Zohalinezhad 2015</a>). Composite Symptom Scores (CSS) improved in both groups (quince syrup versus omeprazole (2 mg/kg/day)). This was seen in infants and young children (aged less than 60 months: discussed above) and 42 children (aged more than 60 months to 18 years) at four and seven weeks compared to baseline. In children aged over five years, at week 7, CSS scores were 37 in the quince group and 43 in the omeprazole group. However, as quince syrup is not clinically prescribable, we have not assessed the certainty of evidence in the summary of findings tables. Please see 'Quince syrup versus other treatments' comparison below for a mean difference (MD). </p> <p><b>Adverse events</b> </p> <p><a href="./references#CD008550-bbs2-0036" title="ZohalinezhadME , ImaniehMH , SamaniSM , MohagheghzadehA , DehghaniSM , HaghighatM , et al. Effects of quince syrup on clinical symptoms of children with symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Complementary Therapies in Clinical Practice2015;21(4):268-76. ZohalinezhadME , ZohalinezhadIS , SamaniA , MohagheghzadehF , DehghaniH . Efficacy of quince (Cydonia oblonga M) syrup in symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Planta Medica2016;82(1):1439. ">Zohalinezhad 2015</a> identified no adverse events in either group (42 children), but the trial did not report the outcome in sufficient detail to allow extraction of summary statistics. </p> <p><b>pH‐impedance indices</b> </p> <p>No studies were available for this outcome.</p> <p><b>Endoscopic findings</b> </p> <p>One study was unclear about how many children had had endoscopy (<a href="./references#CD008550-bbs2-0036" title="ZohalinezhadME , ImaniehMH , SamaniSM , MohagheghzadehA , DehghaniSM , HaghighatM , et al. Effects of quince syrup on clinical symptoms of children with symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Complementary Therapies in Clinical Practice2015;21(4):268-76. ZohalinezhadME , ZohalinezhadIS , SamaniA , MohagheghzadehF , DehghaniH . Efficacy of quince (Cydonia oblonga M) syrup in symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Planta Medica2016;82(1):1439. ">Zohalinezhad 2015</a>), so there were no suitable data for this outcome, and we did not assess evidence certainty. </p> </section> <section id="CD008550-sec-0138"> <p><b>Omeprazole at different doses</b></p> <p>No studies were available for this comparison.</p> </section> </section> <section id="CD008550-sec-0139"> <h6 class="title">Lansoprazole</h6> <section id="CD008550-sec-0140"> <p><b>Lansoprazole versus placebo</b></p> <p>No studies were available for this comparison.</p> </section> <section id="CD008550-sec-0141"> <p><b>Lansoprazole versus other treatments: alginate</b></p> <p><b>Improvement in clinical symptoms</b> </p> <p>One study compared lansoprazole plus alginate versus lansoprazole alone in 36 children (age range: 12 months to 12 years) with GORD (based on symptoms, 24‐hour pH probe and endoscopy), and reported that symptom scores improved in all groups by week 8 (<a href="./references#CD008550-bbs2-0006" title="BorrelliO , ReaP , Bueno De MesquitaM , AmbrosiniA , ManciniV , Di NardoG , et al. Efficacy of combined administration of an alginate formulation (Gaviscon) and Lansoprazole for children with gastroesophageal reflux. Italian Journal of Pediatrics2002;28(4):304-9. ">Borrelli 2002</a>). The trial did not report the outcome in sufficient detail to allow extraction of summary outcome statistics. </p> <p><b>Adverse events</b> </p> <p>One study noted the absence of adverse events (36 children) (<a href="./references#CD008550-bbs2-0006" title="BorrelliO , ReaP , Bueno De MesquitaM , AmbrosiniA , ManciniV , Di NardoG , et al. Efficacy of combined administration of an alginate formulation (Gaviscon) and Lansoprazole for children with gastroesophageal reflux. Italian Journal of Pediatrics2002;28(4):304-9. ">Borrelli 2002</a>), but the study did not report the outcome in sufficient detail to allow extraction of summary statistics </p> <p><b>pH‐impedance indices</b> </p> <p><a href="./references#CD008550-bbs2-0006" title="BorrelliO , ReaP , Bueno De MesquitaM , AmbrosiniA , ManciniV , Di NardoG , et al. Efficacy of combined administration of an alginate formulation (Gaviscon) and Lansoprazole for children with gastroesophageal reflux. Italian Journal of Pediatrics2002;28(4):304-9. ">Borrelli 2002</a> compared lansoprazole plus alginate versus lansoprazole alone in 36 children (age range: 12 months to 12 years) with GORD (based on symptoms, 24‐hour pH probe and endoscopy). Reflux index improved in all groups by week 8. The trial did not report the outcome in sufficient detail to allow extraction of summary outcome statistics. </p> <p><b>Endoscopic findings</b> </p> <p><a href="./references#CD008550-bbs2-0006" title="BorrelliO , ReaP , Bueno De MesquitaM , AmbrosiniA , ManciniV , Di NardoG , et al. Efficacy of combined administration of an alginate formulation (Gaviscon) and Lansoprazole for children with gastroesophageal reflux. Italian Journal of Pediatrics2002;28(4):304-9. ">Borrelli 2002</a> compared lansoprazole plus alginate versus lansoprazole alone in 36 children (range 12 months to 12 years) with GORD (based on symptoms, 24‐hour pH probe and endoscopy). Endoscopic appearances improved in both groups by week 8. The trial did not report the outcome in sufficient detail to allow extraction of summary outcome statistics. </p> </section> <section id="CD008550-sec-0142"> <p><b>Lansoprazole at different doses</b></p> <p><b>Improvement in clinical symptoms</b> </p> <p>One study assessed 63 adolescents (age range: 12 to 17 years) with symptomatic/endoscopic GORD, randomised to lansoprazole 30 mg versus 15 mg (<a href="./references#CD008550-bbs2-0017" title="GunasekaranT , GuptaS , GremseD , KarolM , Pan W-J, Chin Y-L, et al. Lansoprazole in adolescents with gastroesophageal reflux disease: pharmacokinetics, pharmacodynamics, symptom relief efficacy, and tolerability. Journal of Pediatric Gastroenterology and Nutrition2002;35(4):S327-35. ">Gunesekaran 2003</a>). After five days of treatment, the symptom diaries and physician assessments in both groups noted improvements in the frequency and severity of heartburn and other symptoms, but the trial did not report the outcomes in sufficient detail to allow extraction of summary statistics. </p> <p><b>Adverse events</b> </p> <p><a href="./references#CD008550-bbs2-0017" title="GunasekaranT , GuptaS , GremseD , KarolM , Pan W-J, Chin Y-L, et al. Lansoprazole in adolescents with gastroesophageal reflux disease: pharmacokinetics, pharmacodynamics, symptom relief efficacy, and tolerability. Journal of Pediatric Gastroenterology and Nutrition2002;35(4):S327-35. ">Gunesekaran 2003</a> noted that pharyngitis 6% (2/32 in lansoprazole 15 mg) and headache (16% 4/31) were the most commonly‐reported adverse events (63 children), but the study did not report adverse events in sufficient detail to allow extraction of summary statistics. </p> <p><b>pH‐impedance indices and endoscopic findings</b> </p> <p>No studies were available for these outcomes.</p> </section> </section> <section id="CD008550-sec-0143"> <h6 class="title">Esomeprazole</h6> <section id="CD008550-sec-0144"> <p><b>Esomeprazole versus placebo or other treatments</b></p> <p>No studies were available for these comparisons.</p> </section> <section id="CD008550-sec-0145"> <p><b>Esomeprazole at different doses</b></p> <p>Two studies were considered. <a href="./references#CD008550-bbs2-0033" title="ToliaV , YoussefNN , GilgerMA , TraxlerB , IlluecaM . Esomeprazole for the treatment of erosive esophagitis in children: an international, multicenter, randomized, parallel-group, double-blind (for dose) study. BMC Pediatrics2010;10:41-50. [DOI: 10.1186/1471-2431-10-41]ToliaV , YoussefNN , GilgerMA , TraxlerB , IlluecaM . Esomeprazole for the treatment of erosive esophagitis in children: an international, multicenter, randomized, parallel-group, double-blind (for dose) study. Journal of Pediatric Gastroenterology and Nutrition2015;10(1):S24-30. ">Tolia 2010b</a> demonstrated resolution of endoscopically‐proven erosive oesophagitis after eight weeks of esomeprazole in 45/109 children aged one to 11 years. Symptoms and safety data were published by the group separately (<a href="./references#CD008550-bbs2-0016" title="GilgerM , ToliaV , VandenplasY , YoussefN , TraxlerB , IlluecaM . Safety and tolerability of esomeprazole in children with gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2006;43(4):E20-21. GilgerMA , ToliaV , VandenplasY , YoussefNN , TraxlerB , IlluecaM . Safety and tolerability of esomeprazole in children with gastro-esophageal reflux disease. Gastroenterology2015;46(5):S16-23. ">Gilger 2006</a>), and then a post hoc analysis of some of these children with endoscopically‐confirmed GORD (aged 12 months to 36 months old) compared esomeprazole 5 mg or 10 mg daily for eight weeks (<a href="./references#CD008550-bbs2-0032" title="ToliaV , GilgerMA , BarkerPN , IlluecaM . Healing of erosive esophagitis and improvement of symptoms of gastroesophageal reflux disease after esomeprazole treatment in children 12 to 36 months old. Journal of Pediatric Gastroenterology and Nutrition2010;51(5):593-8. ">Tolia 2010a</a>). The trial did not report the outcome in sufficient detail to allow extraction of summary statistics. </p> <p><b>Improvement in clinical symptoms</b> </p> <p>Two studies were considered. <a href="./references#CD008550-bbs2-0033" title="ToliaV , YoussefNN , GilgerMA , TraxlerB , IlluecaM . Esomeprazole for the treatment of erosive esophagitis in children: an international, multicenter, randomized, parallel-group, double-blind (for dose) study. BMC Pediatrics2010;10:41-50. [DOI: 10.1186/1471-2431-10-41]ToliaV , YoussefNN , GilgerMA , TraxlerB , IlluecaM . Esomeprazole for the treatment of erosive esophagitis in children: an international, multicenter, randomized, parallel-group, double-blind (for dose) study. Journal of Pediatric Gastroenterology and Nutrition2015;10(1):S24-30. ">Tolia 2010b</a> reported improvement in reflux symptoms as assessed by physician's global assessment (PGA) and parental diaries, but the trial did not report the outcome in sufficient detail to allow extraction of summary statistics. Subsequently, a post hoc analysis of some of these children with endoscopically‐confirmed GORD (aged 12 months to 36 months old) compared esomeprazole 5 mg or 10 mg daily for eight weeks (<a href="./references#CD008550-bbs2-0016" title="GilgerM , ToliaV , VandenplasY , YoussefN , TraxlerB , IlluecaM . Safety and tolerability of esomeprazole in children with gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2006;43(4):E20-21. GilgerMA , ToliaV , VandenplasY , YoussefNN , TraxlerB , IlluecaM . Safety and tolerability of esomeprazole in children with gastro-esophageal reflux disease. Gastroenterology2015;46(5):S16-23. ">Gilger 2006</a>). They noted 84.2% had improved symptom scores by the final visit, and no difference was reported between low‐dose and high‐dose groups. However, the trial did not report the outcome in sufficient detail to allow extraction of summary statistics. </p> <p><b>Adverse events</b> </p> <p>Two studies were considered. <a href="./references#CD008550-bbs2-0016" title="GilgerM , ToliaV , VandenplasY , YoussefN , TraxlerB , IlluecaM . Safety and tolerability of esomeprazole in children with gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2006;43(4):E20-21. GilgerMA , ToliaV , VandenplasY , YoussefNN , TraxlerB , IlluecaM . Safety and tolerability of esomeprazole in children with gastro-esophageal reflux disease. Gastroenterology2015;46(5):S16-23. ">Gilger 2006</a> noted improvement in reflux symptoms as assessed by PGA and parental diaries, but the study did not report the outcome in sufficient detail to allow extraction of summary statistics. Only 9.3% of participants reported 13 adverse events; the most common were diarrhoea (2.8% (3/108)), headache (1.9% (2/108)), and somnolence (1.9% (2/108)). Vomiting in two participants was not judged to be related to treatment. <a href="./references#CD008550-bbs2-0033" title="ToliaV , YoussefNN , GilgerMA , TraxlerB , IlluecaM . Esomeprazole for the treatment of erosive esophagitis in children: an international, multicenter, randomized, parallel-group, double-blind (for dose) study. BMC Pediatrics2010;10:41-50. [DOI: 10.1186/1471-2431-10-41]ToliaV , YoussefNN , GilgerMA , TraxlerB , IlluecaM . Esomeprazole for the treatment of erosive esophagitis in children: an international, multicenter, randomized, parallel-group, double-blind (for dose) study. Journal of Pediatric Gastroenterology and Nutrition2015;10(1):S24-30. ">Tolia 2010b</a> did not note any additional adverse events. Again, the study did not report the outcome in sufficient detail to allow extraction of summary statistics </p> <p><b>pH‐impedance indices</b> </p> <p>No studies were available for this outcome.</p> <p><b>Endoscopic findings</b> </p> <p>The two available trials did not report the outcome in sufficient detail to allow extraction of summary statistics. </p> </section> </section> <section id="CD008550-sec-0146"> <h6 class="title">Rabeprazole</h6> <section id="CD008550-sec-0147"> <p><b>Rabeprazole versus placebo or other treatments</b></p> <p>No studies were available for these comparisons.</p> </section> <section id="CD008550-sec-0148"> <p><b>Rabeprazole at different doses</b></p> <p><b>Improvement in clinical symptoms</b> </p> <p>Rabeprazole at different doses (0.5 mg/kg and 1 mg/kg) may provide similar symptomatic improvement, based on a single study: <a href="./references#CD008550-bbs2-0018" title="HaddadI , KierkusJ , TronE , UlmerA , HuP , SloanS , et al. Efficacy and safety of rabeprazole in children (1-11 years) with gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2013;57(6):798-807. ">Haddad 2013</a> noted a decrease in the mean 'Total GERD Symptoms and Severity' score. The symptom score improved for 0.5 mg/kg and 1 mg/kg dosing in both the low‐weight group (&lt; 15 kg) (mean ‐13.6 ± 13.1) and (‐9 ± 11.2): MD 4.6 (95% CI ‐2.9 to 12.1), and the high‐weight group (&gt; 15 kg) (‐10.6 ± 11.1) and (‐8.3 ± 9.2): MD 2.3 (95% CI ‐2 to 6.6) by week 12 (1 study, 127 children; very low‐certainty evidence; <a href="./references#CD008550-fig-0008" title="">Analysis 4.1</a>). Please see <a href="./full#CD008550-tbl-0004">summary of findings Table 4</a>. </p> <p><b>Adverse events</b> </p> <p>Rabeprazole at 0.5 mg/kg and 1 mg/kg is likely to give some adverse events, based on a single study: <a href="./references#CD008550-bbs2-0018" title="HaddadI , KierkusJ , TronE , UlmerA , HuP , SloanS , et al. Efficacy and safety of rabeprazole in children (1-11 years) with gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2013;57(6):798-807. ">Haddad 2013</a> noted 95 (84%) children had adverse events, including abdominal pain, nausea, vomiting, bronchopneumonia, gastroenteritis, cough, and choking (1 study, 127 children; very low‐certainty evidence). </p> <p><b>pH‐impedance indices</b> </p> <p>No studies were available for this outcome.</p> <p><b>Endoscopic findings</b> </p> <p>Rabeprazole at different doses may provide endoscopic and histological improvement, based on a single study: <a href="./references#CD008550-bbs2-0018" title="HaddadI , KierkusJ , TronE , UlmerA , HuP , SloanS , et al. Efficacy and safety of rabeprazole in children (1-11 years) with gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2013;57(6):798-807. ">Haddad 2013</a> found that endoscopic scores in both the low‐weight group (0.5 mg/kg mean ‐1.4 ± 1.1) and 1 mg/kg ‐1.1 ± 0.7): MD 0.3 (95% CI ‐0.3 to 0.9) and high‐weight group (0.5 mg/kg ‐1.1 ± 0.7) and (1 mg/kg ‐1 ± 0.9): MD 0.1 (95% CI ‐0.2 to 0.4) improved at week 12 using Hetzel‐Dent criteria (1 study, 127 children; very low‐certainty evidence; <a href="./references#CD008550-fig-0009" title="">Analysis 4.2</a>). Please see <a href="./full#CD008550-tbl-0004">summary of findings Table 4</a>. Histological scores (Grades 1 to 5) also improved: MD ‐0.8 (95% CI ‐1.06 to ‐0.53) but this is not reported in the summary of findings table, as discussed in <a href="#CD008550-sec-0034">Types of outcome measures</a>. </p> </section> </section> <section id="CD008550-sec-0149"> <h6 class="title">Pantoprazole</h6> <section id="CD008550-sec-0150"> <p><b>Pantoprazole versus placebo or other treatments</b></p> <p>No studies were available for these comparisons.</p> </section> <section id="CD008550-sec-0151"> <p><b>Pantoprazole at different doses</b></p> <p>Pantoprazole may or may not improve symptom scores at 0.3 mg/kg, 0.6 mg/kg, and 1.2 mg/kg pantoprazole in children aged one to five years by week 8 with no difference between 0.3 mg/kg and 1.2 mg/kg dosing (0.3 mg/kg mean −2.4 ± 1.7); 1.2 mg/kg −1.7 ± 1.2): MD 0.7 (95% CI ‐0.4 to 1.8; 1 study, 60 children; very low‐certainty evidence) and may confer some to no increase in the risk of adverse events (very low‐certainty evidence). </p> <p><b>Improvement in clinical symptoms</b> </p> <p>Pantoprazole appears to improve symptoms at the different dose‐regimens, based on a single study. <a href="./references#CD008550-bbs2-0002" title="BakerR , TsouVM , TungJ , BakerSS , LiH , WangW , et al. Clinical results from a randomised, double-blind, dose-ranging study of pantoprazole in children aged 1 through 5 years with symptomatic histologic or erosive esophagitis. Clinical Pediatrics2010;49(9):852-65. ">Baker 2010</a> looked at 0.3 mg/kg, 0.6 mg/kg, and 1.2 mg/kg pantoprazole in 60 children (aged one to five years) with symptoms of GORD and endoscopic or histological signs of GORD over eight weeks. Symptom scores improved in all dose‐regimens from baseline to week 8 (0.3 mg/kg MD −2.4, 95% CI −3.2 to −1.5; 0.6 mg/kg MD −0.6, 95% CI −1.7 to 0.5; 1.2 mg/kg MD −1.7, 95% CI −2.9 to −0.39). Symptom scores improved from baseline to week 8 (0.3 mg/kg mean −2.4 ± 1.7); 1.2 mg/kg −1.7 ± 1.2). There was no difference between 0.3 mg/kg and 1.2 mg/kg dosing: MD 0.7 (95% CI ‐0.4 to 1.8). Please see <a href="./full#CD008550-tbl-0005">summary of findings Table 5</a> and <a href="./references#CD008550-fig-0010" title="">Analysis 5.1</a>. Individual symptoms (abdominal pain, burping, heartburn, pain after eating, difficulty swallowing) improved in all groups after eight weeks (1 study, 60 children; very low‐certainty evidence). Two other studies were considered: <a href="./references#CD008550-bbs2-0034" title="TsouVM , BakerR , BookL , HammoAH , SofferEF , WangW , et al. Multicenter, randomized, double-blind study comparing 20 and 40 mg of pantoprazole for symptom relief in adolescents (12 to 16 years of age) with gastroesophageal reflux disease (GERD). Clinical Pediatrics2006;45(8):741-9. ">Tsou 2006</a> assessed 136 children (aged 12 to 16 years) with symptoms of GORD given either pantoprazole 40 mg (n = 68) or pantoprazole 20 mg (n = 68) over eight weeks. In both groups, composite symptom scores reportedly improved from baseline to end of trial from 177 and 174 by at least 100 points, with improvements in the number of vomiting episodes per day, heartburn symptom score, and epigastric pain score, although the trial did not report the results in sufficient detail to allow independent extraction of summary statistics. <a href="./references#CD008550-bbs2-0031" title="ToliaV , BishopPR , TsouVM , GremseD , SofferEF , ComerGM , et al. Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5-11 years) with symptomatic gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2006;42(4):384-91. ">Tolia 2006</a> compared 10 mg, 20 mg, and 40 mg pantoprazole over eight weeks in 53 children (five to 11 years) with symptomatic GORD, and noted symptomatic improvements in all groups treated with pantoprazole, although there was not enough detail to extract summary statistics. </p> <p><b>Adverse events</b> </p> <p>Three studies reported data on adverse events. <a href="./references#CD008550-bbs2-0034" title="TsouVM , BakerR , BookL , HammoAH , SofferEF , WangW , et al. Multicenter, randomized, double-blind study comparing 20 and 40 mg of pantoprazole for symptom relief in adolescents (12 to 16 years of age) with gastroesophageal reflux disease (GERD). Clinical Pediatrics2006;45(8):741-9. ">Tsou 2006</a> found 82% of 136 children reported an adverse event, mainly headache, and in the high‐dose group (40 mg) reported diarrhoea. Five participants had minor derangement of their liver function tests. <a href="./references#CD008550-bbs2-0031" title="ToliaV , BishopPR , TsouVM , GremseD , SofferEF , ComerGM , et al. Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5-11 years) with symptomatic gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2006;42(4):384-91. ">Tolia 2006</a>, assessing 53 children, noted in the pantoprazole 10 mg group the following: headache (seven participants; 36.8%), rhinitis (five participants; 26.3%), and nausea (three participants; 15.8%); in the pantoprazole 20 mg group, the following: headache (five participants; 27.8%) and rhinitis (three participants each; 16.7%); in the 40 mg group, the following: headache (four participants; 25%). <a href="./references#CD008550-bbs2-0002" title="BakerR , TsouVM , TungJ , BakerSS , LiH , WangW , et al. Clinical results from a randomised, double-blind, dose-ranging study of pantoprazole in children aged 1 through 5 years with symptomatic histologic or erosive esophagitis. Clinical Pediatrics2010;49(9):852-65. ">Baker 2010</a>, assessing 60 children aged one to five years, observed no difference between the groups. In the low‐dose group, one participant had diarrhoea and nappy rash; in the medium‐dose group, one participant had sleep disturbance, one had abdominal pain; in the high‐dose group, one participant had rectal bleeding (1 study, 60 participants, very low‐certainty evidence). Unfortunately, due to the multiple different dose‐regimes, it was only possible to include information for <a href="./references#CD008550-bbs2-0002" title="BakerR , TsouVM , TungJ , BakerSS , LiH , WangW , et al. Clinical results from a randomised, double-blind, dose-ranging study of pantoprazole in children aged 1 through 5 years with symptomatic histologic or erosive esophagitis. Clinical Pediatrics2010;49(9):852-65. ">Baker 2010</a> in the summary of findings table in narrative format. </p> <p><b>pH‐impedance indices</b> </p> <p>No studies were available for this outcome.</p> <p><b>Endoscopic findings</b> </p> <p>Two studies reported endoscopy outcomes: there was not enough detail to extract summary statistics. <a href="./references#CD008550-bbs2-0031" title="ToliaV , BishopPR , TsouVM , GremseD , SofferEF , ComerGM , et al. Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5-11 years) with symptomatic gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition2006;42(4):384-91. ">Tolia 2006</a> had observed that endoscopy appearances showed no improvements in any group, and histologically, in the 10 mg pantoprazole group. In those with non‐erosive GORD, 36% improved and no participants with erosive disease were treated within this group. In those receiving pantoprazole 20 mg, of those with non‐erosive GORD, 50% of participants improved (n = 9) with 44% unchanged (n = 8). In those with erosive disease, all three were healed at eight weeks. In those treated with pantoprazole 40 mg, of those with non‐erosive disease, 68% of participants improved (n = 11) with 25% unchanged (n = 4); 6.2% worsened (n = 1). There was no correlation between composite symptom score changes and endoscopy/biopsy changes. In younger children, endoscopy was performed in four participants with erosive changes (<a href="./references#CD008550-bbs2-0002" title="BakerR , TsouVM , TungJ , BakerSS , LiH , WangW , et al. Clinical results from a randomised, double-blind, dose-ranging study of pantoprazole in children aged 1 through 5 years with symptomatic histologic or erosive esophagitis. Clinical Pediatrics2010;49(9):852-65. ">Baker 2010</a>); all four healed, but the trial did not report the outcome in sufficient detail to allow extraction of summary endoscopic statistics. For histology appearances, no scope was performed after treatment in those participants with histological changes only. </p> </section> </section> </section> <section id="CD008550-sec-0152"> <h5 class="title">H₂ antagonists</h5> <section id="CD008550-sec-0153"> <h6 class="title">Ranitidine</h6> <section id="CD008550-sec-0154"> <p><b>Ranitidine versus placebo</b></p> <p>No studies were available for this comparison.</p> </section> <section id="CD008550-sec-0155"> <p><b>Ranitidine versus other treatments</b></p> <p><b>Improvement in clinical symptoms</b> </p> <p>Two studies were considered: <a href="./references#CD008550-bbs2-0011" title="CucchiaraS , MinellaR , IervolinoC , FrancoMT , CampanozziA , FranceschiM , et al. Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis. Archives of Disease in Childhood1993;69:655-9. ">Cucchiara 1993</a> (see above), who found similar improvements in symptoms in those randomised to eight weeks of either higher doses of ranitidine (20 mg/kg/day) or standard doses of omeprazole (40 mg/day/1.73 m<sup>2</sup> surface area). The trial did not report the outcome in sufficient detail to allow extraction of summary statistics. <a href="./references#CD008550-bbs2-0029" title="PfefferkornMD , CroffieJM , GuptaSK , MollestonJP , EckertGJ , CorkinsMR , et al. Nocturnal acid breakthrough in children with reflux esophagitis taking proton pump inhibitors. Journal of Pediatric Gastroenterology and Nutrition2006;42(2):160-5. ">Pfefferkorn 2006</a> noted an improvement in nocturnal acid breakthrough symptoms after three weeks in 18 participants with symptomatic GORD with endoscopic/histological changes (aged one to 13 years) treated with omeprazole, but no additional benefit from additional ranitidine in those with breakthrough symptoms was seen. Symptom scores in both groups reportedly improved from baseline (see omeprazole above), but the trial did not report the outcome in sufficient detail to allow extraction of summary statistics comparing the two groups (symptoms and pH indices) so this study is not reported in the summary of findings table. </p> <p><b>Adverse events</b> </p> <p>Two studies were considered, although one study, <a href="./references#CD008550-bbs2-0029" title="PfefferkornMD , CroffieJM , GuptaSK , MollestonJP , EckertGJ , CorkinsMR , et al. Nocturnal acid breakthrough in children with reflux esophagitis taking proton pump inhibitors. Journal of Pediatric Gastroenterology and Nutrition2006;42(2):160-5. ">Pfefferkorn 2006</a>, noted no adverse events (16 participants). <a href="./references#CD008550-bbs2-0011" title="CucchiaraS , MinellaR , IervolinoC , FrancoMT , CampanozziA , FranceschiM , et al. Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis. Archives of Disease in Childhood1993;69:655-9. ">Cucchiara 1993</a> noted one participant was withdrawn due to a temperature and a respiratory infection, but it was uncertain which treatment group this participant was from (omeprazole or high‐dose ranitidine). The trial did not report the outcome in sufficient detail to allow extraction of summary statistics, or differentiate between infants and children, so these data were not considered in the certainty of evidence. </p> <p><b>pH‐impedance indices</b> </p> <p>Two studies were considered: <a href="./references#CD008550-bbs2-0029" title="PfefferkornMD , CroffieJM , GuptaSK , MollestonJP , EckertGJ , CorkinsMR , et al. Nocturnal acid breakthrough in children with reflux esophagitis taking proton pump inhibitors. Journal of Pediatric Gastroenterology and Nutrition2006;42(2):160-5. ">Pfefferkorn 2006</a> assessed nocturnal acid breakthrough symptoms after three weeks in 16 participants with symptomatic GORD with endoscopic/histological changes (aged one to 13 years) treated with omeprazole. The reflux index did not change from week three (2.0 ± 2.9% in 24 hours) to week 17 after initiation of additional ranitidine (5.1 ± 5.1% in 24 hours): MD 3.1 (95% CI‐1.0 to 7.2), but direct comparison between omeprazole and ranitidine was not possible. <a href="./references#CD008550-bbs2-0011" title="CucchiaraS , MinellaR , IervolinoC , FrancoMT , CampanozziA , FranceschiM , et al. Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis. Archives of Disease in Childhood1993;69:655-9. ">Cucchiara 1993</a> noted improvements in pH indices but was not further considered as the trial did not report the outcome in sufficient detail to allow extraction of summary statistics, and did not differentiate between infants and children so was not considered in the certainty of evidence. </p> <p><b>Endoscopic findings</b> </p> <p>Two studies were considered: <a href="./references#CD008550-bbs2-0029" title="PfefferkornMD , CroffieJM , GuptaSK , MollestonJP , EckertGJ , CorkinsMR , et al. Nocturnal acid breakthrough in children with reflux esophagitis taking proton pump inhibitors. Journal of Pediatric Gastroenterology and Nutrition2006;42(2):160-5. ">Pfefferkorn 2006</a> assessed endoscopy appearances at baseline and week 17 using the Hetzel‐Dent score (grade 0 to 4), and saw an improvement in grade from 3.1 ± 1.4 to 1.6 ± 1.8: MD ‐1.5 (95% CI‐3.1 to 0.1). An improvement in mean histology scores of all participants from baseline (1.8 ± 0.7) to week 17 (0.8 ± 0.9): MD ‐1.0 (95% CI ‐1.8 to ‐0.2) was also seen, but a direct comparison between omeprazole and ranitidine was not possible as ranitidine was introduced at week 3. As discussed above, <a href="./references#CD008550-bbs2-0011" title="CucchiaraS , MinellaR , IervolinoC , FrancoMT , CampanozziA , FranceschiM , et al. Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis. Archives of Disease in Childhood1993;69:655-9. ">Cucchiara 1993</a> noted similar improvements in endoscopic appearances in both the group randomised to eight weeks of higher doses of ranitidine (20 mg/kg/day) and the group receiving standard doses of omeprazole (40 mg/day/1.73m<sup>2</sup> surface area). This result was not further considered as the trial did not report the outcome in sufficient detail to allow extraction of summary statistics, and the trial did not differentiate between infants and children so was not considered in the certainty of evidence. </p> </section> <section id="CD008550-sec-0156"> <p><b>Quince syrup and ranitidine versus ranitidine alone</b></p> <p><b>Improvement in clinical symptoms</b> </p> <p>Ranitidine may provide symptomatic relief but was not superior to quince syrup and ranitidine, based on one study: <a href="./references#CD008550-bbs2-0024" title="NaeimiM , KianifarH , MemarianiZ , KamalinejadM , BijaniA , SaghebiR , et al. Comparison of the efficacy of ranitidine and quince syrup on gastroesophageal reflux disease in children. Complementary Therapies in Medicine2019;45:215-21. ">Naeimi 2019</a> undertook an outpatient double‐blind RCT of ranitidine 8 mg/kg/day plus quince syrup (0.5 mL/kg/day) versus ranitidine alone (8 mg/kg/day) in 96 children aged between one and four years with GORD (diagnosed on clinical symptoms: two of five symptoms (regurgitation or vomiting, poor weight gain for one month, respiratory distress after feeding, feed refusal, and restlessness after feeding)). These symptoms were assessed at two, four, and six weeks with the Global Severity Questionnaire (GSQ‐YC). Comparing the total symptom scores showed that ranitidine was effective but that ranitidine plus quince syrup was superior to ranitidine alone: at week 2 (mean ± SD 17.8 ± 2.6 versus 23.4 ± 4.0), week 4 (11.5 ± 2.3 versus 18.8 ± 3.6), and week 6 (12.2 ± 2.3 versus 21.1 ± 4.1): MD at week 6 was 8.9 (95% CI 7.6 to 10.2). In terms of individual symptoms at six weeks, all symptoms were improved in both groups, but there was greater improvement in vomiting (MD 1.3 (95% CI 0.9 to 1.7)), feed refusal (MD 1.9 (95% CI 1.5 to 2.3)), burping/belching (MD 1.8 (95% CI 1.3 to 2.3)), and abdominal pain (MD 1.0 (95% CI 0.5 to 1.5)) in the ranitidine with quince syrup group. No differences in swallowing difficulties (MD 1.7 (95% CI 1.2 to 2.2)) or choking during eating (MD 0.8 (95% CI 0.3 to 1.3)) were seen between the groups. These differences emerged between two and four weeks after starting treatment. As both groups contained ranitidine, we included the certainty of evidence in the quince syrup section. </p> <p><b>Adverse events</b> </p> <p>There was not enough evidence to assess adverse events appropriately for this comparison. However, one study identified no adverse events in either group (96 children) (<a href="./references#CD008550-bbs2-0024" title="NaeimiM , KianifarH , MemarianiZ , KamalinejadM , BijaniA , SaghebiR , et al. Comparison of the efficacy of ranitidine and quince syrup on gastroesophageal reflux disease in children. Complementary Therapies in Medicine2019;45:215-21. ">Naeimi 2019</a>). </p> <p><b>pH‐impedance indices and endoscopic findings</b> </p> <p>No studies were available for these outcomes.</p> </section> <section id="CD008550-sec-0157"> <p><b>Ranitidine at different doses</b></p> <p>No studies were available for this comparison.</p> </section> </section> <section id="CD008550-sec-0158"> <h6 class="title">Cimetidine and Famotidine</h6> <p>No studies were available for any comparisons.</p> </section> <section id="CD008550-sec-0159"> <h6 class="title">Nizatidine</h6> <section id="CD008550-sec-0160"> <p><b>Nizatidine versus placebo</b></p> <p><b>Improvement in clinical symptoms</b> </p> <p><a href="./references#CD008550-bbs2-0030" title="SimeoneD , CariaMC , MieleE , StaianoA . Treatment of childhood peptic esophagitis: a double-blind placebo-controlled trial of nizatidine. Journal of Pediatric Gastroenterology and Nutrition1997;25(1):51-5. ">Simeone 1997</a> assessed 26 participants (age range: six months to eight years) with histologic evidence of oesophagitis, randomised to either nizatidine 10 mg/kg twice a day or placebo for eight weeks. Improvement of symptoms was only seen in the nizatidine group, with reductions in abdominal pain (MD 1.5 (95% CI −0.6 to 2.4)), chest pain (MD 0.6 (95% CI −0.50 to 1.70)), regurgitation (MD 1.4 (95% CI 0.5 to 2.3)), and vomiting (MD 1.2 (95% CI 0.15 to 2.3)). However, as the trial included some infants under one year of age, we did not include these data in the summary of findings tables. </p> <p><b>Adverse events</b> </p> <p><a href="./references#CD008550-bbs2-0030" title="SimeoneD , CariaMC , MieleE , StaianoA . Treatment of childhood peptic esophagitis: a double-blind placebo-controlled trial of nizatidine. Journal of Pediatric Gastroenterology and Nutrition1997;25(1):51-5. ">Simeone 1997</a> assessed 26 participants (age range: six months to eight years) randomised to either nizatidine 10 mg/kg twice a day or placebo for eight weeks. A single participant on nizatidine had an urticarial rash, and one participant on placebo was withdrawn due to worsened clinical symptoms. Study authors did not mention the adverse event severity or the ages of the affected participants, so we did not assess the certainty of evidence. No other adverse events were noted. </p> <p><b>pH‐impedance indices</b> </p> <p><a href="./references#CD008550-bbs2-0030" title="SimeoneD , CariaMC , MieleE , StaianoA . Treatment of childhood peptic esophagitis: a double-blind placebo-controlled trial of nizatidine. Journal of Pediatric Gastroenterology and Nutrition1997;25(1):51-5. ">Simeone 1997</a> included some infants under one year of age, so we did not include these data in the summary of findings tables. Post‐treatment pH measurement showed improved event rates (reflux index, number of episodes pH &lt; 4, number of episodes &gt; 5 minutes, duration of episodes of pH &lt; 4) in the nizatidine group versus placebo, but the trial did not report the outcome in sufficient detail to allow extraction of summary pH statistics. </p> <p><b>Endoscopic findings</b> </p> <p><a href="./references#CD008550-bbs2-0030" title="SimeoneD , CariaMC , MieleE , StaianoA . Treatment of childhood peptic esophagitis: a double-blind placebo-controlled trial of nizatidine. Journal of Pediatric Gastroenterology and Nutrition1997;25(1):51-5. ">Simeone 1997</a> included some infants under one year of age, so we did not include these data in the summary of findings tables. Endoscopy findings included better healing in 69% of participants in the nizatidine group, but the trial did not report the outcome in sufficient detail to allow extraction of summary endoscopy statistics. </p> </section> <section id="CD008550-sec-0161"> <p><b>Nizatidine versus other treatments or at different doses</b></p> <p>No studies were available for these comparisons.</p> </section> </section> </section> <section id="CD008550-sec-0162"> <h5 class="title">Prokinetics</h5> <section id="CD008550-sec-0163"> <h6 class="title">Domperidone</h6> <section id="CD008550-sec-0164"> <p><b>Domperidone versus placebo</b></p> <p><b>Improvement in clinical symptoms</b> </p> <p><a href="./references#CD008550-bbs2-0005" title="BinesJE , QuinlanJE , TrevesS , KleinmanRE , WinterHS . Efficacy of domperidone in infants and children with gastroesophageal reflux. Journal of Pediatric Gastroenterology and Nutrition1992;14(4):400-5. ">Bines 1992</a> assessed the impact of domperidone over four weeks (double‐blind) then a further four weeks (open‐label) versus placebo in 17 participants (aged five months to 11.3 years). No individual symptom was improved by four weeks. After eight weeks of therapy, 33% of participants treated with domperidone noted an improvement in symptoms. Some improvements were reported after four weeks of little symptom improvement, but as the study included some infants under one year of age, we did not include these data in the summary of findings tables and the trial did not report the outcome in sufficient detail to allow extraction of summary statistics. </p> <p><b>Adverse events</b> </p> <p><a href="./references#CD008550-bbs2-0005" title="BinesJE , QuinlanJE , TrevesS , KleinmanRE , WinterHS . Efficacy of domperidone in infants and children with gastroesophageal reflux. Journal of Pediatric Gastroenterology and Nutrition1992;14(4):400-5. ">Bines 1992</a> noted no serious adverse events, but six participants had self‐limiting diarrhoea (four participants on domperidone, two on placebo). As the study included some infants under one year of age, we did not include these data in the summary of findings tables and the trial did not report the outcome in sufficient detail to allow extraction of summary statistics. </p> <p><b>pH‐impedance indices</b> </p> <p>On pH monitoring, <a href="./references#CD008550-bbs2-0005" title="BinesJE , QuinlanJE , TrevesS , KleinmanRE , WinterHS . Efficacy of domperidone in infants and children with gastroesophageal reflux. Journal of Pediatric Gastroenterology and Nutrition1992;14(4):400-5. ">Bines 1992</a> observed there was only an improvement reported in total reflux episodes, with other metrics unchanged. The low number of participants (with some infants under one year of age) and lack of full (24‐hour) pH probes limited the applicability of this study. The trial did not report the outcome in sufficient detail to allow extraction of summary statistics. </p> <p><b>Endoscopic findings</b> </p> <p>No studies were available for this outcome.</p> </section> <section id="CD008550-sec-0165"> <p><b>Domperidone versus other treatments or at different doses</b></p> <p>No studies were available for these comparisons.</p> </section> </section> <section id="CD008550-sec-0166"> <h6 class="title">Quince syrup</h6> <section id="CD008550-sec-0167"> <p><b>Quince syrup versus placebo</b></p> <p>No studies were available for this comparison.</p> </section> <section id="CD008550-sec-0168"> <p><b>Quince syrup versus other treatments: omeprazole</b></p> <p><b>Improvement in clinical symptoms</b> </p> <p>Quince syrup was as good or better than omeprazole in improving symptoms based on one study (<a href="./references#CD008550-bbs2-0036" title="ZohalinezhadME , ImaniehMH , SamaniSM , MohagheghzadehA , DehghaniSM , HaghighatM , et al. Effects of quince syrup on clinical symptoms of children with symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Complementary Therapies in Clinical Practice2015;21(4):268-76. ZohalinezhadME , ZohalinezhadIS , SamaniA , MohagheghzadehF , DehghaniH . Efficacy of quince (Cydonia oblonga M) syrup in symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Planta Medica2016;82(1):1439. ">Zohalinezhad 2015</a>). In this study in 80 children (aged 0 to 18 years) with GORD, Composite Symptom Scores (CSS) improved in both the quince syrup and omeprazole (2 mg/kg/day) groups. This was seen in infants and young children (aged less than 60 months: discussed above) and 42 children (aged more than 60 months to 18 years) at four and seven weeks compared to baseline. In children aged over five years, at week 7, CSS scores were 43 in the omeprazole group and 37 in the quince group (MD ‐6 (95% CI‐39.9 to 27)). However, as quince syrup is not a prescribable medicine, we did not include this in the summary of findings tables nor assess the certainty of evidence (please see <a href="#CD008550-sec-0029">Methods</a>). </p> <p><b>Adverse events</b> </p> <p>There was not enough evidence to assess adverse events appropriately for quince syrup compared to omeprazole. However, <a href="./references#CD008550-bbs2-0036" title="ZohalinezhadME , ImaniehMH , SamaniSM , MohagheghzadehA , DehghaniSM , HaghighatM , et al. Effects of quince syrup on clinical symptoms of children with symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Complementary Therapies in Clinical Practice2015;21(4):268-76. ZohalinezhadME , ZohalinezhadIS , SamaniA , MohagheghzadehF , DehghaniH . Efficacy of quince (Cydonia oblonga M) syrup in symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Planta Medica2016;82(1):1439. ">Zohalinezhad 2015</a> identified no adverse events in either group (42 children). </p> <p><b>pH‐impedance indices</b> </p> <p>No studies were available for this outcome.</p> <p><b>Endoscopic findings</b> </p> <p>In <a href="./references#CD008550-bbs2-0036" title="ZohalinezhadME , ImaniehMH , SamaniSM , MohagheghzadehA , DehghaniSM , HaghighatM , et al. Effects of quince syrup on clinical symptoms of children with symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Complementary Therapies in Clinical Practice2015;21(4):268-76. ZohalinezhadME , ZohalinezhadIS , SamaniA , MohagheghzadehF , DehghaniH . Efficacy of quince (Cydonia oblonga M) syrup in symptomatic gastroesophageal reflux disease: a double-blind randomized controlled clinical trial. Planta Medica2016;82(1):1439. ">Zohalinezhad 2015</a>, it was unclear how many children had had endoscopy, so we did not consider this result in the certainty of evidence. </p> </section> <section id="CD008550-sec-0169"> <p><b>Quince syrup versus ranitidine</b></p> <p><b>Improvement in clinical symptoms</b> </p> <p>Quince syrup may provide symptomatic relief in addition to ranitidine, based on one study: <a href="./references#CD008550-bbs2-0024" title="NaeimiM , KianifarH , MemarianiZ , KamalinejadM , BijaniA , SaghebiR , et al. Comparison of the efficacy of ranitidine and quince syrup on gastroesophageal reflux disease in children. Complementary Therapies in Medicine2019;45:215-21. ">Naeimi 2019</a> undertook an outpatient double‐blind RCT of ranitidine (8 mg/kg/day) versus ranitidine 8 mg/kg/day plus quince syrup (0.5 mL/kg/day) in 96 children aged between one and four years with GORD diagnosed on clinical symptoms (two of five symptoms (regurgitation or vomiting, poor weight gain for one month, respiratory distress after feeding, feed refusal, and restlessness after feeding)). These were assessed at two, four, and six weeks with the Global Severity Questionnaire (GSQ‐YC). Comparing the total symptom scores showed that ranitidine plus quince syrup was superior to ranitidine alone: at week 2 (mean ± SD 17.8 ± 2.6 versus 23.4 ± 4.0), week 4 (11.5 ± 2.3 versus 18.8 ± 3.6), and week 6 (12.2 ± 2.3 versus 21.1 ± 4.1): MD at week 6 8.9 (95% CI 7.6 to 10.2). In terms of individual symptoms at six weeks, all symptoms were improved in both groups, but there was greater improvement in vomiting (MD 1.3 (95% CI 0.9 to 1.7)), feed refusal (1.9 (95% CI 1.5 to 2.3)), burping/belching (1.8 (95% CI 1.3 to 2.3)), and abdominal pain (1.0 (95% CI 0.5 to 1.5)) in the ranitidine with quince syrup group. No differences in swallowing difficulties (MD 1.7 (95% CI 1.2 to 2.2)) or choking during eating (0.8 (95% CI 0.3 to 1.3)) were seen between the groups. These differences emerged between two and four weeks after starting treatment. However, as quince syrup is not a prescribable medicine, we did not include this result in the summary of findings tables nor assess the certainty of evidence (see above). </p> <p><b>Adverse events</b> </p> <p>There was not enough evidence to assess adverse events appropriately for quince syrup compared to ranitidine alone. However, <a href="./references#CD008550-bbs2-0024" title="NaeimiM , KianifarH , MemarianiZ , KamalinejadM , BijaniA , SaghebiR , et al. Comparison of the efficacy of ranitidine and quince syrup on gastroesophageal reflux disease in children. Complementary Therapies in Medicine2019;45:215-21. ">Naeimi 2019</a> identified no adverse events in either group (96 children). </p> <p><b>pH‐impedance indices and endoscopic findings</b> </p> <p>No studies were available for these outcomes.</p> </section> <section id="CD008550-sec-0170"> <p><b>Quince syrup at different doses</b></p> <p>No studies were available for this comparison.</p> </section> </section> </section> <section id="CD008550-sec-0171"> <h5 class="title">Compound alginate preparations</h5> <section id="CD008550-sec-0172"> <h6 class="title">Alginate versus placebo</h6> <p>No studies were available for this comparison.</p> </section> <section id="CD008550-sec-0173"> <h6 class="title">Alginate versus other treatments: lansoprazole</h6> <p><b>Improvement in clinical symptoms</b> </p> <p>No suitable data were available for this outcome; one study was considered. Gaviscon liquid was assessed by <a href="./references#CD008550-bbs2-0006" title="BorrelliO , ReaP , Bueno De MesquitaM , AmbrosiniA , ManciniV , Di NardoG , et al. Efficacy of combined administration of an alginate formulation (Gaviscon) and Lansoprazole for children with gastroesophageal reflux. Italian Journal of Pediatrics2002;28(4):304-9. ">Borrelli 2002</a>, who, as discussed above, noted improvements in symptoms in children (aged 12 months to 12 years) with erosive oesophagitis given alginate alone, and noted that the greatest improvement in symptoms was seen in children treated with alginate and lansoprazole. The trial did not report the outcome in sufficient detail to allow extraction of summary statistics. </p> <p><b>Adverse events</b> </p> <p>There was not enough evidence to assess adverse events appropriately for alginates compared to lansoprazole. <a href="./references#CD008550-bbs2-0006" title="BorrelliO , ReaP , Bueno De MesquitaM , AmbrosiniA , ManciniV , Di NardoG , et al. Efficacy of combined administration of an alginate formulation (Gaviscon) and Lansoprazole for children with gastroesophageal reflux. Italian Journal of Pediatrics2002;28(4):304-9. ">Borrelli 2002</a> noted no adverse events. </p> <p><b>pH‐impedance indices</b> </p> <p><a href="./references#CD008550-bbs2-0006" title="BorrelliO , ReaP , Bueno De MesquitaM , AmbrosiniA , ManciniV , Di NardoG , et al. Efficacy of combined administration of an alginate formulation (Gaviscon) and Lansoprazole for children with gastroesophageal reflux. Italian Journal of Pediatrics2002;28(4):304-9. ">Borrelli 2002</a> noted improvements in pH indices in children (aged 12 months to 12 years) with erosive oesophagitis given alginate alone, and noted that the greatest improvement was seen in children treated with alginate and lansoprazole. The trial did not report the outcome in sufficient detail to allow extraction of summary statistics. </p> <p><b>Endoscopic findings</b> </p> <p><a href="./references#CD008550-bbs2-0006" title="BorrelliO , ReaP , Bueno De MesquitaM , AmbrosiniA , ManciniV , Di NardoG , et al. Efficacy of combined administration of an alginate formulation (Gaviscon) and Lansoprazole for children with gastroesophageal reflux. Italian Journal of Pediatrics2002;28(4):304-9. ">Borrelli 2002</a> noted improvements in endoscopic indices in children (aged 12 months to 12 years) with erosive oesophagitis given alginate alone, and noted that the greatest improvement was seen in children treated with alginate and lansoprazole. The trial did not report the outcome in sufficient detail to allow extraction of summary statistics. </p> </section> <section id="CD008550-sec-0174"> <h6 class="title">Alginate at different doses</h6> <p>No studies were available for this comparison.</p> </section> </section> <section id="CD008550-sec-0175"> <h5 class="title">Antispasmodics</h5> <section id="CD008550-sec-0176"> <h6 class="title">Baclofen</h6> <section id="CD008550-sec-0177"> <p><b>Baclofen versus placebo</b></p> <p><b>Improvement in clinical symptoms</b> </p> <p>No studies were available for this outcome.</p> <p><b>Adverse events</b> </p> <p>There was not enough evidence to assess adverse events appropriately for baclofen. <a href="./references#CD008550-bbs2-0025" title="OmariTI , BenningaMA , SansomL , ButlerRN , DentJ , DavidsonGP . Effect of baclofen on esophagogastric motility and gastroesophageal reflux in children with gastroesophageal reflux disease: a randomized controlled trial. Journal of Pediatrics2006;149(4):468-74. ">Omari 2006</a> noted no adverse events in the baclofen group in the 48 hours following the trial. </p> <p><b>pH‐impedance indices</b> </p> <p>A single study compared baclofen to placebo in a double‐blinded RCT in 30 children with resistant GORD (mean age 10.0 ± 0.8 years) (<a href="./references#CD008550-bbs2-0025" title="OmariTI , BenningaMA , SansomL , ButlerRN , DentJ , DavidsonGP . Effect of baclofen on esophagogastric motility and gastroesophageal reflux in children with gastroesophageal reflux disease: a randomized controlled trial. Journal of Pediatrics2006;149(4):468-74. ">Omari 2006</a>). Children were assessed with manometry/pH for two hours after they were given 0.5 mg/kg baclofen or placebo. The primary outcome (measurement of the incidence of transient lower oesophageal sphincter relaxations (TLESR)) was not a prespecified outcome of this review. The <a href="./references#CD008550-bbs2-0025" title="OmariTI , BenningaMA , SansomL , ButlerRN , DentJ , DavidsonGP . Effect of baclofen on esophagogastric motility and gastroesophageal reflux in children with gastroesophageal reflux disease: a randomized controlled trial. Journal of Pediatrics2006;149(4):468-74. ">Omari 2006</a> study assessed pH indices, but did not report the outcome in sufficient detail to allow extraction of summary pH statistics. </p> <p><b>Endoscopic findings</b> </p> <p>No studies were available for this outcome.</p> </section> <section id="CD008550-sec-0178"> <p><b>Baclofen versus other treatments or at different doses</b></p> <p>No studies were available for these comparisons.</p> </section> </section> </section> </section> <section id="CD008550-sec-0179"> <h4 class="title">III. Other subgroups</h4> <p>We identified no studies assessing the efficacy of drug treatment in children with neurodisability and GORD. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008550-sec-0180" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008550-sec-0180"></div> <p>We included a total of 36 trials assessing 2251 participants in this review. We were able to extract summary data from 14 RCTs, with the remaining studies having insufficient data for extraction. </p> <section id="CD008550-sec-0181"> <h3 class="title" id="CD008550-sec-0181">Summary of main results</h3> <p>In this review, we cover a wide range of potential treatments for GOR/GORD in a range of population groups. We place the extracted summary data into context with other studies, where available. The Cochrane Gut Group ran the review searches independently to ensure reproducibility. </p> <p>Overall, the evidence evaluating the role of medications in GORD is of very low certainty. There are several reasons for this, including the heterogeneity of the population, the lack of head‐to‐head trials, variation in outcome measures, and variability in how well outcome measures (e.g. symptom scores/reflux index/endoscopic appearances) correlate in estimating the severity of GORD. There is also a group of infants and children who have physiological reflux that is problematic but not a pathological disease. </p> <p>Below, we present outcomes (symptom scores, pH‐impedance indices, endoscopic/histological appearances, and adverse events) structured by population (first infants, then children), then by treatment class. We discuss evidence certainty if we were able to extract summary data, and outline our findings below. </p> <section id="CD008550-sec-0182"> <h4 class="title">I. Infants</h4> <section id="CD008550-sec-0183"> <h5 class="title">Proton pump inhibitors</h5> <p>Please see <a href="./full#CD008550-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD008550-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD008550-tbl-0003">summary of findings Table 3</a>. </p> <p>For proton pump inhibitor studies with extracted summary data, there is very low‐certainty evidence based on single studies that infants with GOR and GORD may or may not benefit from omeprazole and esomeprazole. There is very low‐certainty evidence that PPIs improve reflux index and other pH probe markers of GORD, and the correlation between pH probe results and direct symptomatic benefit was very weak in infants. There were no suitable data regarding adverse events or endoscopic metrics in any study in infants. Other studies – from which we could not extract summary statistics – showed mixed efficacy. </p> <section id="CD008550-sec-0184"> <h6 class="title">Omeprazole</h6> <p>One study (with summary data extracted) compared omeprazole to placebo in infants only. This study noted that crying occurred in both omeprazole‐treated and untreated irritable infants, concluding that the cry/fuss time decreased spontaneously with time, and that empirical acid suppression was not indicated in this group. One study (with summary data extracted) comparing omeprazole and ranitidine noted similarly improved GORD symptom scores in infants. </p> </section> <section id="CD008550-sec-0185"> <h6 class="title">Lansoprazole</h6> <p>No studies provided suitable summary data. Of the studies without summary data, one found no symptomatic difference between lansoprazole and placebo, and of those who went on to take lansoprazole open‐label, there was no improvement in symptoms. Many participants may have had physiological reflux, and a risk of adverse events was noted, including lower‐respiratory tract infections in infants treated with lansoprazole. </p> </section> <section id="CD008550-sec-0186"> <h6 class="title">Esomeprazole</h6> <p>One study of neonates showed very low‐certainty evidence that esomeprazole was no better than placebo in treating the total number of GORD symptoms (from video monitoring) and GORD‐related signs (from cardiorespiratory monitoring). One other study of older infants without summary data reported that infants treated with esomeprazole had improved symptoms and improved reflux index compared to those treated with antacid. For different doses of esomeprazole, one other study without summary data noted improved clinical symptomsin the low‐dose group. In terms of adverse events in the same study, one infant (with pre‐existing colic) withdrew with irritability. Reflux index was improved in both groups, with greater improvement seen in the lower‐dose group. </p> </section> <section id="CD008550-sec-0187"> <h6 class="title">Pantoprazole</h6> <p>There were no studies assessing symptomatic improvements in infants treated with pantoprazole. However, in terms of pH indices, one study (with summary data extracted) assessing infants only noted improvements in reflux index from baseline in both groups, as well as in number of episodes, number of reflux episodes lasting more than five minutes, and duration of the longest reflux episodes (very low‐certainty evidence). </p> </section> <section id="CD008550-sec-0188"> <h6 class="title">Rabeprazole</h6> <p>There were no studies comparing rabeprazole to placebo or to other drugs. For rabeprazole at different doses, we were unable to extract any summary data. However, a withdrawal study noted no difference in primary symptom scores, and equally high rates of adverse events (diarrhoea, constipation, flatulence, crying, and rash) between groups. </p> </section> </section> <section id="CD008550-sec-0189"> <h5 class="title">H₂ antagonists</h5> <p>The evidence is very uncertain about the effect of H₂ antagonists on outcome. For H₂ antagonists, based on extracted summary data, there is very low‐certainty evidence based on a single study that infants with GORD may or may not have symptomatic benefit from ranitidine. Other studies – from which we could not extract summary statistics – showed mixed efficacy for ranitidine, famotidine, cimetidine, and nizatidine. </p> <section id="CD008550-sec-0190"> <h6 class="title">Ranitidine</h6> <p>In terms of studies involving infants only, one study with summary data comparing ranitidine to omeprazole showed that the two agents were equivalent in improving symptom scores for infants with symptoms of GORD. For studies without summary data, one study without a control arm reported improved vomiting and respiratory symptoms, but no change in irritability, arching, or feed refusal over two weeks. For adverse events, no summary data were available, but two other studies found no adverse events. One other study assessing both infants and children found similar improvements in symptoms, 24‐hour pH and endoscopic indices in those given either standard doses of omeprazole or high doses of ranitidine (20 mg/kg/day) in children refractory to standard‐dose ranitidine. </p> </section> <section id="CD008550-sec-0191"> <h6 class="title">Cimetidine</h6> <p>No studies provided suitable summary data for assessment, so no robust judgement about the certainty of evidence of efficacy or risk of adverse events can be made. One RCT without summary data compared cimetidine to Maalox in infants and young children with GORD, based on symptoms, oesophagitis on endoscopy, and acid reflux on pH probe. This study reported that cimetidine and Maalox provided symptomatic relief, and reflux index and endoscopic appearances were also improved in both groups. </p> </section> <section id="CD008550-sec-0192"> <h6 class="title">Famotidine</h6> <p>No studies provided suitable summary data for assessment, so no robust judgement about the certainty of evidence of efficacy or risk of adverse events can be made. In terms of studies without summary data,one study noted slight improvement in regurgitation frequency/volume and crying time and improved global assessments by parents and physicians. However, only eight of 35 participants completed phase 2 (double‐blind withdrawal versus placebo), giving insufficient data. A high proportion of infants experienced adverse events, including agitation or irritability, somnolence, weight loss, headache, vomiting, hiccups, candidiasis, and asymptomatic neutropenia which resolved.There were no data regarding pH or endoscopic indices. </p> </section> <section id="CD008550-sec-0193"> <h6 class="title">Nizatidine</h6> <p>No studies provided suitable summary data for assessment, so no robust judgement about the certainty of evidence of efficacy can be made. However, one study of children and infants reported improved symptoms in the nizatidine group and only one participant had an adverse event (urticaria). Post‐treatment pH‐indices showed improved reflux index, number of episodes of pH less than 4, number of episodes of more than five minutes, and duration of episodes of pH less than 4 in the nizatidine group compared to those given placebos. Endoscopy findings included better healing in a high proportion of participants in the nizatidine group. </p> </section> </section> <section id="CD008550-sec-0194"> <h5 class="title">Prokinetics</h5> <p>As discussed above, we did not assess metoclopramide here, and there were no studies of prokinetics with suitable summary data, so no robust judgement about the certainty of evidence of efficacy can be made. </p> <section id="CD008550-sec-0195"> <h6 class="title">Domperidone</h6> <p>No studies provided suitable summary data for assessment. In terms of symptom improvements, there were no studies of infants alone, but two studies involved infants and children older than one year. One found no improvement in symptoms between domperidone and placebo; the other study noted individual symptoms improved after four weeks (double‐blind); after a further four weeks (open‐label), only a few participants given domperidone noted further symptom improvement. In terms of adverse events, one short study reported no adverse events. Three studies measured pH indices. One very short‐term study (8‐hour epochs) noted reflux frequency increased in the domperidone group, but duration was improved. In another study, no difference between domperidone and placebo was seen, but the placebo included an added thickener (Medigel 1%). The final study found no difference in reflux index and only improvement in total reflux episodes. </p> </section> <section id="CD008550-sec-0196"> <h6 class="title">Erythromycin</h6> <p>No studies provided suitable summary data for assessment, so no robust judgement about the certainty of evidence of efficacy or risk of adverse events can be made. One study compared erythromycin in preterm infants over one week to placebo, and found no difference between the two groups in either number of apnoeas/bradycardias and desaturations or reflux events. </p> </section> <section id="CD008550-sec-0197"> <h6 class="title">Quince syrup</h6> <p>Quince syrup is a traditional Persian medicine. One study compared it to omeprazole, which demonstrated improvement in symptom scores for both the infant groups, and older children from baseline. However, no difference between the treatment groups (quince syrup or omeprazole) was reported. The improvement in symptoms was present at four weeks after initiation of therapy and sustained at the 7‐week follow‐up. Quince syrup was also compared in combination with ranitidine to ranitidine alone in another study in children. Trialists noted improved global symptom scores, with improvements in vomiting, refusal of eating, burping/belching, and abdominal pain. The evidence for use of quince is limited, with only two studies with relatively small numbers and short follow‐up. We did not assess the certainty of the evidence as this medicine is not clinically available. </p> </section> </section> <section id="CD008550-sec-0198"> <h5 class="title">Compound alginate preparations</h5> <p>No studies provided suitable summary data for assessment, so no robust judgement about the certainty of evidence of efficacy or risk of adverse events can be made. </p> <section id="CD008550-sec-0199"> <h6 class="title">Sodium+magnesium alginate</h6> <p>There were no summary data available to assess the certainty of evidence for sodium+magnesium alginate (Gaviscon Infant). We identified five studies without summary data; two of these evaluated the current formulation. Both studies noted symptomatic improvement, limited by short follow‐up. In terms of pH indices, one study only noted an improvement in reflux height on manometry, with no other differences when compared to placebo in a short‐term study. Assessing older preparations of Gaviscon Infant, three studies showed some to no difference in pH indices after 24 hours of treatment with sodium+magnesium alginate. </p> </section> <section id="CD008550-sec-0200"> <h6 class="title">Magnesium alginate</h6> <p>There were no summary data available to assess the certainty of evidence for magnesium alginate. Of the remaining studies without summary data, one study compared magnesium alginate to thickener. Both groups containing formula‐fed infants improved, with no differences in symptom score reduction between magnesium alginate and thickened formula. There was a breastfed study group which was not placebo‐controlled. One open‐label RCT noted symptom scores were reportedly reduced in the magnesium alginate‐plus‐simethicone group compared with thickened formula or reassurance groups, although there was some improvement in all groups, with the study limited by relatively small numbers and 8‐week follow‐up. Whilst there were no summary data, no adverse events were seen in the magnesium alginate group.No studies provided suitable summary data on pH or endoscopic indices for assessment. </p> </section> </section> <section id="CD008550-sec-0201"> <h5 class="title">Antispasmodics</h5> <section id="CD008550-sec-0202"> <h6 class="title">Baclofen</h6> <p>No studies provided suitable summary data for assessment, so no robust judgement about the certainty of evidence of efficacy or risk of adverse events can be made. </p> </section> </section> </section> <section id="CD008550-sec-0203"> <h4 class="title">II. Children older than one year of age</h4> <section id="CD008550-sec-0204"> <h5 class="title">Proton pump inhibitors</h5> <p>Please see <a href="./full#CD008550-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD008550-tbl-0005">summary of findings Table 5</a>. </p> <p>In children over one year of age, very low‐certainty evidence indicates that PPIs may or may not help GORD outcomes. Single studies with summary data extracted showed PPIs may or may not improve symptom scores, or erosive changes on endoscopy due to GORD, particularly in older children. There were very low‐certainty summary data assessing frequency of adverse events, and no robust summary data regarding pH indices in older children. Other studies – from which we could not extract summary statistics – showed efficacy. </p> <section id="CD008550-sec-0205"> <h6 class="title">Omeprazole</h6> <p>No studies had suitable summary data. Of three other studies, one study comparing omeprazole with high‐dose ranitidine noted similar improvements in symptoms, endoscopic findings, and reflux index. No significant adverse events were noted. A second study compared omeprazole to quince syrup in both infants and older children, and found that both treatments provided similar improvements in symptom scores from baseline. We extracted summary data for older children (&gt; 60 months of age) but did not present these in a summary of findings table (very low‐certainty evidence). There are insufficient data from RCTs about the long‐term safety of omeprazole. </p> </section> <section id="CD008550-sec-0206"> <h6 class="title">Lansoprazole</h6> <p>No studies provided suitable summary data for assessment, so no robust judgement about the certainty of evidence of efficacy or risk of adverse events can be made. Of the studies without summary data, one study in children aged one to 12 years, reported symptom scores improving in all groups, with the lansoprazole and alginate group superior to the other two groups. A 24‐hour pH study also showed improved reflux index, with the lansoprazole and alginate group superior to the other two groups. Endoscopy appearances were much improved in all three groups. No adverse events were reported. In older children (12‐ to 17‐year‐old children), one study of lansoprazole at different doses noted after five days that reflux symptoms were better in both groups. There are insufficient data from RCTs about the long‐term safety of lansoprazole. </p> </section> <section id="CD008550-sec-0207"> <h6 class="title">Esomeprazole</h6> <p>No studies provided suitable summary data for assessment in children, and only studies of esomeprazole at different doses were available. It was not possible to ascertain the certainty of evidence. Of the linked studies without summary data, one studynoted improvement in reflux symptoms, as assessed by physician's global assessment and parental diaries. Reported adverse events included diarrhoea, headache, and somnolence. One other study did not note any additional adverse events. There were no data presented on pH indices. One study noted endoscopic improvement in all groups, with a post hoc analysis of some participants with endoscopically‐confirmed GORD (aged 12 months to 36 months) showing improved symptoms but no difference between low‐dose and high‐dose groups. Repeat endoscopy showed healing in all, confirmed on histology. </p> </section> <section id="CD008550-sec-0208"> <h6 class="title">Rabeprazole</h6> <p>Please see <a href="./full#CD008550-tbl-0004">summary of findings Table 4</a>, <a href="./references#CD008550-fig-0008" title="">Analysis 4.1</a>, and <a href="./references#CD008550-fig-0009" title="">Analysis 4.2</a>. One study provided suitable summary data for assessment in children older than one year of age, but only data regarding rabeprazole at different doses were available. Rabeprazole at different doses (0.5 mg/kg and 1 mg/kg) may provide similar symptomatic improvement (very low‐certainty evidence). There was an equivalent adverse event profile in both the low‐ and higher‐dose rabeprazole groups. There were no data for pH indices. Rabeprazole at different doses is likely to provide endoscopic and histological improvement,with a minimal clinically useful difference between doses in low‐weight and high‐weight groups (very low‐certainty evidence). </p> </section> <section id="CD008550-sec-0209"> <h6 class="title">Pantoprazole</h6> <p>Please see <a href="./full#CD008550-tbl-0005">summary of findings Table 5</a> and <a href="./references#CD008550-fig-0010" title="">Analysis 5.1</a>. One study of pantoprazole at different doses provided suitable summary data of clinical symptoms for assessment. Pantoprazole appears to improve symptoms at the different dose regimens in one study with summary data (very low‐certainty evidence<i>).</i> Two other studies without summary data noted symptomatic improvements in all groups. One study had summary data for adverse events. It noted diarrhoea, nappy (i.e. diaper) rash, sleep disturbance, abdominal pain, and rectal bleeding (one participant each) (very low‐certainty evidence). The remaining two studies noted high rates of adverse events (mainly headache). There were no summary data available for pH indices or endoscopic outcomes. Two other studies noted endoscopy outcomes, finding no correlation between symptom scores and endoscopy/biopsy changes. </p> </section> </section> <section id="CD008550-sec-0210"> <h5 class="title">H₂ antagonists</h5> <p>The evidence is very uncertain about the effect of H₂ antagonists on outcome, due to the absence of summary data. In those studies from which we could not extract summary statistics, the H₂ antagonists ranitidine, cimetidine, and nizatidine showed efficacy in terms of symptom score, pH indices, and endoscopic appearances. </p> <section id="CD008550-sec-0211"> <h6 class="title">Ranitidine</h6> <p>No studies provided suitable summary data for assessment in children. One study found similar improvements in symptoms, 24‐hour pH probe data indices, and endoscopy appearances in those receiving eight weeks of either standard doses of omeprazole or high doses of ranitidine in children who had not responded to standard‐dose ranitidine. One other study looked at the addition of ranitidine or placebo, to reduce nocturnal acid breakthrough, in children who had recently started on omeprazole. In this study, symptom scores, pH indices, and endoscopic appearances reportedly improved over 17 weeks, with no difference between ranitidine and placebo groups. There was therefore no additional benefit seen from supplementation of PPI therapy with ranitidine. </p> </section> <section id="CD008550-sec-0212"> <h6 class="title">Cimetidine</h6> <p>No studies provided suitable summary data for assessment, so no robust judgement about the certainty of evidence of efficacy or risk of adverse events can be made. The only RCT compared cimetidine to Maalox over 12 weeks in infants and young children with a diagnosis of GORD, based on symptoms, oesophagitis on endoscopy, and acid reflux on pH probe. This study reported that cimetidine and Maalox provided symptomatic relief, and that reflux index and endoscopic appearances were also improved in both groups. </p> </section> <section id="CD008550-sec-0213"> <h6 class="title">Famotidine</h6> <p>No studies provided suitable summary data for assessment, so no robust judgement about the certainty of evidence of efficacy or risk of adverse events can be made. </p> </section> <section id="CD008550-sec-0214"> <h6 class="title">Nizatidine</h6> <p>No studies provided suitable summary data for assessment, so no robust judgement about the certainty of evidence of efficacy can be made. However, one study reported improved symptoms in the nizatidine group. No summary data could be extracted regarding adverse events, but the study reported only one participant with urticaria. Post‐treatment pH indices showed improved reflux index, number of episodes of pH less than 4, number of episodes of more than five minutes, and duration of episodes of pH less than 4 in the nizatidine group compared to placebo. Endoscopy findings included better healing in the majority of participants in the nizatidine group. </p> </section> </section> <section id="CD008550-sec-0215"> <h5 class="title">Prokinetics</h5> <section id="CD008550-sec-0216"> <h6 class="title">Domperidone</h6> <p>No studies provided suitable summary data for assessment, so no robust judgement about the certainty of evidence of efficacy or risk of adverse events can be made. RCTs evaluating the use of domperidone included two studies involving infants and children older than one year. One study found no difference in improvement in symptoms between domperidone and placebo, but that the thickened feeds (Medigel 1%) could account for improvements in pH outcomes in the placebo group. Symptom improvement remained through six months of follow‐up. One shorter‐term study noted individual symptoms were improved after four weeks (double‐blind). After a further four weeks of domperidone(open‐label) versus placebo, only a low proportion of participants treated with domperidone noted an improvement in symptoms. On pH probe, there was only improvement in total reflux episodes, and some improvement in growth metrics was seen. </p> </section> <section id="CD008550-sec-0217"> <h6 class="title">Erythromycin</h6> <p>No studies provided suitable summary data for assessment, so no robust judgement about the certainty of evidence of efficacy or risk of adverse events can be made. </p> </section> <section id="CD008550-sec-0218"> <h6 class="title">Quince syrup</h6> <p>Two studies provided summary symptom data in children older than one year. However, as discussed in the <a href="#CD008550-sec-0029">Methods</a> and <a href="./full#CD008550-sec-0058">Results</a>, we have not created a summary of findings table or assessed evidence certainty. One study comparing quince syrup with omeprazole demonstrated improved symptom scores for older children from baseline, with no difference between groups. The improvement in symptoms was present at four weeks after initiation of therapy and sustained at the 7‐week follow‐up. Quince syrup with ranitidine compared to ranitidine alone showed improved global symptom scores in both groups, with ranitidine and quince syrup superior to ranitidine alone for individual symptoms. There were not enough summary data to appropriately assess evidence certainty for adverse events. However, both studies identified no adverse events. </p> </section> </section> <section id="CD008550-sec-0219"> <h5 class="title">Antispasmodics</h5> <section id="CD008550-sec-0220"> <h6 class="title">Baclofen</h6> <p>A single study showed improvement in acid reflux and transient lower‐oesophageal sphincter relaxations in children treated with baclofen, but this was a short‐duration (2‐hour) trial (<a href="./references#CD008550-bbs2-0025" title="OmariTI , BenningaMA , SansomL , ButlerRN , DentJ , DavidsonGP . Effect of baclofen on esophagogastric motility and gastroesophageal reflux in children with gastroesophageal reflux disease: a randomized controlled trial. Journal of Pediatrics2006;149(4):468-74. ">Omari 2006</a>), with no other studies available in this group. </p> </section> </section> </section> </section> <section id="CD008550-sec-0221"> <h3 class="title" id="CD008550-sec-0221">Overall completeness and applicability of evidence</h3> <p>We consider the completeness and applicability of evidence for each class of medication in turn, in infants and children with GORD. Overall, all but two studies were conducted on outpatients across primary and secondary care, where the vast majority of infants and children present with symptoms. The very low‐certainty evidence is likely to be applicable to inpatient infants and children diagnosed with GOR and GORD and augment the two neonatal studies, though further studies would confirm this. There were three studies in lower‐middle‐income settings and 33 in high‐income settings, but no studies of infants or children with GORD in low‐income settings (see <a href="./references#CD008550-bbs2-0125" title="World Bank. Country and Lending Groups classification of countries by income. datatopics.worldbank.org/world-development-indicators/the-world-by-income-and-region.html Accessed prior to 20 May 2023.">World Bank 2022</a> for definitions). In terms of outcomes, symptom scores summary data were often available, but adverse events summary data were often lacking. There was evidence of incomplete reporting regarding endoscopic findings and pH indices in three studies. These procedures may discourage recruitment, and are generally only available in tertiary centres. </p> <section id="CD008550-sec-0222"> <h4 class="title">Proton pump inhibitors</h4> <p>There is incomplete evidence for commonly used PPIs, as the results are based on single studies, with heterogeneity of case definition in infants. There were insufficient data (one study of esomeprazole) involving premature and term neonates and no data on children with neurodisability. There were also insufficient data about the most effective PPI in infants and children, though we presented data on adverse events profiles where available, and included overall messages suggested by studies without summary data for context. Long‐term safety needs to be evaluated, and consistency between studies regarding symptom scoring would help meta‐analysis. </p> </section> <section id="CD008550-sec-0223"> <h4 class="title">H₂ antagonists (ranitidine and nizatidine)</h4> <p>With so few RCTs in infants or children, and no appropriate head‐to‐head comparisons against PPIs, meta‐analysis to further investigate the effect of treatment was not possible. Our interpretation of summary data was limited to single studies. No RCTs evaluated the use of H₂ antagonists in physiological reflux. Subgroups of particular importance in which evidence is lacking include neonates and premature babies, as well as children with neurodisability. Evidence of efficacy in resource‐limited settings would also be useful to consider. </p> </section> <section id="CD008550-sec-0224"> <h4 class="title">Prokinetics</h4> <p>For domperidone and erythromycin, there were no studies based on summary data in infants or children. Further studies will substantially alter our understanding of the effect size, either compared to placebo or the other prokinetic agent. There are major limitations in published study design and length of follow‐up. Subgroups of particular importance include neonates and children with neurodisability, for which there are no studies in domperidone or erythromycin. </p> </section> <section id="CD008550-sec-0225"> <h4 class="title">Other agents</h4> <p>The utility of quince syrup in settings outside the single country in which it has been studied needs to be evaluated, as there may be other confounding factors that may affect efficacy in other settings. As quince syrup is not clinically available for prescription, it is difficult to assess how applicable the summary data are. </p> <p>There were no studies in alginates based on summary data in infants or children over one year of age. Further studies in infants will substantially alter our understanding of the effect size, particularly as the available formulations have evolved over the past three decades. </p> <p>Further studies to assess whether baclofen has a role in improving GORD in children with neurodisability, who are often prescribed baclofen for concomitant spasticity, would be useful. We have not found enough additional trials in this update to change our assessment of the evidence. </p> <p>No studies assessed whether children who did not improve with treatment went on to need fundoplication. </p> </section> </section> <section id="CD008550-sec-0226"> <h3 class="title" id="CD008550-sec-0226">Certainty of the evidence</h3> <p>We have included decisions about the certainty of the evidence within the summary of findings tables and considered whether risk of bias affected the certainty of the results enough to merit downgrading the evidence certainty. We appraised the general certainty of all the studies using GRADE criteria. There were insufficient trials for meta‐analysis or a funnel plot to investigate reporting (publication) bias. We would have conducted a sensitivity analysis if the exclusion of studies with a high risk of bias was required. </p> <p>As discussed above, the overall GRADE ratings for the certainty of evidence were all very low as the evidence was mainly based on single studies, with significant methodological concerns about several studies (as summarised in <a href="#CD008550-sec-0071">Risk of bias in included studies</a>, <a href="#CD008550-fig-0002">Figure 2</a>, and <a href="#CD008550-fig-0003">Figure 3</a>). Only nine studies specified the method of allocation, and 13 studies specified the blinding technique. Fifteen studies had a low risk of attrition bias, but only five studies were found to be at low risk for selective reporting bias. Only three studies had independent funding; pharmaceutical companies provided support for manuscript‐writing and funding in several studies. None of the studies assessed in this update has improved the certainty of the evidence, meaning that further studies would add substantially to the evidence base. There was considerable heterogeneity, such as: outcomes analysed by different symptom scores; different participant groups (infants versus children, GOR versus GORD); PPIs in different dosing comparisons, rather than comparing different agents; and different indices (for example, on 24‐hour pH/impedance monitoring). Further comparative studies in both infants and children are likely to improve the certainty of evidence. </p> </section> <section id="CD008550-sec-0227"> <h3 class="title" id="CD008550-sec-0227">Potential biases in the review process</h3> <p>The strengths of this review include the incorporation of further papers to reinforce the evidence base and the use of a similar systematic literature search (including handsearching) of multiple databases and relevant reviews, using wide search terms. The last update to the search was on 17 September 2022. Three review authors appraised each study, and a statistician verified the statistical analysis. Questions about newer studies (published from 2018 onward) were addressed by writing to the study authors, but we received no replies. Additional author data would help the robustness of evidence appraisal. There are no conflicts of interest to declare. Potential weaknesses of the review include the absence of sufficient summary data to perform a meta‐analysis (and inability to perform a sensitivity analysis to test robustness), the inclusion of studies with few children, the short study duration of most studies, and the degree of outcome heterogeneity affecting the accuracy of conclusions. </p> </section> <section id="CD008550-sec-0228"> <h3 class="title" id="CD008550-sec-0228">Agreements and disagreements with other studies or reviews</h3> <p>This review is broadly consistent with <a href="./references#CD008550-bbs2-0111" title="RosenR , VandenplasY , SingendonkM , CabanaM , DiLorenzoC , GottrandF , et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. Journal of Pediatric Gastroenterology and Nutrition2018;66(3):516-54. [DOI: 10.1097/MPG.0b013e3181b7f563]">NASPGHAN‐ESPGHAN guidelines 2018</a>, and National Institute for Health and Care Excellence (NICE) guidelines (<a href="./references#CD008550-bbs2-0113" title="National Institute for Health and Care Excellence. Gastro-oesophageal reflux disease in children and young people: diagnosis and management (NG1); October 2019. www.nice.org.uk/guidance/ng1.">NICE 2019</a>). Other reviews, which include other study designs (such as case‐control and cohort studies), draw similar conclusions about the paucity of evidence, and call for further research, particularly into the subgroups discussed above (<a href="./references#CD008550-bbs2-0113" title="National Institute for Health and Care Excellence. Gastro-oesophageal reflux disease in children and young people: diagnosis and management (NG1); October 2019. www.nice.org.uk/guidance/ng1.">NICE 2019</a>; <a href="./references#CD008550-bbs2-0122" title="TigheMP , AfzalNA , BevanA , BeattieRM . Current pharmacological management of gastro-esophageal reflux in children. Pediatric Drugs2009;11(3):185-202.">Tighe 2009</a>). </p> <p>We identified no data regarding alerts of concern for specific medications, as discussed in the <a href="#CD008550-sec-0011">Description of the intervention</a> section. For example, for ranitidine, we identified no patients experiencing tachyphylaxis in the studies assessed, but this has been identified elsewhere as a concern (<a href="./references#CD008550-bbs2-0100" title="HymanPE , AbramsC , GarveyTO . Ranitidine tachyphylaxis. Gastroenterology1985;88:1426.">Hyman 1985</a>). Additionally, a multicentre observational study noted a nearly seven‐fold increased relative risk of necrotising enterocolitis (95% CI 1.7 to 25.0) in ranitidine‐treated very low birth weight infants (<a href="./references#CD008550-bbs2-0068" title="TerrinG , PassarielloA , De CurtisM , MangusoF , SalviaG , LegaL , et al. Ranitidine is associated with infections, necrotizing enterocolitis, and fatal outcome in newborns. Pediatrics2012;129:e40. ">Terrin 2012</a>), but no studies we analysed identified this complication. Domperidone does not have a Food and Drug Administration (FDA) licence for marketing in the USA, and NICE guidance advises 'do not use' except in specialist paediatric settings (<a href="./references#CD008550-bbs2-0113" title="National Institute for Health and Care Excellence. Gastro-oesophageal reflux disease in children and young people: diagnosis and management (NG1); October 2019. www.nice.org.uk/guidance/ng1.">NICE 2019</a>), but no studies we analysed identified this complication. There is a known association between erythromycin and development of pyloric stenosis (<a href="./references#CD008550-bbs2-0084" title="CooperWO , GriffinMR , ArbogastP , et al. Very early exposure to erythromycin andinfantile hypertrophic pyloric stenosis. Archives of Pediatrics &amp; Adolescent Medicine2002;156:647-50.">Cooper 2002</a>), as well as potential side effects affecting the neonatal microbiome and antimicrobial resistance. NICE guidance advises 'do not use' except in specialist paediatric settings (<a href="./references#CD008550-bbs2-0113" title="National Institute for Health and Care Excellence. Gastro-oesophageal reflux disease in children and young people: diagnosis and management (NG1); October 2019. www.nice.org.uk/guidance/ng1.">NICE 2019</a>), but no studies we analysed identified this complication. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD008550-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/media/CDSR/CD008550/urn:x-wiley:14651858:media:CD008550:CD008550-FIG-01" target="_blank"><b></b></a></p> </div><img alt="PRISMA study flow diagram" data-id="CD008550-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008550.pub3/media/CDSR/CD008550/image_n/nCD008550-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/media/CDSR/CD008550/image_t/tCD008550-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/full#CD008550-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/media/CDSR/CD008550/image_n/nCD008550-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008550-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/media/CDSR/CD008550/urn:x-wiley:14651858:media:CD008550:CD008550-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD008550-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008550.pub3/media/CDSR/CD008550/image_n/nCD008550-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/media/CDSR/CD008550/image_t/tCD008550-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/full#CD008550-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/media/CDSR/CD008550/image_n/nCD008550-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008550-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/media/CDSR/CD008550/urn:x-wiley:14651858:media:CD008550:CD008550-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements presented as percentages across all included studies" data-id="CD008550-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008550.pub3/media/CDSR/CD008550/image_n/nCD008550-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/media/CDSR/CD008550/image_t/tCD008550-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/full#CD008550-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/media/CDSR/CD008550/image_n/nCD008550-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008550-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/media/CDSR/CD008550/urn:x-wiley:14651858:media:CD008550:CD008550-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Omeprazole compared to placebo for infants with GORD, Outcome 1: Improvement in cry/fuss time" data-id="CD008550-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008550.pub3/media/CDSR/CD008550/image_n/nCD008550-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/media/CDSR/CD008550/image_t/tCD008550-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Omeprazole compared to placebo for infants with GORD, Outcome 1: Improvement in cry/fuss time </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/references#CD008550-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/media/CDSR/CD008550/image_n/nCD008550-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008550-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/media/CDSR/CD008550/urn:x-wiley:14651858:media:CD008550:CD008550-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Omeprazole compared to placebo for infants with GORD, Outcome 2: Improvement in reflux index" data-id="CD008550-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008550.pub3/media/CDSR/CD008550/image_n/nCD008550-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/media/CDSR/CD008550/image_t/tCD008550-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Omeprazole compared to placebo for infants with GORD, Outcome 2: Improvement in reflux index </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/references#CD008550-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/media/CDSR/CD008550/image_n/nCD008550-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008550-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/media/CDSR/CD008550/urn:x-wiley:14651858:media:CD008550:CD008550-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Omeprazole compared to ranitidine for infants with GORD, Outcome 1: Improvement in symptom scores (WGSS)" data-id="CD008550-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008550.pub3/media/CDSR/CD008550/image_n/nCD008550-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/media/CDSR/CD008550/image_t/tCD008550-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Omeprazole compared to ranitidine for infants with GORD, Outcome 1: Improvement in symptom scores (WGSS) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/references#CD008550-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/media/CDSR/CD008550/image_n/nCD008550-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008550-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/media/CDSR/CD008550/urn:x-wiley:14651858:media:CD008550:CD008550-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Esomeprazole compared to placebo for infants with GORD, Outcome 1: Improvement in number of GORD‐related symptoms and signs" data-id="CD008550-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008550.pub3/media/CDSR/CD008550/image_n/nCD008550-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/media/CDSR/CD008550/image_t/tCD008550-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Esomeprazole compared to placebo for infants with GORD, Outcome 1: Improvement in number of GORD‐related symptoms and signs </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/references#CD008550-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/media/CDSR/CD008550/image_n/nCD008550-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008550-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/media/CDSR/CD008550/urn:x-wiley:14651858:media:CD008550:CD008550-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Rabeprazole at higher doses (1 mg/kg) compared to rabeprazole at lower doses (0.5 mg/kg) for GORD in children older than 1 year, Outcome 1: Improvement in symptom score ('Total GERD Symptoms and Severity' score)" data-id="CD008550-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008550.pub3/media/CDSR/CD008550/image_n/nCD008550-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/media/CDSR/CD008550/image_t/tCD008550-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Rabeprazole at higher doses (1 mg/kg) compared to rabeprazole at lower doses (0.5 mg/kg) for GORD in children older than 1 year, Outcome 1: Improvement in symptom score ('Total GERD Symptoms and Severity' score) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/references#CD008550-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/media/CDSR/CD008550/image_n/nCD008550-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008550-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/media/CDSR/CD008550/urn:x-wiley:14651858:media:CD008550:CD008550-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Rabeprazole at higher doses (1 mg/kg) compared to rabeprazole at lower doses (0.5 mg/kg) for GORD in children older than 1 year, Outcome 2: Improvement in endoscopic scores (Hetzel Dent scores)" data-id="CD008550-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008550.pub3/media/CDSR/CD008550/image_n/nCD008550-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/media/CDSR/CD008550/image_t/tCD008550-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Rabeprazole at higher doses (1 mg/kg) compared to rabeprazole at lower doses (0.5 mg/kg) for GORD in children older than 1 year, Outcome 2: Improvement in endoscopic scores (Hetzel Dent scores) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/references#CD008550-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/media/CDSR/CD008550/image_n/nCD008550-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008550-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/media/CDSR/CD008550/urn:x-wiley:14651858:media:CD008550:CD008550-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Pantoprazole in higher doses (1.2 mg/kg) compared to pantoprazole at lower doses (0.3 mg/kg) for GORD in children older than 1 year, Outcome 1: Improvement in symptom scores (WGSS)" data-id="CD008550-fig-0010" src="/cdsr/doi/10.1002/14651858.CD008550.pub3/media/CDSR/CD008550/image_n/nCD008550-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/media/CDSR/CD008550/image_t/tCD008550-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Pantoprazole in higher doses (1.2 mg/kg) compared to pantoprazole at lower doses (0.3 mg/kg) for GORD in children older than 1 year, Outcome 1: Improvement in symptom scores (WGSS) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/references#CD008550-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/media/CDSR/CD008550/image_n/nCD008550-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD008550-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Omeprazole compared to placebo for GORD in infants</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Omeprazole compared to placebo for GORD in infants</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> infants with GORD<br/><b>Setting:</b> outpatients<br/><b>Intervention:</b> omeprazole<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with omeprazole</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in symptoms in infants<br/>assessed with: cry/fuss diary (minutes/day)<br/>Follow‐up: mean 2 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean improvement in symptoms in infants was <b>‐66</b> minutes/day </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>10 minutes/day lower</b><br/>(89.1 lower to 69.1 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cry/fuss time in infants between 3 and 12 months of age (mean 5.4 months) improved from 246 ± 105 minutes/day at baseline (mean +/‐ SD) to 191 ± 120 minutes/day in the omeprazole group and from 287 ± 132 minutes/day to 201 ± 100 minutes/day in the placebo group (mean difference (MD) 10 minutes/day lower (95% confidence interval (CI) ‐89.1 to 69.1)) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>There were no reports of adverse events in either the omeprazole or placebo group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in pH metrics in infants<br/>assessed with: reflux index<br/>Follow‐up: mean 2 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean improvement in pH metrics in infants was <b>1.9</b> % of time in 24 hours </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>7% of time in 24 hours lower</b><br/>(4.66 lower to 9.34 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In the omeprazole group, the reflux index improved from 9.9 ± 5.8% in 24 hours to 1.0 ± 1.3% in 24 hours. In the placebo group, the reflux index improved from 7.2 ± 6.0% in 24 hours to 5.3 ± 4.9% in 24 hours. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endoscopic metrics ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no data to assess this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_429021146969853213" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_429021146969853213</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Risk of bias: outcomes were assessed with behaviour diary (potential for recall bias) and visual analogue score (potential for parental observer bias). There were concerns that some of these infants may not have had significant endoscopic or reflux index changes at inclusion. North American Society of Paediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) guidance in place at the time considered reflux index &gt; 10% to be pathological in infants, and no evidence of reflux oesophagitis was seen (erosions or ulcers) at entry endoscopy. The inclusion criteria considered loss of vascular pattern or friability enough for inclusion. Only seven infants had both endoscopic changes and reflux index &gt; 5%. With these concerns, we have downgraded the evidence by one step. <br/><sup>b</sup>Imprecision: for Moore 2003, there was a wide confidence interval crossing the clinical decision threshold and only 15 infants in each group so we have downgraded the evidence by two steps.<br/><sup>c</sup>Risk of bias: there were concerns that some of these infants may not have had significant endoscopic or reflux index changes at inclusion. NASPGHAN guidance in place at the time considered reflux index &gt; 10% to be pathological in infants, and no evidence of reflux oesophagitis was seen (erosions or ulcers) at entry endoscopy. The inclusion criteria considered loss of vascular pattern or friability enough for inclusion. Only seven infants had both endoscopic changes and reflux index. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Omeprazole compared to placebo for GORD in infants</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/full#CD008550-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008550-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Omeprazole compared to ranitidine for GORD in infants</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Omeprazole compared to ranitidine for GORD in infants</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> GORD in infants<br/><b>Setting:</b> outpatients<br/><b>Intervention:</b> omeprazole<br/><b>Comparison:</b> ranitidine </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with ranitidine</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with omeprazole</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in symptoms in infants<br/>assessed with: weekly gastro‐oesophageal reflux score (WGSS)<br/>Follow‐up: mean 2 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean improvement in symptoms in infants was <b>‐44.5</b> points </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>4.97 points lower</b><br/>(2.47 lower to 7.33 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Omeprazole (0.5 mg/kg/day) appears to provide some symptomatic benefit in infants between 2 and 12 months old, with improved scores after 2 weeks (51.93 ± 5.42 to 2.43 ± 1.15) equivalent to ranitidine (2 to 4 mg/kg/day) with scores improving (47 ± 5.6 to 2.47 ± 0.58): no differences between omeprazole and ranitidine were noted: MD ‐4.97 (95% CI ‐2.47 to ‐7.33). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events in infants ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data were available for this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in pH metrics in infants ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data were available for this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in endoscopic findings in infants ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data were available for this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_429020868699799221" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_429020868699799221</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Risk of bias: the certainty of evidence was downgraded by two steps due to issues with blinding (performance bias) as omeprazole was delivered as a capsule and ranitidine as a syrup so parents would be aware which medication was being offered. In addition, 16 infants were lost to follow‐up (attrition bias), severe pneumonia, premature discontinued drugs, and parental issues with the questionnaire<br/><sup>b</sup>Imprecision: as the confidence intervals do not overlap the clinical decision threshold between recommending and not recommending treatment, and the study had very small numbers, we downgraded the certainty of evidence by two steps (very serious), but the certainty of evidence was already very low. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Omeprazole compared to ranitidine for GORD in infants</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/full#CD008550-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008550-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Esomeprazole compared to placebo for GORD in infants</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Esomeprazole compared to placebo for GORD in infants</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> GORD in infants<br/><b>Setting:</b> inpatients in 3 neonatal intensive care units<br/><b>Intervention:</b> esomeprazole<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with esomeprazole</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in symptoms and signs in infants<br/>assessed with: total number of gastro‐oesophageal reflux disease (GORD) symptoms <br/>Follow‐up: mean 2 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean improvement in symptoms and signs in infants was <b>‐24.5</b> episodes </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>3.2 episodes fewer</b><br/>(4.6 fewer to 1.8 fewer) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Included data from premature babies to 1 m corrected gestational age. No data in older infants. For total number of GORD symptoms (from video monitoring) and GORD‐related signs (from cardiorespiratory monitoring), the esomeprazole group improved from baseline 184.7 (78.5) to 156.7 (75.1) and placebo group improved from 183.1 (77.5) to 158.3 (75.9). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>It was not possible to extract summary data, although there were no reported differences between the placebo and esomeprazole groups. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>pH indices ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data were available for this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endoscopic metrics ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data were available for this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_429020489057615413" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_429020489057615413</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Risk of bias: the certainty of evidence was downgraded by one step as the study was terminated early due to poor recruitment (the power calculation estimated needing 38 neonates in each group).<br/><sup>b</sup>Indirectness: the certainty of evidence was downgraded by one step as the population studied (neonates) is only a part of the population under assessment (infants).<br/><sup>c</sup>Imprecision: the certainty of evidence was downgraded by two steps due to small numbers and wide confidence intervals crossing the clinical decision threshold.<br/><sup>d</sup>Publication bias: this single study was industry‐funded, with support for manuscript‐writing, but the certainty of evidence was not downgraded by one step, as already at 'very low' </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Esomeprazole compared to placebo for GORD in infants</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/full#CD008550-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008550-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Rabeprazole at higher doses (1 mg/kg) compared to rabeprazole at lower doses (0.5 mg/kg) for GORD in children over 1 year of age</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Rabeprazole at higher doses (1 mg/kg) compared to rabeprazole at lower doses (0.5 mg/kg) for GORD in children over 1 year of age</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> GORD in children over 1 year of age<br/><b>Setting:</b> outpatients<br/><b>Intervention:</b> rabeprazole at higher doses (1 mg/kg)<br/><b>Comparison:</b> rabeprazole at lower doses (0.5 mg/kg) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with rabeprazole at lower doses (0.5 mg/kg)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with rabeprazole at higher doses (1 mg/kg)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in symptoms<br/>assessed with: 'Total GORD Symptoms and Severity' score<br/>Follow‐up: mean 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean improvement in symptoms was <b>‐9.9</b> points </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>2.3 points higher</b><br/>(2 lower to 6.6 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rabeprazole at 0.5 mg/kg and 1 mg/kg may provide similar symptom improvement: in the 0.5 mg/kg group, symptom score improved in both the low‐weight (&lt; 15 kg) (n = 21 mean ‐10.6 ± SD 11.13)) and high‐weight (&gt; 15 kg) groups (n = 44 mean ‐13.6 ± 13.1). In the 1 mg/kg group, scores improved in the low‐weight (n = 19, ‐9 ± 11.2)) and higher‐weight groups (n = 43, ‐8.3 ± 9.2). For the higher‐weight group, MD 2.3 (95% CI ‐2 to 6.6), and low‐weight group: 0.5 mg/kg vs 1 mg/kg: MD 4.6 (95% CI ‐2.9 to 12). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events<br/>assessed with: parent‐reported events </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Rabeprazole at 0.5 mg/kg and 1 mg/kg may lead to some adverse events: 95 (84%) children had adverse events, including abdominal pain, nausea, vomiting, bronchopneumonia, gastroenteritis, cough, and choking. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no difference between the groups.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in endoscopic appearances<br/>assessed with: Hetzel‐Dent score<br/>Follow‐up: mean 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean improvement in endoscopic appearances was <b>‐1.4</b> points </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>0.1 points higher</b><br/>(0.23 lower to 0.43 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In the 0.5 mg/kg group, endoscopic appearances improved in both the low‐weight (‐1.4 ± 1.06) and higher‐weight groups (‐1.2 ± 0.75). In the 1 mg/kg group, endoscopic appearances also improved in the low‐weight (‐1.1 ± 0.72) and high‐weight groups (‐1.0 ± 0.85). In the low‐weight group: 0.5 mg/kg vs 1 mg/kg: MD 0.30 (95% CI ‐0.27 to 0.87) and in the higher‐weight group MD 0.1 (95% CI ‐0.23 to 0.43). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>pH indices ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data were available for this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_429021824944230742" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_429021824944230742</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Risk of bias: the certainty of evidence was downgraded by one step for selection bias: 30% of children had already received proton pump inhibitors, 15% H2 antagonists, and 2% prokinetics. 15% of participants had also withdrawn.<br/><sup>b</sup>Imprecision: the certainty of evidence was downgraded by one step as the wide confidence intervals crossed the clinical decision threshold.<br/><sup>c</sup>Publication bias: the certainty of evidence was downgraded by one step as this was a single study and was industry‐funded, with assistance in manuscript preparation, and authors were employed by a pharmaceutical company. The study design involved the same medication at different doses which is less clinically useful than comparison to placebo or an alternative medication. We do not have other studies to assess whether this would have had a material impact. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Rabeprazole at higher doses (1 mg/kg) compared to rabeprazole at lower doses (0.5 mg/kg) for GORD in children over 1 year of age</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/full#CD008550-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008550-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Pantoprazole in higher doses (1.2 mg/kg) compared to pantoprazole at lower doses (0.3 mg/kg) for GORD in children over 1 year of age</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Pantoprazole in higher doses (1.2 mg/kg) compared to pantoprazole at lower doses (0.3 mg/kg) for GORD in children over 1 year of age</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> GORD in children over 1 year of age<br/><b>Setting:</b> outpatients<br/><b>Intervention:</b> pantoprazole in higher doses (1.2 mg/kg)<br/><b>Comparison:</b> pantoprazole at lower doses (0.3 mg/kg) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with pantoprazole at lower doses (0.3 mg/kg)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Pantoprazole in higher doses (1.2 mg/kg)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in symptoms<br/>assessed with: weekly gastro‐oesophageal reflux score (WGSS)<br/>Follow‐up: mean 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean improvement in symptoms was <b>‐2.37</b> points </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>0.7 points higher</b><br/>(0.4 lower to 1.8 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pantoprazole appears to improve symptoms at 0.3 mg/kg, 0.6 mg/kg, and 1.2 mg/kg pantoprazole in 60 children aged 1 to 5 years. Symptom scores improved from baseline to week 8 (0.3 mg/kg MD ‐2.4, 95% CI ‐3.2 to ‐1.5; 1.2 mg/kg ‐1.7, 95% CI ‐2.9 to ‐0.39). There was no difference between 0.3 mg/kg and 1.2 mg/kg dosing: MD 0.7 (95% CI ‐0.4 to 1.8). Individual symptoms (abdominal pain, burping, heartburn, pain after eating and difficulty swallowing) improved in all groups after 8 weeks. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events<br/>assessed with: individual symptom reporting<br/>Follow‐up: 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Pantoprazole at all doses investigated may lead to adverse events: in the 0.3 mg/kg group, 1 child developed diarrhoea and nappy rash; in the 0.6 mg/kg group, 1 child had sleep disturbance and 1 developed abdominal pain; and in the 1.2 mg/kg group, 1 child had rectal bleeding. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no difference between the groups.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in pH indices ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data were available for this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in endoscopic metrics ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data were available for this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_429032441167302611" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_429032441167302611</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Risk of bias: we downgraded the certainty of evidence by one step as no comment was made about blinding and randomisation technique.<br/><sup>b</sup>Imprecision: we downgraded the certainty of evidence due to the small sample size, which would not meet the optimal information size, and confidence intervals that cross the decision‐making threshold. We would have downgraded by two steps but the certainty of evidence was already 'very low'.<br/><sup>c</sup>Publication bias: we downgraded the certainty of evidence by one step as this study was industry‐funded with support with manuscript writing. The study design involved the same medication at different doses which is less clinically useful than comparison to placebo or an alternative medication. It is difficult to estimate the degree of effect given other studies were not available to compare. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Pantoprazole in higher doses (1.2 mg/kg) compared to pantoprazole at lower doses (0.3 mg/kg) for GORD in children over 1 year of age</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/full#CD008550-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008550-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Omeprazole compared to placebo for infants with GORD</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Improvement in cry/fuss time <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Improvement in reflux index <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Omeprazole compared to placebo for infants with GORD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/references#CD008550-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008550-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Omeprazole compared to ranitidine for infants with GORD</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Improvement in symptom scores (WGSS) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Omeprazole compared to ranitidine for infants with GORD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/references#CD008550-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008550-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Esomeprazole compared to placebo for infants with GORD</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Improvement in number of GORD‐related symptoms and signs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Esomeprazole compared to placebo for infants with GORD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/references#CD008550-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008550-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Rabeprazole at higher doses (1 mg/kg) compared to rabeprazole at lower doses (0.5 mg/kg) for GORD in children older than 1 year</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Improvement in symptom score ('Total GERD Symptoms and Severity' score) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 Children &gt; 15 kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.2 Children &lt; 15 kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Improvement in endoscopic scores (Hetzel Dent scores) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.1 Children &gt; 15 kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.2 Children &lt; 15 kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Rabeprazole at higher doses (1 mg/kg) compared to rabeprazole at lower doses (0.5 mg/kg) for GORD in children older than 1 year</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/references#CD008550-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008550-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Pantoprazole in higher doses (1.2 mg/kg) compared to pantoprazole at lower doses (0.3 mg/kg) for GORD in children older than 1 year</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Improvement in symptom scores (WGSS) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Pantoprazole in higher doses (1.2 mg/kg) compared to pantoprazole at lower doses (0.3 mg/kg) for GORD in children older than 1 year</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008550.pub3/references#CD008550-tbl-0010">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008550.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD008550-note-0010">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008550-note-0015">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD008550-note-0009">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD008550-note-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="id#CD008550-note-0016">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="ja#CD008550-note-0014">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD008550-note-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="nl#CD008550-note-0019">Nederlands</a> </li> <li class="section-language"> <a class="" href="pl#CD008550-note-0017">Polski</a> </li> <li class="section-language"> <a class="" href="ro#CD008550-note-0018">Română</a> </li> <li class="section-language"> <a class="" href="th#CD008550-note-0013">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD008550-note-0011">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD008550-note-0012">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008550\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008550\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008550\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008550\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008550\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008550\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008550\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008550\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008550\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008550\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008550\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008550\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008550\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008550\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008550\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008550\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008550\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008550\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=9nGOjNGw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008550.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008550.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008550.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008550.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008550.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740724858001"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008550.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740724858005"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008550.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e6d11dfaef4ca',t:'MTc0MDcyNDg1OC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 